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Abstract 
The poor aqueous solubility of many APIs, such as felodipine, are significant dissolution rate 
limiting factors that often lead to poor oral systemic bioavailability. Solid dispersions have been 
used as a formulation approach to improve drugs dissolution properties. Most of the reported solid 
dispersion formulations in the literature are binary mixtures with limited functionalities (with 
enhancing dissolution being the primary function). The aim of this study is to design, characterise 
and evaluate complex solid dispersions with intentionally designed microstructures (in the form 
of phase separations). The potential functionalities of these microstructures were explored by this 
project. In our view, the complex formulations are more representative of real pharmaceutical 
products in their final forms.  
HME-IM is a single processing technique for fabricating formulations with high geometric 
precision in a rapid, efficient and environmentally friendly way.  It was used as the main 
processing method to produce the solid dispersion based buccal patches in this project. The 
patches were thoroughly characterised using conventional techniques including DSC, MTDSC, 
TGA, DVS, ATR-FTIR, PXRD, SEM, EDS, IR imaging, mucoadhesion and in vitro dissolution 
testing. In order to address the spatial distribution of the phase separations, two non-conventional 
characterisation methods, thermal analysis by structural characterisation and X-ray micro-
computed tomography, were introduced to provide novel insights into the heterogeneity and phase 
distribution of these formulations. The results revealed that HME-IM patches with 10% drug 
loading were unsaturated while those with 20-30% w/w drug concentration were saturated or even 
supersaturated. HME-IM patches containing TPGS were more solubilising to felodipine and more 
stable compared to Tween 80 containing systems. Thermal analysis by structural characterisation 
provided rapid detection of heterogeneity and the thermal dissolution of crystalline drug fraction 
while XµCT provided microscale spatial distribution of different phases. Having shown the 
advantages of using polymeric blends to formulate solid dispersions that were demonstrated by 
the felodipine buccal patches, we further explored the use of polymer blends for improving the 
FDM 3D printability of pharmaceutical solid dosage forms with the potential applications in 
personalised medicine.  
This project demonstrated the potential and formulation principles of using HME-IM and FDM 
3D printing as formulation methods for production of polymer blend based complex solid 
dispersions for the purposes of enhanced bioavailability of poorly soluble drugs and providing 
personalised medicines. 
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1.1 The mystery of poor water solubility of active pharmaceuticals 
Poor water solubility due to the hydrophobic nature of ~ 40% of the newly discovered 
pharmaceutically active chemical entities (due to the chemistry of their active forms) comprises 
a challenging problem that affects their dissolution from the final products (1, 2). The equilibrium 
solubility of any chemical compound is an essential feature that can be changed only by chemical 
structure modification while the dissolution rate is an extrinsic property that can be modified by 
chemical, physical, and crystallographic changes like complexation, surface properties, particle 
size, solid state modification and formulation based solubilisation (3). According to U.S Food and 
Drug Administration (FDA), World Health Organisation (WHO) and European Medicines 
Agency (EMA), drugs are generally classified into four classes according to biopharmaceutics 
classification system (BCS). The classification is based on their aqueous solubility and 
permeability through the intestinal barriers at the site of absorption as a tool to predict their 
pharmacokinetic performances (4). Drugs are termed highly soluble when their highest strength 
is soluble in 250 mL or less aqueous solution within the pH range of 1- 6.8 at 37 ± 1 ̊C. In addition, 
the expression ‘high permeable’ indicates not less than 85% of the administered dose (based on 
mass balance or in comparison to an intravenous reference dose) is absorbed through the intestinal 
site of absorption (5). The different classes with examples of various drugs are presented in 
Figure 1.1. 
 
Figure 1.1: Biopharmaceutics classification system (BCS) with examples; adapted from references 
(6-8) 
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Solubility and/or dissolution rate are considered as critical parameters that control the 
development of any pharmaceutical product starting from the formulation process and ending by 
the different drug disposition stages inside the human body. Also, their impacts extend to later 
stages after the intake of medication to include the release profile, absorption, bioavailability, 
distribution, metabolism and excretion (3, 9, 10).  
Over the last decades, researchers have developed a variety of strategies to overcome this problem 
like salt formation, complexation, co-crystals, nanocrystals, prodrug formation, lipid-based drug 
delivery systems and solid dispersions.  Each one of these approaches has its advantages and 
limitations. Salt formation significantly increases the solubility, however, it is only applicable to 
acidic and basic drugs (11). Complexation using inclusion excipients like cyclodextrins enhance 
the solubility of hydrophobic drugs by trapping them in their central cavity. The formation of 
these solubilisation complexes is controlled by the size of the cyclodextrin ring and the guest 
molecule and the presence of interaction between them (12). Co-crystals can increase the 
solubility of this category of drugs by lowering the lattice energy and increasing the solvent 
affinity. However, the flexibility to formulate those drugs as co-crystals is limited by safety 
restrictions on the concentrations of coformers such as malic acids which forms co-crystals with 
itraconazole in a maximum allowable combination of less than 7% (13). Also, reducing the 
particle size by using nanocrystals approach led to the development of marketed products such as 
nabilone (Cesamet®/Lilly) and fenofibrate (Tricor®/Abbott) oral nanocrystal formulations 
through enhancing the dissolution rate by the enormous increase in the surface area exposed to 
solvent action (14). However, it was reported that physiological factors like pH variations, the 
composition of the gastric juices and GI peristalsis could affect the redispersion of nanocrystals 
resulting in a failure to achieve good in vivo performance (15). Reducing particle size may also 
be compromised by the extensive precipitation and the high recrystallisation tendency of the drug. 
It should be mentioned that very fine particles may express poor wetting properties, aggregation 
and agglomeration and difficulty in handling such particles during formulation and manufacturing 
processes (16-18). Furthermore, prodrug approach was shown to improve the solubility of poorly 
water soluble drugs, but this involves modification of drug’s chemical structure which is generally 
not favourable to overcome solubility limitations (19). Lipid-based drug delivery systems offer 
the advantage of dissolving lipophilic drugs. A variety of lipids, surfactants or mixtures of lipids 
and surfactants were used to omit the dissolution step which acts as the limiting parameter for the 
absorption of poorly water soluble drugs (20-22). However, this formulation strategy may be 
affected by some challenges like physical changes and oxidative degradation over time which 
might have a potential impact on drug stability and formulation performance (23). Another 
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approach to improve the solubility and dissolution rate of poorly water soluble drugs is through 
the use of solid dispersions. The solubility and/or dissolution enhancement by this method is 
achieved majorly by converting the drug from its crystalline state to typically molecularly level 
solid dispersion. The major drawback of this formulation based technology is the physical 
stability of the dispersed drug in the formulation (24, 25).  It should be mentioned that lipid-based 
formulations can be processed as solid dispersions to prepare drug delivery systems for improved 
dissolution properties of poorly water soluble drugs (21, 26).   
1.2 Solid dispersions 
Pharmaceutical solid dispersions are systems in which the APIs are distributed in a carrier 
composed of one or more pharmaceutical excipients (27, 28). The interest in solid dispersions is 
growing rapidly in the last five decades owing to the advantages offered by this type of 
preparations like the improvement in the bioavailability of poorly water-soluble drugs (BCS class 
II) through increasing their solubility and/or dissolution rates (18). The importance of this 
approach compared to other methods used for achieving this purpose is attributed to the flexibility 
in combining the drugs with a very wide range of pharmaceutically approved excipients having 
different functionalities to achieve the desired objectives of formulation. Excipients with wide 
variety of physicochemical properties like different chemical structures, molecular weights, 
crystalline, amorphous, lipidic, hydrophilic, amphiphilic, viscous, liquids, semisolids, solids can 
be used in fabricating solid dispersions. In addition, solid dispersions as blends are not restricted 
with certain stoichiometric mixing ratios which enable researchers to use a wide range of 
concentrations depending on the miscibility between the different components. Furthermore, 
there are several methods can be utilised for the fabrication of these formulations with different 
formulation strategies and applications that may be used to overcome preparation challenges (29-
32). However, there are only a few products marketed as therapeutically effective and stable 
formulations to be used by the patients to cure diseases mainly due to physical stability issues 
(18). An illustration of the structure of different solid dispersions is shown in Figure 1.2. 
Depending on the physical states of the drug and the carrier, several types of solid dispersions 
with single or multiple phases can be formed.   
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Figure 1.2: An illustration of phase composition of different types of solid dispersions 
Poorly water soluble drugs are mostly crystalline compounds characterised by long-range three-
dimensional order of arrangement of molecules (Figure 1.2). On the other hand, amorphous forms 
are disordered compounds lacking this property and have only short range of order (33). Also, 
polymorphic forms are crystalline forms belong to the same drug with different crystalline 
structures having various molecular arrangements caused by differences in packing and/or 
molecular conformations (34). Polymorphic forms are different in their thermodynamic (like 
melting temperature), kinetic (such as dissolution rate), packing (like density), surface (such as 
surface free energy) and mechanical properties (like hardness) (35).  
Solid dispersions enhance the solubility and/or dissolution of poorly water-soluble drugs by 
different mechanisms. These mechanisms include converting the drug into molecular level, 
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amorphous or other polymorphic forms having higher solubility and/or dissolution properties (27, 
36). The higher surface free energy of the molecularly dispersed and amorphous forms compared 
to crystalline form is the driving force responsible for the improvement in solubility and/or 
dissolution characteristics as shown in Figure 1.3. In addition, other factors like the decrease in 
particle size, reduction in agglomeration and aggregation, interaction with other excipients to 
form complexes and enhanced wettability are also contributing to such improvement in drug 
solubility and/or dissolution properties (27, 36). Increasing the dissolution properties by solid 
dispersions through particle size reduction is based on the assumption that the components of 
these dispersions crystallise as very small particles. Consequently, when these particles come into 
contact with the dissolution media, the larger surface area exposed to the solvent action of these 
small particles enhance the dissolution rate (37).  
 
Figure 1.3: Surface free energy of crystalline compared to amorphous and molecularly dispersed 
drugs in solid dispersions; adapted from reference (38). 
1.2.1 Classification of solid dispersions according to the physical state of the 
drug and the carrier 
Based on the physical state of the drug and the carrier excipient(s), solid dispersions can be 
classified into many classes as illustrated in Figure 1.4 
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Figure 1.4: Classification of solid dispersions based on the physical state and distribution of phases; 
adapted from reference (36) 
1.2.1.1 Eutectic mixtures 
Eutectic mixtures are solid dispersions having a melting point (eutectic temperature) lower than 
that of its original components. The mixture is single phase in the liquid state and phase separated 
crystalline mixture in the solid state (36, 38, 39). An intimate physical interaction such as 
hydrogen bonding is a critical factor in causing the melting point depression of the system in the 
solid state. This kind of solid dispersions can be formed between drugs, excipients and their 
mixtures (40). Eutectic mixtures are further classified into monotectic and typical eutectic solid 
dispersion depending on how close the eutectic temperature to the melting point of individual 
constituents. Monotectic solid dispersions have eutectic point close to one of the mixture 
ingredients while in the case of typical eutectic systems the eutectic temperature lies in the middle 
area away from individual constituents (38, 39).  
Several poorly water soluble drugs showed to form eutectic mixtures resulting in an enhancement 
in their dissolution properties. It was reported that ibuprofen solubility is improved by eutectic 
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mixture formation with menthol resulting in a significant improvement in the initial plasma 
concentration of the drug (41).  Also, the dissolution rates of acetylsalicylic acid, benzoic acid 
and phenylacetic acid were found to be higher by the formation of eutectic mixtures with choline 
chloride and menthol at specific mixing proportions (42).  
Furthermore, eutectic mixture of urea and efonidipine hydrochloride ethanolate was reported to 
be formed by microwave radiation treatment in which the eutectic point was depressed 70 ̊C and 
40 ̊C with respect to the melting temperature of the drug and urea respectively (43). The phase 
diagram of this class of solid dispersions is illustrated in Figure 1.5. 
 
 
Figure 1.5: Simple eutectic mixture phase diagram with negligible solid solubility 
1.2.1.2 Solid solutions 
Solid solutions or often called mixed crystals are solid dispersions in which the components of 
the mixture in the solid state are crystallised together as a single phase homogeneous system. The 
dissolution properties of poorly water soluble drugs using this system are higher compared to the 
aforementioned eutectic mixture. The improved dissolution is attributed to particle size reduction 
to the maximum degree in which the drug is existing at the molecular level (36). Solid solutions 
are classified according to the extent of miscibility between the components of the system into 
continuous and discontinuous solid solutions. In the former, the constituents of the blends are 
miscible in all proportions while in the later there is incomplete miscibility between the individual 
ingredients. They also are subdivided into interstitial and substitutional solid dispersions. 
Chapter 1   Introduction  
 
9  School of Pharmacy / University of East Anglia 
 
Interstitial solid solutions, the solid solute molecules fill the interstitial spaces between the solid 
solvent molecules while in the case of substitutional type, the guest solute molecules substitute 
the solvent ones (27, 36, 44, 45). According to the similarities in their structure and/or the open 
spaces in the crystal of the solvent (host crystal), the solute (guest) can orient itself in a specific 
manner giving the dispersion its final characteristics.  
The phase diagrams of the continuous and the discontinuous solid solutions are illustrated in 
Figures 1.6 A and B, respectively. Also, an illustration of the substitutional and the interstitial 
types of solid solutions is shown in Figure 1.7. 
 
Figure 1.6: Continuous (A) and discontinuous (B) solid solution phase diagrams 
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Figure 1.7: Schematic representation of substitutional solid solution (left) and interstitial solid 
solution (right). Black hexagons represent drug molecules (guest) while the orange hexagons 
represent the carrier (host) molecules 
In the literature, it has been reported that several hydrophobic drugs form crystalline solid 
solutions with some excipients. The possible formation of interstitial solid solution between 
clofibrate and various molecular weight grades of PEG was considered as the contributing factor 
for enhancing the dissolution properties of the drug (46). Similar findings were concluded in the 
case of the oxazepam where its dissolution profiles are significantly enhanced by solid solution 
formation with PEG (47). However, other more recent studies showed that drugs dispersed in 
PEG are more likely distributed as molecularly dispersed in the amorphous fraction of these 
polymers or as nanocrystals that reported to be distributed into the interfibrillar, interlamellar or 
interspherulitic spaces of the PEG/PEO polymer carriers (48-51). Nevertheless, members of PEG 
polymers and other polymers are also reported to form cocrystals or mixed crystals with several 
drugs such as griseofulvin (52-55). 
1.2.1.3 Glass solutions and suspensions 
The third category of solid dispersions is glass dispersions in which the drug is either molecularly 
dispersed as single phase (glass solution) or phase separated mixtures in which the drug present 
as amorphous domains and/or crystalline fraction distributed in an amorphous polymer or 
polymeric blend (glass suspension) as illustrated in Figure 1.8 (56, 57).  
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Figure 1.8: Schematic representation of glass solutions and suspensions 
This class has attracted the attention of researchers to formulate amorphous solid solutions for 
poorly water soluble drugs like BCS class II because these mixtures have the maximum ability to 
improve the dissolution rate and the solubility of these drugs. Unlike crystalline or semi-
crystalline systems, the individual molecules of amorphous systems lack the repetitious order and 
distributed randomly which makes the incorporation of the drug in the interstitial spaces between 
the polymer chains easier compared to crystalline polymers. Due to the lack of crystallinity, 
amorphous systems exhibit a characteristic behaviour of existing in the solid-like (glass) and 
liquid-like (supercooled liquid or rubbery) states depending on their temperature. The range of 
temperatures in which the system transforms from its glass to supercooled liquid states is termed 
the glass transition (Tg). Several theories explained the physics behind this thermal event like the 
free volume, configurational entropy, potential energy landscape and mode coupling theories.  
The Tg is mostly considered as an important parameter to estimate the stability and miscibility of 
amorphous solid dispersions due to the significant variation in the properties of the system above 
and below this thermal event. The solubility/dissolution properties of many poorly water soluble 
drugs have been reported to be significantly enhanced by the formation of molecular level 
amorphous solid dispersions (24, 25, 29, 44).  
Amorphous polymers like PVP, HPMC and HPMC-AS are found to stabilise molecularly 
dispersed celecoxib resulting in an improvement in its release profile (58). The same polymers 
have found to improve the dissolution and maintain supersaturation in solution state for variable 
periods depending on the type of polymer and the loading percentage of the model drug danazol 
(59). Furthermore, an amorphous polymeric blend of PVP K90 and Eudragit E100 showed 
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significant enhancement in the dissolution profile and stability of molecularly dispersed poorly 
water soluble drug indomethacin (60). 
1.2.1.4 Amorphous precipitations in crystalline carrier 
In this type of solid dispersions, the solute (drug) phase is separated as amorphous domains in the 
crystalline carrier. Since the amorphous form is expected to have higher solubility compare to 
crystalline form, this category of solid dispersions can be considered as a mean to improve the 
dissolution properties of poorly water soluble drugs (44). The presence of phase separated fraction 
of amorphous indomethacin in the semicrystalline polymer PEG 6000 is an indication of the 
presence of this kind of solid dispersion (48). Similar findings have also confirmed the 
precipitation of amorphous bifonazole and acetaminophen in semicrystalline PEO−PPO−PEO 
triblock copolymers (Poloxamers® 188 and 407) solid dispersions (61). It was reported that 
amorphous glibenclamide precipitated in the semi-crystalline PEG 4000 is a possible explanation 
for the improvement in the dissolution properties of the drug (62). 
1.2.1.5 Compound or complex formation 
Complex formation between poorly water soluble drugs and hydrophilic carriers can also be 
considered as mean to improve their dissolution profiles and consequently enhance their 
bioavailability. Several examples of hydrophilic carriers have demonstrated their ability to form 
complexes with drugs such as cyclodextrins, PVP, PEG and PEO. Cyclodextrins are cyclic 
compounds characterised by hydrophobic interior cavities and the ability to form noncovalent 
inclusion complexes with a variety of drugs (27, 63-66). PVP as a hydrophilic amorphous polymer 
used widely for preparing solid dispersions has also reported to form complexes with BCS class 
II drugs resulting in an increase in their aqueous dissolution properties (67-69). In addition, 
hydrophilic solid dispersions of PEG and PEO have been shown to form soluble complexes with 
hydrophobic drug molecules such as griseofulvin, diflunisal and carbamazepine (54, 70, 71). The 
schematic representation of these complexes is illustrated in Figure 1.9. 
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Figure 1.9: Schematic representation of drug-PEG inclusion complexes; adapted from reference (54) 
1.2.1.6 Combination solid dispersions  
Solid dispersions can exist as a mixture of two or more of the previously mentioned classes in 
single system depending on the number, characteristics and the degree of interaction between 
their constituents. Consequently, the global improvement in the dissolution profile of poorly water 
soluble drugs can be explained based on the individual class of solid dispersions. It was reported 
that PEO based mucoadhesive buccal patches of the antifungal drug ciclopirox olamine were 
heterogeneous solid dispersions composed of multiple phases of molecularly dispersed, 
amorphous, crystalline fractions resulting in an overall improvement of the poorly water soluble 
drug from its final formulation (50). Also, the structural diversity of the polymeric carriers was 
found to control the formation of multiphasic solid dispersions of acetylsalicylic acid prepared by 
freeze drying as seen using solid state NMR (72). Furthermore, the immiscibility between 
different polymers in polymeric blend solid dispersions found to form multiphasic solid 
dispersions of different characteristics (73). 
1.3 Drug-polymer miscibility predictions for solid dispersion development  
Theoretical prediction methods are considered as important approaches during the development 
of pharmaceutical products for selecting the most suitable excipients candidates for active 
pharmaceuticals. These approaches have been widely used for predicting quantitative structure-
property relationships like solubility, permeability and biopharmaceutical profiles using a variety 
of methods (74-76). Concerning solid dispersions, these methods are also adapted to predict the 
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miscibility and stability of drugs in the different carriers as a preformulation strategy to select the 
best excipient candidates that show the highest solubilisation and stabilisation properties (77-80). 
Maintaining the stability of molecular level solid dispersions is a key parameter to ensure the 
enhancement in the solubility/dissolution properties of poorly water soluble drugs. Failure to 
achieve this requirement is expected to partially or completely abolish the formulation objectives 
behind solid dispersions. Using these predictions, it would be possible to select with higher 
certainty and more time and cost effective way the suitable carrier excipients that are more likely 
producing successful formulations.  
Solubility and miscibility are critical physical parameters in the formulation of solid dispersions 
(3). Quantitatively, solubility is the concentration of solute in a saturated solution at a certain 
temperature while qualitatively it can be defined as the spontaneous interaction of two or more 
compounds to form a homogenous molecular dispersion (3). On the other hand, miscibility is used 
as a term describing the mutual solubilities of the components of the solution in liquid-liquid 
systems (3). Based on this, solutions are classified as subsaturated, saturated and supersaturated 
depending on the concentration of the solute in the solution below, at or above the saturation limit 
at specified temperature respectively (81). The degree of saturation of the system is critically 
affecting the physical state of the drug in the solid dispersion. Systems with drug concentrations 
at or above the saturation limits are more likely subjected to physical stability problems like phase 
separation affecting the quality of the product (82). Thus, predicting the solubility of the drug in 
the polymeric carrier system is crucial as it gives an indication of the solubilisation limits of the 
carrier which in turn may affect the stability of the final formulation.    
1.3.1 Solubility parameter approach 
 The solubility parameter (δ) approach is one of the widely used prediction methods for the 
estimation of the solubility between the components of mixtures including polymer-drug blends 
(83, 84). This approach is based on the observation that the solubility of a polymer in organic 
solvents can be expressed directly by its cohesive properties which can be quantitatively 
expressed as the cohesive energy. The cohesive energy per unit volume is termed as the cohesive 
energy density. Hildebrand in 1936 proposed the square root of the cohesive energy density as a 
parameter to describe the behaviour of certain solvents. In 1949, this parameter was named as 
solubility parameter and given its known symbol (δ). Because the chemical structure of the 
polymer is largely the determinant of its solubility in different organic solvents, the similarity in 
the chemical structure of both compounds is in favour of solubility ‘like dissolves like’ (3). This 
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means that the solubility of the two components is in favour if their solubility parameters are 
similar. It should be mentioned that the solubility parameter of the polymer is defined as the 
square root of the cohesive energy density at room temperature in its amorphous state as shown 
in Equation 1.1.  
δ =   ………………... Equation 1.1 
where δ is the solubility parameter at 298 K in (J/cm3)1/2 or (MJ/m3)1/2 or MPa1/2, Ecoh is the 
cohesive energy (J/mol) and V is the molar volume (cm3. mol -1). It should be mentioned that the 
Ecoh is determined for low molecular weight liquids by calculating the closely related molar heat 
of evaporation (∆Hvap) at constant temperature as seen in Equation 1.2.   
Ecoh ≈ ΔHvap − RT………….……... Equation 1.2 
where R is representing gas constant and T is the absolute temperature. 
The group contribution method was derived by Dunkel (1928) who considered the Ecoh of low 
molecular weight compounds as additive property. The same approach was applied to the 
polymers by other researchers like Hayes (1961), Di Benedetto (1963), Hoftyzer and Van 
Krevelen (1970) and Fedors (1974). Depending on the method used for estimating the cohesive 
energy, the values obtained are different between authors. It was found that the solubility of many 
amorphous polymers and other liquids are not only dependent on the dispersion forces between 
structural units as stated by Hildebrand, but also dependent on polar interactions and hydrogen 
bonding of interacting groups. Thus, the refined cohesive energy can be formally expressed as:  
Ecoh = Ed + EP + Eh ……………..... Equation 1.3 
where Ed is dispersive forces contribution, EP is polar forces contribution and Eh is hydrogen 
bonding forces contribution. Equation 1.3 can be expressed in terms of the solubility parameter 
based on the three contributing components as follow: 
   δ2 = δd2 + δp2 + δh2……………..... Equation 1.4 
Hoftyzer and Van Krevelen method was widely used to calculate the solubility parameters of the 
drug and polymer blends using Equations 1.5-1.8. 
                   δ = δd2 + δp2+δh2……………..... Equation 1.5 
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                                                 δd = Ʃ Fdi  ……………..... Equation 1.6 
                                                 δp = Ʃ F2 pi  ……………..... Equation 1.7      
                                                δh =   Ʃ   ……………..... Equation 1.8      
where δ is solubility parameter (MJ/m3)½, Fdi is the dispersion component of the molar attraction 
constant (MJ/m3)½. mol-1, Fpi is the polar component of the molar attraction constant (MJ/m3). 
mol-1, Ehi is hydrogen bonding energy component J.mol-1 and V is molar volume cm3. mol -1.  The 
solubility parameters of the drug and other excipients are also calculated by Hoy group 
contribution method using Equations 1.9-1.11. 
δ = (Fi+ B)# ……………..... Equation 1.9      
δ = (Fi+ B/%)# ……………..... Equation 1.10      
n = 0.5/ΔT …………….....Equation 1.11     
where δ is total Solubility parameter (MJ/m3)½, Fi is molar attraction function (MJ/m3)½. mol-1, B 
is the base value (which is 277 in this case), n is the number of monomers per effective chain 
segment of the polymer, ∆T is Hoy correction for non-ideality for polymers and V is the molar 
volume cm3.mol -1.  
1.3.2 Melting point depression approach 
Melting point depression can also be used as an approach to investigate drug-polymer and 
polymer-polymer miscibilities as a preliminary step before solid dispersion preparation (85-87). 
This method is based on the fact that melting of compounds occurs at temperatures at which the 
chemical potential of the crystalline solid is equal to that of the molten state. If the drug and the 
polymer are miscible, the chemical potential of the mixture is expected to be less than that of pure 
amorphous form of the drug. In this case, the depression in melting temperatures of different 
drugs in the same polymer gives an indication of the miscibility of these drugs in that polymer 
(79, 85, 88). Thermodynamically, solubility can be an endothermic, athermic or exothermic event. 
Weak exothermic, athermic and endothermic mixing usually accompanied by small or no melting 
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point depressions. However, strong depressions are usually occurring with strong exothermic 
mixing. For immiscible drug-carrier blends, no depression in the onset of melting for the drug is 
expected to be observed as the melting of the drug is not affected by the presence or the absence 
of the carrier (79).  Depression of melting can be used to construct plots of Gibbs of free energy 
of mixing and phase diagrams for drug-polymer mixtures using the experimental data from DSC 
and some theoretical equations derived from Flory-Huggins (F-H) interaction theory (77, 78, 89). 
F-H theory is widely used to investigate polymer-polymer miscibility and polymer-solvent 
miscibility as a modification of the original solution theory. By considering the amorphous form 
of drugs as a solvent, F-H lattice theory provides a rational explanation for the thermodynamics 
of drug-polymer solubility (85). Based on this theory, the ∆Gmix can be expressed in Equations 
1.12-1.13 (77, 85, 87): 
ΔGmix = ΔHmix + TΔSmix ………………………………… Equation 1.12 
ΔGmix = RT (ɸdrug ln ɸdrug + (ɸpolymer/m) lnɸpolymer + χdrug-polymer ɸdrug ɸpolymer … Equation 1.13     
where ∆Gmix is the Gibbs free energy of mixing, ΔHmix is the enthalpy of mixing, T is the absolute 
temperature, ΔSmix is the entropy of mixing, R is the gas constant, ɸdrug is the drug volume fraction, 
ɸpolymer is the polymer volume fraction, m is the ratio of the volume of polymer chain to the volume 
of the drug molecule and χdrug-polymer is F-H drug-polymer interaction parameter. 
Depression of melting due to the presence of the polymer can be correlated to interaction 
parameter (χ) at specified temperature using the DSC data and Equation 1.14 (77-79, 85, 87, 88): 
(1/Tm depressed) - (1/Tm pure) = R/ΔHf [lnɸdrug +(ɸpolymer/m) lnɸpolymer + χdrug-polymer ɸ2polymer]… 
Equation 1.14 
where Tm depressed is the depressed melting temperature of the drug due to the presence of the 
polymer (sometimes expressed as the onset or offset of the melting peak), Tm pure is the melting 
temperature of pure drug and ∆Hf is the melting enthalpy of pure drug. The interaction parameter 
(χdrug-polymer) can be obtained by plotting (1/Tm depressed) - (1/Tm pure) * (∆Hf /-R) -  ln ɸdrug - (1- 1/m) 
ɸpolymer versus ɸ2polymer using the DSC results of the drug-polymer binary physical mixtures with 
high drug loadings (more than 70% w/w drug loading) and slow heating rates (0.5-1 ̊C/min). The 
slope of the line is the interaction parameter at that temperature. The drug-polymer interaction 
parameter (χ) at room temperature can also be calculated from the solubility parameter using 
Equation 1.15 (77, 78, 85, 88): 
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χdrug-polymer = (V0/RT) (δdrug - δpolymer)2…………….....Equation 1.15      
where V0 is representing the volume of the lattice site, δdrug and δpolymer are the solubility 
parameters of the API and the polymer respectively. In order to calculate the drug-polymer 
interaction parameter (χ) at any temperature, the interaction parameters determined from the 
previous two approaches (solubility parameter using Equation 1.15 and melting point 
depression using Equation 1.14) can be substituted in the simplified Equation 1.16 to generate 
a series of interaction parameters at different temperatures (77, 85). 
χdrug-polymer = A +(B/T) …………….....Equation 1.16      
where A and B are values of the temperature-independent term (entropic contribution) and the 
value of the temperature dependent term (enthalpic contribution), respectively. Plots ∆Gmix/RT 
versus volume fraction of the drug (ɸdrug) using the calculated interaction parameters at different 
temperatures can be used as an indication about drug-polymer miscibility as a function of drug 
volume fraction. Negative values of ∆Gmix/RT give an indication about drug-polymer miscibility 
while positive values indicate immiscibility of the binary system. This can be further extended to 
constructing drug-polymer phase diagram using the calculated interaction parameters at different 
temperatures and drug concentrations as illustrated in Figure 1.10.    
 
Figure 1.10: Typical phase diagram for binary drug-polymer blends as a function of temperature 
and composition; adapted from reference (90) 
The phase diagram can provide predictions about the stability of drug-polymer mixtures with 
changes in temperature and composition during processing and storage. The binodal curve 
represents the phase boundary. Outside it, the system exists as a single phase molecularly miscible 
system in all compositions. This boundary can be determined using Equations 1.13 and 1.16 and 
depends on the favourable mixing based on ∆Gmix (negative value). In this case, even if the mixing 
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is not achieved at ambient temperature, the system can be molecularly dispersed at elevated 
temperature and/or at lower drug loading due to the changes in the thermodynamics of the system 
(77, 78, 85, 90). On the other hand, the spinodal boundary is determined by setting the second 
derivative of ∆Gmix equal to zero as shown in Equation 1.17 (77, 78, 85, 90). 
(1/ ɸdrug) + (1/ ɸpolymer) +2 χdrug-polymer = 0 …………….....Equation 1.17     
The system below the spinodal boundary is unstable leading to phase separation without any 
significant energy barriers. Despite the thermodynamically unfavourable mixing below the 
spinodal curve, the system may be still kinetically stabilised ‘trapped’ by the reduced molecular 
mobility caused by the glassy nature of the polymer (77, 78, 85). The zone between the spinodal 
and binodal curves representing the metastability zone. In the metastable region, the system is 
predicted to form drug-rich and polymer-rich domains without drug recrystallisation (77, 78, 85). 
1.4 Thermodynamics of solid dispersions  
1.4.1 Physical stability of solid dispersions 
Despite the valuable advantages of solid dispersions for improving the solubility and/or 
dissolution properties of poorly soluble drugs over the last 40 years, only a few number of these 
preparations have been translated into marketed products (27, 91-93). The most important reason 
behind this is their physical instability which may lead to drug recrystallisation resulting in a 
reduction in the dissolution profiles and bioavailability (27, 91-93). In order to fully understand 
the physical stability of solid dispersions, it is important to explain the key factors that affect 
physical behaviour of these preparations including glass transition temperature, molecular 
mobility, phase separation of the dispersed drug and/or the components of the carrier.  
1.4.1.1 Glass transition (Tg)  
Glass transition (Tg) is a physical property characteristic of amorphous materials which can be 
defined as a range of temperature degrees over which the material converts from its solid ‘glassy’ 
state to its liquid ‘rubbery’ state and vice versa. Typically, single phase amorphous system has 
single glass transition temperature (24). Unlike melting which is first order phase transition (the 
derivative of change in the free energy ∆G with respect to temperature is not equal to zero), the 
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Tg is a second order phase transition in which the second derivative of change in the free energy 
∆G with respect to temperature is not equal to zero while the first derivative is equal to zero. 
Using DSC, the Tg is seen as a step reflecting a transition in the heat capacity (∆Cp) during the 
heating or cooling cycles.  Figure 1.11 explains the possible pathways through which a crystalline 
material exists in a liquid state above melting converts into a solid state with crystalline or glassy 
properties passing through crystallisation or glass transition events respectively. When the cooling 
rate is slow enough, crystallisation process occurs at a temperature corresponding to melting point 
(assuming no supercooling happens). The formation of crystallised material (bottom line of 
Figure 1.11) shows a dramatic reduction in the thermodynamic parameters of the system (free 
volume ‘the difference between the total volume and the volume occupied by the individual 
molecules of the system’, enthalpy and entropy). The reduction in the free volume is attributed to 
the high order of arrangement of the molecules in the crystal lattice. However, when the cooling 
rate is too rapid for the crystallisation to occur, the liquid enters the super-cooled liquid ‘rubbery’ 
state without any discontinuity in the aforementioned thermodynamic parameters. Further cooling 
the rubbery state will lead to the glass transition step in which there is a loss of the kinetic 
equilibrium and the material becomes immobile as it acquires the characteristics of glass solid 
with a decrease the molecular mobility in a discontinuous manner. The Tg is a kinetic process 
affected by the cooling rate and therefore lower Tg values are expected for slow cooling rates as 
illustrated in Figure 1.11 (94, 95). It should be mentioned that the average time scale of molecular 
motion of < 100 s and viscosity between 10-3 and 1012 Pa.s for the rubbery state while for the 
glassy state, the mobility is hugely reduced with an increase in the viscosity >  1012 Pa.s (95-97).  
 
Figure 1.11: Schematic representation of glass transition (Tg) and comparison between the 
behaviours of crystalline and glass forming systems; adapted from reference (94) 
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The Tg of amorphous solid dispersion mixtures can be estimated using different theoretical and 
empirical equations like Fox and Gordon-Taylor (G-T) equations as a function of mixture 
composition. Compared to G-T equation, Fox equation assumes that the components of the 
amorphous blend have the same density and does not include the changes in thermal expansivity 
of the Tg in its expression. The two equations for binary drug-polymer mixture can be described 
in Equations 1.18-1.20 (24, 98): 
Fox equation:  
1/Tg mix =(wdrug/Tg drug) + (wpolymer/Tg polymer) …………….....Equation 1.18     
G-T equation:  
Tg mix = (wdrug × Tg drug) + (Kwpolymer × Tg polymer)/( wdrug + Kwpolymer) ………...Equation 1.19     
where Tg mix is the predicted Tg of drug-polymer blend, wdrug is the weight fraction of the drug, Tg 
drug is the Tg of the drug, wpolymer is the weight fraction of the polymer, Tg polymer is the Tg of the 
polymer, and K is a constant derived from the true densities (ρdrug and ρpolymer) and the change in 
thermal expansivity of Tg (∆αdrug and ∆αpolymer) of the two components of the mixture (24, 98). 
K = (ρdrug × Δαpolymer)/(ρpolymer × Δαdrug) …………….....Equation 1.20    
It should be mentioned that G-T equation assumes ideal volume additivity of both constituents 
and no specific interaction between them ‘ideal mixing behaviour’(24). Experimentally, ideal 
mixing between the different components of solid dispersions is expected to give comparable 
results to the predicted results estimated using G-T equation. However, positive or negative 
deviations from the predicted Tg values reflects non-ideality of mixing. Positive deviation results 
from the interaction between the components of the mixture. On the other hand, the diffusion of 
the small molecular weight drug inside the polymer leading to a higher free volume than the 
anticipated one in G-T equation and/or the weaker drug-polymer interactions compared to the 
original drug-drug interactions causes the negative deviation (24, 99).  
1.4.1.2 Molecular mobility 
An essential parameter that governs the physical stability of any molecular level solid dispersion 
is the molecular mobility of the drug in the dispersion (97, 100). It was reported that the overall 
molecular mobility of molecularly dispersed drug is the result of different kinds of molecular 
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rearrangements including global mobility (α-relaxation), local mobility (β-relaxation) and 
secondary relaxations due to self-association through hydrogen bonding depending on the storage 
temperature and the Tg temperature of the system. α-relaxation has been thought as an important 
factor that determines the physical stability of molecularly dispersed drugs in solid dispersions 
(96).  
Molecular mobility for amorphous systems is usually expressed in terms of the relaxation time 
(τ) and it may be caused by several processes including enthalpic relaxation, volume relaxation, 
dielectric relaxation and or spin-lattice relaxation (100-102). Molecular mobility as the reciprocal 
of relaxation time can be determined using a variety of methods like MTDSC, dielectric relaxation 
spectroscopy, and solid-state NMR spectroscopy. Using MTDSC, the relaxation time can be 
estimated using some empirical equations like the empirical Kohlrausch-William-Watts, Adam-
Gibbs and Vogel-Tammann-Fulcher equations (103, 104).  
1.4.2 Factors affecting physical stability of solid dispersions 
Physical instability of molecular level amorphous solid dispersions is most commonly happened 
above rather than below the Tg. This second order phase transition is usually considered as a 
benchmark for monitoring the stability of these systems. As a general rule, amorphous dispersions 
stored at temperatures 50 C̊ below their Tg are mostly considered as physically stable with 
negligible crystallisation tendency (24). Accordingly, the effect of storage temperature relative to 
Tg is recognised as important parameter and its impacts are complex because it can control the 
physical stability in different pathways with variable outcomes. As an example, storing 
amorphous solid dispersions at low temperature can decrease the recrystallisation rate of 
molecularly dispersed drug due to the increased viscosity of the dispersing phase leading to 
reduction in the mobility. At the same time, this may support the formation of new nucleation 
sites leading to more crystal growth (105). Taking into consideration that storing the samples at 
lower temperatures reduces the thermodynamic solubility of the dispersed drug in the carrier (24). 
Thus, and depending on the observed growth, it can be concluded which pathway is the dominant; 
the diffusion or the thermodynamic and based on that the storing temperature may have a positive 
or negative impacts on the physical stability of the system under investigation (105). 
It was observed that the presence of other excipients can affect the magnitude of α-relaxation 
process significantly. Global mobility was found to be directly proportional to the extent of the 
plasticising activity of the inactive components of the formulation. Water is one of the frequently 
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included excipients in the formulation either intentionally as a component of the preparation or 
accidently due to the entrapped moisture during processing and/or storage. In addition, it has low 
Tg and strong plasticising activity, therefore, it is shown to play a critical role in increasing the 
global mobility of the system and enhancing drug crystallisation from its dispersion (106, 107). 
In other words, the increased hygroscopicity of the formulation due to moisture uptake leads to 
increase the chemical potential of the dispersed drug and increase the degree of supersaturation 
and the thermodynamic driving force of crystallisation (108-110). On the other hand, some 
polymers with antiplasticising activity and/or hydrogen bonding ability help to maintain the 
physical stability of the dispersion and inhibit the recrystallisation process (111, 112).   
For solid dispersions containing semicrystalline excipients, physical stability studies followed 
different approach compared to molecular level amorphous solid dispersions. For these 
heterogeneous systems, monitoring physical stability usually conducted by investigating 
parameters like the stability of crystalline relative to amorphous domains and the possibility of 
crystal thickening. In addition, the tendency of these complex mixtures to undergo phase 
separation of the molecularly dispersed drug in the amorphous fraction and its relationship with 
the percentage of drug loading and the effect of external factors like storage temperature and 
relative humidity on the whole system. These studies also provide information about the physical 
stability changes in the carrier like the increase in the crystalline fraction of the semicrystalline 
carrier at the expense of the amorphous domain which is responsible about the solubilisation of 
poorly water-soluble drugs on the molecular level (48, 113-117).  
1.4.3 Phase separation 
Physical instability of solid dispersions generally leads to phase separation of their individual 
components resulting in a partial or complete lack of the dissolution enhancement (3, 24). The 
concept of phase separation has been used to describe different cases related to solid dispersions. 
It has been used to indicate the conversion of the active pharmaceuticals from molecularly 
dispersed status to separated amorphous domains or crystalline fractions (3, 24). In this case, the 
phase separation is dependent on the inherent recrystallisation tendency of the drug, Tg of the 
system relative to storage temperature, viscosity of the dispersing phase, the presence or absence 
of interaction between the dissolved drug and the carrier, storage temperature and relative 
humidity (3, 24). In addition, phase separation sometimes used to describe the miscibility between 
immiscible/partially miscible polymeric blend as illustrated in Figure 1.12. These multiphasic 
matrices were recently demonstrated their superiority to solubilise, stabilise the drug as a 
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molecularly dispersed multicompartmental system with more resistance to mechanical stress 
caused by further formulation processing (73). Phase separation in both meanings is discussed in 
details in Chapter 4 as a formulation strategy for improving the solubility of poorly water soluble 
drugs.  
 
Figure 1.12: Schematic representation of intentionally phase separated drug loaded polymeric blend; 
adapted from reference (73) 
1.4.4 Approaches developed to improve physical stability of solid 
dispersions 
Several strategies have been adapted to reduce the molecular mobility of dispersed drugs to 
improve their physical stability in their dispersion. The use of polymeric carriers with higher Tg 
relative to storage temperature can help to restrict the mobility of molecularly solubilised drugs 
by antiplasticising effect. This can lead to an increase in the viscosity of the matrix and reduction 
in the diffusion of the drug to form aggregates as a preliminary step that leads to the formation of 
drug crystal lattice (118-120). This approach has been found to be unreliable as the inherent 
recrystallisation tendency of the drug plays a critical role in the devitrification process in addition 
to the difference between the Tg of the system and the temperature of storage (24, 121, 122). Thus, 
another mechanism that can be used to stabilise the solubilised drug by effective interaction with 
the carrier component(s) through ionic, hydrogen, dipole-dipole and ion-dipole interaction have 
been proven as a successful approach to improve the miscibility and stability of solid dispersions 
(111, 123, 124). It should be mentioned that the majority of polymers used in the fabrication of 
solid dispersions have structural sites to interact with drugs’ molecules in the dispersions. 
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However, there are some examples of stable solid dispersions in which there is no specific 
interactions were detected between the dispersed drug and the carrier (120, 125).  
Physical stability of the molecularly dispersed drug is a critical factor not only in the solid state 
during the storage period of the shelf life of the product which may be affected by factors like 
relative humidity and temperature, but also after dissolution in the aqueous dissolution medium 
at the site of dissolution and absorption. The enhanced apparent solubility and dissolution rates 
by solid dispersions generate thermodynamically metastable supersaturated solutions which may 
cause the precipitation of the drug in the more stable crystalline form. Recrystallisation of the 
drug at the site of absorption is most likely will reduce the concentration of the drug available for 
absorption abolishing the gained advantage of dissolution enhancement via the solid dispersion 
approach. Drug recrystallisation can happen either before the liberation of the drug from the 
matrix after contact with the dissolution medium or after achieving supersaturated concentrations 
under non-sink conditions (126-128). It should be mentioned that the recrystallisation of poorly 
water soluble drugs from their supersaturated solutions is dependent on the drug loading 
percentage and the type of the polymer included in the formulation (129).   
In order to physically stabilise the drug in its supersaturated solution, several approaches have 
been used to inhibit drug recrystallisation through the use of different excipients like polymers, 
surfactants and cyclodextrins. Drugs recrystallisation involves several stages: formation of 
supersaturation, nucleation (formation of stable nuclei) and crystal growth. The formation of 
stable nuclei is the result of diffusion of drug molecules in the supersaturated state and collide to 
each other to form stable and effective nucleating cluster to start the growth process. The diffusion 
rate is an important parameter that controls the nucleation process (130, 131). Materials used to 
maintain supersaturation concentrations functions by different mechanisms that can inhibit the 
nucleation and/or crystal growth including (130, 131): 
1. Changing the properties of the dissolution medium like saturated solubility and surface 
tension. 
2. Altering crystal-medium adsorption layer interface. 
3. Blocking crystal growth by selective adsorption to the interface of the crystal. 
4. Disrupting surface growth layers by adsorption between these layers. 
5. Adsorption into rough growth surfaces making them smooth and flat. 
6. Changing crystal face surface energy which may alter the level of solvation. 
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It was found that polymers like PVP, PEG 400 and HPMC act as growth inhibitors by different 
mechanisms like hydrogen bonding, adsorption to the crystal and accumulating at the bulk crystal 
interface thus providing resistance to the diffusion of the molecules. Also, HPMC was found to 
act as crystal habit modifier by having different crystal faces adsorption capacities. The extent of 
adsorption is affected by the hydrogen bonding functional groups exposed at each face of the 
growing crystal (130-132). Furthermore, some polymers can prevent recrystallisation of certain 
drugs by increasing their saturated solubility and reduction in the level of supersaturation (133). 
Surfactants also have been shown to decrease the tendency to recrystallisation by micelles 
solubilisation and alteration the surface tension at the bulk crystal interface. They can also modify 
the habit and the size distribution of recrystallised materials (133-135). Additionally, the presence 
of surfactants during the recrystallisation of drugs from supersaturated solutions was shown to be 
the preferentially target the process into certain polymorphic forms by inhibiting the polymorphic 
transformation from metastable to stable polymorphic forms of drugs (136). It was reported that 
polymorph IV of celecoxib was generated from precipitated drug suspension in the presence of 
HPMC and Polysorbate 80. The formation of this polymorphic form was explained by changing 
in bulk diffusivity of drug molecules (bulk viscosity), surface tension and supersaturation induced 
by the presence of the two excipients. This leads to formulation controlled crystallisation 
(concentration and ratio dependent) which is thought as very important subject in pharmaceutical 
industry research investigations (137). Cyclodextrins also shown to play a role in inhibiting 
nucleation by the formation of inclusion complexes resulting in an enhancement in their 
solubility. These group of inclusion compounds were also reported to retard nucleation by non-
complexation mechanisms similar to that of the aforementioned for polymers (131). It should be 
mentioned that the existence of cyclodextrins in drugs’ supersaturated solutions can play a 
significant role in polymorphic transformation and crystal habit modifications (138, 139). 
1.4.5 Other drawbacks of solid dispersions 
 Solid dispersions with their valuable advantages of improving the apparent solubility and 
dissolution rate of poorly water soluble drugs have some drawbacks reflected directly on the 
limited number of marketed products (27, 91-93). These problems are most importantly related 
to the physical stability of the dispersed drug in the carrier matrix during processing, storage and 
dissolution at the site of absorption (discussed in the previous section). Besides, impacts of 
thermal degradation, residual of solvents, downstream processing during and after solid 
dispersions formulation into their final dosage forms and ability to scale up to manufacturing 
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levels are also critical factors in the development of these preparations into marketed medicines 
(18, 24, 32). 
1.4.5.1 Impacts of thermal degradation  
Solid dispersions can be prepared by different methods including melting, solvent or melting-
solvent methods. Depending on the method of preparation, there are some problems related to 
processing that hinder these preparations from reaching the marketing stage as safe, effective and 
convenient products. Preparation by melting methods sometimes involves the use of high 
temperatures to thermally incorporate the drug in the carrier(s) which may cause the thermal 
degradation of one or all the constituents of the mixture resulting from high shear forces and high 
processing temperatures (139). It was found that partially hydrolysed PVA polymers are more 
susceptible to thermo-mechanical degradation compared to fully hydrolysed PVA grades when 
exposed to multiple extrusions at an elevated temperature above 200 ̊C. The degradation was 
attributed to the presence of the vinyl acetate group in their structures (140). In addition, it was 
reported that spray drying can cause the degradation of drugs during the rapid drying from their 
slurries affecting the quality of the final product (141). Furthermore, some excipients like PEG 
and Tween 80 were reported to be liable to random chain scission resulting in a reduction in the 
chain length (molecular weight) due to thermal oxidative degradation (142-145). For PEG 
polymers, members of low molecular weights are more susceptible to degradation compared to 
higher molecular grades (144). The chemical stability of the excipients during processing and 
storage is an important parameter to be investigated as it may affect the quality and safety of the 
product and determine the suitable processing and storing conditions required to keep the 
formulation within the design requirements. The details of PEG and Tween 80 degradation is 
studied in details in Chapter 6.   
1.4.5.2 Impacts of residual solvents  
Preparation of solid dispersion by solvent evaporation methods involves solubilisation of the 
components in an organic solvent followed by evaporation of the solvent using a variety of 
techniques. The problems facing this approach are related to the entrapment of certain quantity of 
the organic solvents in the dispersions which might affect their suitability for therapeutic 
applications. Also, since organic solvents have reduced Tg temperatures, their entrapment in solid 
dispersions may have a plasticising effect which may criticise the physical stability of molecularly 
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dispersed drugs in the final products during storage. Thus, efficient solvent removal is one of the 
essential requirements for designing high-quality products based on solid dispersion approach 
(32, 146, 147).   
1.4.5.3 Impact of downstream processing  
Solid dispersions prepared via different processing methods are mostly intermediate products that 
need further processing to reach the final product stage (148-150). According to pharmacopoeias, 
each dosage form should meet certain quality control and compendial requirements to be 
approved for marketing as a commercial medicine. As an example, tablets should have certain 
physical specifications including weight, weight variation, drug content uniformity, thickness, 
hardness, disintegration time and dissolution profile in addition to the general features like 
diameter, size, shape and colour (151). Adding to that the difficulty to give the dosage form its 
desired functionality like orally disintegrating and floating dosage forms using conventional 
fabrication methods of solid dispersions (148, 149, 151, 152). This makes the production of solid 
dispersions as final dosage forms in a single processing technique is challenging process and not 
easy to be achieved for the vast majority of formulations reported in the literature. The problems 
encountered during the attempts to produce commercially successful dosage forms like tablets 
and capsules for clinical applications based on solid dispersions involve many difficulties like 
milling, sifting, poor flow and mixing properties, poor compressibility characteristics, and 
stability problems (18). It was reported that milling can destabilise supersaturated amorphous 
solid dispersion produced by hot melt extrusion by increasing the molecular mobility leading to 
phase separation (153). Also,  it was found that compression can increase the extent of 
crystallisation of amorphous indomethacin due to increase in the molecular mobility caused by 
mechanical deformation. The increased tendency of crystallisation was caused by the significant 
elevation of the heat of crystallisation (∆Hc) and the reduced onset of crystallisation (154). It was 
also reported that the force of compression induced the phase separation of naproxen-PVP K25 
and itraconazole-soluplus amorphous solid dispersions by plastic deformation that causes 
weakening and/or disruption of intermolecular hydrogen bonding between drug and polymer 
(155, 156). However, other study showed that compression force at and above a critical value 
(250 MPa) significantly affects the intrinsic dissolution rate (IDR) (defined as drug release per 
accessible area mg/cm2) of amorphous indomethacin compacts leading to significant change in 
the corresponding IDR of the drug containing solid dispersion. The reduction in the IDR was 
attributed to the change in the surface available for dissolution (157). Interestingly, compression 
force and dwell time of compression were found to improve the miscibility of supersaturated 
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phase separated amorphous solid dispersions prepared by spray drying. The improved miscibility 
of the double Tg phase system by the application of pressure is explained by the reduction in the 
drug-rich domain size of about 30 nm to lower size caused by stressful deformation of glassy 
polymer and glassy solid dispersion causing remixing of the phases and the formation of the more 
homogenous system (158).  
1.5 Manufacturing of solid dispersions  
Solid dispersions are prepared by three major methods namely melting (fusion), solvent 
evaporation and melting solvent methods. The first two methods are the most commonly used 
techniques for the preparation of solid dispersions (32). In thermal processing techniques like hot 
melt extrusion and injection moulding, the active pharmaceuticals and other formulation 
excipients are melted/softened and mixed at a temperature above the lowest melting/Tg of all or 
some ingredients of the mixture. After melting/softening and blending at elevated temperature, 
the melt is then cooled to the solid state using a variety of cooling techniques (32). Solvent 
evaporation can be achieved by using different methods like freeze drying  (159), rotary 
evaporation (160), spray drying (161), electrospinning (162), electrospraying (163) and 
supercritical fluid (SCF) process (164). Solid dispersions prepared using solvent evaporation 
methods by dissolving the drug and the carrier in an organic solvent (or a mixture of solvents) 
followed by the evaporation of the solvent (32). The quality of the solid dispersion prepared by 
this method is highly affected by the solvent system used and its removal rate (165). Different 
organic solvents were used in this approach such as ethanol (166-168), chloroform (169), 
methanol/chloroform mixture (126) or ethanol/dichloromethane mixture (170). The major 
advantage of this method over thermal processing techniques is the avoidance of subjecting the 
drug to thermal degradation especially for drugs that are sensitive to heat (171). However, 
complete solvent removal from the final products and the environmental issues caused by the use 
of large quantities of organic solvents is often problematic (165). This study focused on the use 
of thermal based hot melt extrusion in conjunction of injection moulding (HME-IM) and fused 
deposition modelling (FDM) 3D printing methods for preparing solid dispersions of poorly water 
soluble drugs.  
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1.5.1 Hot melt extrusion (HME) 
HME is a highly recognised technique in the fabrication of solid dispersions based formulations 
with high scalability and diversity of pharmaceutical applications. This method which is primarily 
used in plastic, rubber and food industries was first introduced in the early 1930s and then applied 
in the pharmaceutical field at the beginning of 1970s (30, 32, 172). HME has many advantages 
compared to other solid dispersions processing methods. In addition to improving the 
bioavailability of poorly water-soluble drugs via molecularly dispersing poorly soluble drugs in 
hydrophilic carriers, HME functions as a safe and environmentally friendly process that can 
exclude any organic solvents during preparation (30). Also, HME is anhydrous method thus 
aqueous hydrolytic pathway can be eliminated which may affect the integrity of the active 
ingredients (173). Furthermore, using HME, it can be possible to overcome the compressibility 
problems of poorly compactable drugs because dosage forms of these drugs can be made in 
different shapes and sizes using additional geometry designing techniques (173, 174). It should 
be mentioned that dosage forms produced by this method show a higher degree of content 
uniformity for low dose drugs compared to other methods of pharmaceutical products formulation 
(175). Depending on the processing temperature and residence time, it can be possible to load 
higher percentages of drug contents in solid dispersions compared to other methods (173). HME 
combined with injection moulding acts as a continuous process with minimum processing steps 
and high efficiency which means that it is time-consuming because it excludes the required time 
for drying when solvents are involved during the formulation (176). Due to the flexibility of using 
a variety of excipients and mixing proportions, this technique can be used to produce dosage 
forms with controlled or immediate release, floating, fast dissolving formulations (tablets, 
capsules, films, pellets and implants). These formulations can be utilised to deliver a variety of 
drugs through different sites like oral, transmucosal, transdermal and implantation routes of 
administration (32, 173, 177). 
There are two types of HME processes based on the addition of solvents to the mixture before 
the extrusion process: wet and dry HME processes. Wet HME involves the addition of certain 
solvent before processing to improve the quality of the product due to the softening and 
plasticising advantages of the added solvent (178). This process is also used to minimise the heat 
employed during extrusion to avoid the degradation of the components of the formulation. The 
dry HME process is the most commonly used method without the incorporation of any solvent 
(green process) and the extrusion process is entirely achieved by the use of heat (179). 
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1.5.1.1 Types of extruders 
Hot-melt extrudates are generally produced by two types of machines namely screw extruders 
and ram extruders. The difference between these two kinds of equipment is that the former 
contains a screw rotating in a heated barrel while the latter has a ram or piston capable of 
generating high pressure to pump the extrudate into the die (179). The main disadvantage of ram 
extrusion is the limited melting capacity which results in a poor thermal uniformity in all portions 
of the extrudate. On the other hand, high shearing stress and uniform mixing can be achieved by 
using screw extruder. Screw extruders are composed of three portions including a part for 
transport and mixing of the fed materials, a mould for forming, and downstream auxiliary 
equipment for solidification, milling and collection of the finished products. These types of 
extruders have a feeding hopper, heating barrel with controlled temperature, rotating screw, die, 
and heating and cooling systems. Also, the equipment may be provided with other parts like mass 
flow feeder to control the feeding rate, analytical devices to investigate the properties of the 
extrudates, liquid and solid side stuffers, vacuum pumps, pelletizers, and others (179).     
There are two types of screw extruders: single and twin screw extruders depending on the number 
of screws contained within the barrel (Figure 1.13 A and B). The most commonly used is the 
single screw extruder in which single screw ‘with various dimensions depending on the extruder’ 
rotating within the barrel for the feeding, mixing, melting and pumping of the extrudates. Single 
screw extruders are either flood fed or starve fed and most commonly they are of the flood feed 
type in which the rate of output can be controlled by the hopper over the feed throat and the speed 
of screw rotation. Melting of the fed materials can be brought about by the energy of the heaters 
and the shear caused by the screw. At the end of the process, the extrudates are produced by 
pumping the melted mixture into the die (178).  
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Figure 1.13: Types of hot melt extruders; A and B are single and twin screw extruders; C and D are 
the co-rotating and the counter rotating types; adapted from reference (30) 
There are two types of twin extruders depending on the design of the screws contained within the 
extruder: co-rotating and counter-rotating twin extruders (Figure 1.13 C and D). The second one 
is used when very high stress is needed, but they have several drawbacks like the potential 
entrapment of air, excessive pressure generation and low maximum screw speed and output. On 
the contrast, the co-rotating twin extruders can produce higher output rates because the rotation 
of the screws is higher than that of the counter-rotating type. In addition, they exhibit good mixing 
and mass transport characteristics. Furthermore, the wearing of the barrel and the screws is found 
to be lower than that of the other type. Twin screw extruders are further classified into non-
intermeshing and fully intermeshing where the latter is the most commonly used type because it 
provides self-wiping function thus preventing stasis of the soft mass which may lead to 
degradation (179). Twin-screw extruders may offer some advantages over the single-screw type 
involving including easier materials feeding, better dispersing abilities, substances processed are 
less subjected to overheating and shorter processing time. However, this type may be considered 
as more complicated compared to single screw extruders and more expensive (180). 
The geometry of the screws is variable and dependent on the individual equipment as seen in 
Figure 1.14.  
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Figure 1.14: General design of extruder screw; adapted from reference (181) 
The length and diameter are usually correlated and expressed as L/D ratio. It is important to note 
that the residence time within the extruder is also different and depends on many parameters such 
as the L/D ratio, the type of the device, the design of the screw(s) and the method of operation 
(179). Screws are designed to contain three distinct sections to perform the functions inside the 
barrel. The first region is responsible for the bulk transfer of the materials from the hopper to the 
barrel, while the next section is concerned to compression, softening and melting of the mixture. 
The melting of the feedstock is resulted by the energy generated from the shearing of the rotating 
screw (mechanical shearing stress) and the heating systems in the equipment by conduction 
(thermal stress). The diameter of the barrel cavity in the compression region is smaller than that 
of the conveying section to increase the pressure and remove any entrapped air bubbles within 
the melt. Finally, the metering section is responsible about the uniform pumping of the extrudate 
into the die which is attached to the end of the equipment. The final shape of the extrudates is 
determined by the shape and design of the dies. It should be mentioned that the size of the 
extrudate is not remained constant after cooling. This is attributed to the swelling in the cross-
section of the product resulting from the recovery or relaxation of the individual polymer chains 
after the deformation caused by screw rotation. This phenomenon is called die swell, and it 
depends on the polymer viscoelastic features. The extrudates are then solidified by different 
methods like using air, N2, stainless steel rolls or conveyors, or water (179).  
The main controlling parameters that can affect the extrusion process are the barrel temperature, 
feeding rate, screw rotation speed and motor load and the generated pressure of the molten mass. 
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Barrel temperature is usually set based on the melting or glass transition of the material(s) to be 
extruded. Increasing the feeding rate and screw speed affect the load applied to the motor and the 
pressure generated inside the barrel (182). It was reported that the design of extruder screws might 
significantly influence the efficiency of the extrusion process and the properties of the processed 
materials like crystallinity and dissolution properties (180, 183, 184). The residence time inside 
the extruder is also an important factor that affects the extrusion process (5 seconds to 10 minutes), 
and it depends on the L/D ratio, type of the extruder, screw design and how is it operating (179).  
1.5.1.2 Requirements of successful processing  
In order to produce successful extrudates, the following requirements should be considered (179, 
183, 185): 
1. Substances to be extruded should possess high levels of purity and safety and have the ability 
to melt/soften easily and solidify rapidly after the completion of the process. 
2. The mixture to be extruded should have good flowing characteristics, and this can be achieved 
by ensuring that the angle of the hopper is greater than the angle of repose of the mixture. 
This should be achieved to prevent the erratic flow of the feedstock in the extruder and the 
use of the force-feeding device can be used to fulfil this purpose. 
3. Efficient feedstock transfer is an important factor to maintain the pressure at the compression 
and metering zones. Failure to achieve uniform feeding may cause the surge phenomenon in 
which cyclical changes in the output rate, head pressure, and the quality of the product. 
4. The melting region should be within the temperature range 15-60 ˚C above the melting 
temperature of the semicrystalline polymer or the glass transition temperature (Tg) of the 
amorphous polymer. 
5. In order to obtain an efficient fusion processing, polymers having low melt viscosities and 
high thermal conductivities should be employed. 
6. Using screws with different designs may improve the melting process and also help to 
facilitate the transfer of feedstock through the extruder. 
7. Care should be taken to ensure the melting of all the solid matter to avoid the blockage of the 
extruder cavity and the formation of surge phenomenon. 
8. Excessive processing conditions can result in chain scission, depolymerisation or thermal 
degradation of the polymer. 
HME as a process should be carried out under certain conditions, and the selection of the proper 
conditions is dependent on many parameters including (179, 186): 
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1. The chemical stability and physical properties of the drug and the carrier. 
2. The viscosity of the melt. 
3. The molecular weight of the polymer. 
4. The Tg temperature of the amorphous polymers or the melting temperature (Tm) if it is 
semicrystalline.  
1.5.1.3 Suitable APIs candidates for HME 
Drugs liable to be processed by HME method should possess thermal, chemical and physical 
stability during and after the extrusion process (179). HME is widely used as thermal processing 
method to produce solid dispersions for water poorly soluble BCS class II drugs for the purpose 
of improving their bioavailability through dissolution enhancement (187). In addition, improving 
the dissolution BCS class IV drugs through fabrication as solid dispersions with hydrophilic 
excipients can be considered as an approach that may help to enhance their bioavailability (188-
190). Because HME is solvent-free processing technique, it is considered as a very attractive 
approach for drugs exhibiting hydrolysis pathways during processing using solvent systems like 
water or hydroalcoholic mixtures. It should be mentioned that some extruder systems can be 
operated in an oxygen-free processing environment making the technology suitable for drug 
candidates exhibiting oxidation during preparation (179). Furthermore, HME may offer an 
advantage of overcoming the poor compressibility problem of some drugs by extruding 
formulation mixtures followed by improving the compressibility through solid dispersions or 
directly moulding them into their final dosage form geometry (191, 192).   
1.5.1.4 Functional excipients used in HME solid dispersions  
In addition to the active ingredients, the following components may be used in the formulation of 
solid dispersions using HME (83, 179): 
1. Carriers 
2. Release-modifying agents 
3. Plasticisers  
4. Antioxidants 
5. Miscellaneous excipients like surfactants and bulking agents, 
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Carriers  
In order to disperse drugs as molecular level solid dispersions using HME, a wide range of carriers 
having different physicochemical properties have been used as single or blend of two or more 
carrier components. The main classes of excipients used as carriers used in solid dispersion 
approach with examples are illustrated in Table 1.1 (165). 
Table 1.1: Chemical classes of carriers with examples used as vehicles for solid dispersions 
preparation by HME; adapted from reference (165) 
Carrier type Examples 
Polymers PVP, Eudragit, PVA, PEG, Zein 
Sugars Sucrose, dextrose, mannitol 
Acids Citric, succinic 
Miscellaneous Pentaerythritol, urea, urethane, hydroxyalkyl xanthins, cyclodextrins 
 
These carriers are different in their melting and/or glass transition temperatures (Tg), crystallinity 
or amorphousness, water solubility, molecular weight, melt viscosity, thermoplasticity, and 
stability during and after processing. The following general characteristics were suggested as the 
general properties the carrier should possess (24, 29, 193): 
1. Suitable aqueous solubility and rapid intrinsic dissolution properties if the immediate 
release is required. 
2. Compatible and significantly interacting with the drug with complete miscibility to form 
single phase solid dispersion system. 
3. Can increase the water solubility/ dissolution rate of the dispersed drug. 
4. Ability to solubilise and stabilise the drug both in the solid and liquid states.  
5. Chemically, physically and thermally stable. 
6. Unable to form stable complexes that can retard the dissolution of the drug when fast 
dissolution is required. 
7. The carrier should melt/soften at low temperature and solidify very quickly to maintain 
the drug dispersed as molecular dispersion.   
8. Non-toxic within the pharmaceutical use limits. 
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9. It does not have any pharmacological activity. 
Release-modifying agents 
The release mechanism of drugs from solid dispersions designed for immediate release (to achieve 
maximum absorption) could be either drug or carrier dominant process. When the dispersions 
come into contact with aqueous medium, the carrier is either dissolves or swells to form a gel 
layer. In this case, the fraction of the drug in the solid dispersion relative to the carrier, ability of 
the drug to diffuse through the carrier layer and the layer viscosity are important factors that 
determine the carrier release controlling ability. However, if the drug is insoluble or sparingly 
soluble in the carrier’s gel layer, it can be released directly into the dissolution medium, and its 
release is dependent on the properties of the drug itself like polymorphic form, particle size and 
inherent solubility. These two scenarios are often happening simultaneously in which the release 
is partly drug controlled and the other part is carrier dominant through the formed gel layer (27, 
32). It was reported that the mechanism of release of felodipine from hydrophilic polymers like 
PEG and PVP is affected by many factors like the particle size of the drug, proportion of the drug, 
and the properties of the polymer in the dispersion. Concerning drug loading, carrier controlled 
release mechanism by diffusion through the polymer layer at low drug loadings and drug 
controlled release mechanism at high drug contents are the expected mechanisms of drug release 
from the different formulations (68).  
Due to the advances in this technology and its flexibility to process a wide range of excipients 
with different formulation functionalities, a recent trend of using this approach for controlling the 
release of drugs in addition to enhancing their solubility/dissolution characteristics (27). 
Controlling the release of APIs dispersed in solid dispersions offers a number of potential 
advantages over traditional formulations like achieving uniform and extended therapeutic effect, 
reducing dosing frequency, improving the bioavailability, reducing dose strength, reducing 
adverse effects and improve patients’ adherence to medications (66). Most commonly this 
formulation strategy can be achieved by a using a carrier with water insoluble or slowly dissolving 
properties instead of hydrophilic fast-dissolving ones. Depending on the characteristics of the 
prepared controlled release solid dispersions, the release mechanisms could be either diffusion, 
erosion or swelling followed by diffusion (32, 66). Examples of these release controlling agents 
are EC, HPMC, HPMC-AS, PVAc, chitosan, methacrylic acid copolymers and PEO which are 
widely used polymers to control the release of drugs (3, 194, 195).  It was reported that 
domperidone buccal films prepared by hot melt extrusion using PEO N750 and HPMC E5 LV 
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were successfully sustaining the release of the drug resulting in a 93.62 ± 2.84% drug release and 
63.36 ± 2.12% of drug permeation after 6 hours (196).  
Plasticisers  
Plasticisers are low molecular weight substances that have the ability to increase the free volume 
between the polymeric chains resulting in an increase in the entropy and mobility of the polymer 
chains and hence lowering the glass transition temperature (Tg) of plasticised polymers compared 
to non-plasticised ones. The increase in the mobility and entropy makes the polymer chains more 
flexible and the dispersion more diffusible which enables the dispersed drug to diffuse in higher 
rates depending on the concentration of the plasticiser (3, 187). The intermolecular forces of the 
secondary valence between the plasticiser and the polymer are responsible for this change in the 
characteristics of plasticised polymer (197). Examples of plasticising agents used in the process 
include triacetin, triethyl citrate, glycerol monostearate, diethyl phthalate, low molecular weight 
PEG, and surfactants (such as Tween 80, vitamin E TPGS and sodium docusate) (184, 198-201).  
 
HME as a thermal processing technique is characterised by high shearing stress and therefore the 
presence of plasticiser in the formulation is reported to make the extrusion process more efficient 
and at relatively lower processing temperature (202).  This potential advantage has an impact on 
reducing the thermal degradation of drugs and other formulation ingredients when processed at 
high temperatures (180). It was reported that plasticisers are effective in reducing the melt 
viscosity of viscous polymers resulting in extrudable mixtures at suitable processing 
temperatures. (203). They are also efficient in reducing the tensile strength of formulations 
prepared by hot melt extrusion compared to non-plasticised mixtures (203-205). 
 
Antioxidants 
Antioxidants are agents that protect the dispersed drug and any other formulation ingredient(s) 
from the oxidative degradation pathways (144). These agents are classified as preventive and 
chain-breaking antioxidants. The preventive antioxidants or oxygen scavengers act by preventing 
the initiation of a free radical chain reaction. Examples of such type are citric acid, ascorbic acid 
and EDTA. On the other hand, chain-breaking antioxidants act by blocking the oxidation reaction 
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and preventing their propagation. There are many examples of these agents like butylated 
hydroxyanisole, butylated hydroxytoluene, and vitamin E TPGS (179). 
It was reported that polymers like PEG and PEO undergo thermal oxidative degradation when 
exposed to processing at elevated temperatures in the presence of oxygen (145). The degradation 
was attributed to random chain scission resulting from the free radical attack which leads to the 
formation of different degradation products with low molecular weights and melting points. These 
polymers are susceptible to thermal degradation due to a reduction in the activation energy 
required for hydrogen abstraction caused by the high strains exists at the chain folds of their 
lamellar structure (145). Because these polymers are semicrystalline, the degradation is shown to 
occur in the amorphous domains rather than the crystalline fractions which indicates that highly 
crystalline fractions are less susceptible to this chemical instability problem. This is attributed to 
the oxygen diffusion to the amorphous fraction is significantly higher compared to the highly 
ordered crystalline domains (144). Also, Tween 80 was reported to be degraded by autoxidation 
and hydrolysis mechanisms. Thermally activated autoxidation leads to the formation of free 
radicals that cause the degradation (142, 143, 206).  
Vitamin E and its derivatives were found to possess antioxidant activity that can help to prevent 
the oxidation of drugs in their formulation. Vitamin E TPGS antioxidant micelles were found to 
solubilise and stabilise the new cytotoxic quinolinone derivatives against oxidation compared to 
cyclodextrins and other excipients contained in the formulations (207). It was also reported that 
vitamin E succinate and vitamin E TPGS are acting as stabilisers for PEO dispersions prepared 
by HME and their antioxidant activity is dependent on their hydrophilic character (144). 
1.5.2 Injection moulding (IM) 
Injection moulding (IM) is a rapid and versatile technique that introduced firstly in plastic 
manufacturing to produce objects with different geometries. This process entails the injection of 
the molten mass under specified conditions of temperature and pressure into a die with specific 
dimensions followed by cooling to achieve solidification then the final product is released from 
the mould (208). This technology was firstly patented to be used for the fabrication of medicines 
for oral administration by embedding drug(s) in a thermoplastic resinous material(s) suitable for 
injection moulding by Ciba-Geigy Corporation in 1969 (209). IM is also employed in the 
pharmaceutical field for the manufacturing of cosmetics, dosage form packaging and other 
advanced biomedical devices like scaffolds and microneedles (210, 211).  
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The advantages of using IM technology in the manufacturing of pharmaceutical products include: 
1. It is entirely automated and continuous process that can be scaled up easily (208). 
2. Dosage forms and other pharmaceutical devices can be produced in very defined shapes and 
geometries depending on the dimensions of the die used with higher composition uniformity 
(208).  
3. It is highly efficient and time-saving technology because it needs only short time to produce 
the dosages in their final forms (208). 
4. It excludes the use of solvents during processing which in turn lowers the cost of production 
and preserve the stability of drugs susceptible to degradation when manufactured in the 
presence of solvents (208). 
5. Processing conditions like the heat and pressure provide the opportunity to kill the microbes 
and help in making the dosage form auto-sterilised by IM compared to the other preparation 
techniques (212). 
6. IM produces solid dispersions with improved dissolution rates of poorly soluble drugs which 
may lead to enhancement in the bioavailability. It should be mentioned that improving drugs’ 
bioavailability may have a great impact on reducing drugs’ side effects by reducing the dose 
strength required to achieve the therapeutic effect (179, 213).  
7.  Using IM, the closure characteristics of capsules cap and body design can be modified to 
overcome problems associated with capsule manufacturing. Furthermore, IM can be used 
when dipping moulding is not suitable such as the case of manufacturing of capsules shells 
from non-gelatinous based sources (208). As it is known that some patients have certain 
restrictions regarding the use of gelatin shells due to dietary or religious reasons. The 
replacement of gelatin by other substances may exclude their manufacturing by dipping 
method, and IM can be an alternative method to produce gelatin free capsule shells (214, 
215).  
8. IM was used as a potential approach for the production of a variety of pharmaceutical 
products like matrix tablets (216-219), implants (220, 221) and intravaginal inserts (222). 
1.5.2.1 Injection moulding processing 
IM machines used for plastic and pharmaceutical application are consisting of two parts: 
plasticating/injecting unit and clamping unit with different configurations like horizontal or 
vertical (Figure 1.15). The plasticating/injecting unit has a design similar to that of the extruder 
where mixtures can be fed, mixed and melted by the actions of the rotating screw(s) and the 
heating systems present in the barrel of the system. The terminal portion of the IM machine is the 
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die which is generally composed of two halves that joined to form a 3D space that represents the 
final shape and size of the product. Moulds with many cavities can also be used to produce more 
than one unit in the same cycle. One of the two pieces of the mould is stationary, and the other is 
mobile to be easily coupled to form the closed die or separate to form the opened mould. The 
function of the clamping unit is to maintain the mould closed during the injection process. To 
achieve this purpose, the clamping force should be more than the injection force to prevent the 
opening of the mould during the injection process. After injection of the molten mixture, the 
mould is allowed to cool by the cooling system equipped with the device until the complete 
solidification of the matrix. The solidified product is then released by opening the die and ejected 
by pins present in the mobile half of the mould. Usually, IM process is a continuous process in 
which melting, injection, moulding, cooling and ejection of the final product are done in the same 
equipment. However, sometimes separated equipment can be used to achieve this purpose like 
the use of the extruder as the plasticating unit and then the matrix should be maintained at suitable 
conditions of temperature and transferred to another device where the injection process is to be 
completed (208). 
 
Figure 1.15: Injection moulding (IM) machine, adapted from reference (208) 
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1.5.2.2 Scale-up of solid dispersions to manufacturing level 
Despite the enormous number of research conducted in the field of solid dispersions for improving 
the dissolution properties of poorly water soluble drugs especially BCS class II drugs, only very 
little number of pharmaceutical products were commercialised as approved medicines (32, 177). 
The limited commercialisation of these preparations is partly attributed to problems in scaling up 
into marketed products. These problems may be related to the physical instability of the 
molecularly dispersed drug in the system, thermal degradation, solvent residuals and changes 
during downstream processing. Also, the fabrication technologies may also play a major role in 
the commercialisation process. Examples of products that have been commercialised using hot 
melt extrusion and its advanced version Meltrex™ include Cesamet® (nabilone -PVP), Rezulin® 
(troglitazone-HPMC), Kaletra® (Meltrex™) (lopinavir - ritonavir- PVPVA) tablets. This is an 
indication of scalability of this processing technique compared to other solvent evaporation 
methods such as electrospinning (32). 
1.5.3 Fused deposition modelling (FDM) 3D printing as a new method for 
fabricating solid dispersions   
The process of forming objects in 3D generally falls into one of three major categories; forming, 
subtractive and additive manufacturing. The first class involves reshaping the object into different 
geometry without subtraction or addition like vacuum moulding. Subtractive manufacturing is 
another class in which the unwanted parts of the objects can be removed using certain cutting tool 
which is one of the techniques used in 3D object production. 3D printing is an example of the 
additive manufacturing process in which rapid synthesis of precisely modelled objects can be 
achieved with the assistance of computer-based designs. 3D printing as advanced and rapidly 
growing technology can be performed using a variety of technologies, operation principles and 
materials as illustrated in Table 1.2 (223).   
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Table 1.2: Summary of 3D printing techniques, their operation principles and materials used in the 
fabrication of objects, adapted from reference (223) 
3D printing technology Principle of printing materials used 
Stereolithography apparatus (SLA) Optical polymer resin 
Digital light projection (DLP) Optical polymer resin 
Multijet /poly jet  Optical polymer resin 
Continuous liquid interface production (CLIP) Optical polymer resin 
Selective laser sintering (SLS) Optical polymer powder 
Selective heat sintering (SHS) chemical/ mechanical polymer powder 
Binder jetting chemical/ mechanical polymer powder 
Fused deposition modelling (FDM) Thermal polymer filament 
Laminated object manufacturing (LOM) Thermal polymer films 
 
Fused deposition modelling (FDM) or sometimes called fused filament fabrication (FFF) 3D 
printing was originally introduced during the 1980s as a branch of the additive manufacturing 
(AM) technology. FDM 3D printing is a thermal based 3D printing technique and has recently 
attracted the interest of researchers in many fields including pharmaceutical formulations design 
(224-226), food technology (227), and tissue engineering (228).  
1.5.3.1 FDM 3D printing process 
FDM 3D printing technology is an extension to the well-known hot melt extrusion (HME) or 
injection moulding (IM) techniques with the exception that the mould is not needed to get objects 
with specific and precise geometry (223, 229). The key element of FDM 3D printing is the 
extrusion process, which allows the thermally softened material strips to be deposited in a ‘writing’ 
mode. It principally works by converting a pre-designed software digital file coding the 3D object 
into a real object by adding a consecutive series of layers of molten or semi-liquid modelling 
material. Pre-made filaments with a specific diameter are needed for feeding into the printer. The 
modelling material in the printing state is pushed through a temperature-controlled 3D printing 
nozzle having a certain diameter at a pre-adjusted speed into a temperature controlled building 
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platform (Figure 1.16). Depending on the dimensions of the object, the printer nozzle moves in 
the X-Y plane in a particular pattern (determined by the shape of the object) creating the first layer. 
Successive layers are printed by moving either the nozzle or the platform through the Z plane 
with a distance equivalent to the layer thickness. The temperature of the platform is usually less 
than that of the extrusion head allowing the printed material to solidify between each layer. It 
should be mentioned that FDM printing can be performed using one or more printing heads 
depending on the design of the printer (223, 229).  
 
Figure 1.16: An illustration explains fused deposition modelling (FDM) 3D printing technology; 
adapted from reference (223) 
1.5.3.2 Pharmaceutical applications of FDM 3D printing technology  
An encouraging trend of using 3D printing in pharmaceutical manufacturing has been established 
by the approval of Spritam®, which is the first FDA-approved 3D printed oral dosage form. This 
first 3D printed commercial drug product used ZipDose® technology, which is a wet power 
deposition 3D printing method. There is a broad range of 3D printing technologies that operate 
via thermal or solvent evaporation mechanisms. Also, because FDM 3D printing is an advanced 
modification of HME and IM, it can be expected that the advantages mentioned for these two 
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techniques may apply to FDM 3D printing. The following advantages or applications can be 
achieved through the use of FDM 3D printing:    
1. Fabricating medicines as combination drug therapies for treating patients with diseases 
require multiple actives such as complex cardiovascular treatment regimens or for 
patients suffering from multiple diseases at the same time (230).    
2. Producing patients’ personalised medicines according to patients’ needs to improve the 
quality of treatment and consequently lead to higher percentages of patients’ adherence 
to medications (230). 
3. Using this technology with the advantages of flexibility in computer-aided design and the 
invention of multiple head 3D printers, it is possible to design products with different 
geometries and configurations. These products can be used to control the dissolution 
profiles of the incorporated drug(s) according to the desired effect (224). 
4. Reducing the cost of production by eliminating the unnecessary resources. This can be 
achieved by saving the cost of the quantities of the actives and the excipients over the 
need of the patients (231).    
5. This technology is fast for producing items such as prosthetics and implants compared to 
conventional methods which require milling, forging and long delivery time (232). 
6. It is very flexible in producing dosage forms and drug delivery systems with a wide 
variety of applications and administration sites like oral fast disintegrating, floating, 
colon-targeted, multiple phasic and implantable systems (233). 
7. Improving the solubility/dissolution of poorly water soluble drugs (especially BCS class 
II) via solid dispersion approach which leads to improved bioavailability of these drugs 
(233).  
Currently, FDM 3D printing is facing some limitations in the pharmaceutical field to develop 
more personalised medications. The suitability of pharmaceutically approved excipients for FDM 
3D printing purposes is one of the most important challenges. This is because nowadays 
commercially available filaments such as ABS, PVA, PLA and PCL filaments are either not 
suitable for pharmaceutical use or not flexible to fit with the broad field of FDM 3D printing 
application (233). In addition, thermal degradation may happen due to the use of high processing 
temperature required for FDM 3D printing which might cause the loss of the therapeutic activity 
of the APIs and the generation of the degradation products with the possibility of their harmful 
effects (230). Furthermore, the low and incomplete drug loading efficiency when drug loading 
performed by soaking of commercially available filaments (PVA) in saturated organic solutions 
of drugs  (226).  
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1.6 Drug delivery through peroral routes  
There are many different routes for drug administration to achieve the intended pharmacological 
activity. The most commonly used is the peroral route where the dosage form is administered 
through the oral cavity, and the drug is absorbed through the GI tract including the mouth cavity 
(234). This route offers a number of advantages compared to the other routes including its 
suitability for self-administration of drugs. Also, oral dosage forms do not need to be sterilised, 
and relatively larger amounts of drugs can be administered through the GI tract (9).  
The factors that affect drug absorption through the GI tract are varied according to the different 
regions of this system. For example, drugs absorbed from the intestine may be affected by the 
gastric emptying time, presence of food and the influence of gastric secretions. However, some 
parts of the GI tract like the mouth cavity may offer interesting opportunities to overcome certain 
obstacles encountered when drugs are passing through the other parts of GI tract like the stomach 
and small intestine. These drawbacks may be related to the failure to achieve the effective plasma 
concentration of medication, drug destruction by the enzymatic attack and extensive first-pass 
metabolism in the liver after absorption. These reasons motivate researchers to investigate the 
possibility of delivering drugs via the mouth cavity. The delivery of APIs through the mouth 
cavity can be divided into three types including sublingual, buccal and local (235). Sublingual 
drug delivery in which drugs are delivered to the systemic circulation through the mucosal 
membranes lining of the ventral surface of the tongue and the floor of the mouth. On the other 
hand, drugs can also be delivered systemically through the buccal mucosa lining the cheeks and 
the area between the gums and upper and lower lips. Periodontal, gingival and odontal drug 
delivery systems are used for local treatment of diseases of the oral cavity, main aphthous ulcers, 
bacterial and fungal infections and periodontal conditions (220). 
1.6.1 Buccal drug delivery 
1.6.1.1 Physiology of oral cavity 
The oral cavity is completely covered by membranes composed of relatively smooth mucus 
containing large number of small glands. It consists of the epithelium, basal lamina (links the 
epithelium to connective tissue), lamina propria (connective tissue) and submucosa (which 
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contains loose glandular or fatty connective tissue and main nerves and blood vessels) as 
illustrated in Figure 1.17 (236, 237): 
The epithelium is multilayered lining with various degrees of differentiation, and thus it differs 
from that of the GI which is simple and composed of a single layer of cells, (238). The outermost 
layer of the oral mucosa is composed of stratified squamous epithelium which has a mitotically 
active basal cell layer similar the stratified squamous epithelia present in the rest of the body. The 
differentiation is advancing as the layers become closer to the surface where cells are shed from 
the epithelium surface (239). It should be mentioned that most rodent models have keratinised 
outer layer while in humans, a non-keratinised buccal epithelium, much like other larger mammals 
including dog, pig and monkey (237). 
The thickness of the epithelium of the buccal mucosa is about 40-50 cell layer thick (500-800 
µm) while that of the sublingual region is somewhat thinner. The size of the epithelial cells is 
increased and the cells become flattened as they transfer from the basal layers to the surface of 
the epithelium. Also, the buccal epithelium has a turnover time estimated about 5-6 days. The 
composition of oral epithelium is different according to the various sites in the oral cavity. The 
epithelium of the gingiva and hard palate are keratinised and they are similar to that of the 
epidermis because these regions are more likely subjected to mechanical stress. However, a non-
keratinised epithelium is found in the soft palate, sublingual and buccal regions (240). 
 
Figure 1.17: Cross-section of the mucosa of the buccal cavity; adapted from reference (237) 
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Keratinised tissue is characterised by being robust, dehydrated and capable of resisting chemical 
damage and it covers a surface area of about 50% of the oral cavity. On the other hand, non-
keratinised tissue has higher flexibility, and it occupies approximately 30% of the total surface 
area. It should be mentioned that 60 to 75% of adults have sebaceous glands in their oral mucosa 
of the buccal mucosa and upper lip and they appear as pale yellow spots. In addition, small 
salivary glands openings can be seen in many areas. Concerning blood circulation, the oral 
mucosa has more blood vessels compared to the skin. The majority of the venous blood of the 
oral mucosa return circulates to the internal jugular vein. The lamina propria also contains 
lymphatic capillaries appear as blind cavities in the papillae (236).    
Concerning the biochemical composition, the oral mucosa is characterised by the presence of 
large quantities of a protein in the cells of all layers in both keratinised and non-keratinised types 
of epithelia. This protein is termed keratin, and it has a relative molecular mass ranging from 
40,000 to 70,000 g/mole. The lower molecular weight keratin is present in the non-keratinised 
cells mucosa. However, the higher keratins are predominantly present in the mucosa of the 
keratinised cells. It should be mentioned that keratinisation is a relative process, and the 
description noted above represents the extremes cases of keratinisation. It has been suggested that 
the water permeability of oral epithelium is related to its lipid content (241). The buccal mucosa 
is more permeable compared to other parts of oral cavity such as the gingiva and palate because 
it contains fewer quantities of acyl ceramides and ceramides. Epithelial cells are surrounded by 
material composed of carbohydrate-protein complexes. This intercellular ground substance is 
thought to be responsible for cells adhesion and serving as a lubricant to facilitate the movement 
of the cells relative to each other (241). The oral epithelium also contains some intercellular 
junctions such as gap junctions, tight junctions, and desmosomes and/or hemidesmosomes. The 
membranes of adjacent epithelial cell are separated by gap junctions of approximately 2-5 nm. 
These gaps are thought to be continuous which allow the passage of compounds having a 
molecular mass of several thousand daltons (240). 
Mucus 
Mucus is a gel-like complex aqueous mixture that covers the entire surface of the oral cavity. The 
function of this layer is providing protection to the underlying epithelial cells from the various 
environmental conditions and the effect of enzymes and other chemical substances. It is a viscous 
and elastic hydrogel composed mainly of water ~ 95%, 0.5-5% water-insoluble glycoproteins, 
together with small quantities of other substances like proteins, lipids, enzymes, electrolytes, 
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nucleic acid, sloughed epithelial cells and bacteria (242, 243). The constituents of mucus may 
differ depending on the site of secretion, the intended protective and mechanical function and the 
presence of illnesses (244).  
The major component of mucus is mucin which has two forms: soluble secretory mucin and 
membrane-bound mucin (245). The former is responsible for the formation of the gel-like 
structure of the mucus due to its higher molecular weight and its ability to form intermolecular 
linkages through the disulfide bridges. The membrane-bound mucin does not have the ability to 
form the intermolecular disulfide linkages, but it has a hydrophobic portion that binds the 
molecule to the plasma membrane of the epithelial cells (246-248). Mucin is composed of 
oligosaccharides (70-80% of their total weight) which are linked via O-glycosidic linkages to a 
peptide core which constitutes 10-30% of the total weight of the mucin (242). The 
oligosaccharides are varying in their length (2-15 sugar units) and they have a branched structure 
(249). In general, mucins differ according to their molecular size, the composition of their sugar 
moiety, sequence and the length of their chains (250, 251). Mucins isolated from the same glands 
are not identical, and they do not have the same molecular size (252). The protein core of mucins 
composed of high quantities amino acids such as serine, threonine, alanine, glycine, proline and 
low levels of aromatic amino acids (253). The most common monosaccharides attached to the 
protein core are N-acetylgalactosamine, N-acetylglucosamine, galactose, fucose and sialic acid  
(250). The net negative charge of the oligosaccharides and the entire mucins are due to the 
presence of sialic acid and other sulphate residues (242).  
Several studies demonstrated that mucous layer might act as a membrane that limits the absorption 
of drugs through the mucosa. On the contrary, this layer may provide an excellent mean for 
sustained or prolonged drug delivery by designing mucoadhesive drug delivery systems (243). 
The factors that affect the diffusion coefficient of the molecules through the mucous layer include 
the relative size of the drug molecule, the effective pore size of the of the mucus gel formed by 
the association of mucin macromolecules and any interaction between the drug and the 
components of the mucous membrane. As the molecule size of the drug increased the diffusion 
coefficient is decreased i.e. there is an inverse proportion between the molecular weight of the 
drug and the diffusion through the mucous membrane. The diffusion of small and uncharged 
molecules through the mucous layer seems not to be considerably affected by the mucous 
membrane compared to larger or charged (cationic) molecules. On the other hand, as the mesh 
size of the mucous network increase, the diffusivity of the drug is also increased (254). 
Furthermore, any interaction between the drug and the components of the mucous layer can 
reduce or prohibit the penetration of the drug through the mucous membrane (255-257). 
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Saliva 
Salivary fluid is excreted into the human mouth cavity (1-2 litres/ day) as a continuous and low 
basal secretion rate of 0.5 mL/min. Higher rates of secretions of more than 7 mL/min increased 
rapidly by the thought, smell and/or taste of food. The parasympathetic system is responsible for 
the control of salivary secretion. Saliva is characterised by being viscous, opalescent, colourless 
and hypotonic compared to plasma. The specific gravity of the salivary fluid is about 1.003, and 
its pH varies between 7.4 - 6.2 with lower pH at higher secretion rates. The salivary fluid is a 
mixture of water, proteins, mucus, mineral salts and amylase (236). Saliva also contains ions such 
as Na+, K+, Cl- and HCO3-. Na+ and Cl- are reabsorbed in the ducts of the salivary glands while 
K+ and HCO3- are secreted to control the electrolyte balance depending upon the rate of saliva 
secretion (236). Salivary fluid also contains enzymes such as α-amylase and ptyalin which can 
hydrolyze polysaccharides such as glycogen and starch to small molecules. Also, different 
esterases, mainly carboxylesterases also exist in the salivary fluid, and these may hydrolyse ester 
prodrugs or APIs containing susceptible ester groups (236, 258). 
1.6.2 Drug absorption through buccal route 
The absorption of APIs across the buccal mucosa involved two pathways: 1) intracellular (through 
the cells) and 2) intercellular or paracellular (between the cells). Both hydrophilic and lipophilic 
drug molecules can penetrate the buccal mucosa through these paths. The intracellular pathway 
offers a greater surface area for diffusion, but drugs passing by this mechanism may suffer from 
a significant diffusional resistance when they cross the aqueous and lipid compartments of the 
buccal epithelial cells. The mechanism by which water soluble compounds diffuse transcellularly 
involves the penetration of these molecules through the aqueous pores of the cell membrane. This 
is followed by the diffusion via the cytoplasm, and the process continued from cell to another 
across the epithelium (259). In addition, specialised transport mechanisms also participate in the 
absorption of drugs through the intracellular pathway (260-262). Lipophilic drugs can traverse by 
this pathway by partitioning through the lipid bi-layer of the cell envelope of the epithelial cells 
(259). On the other hand, drugs can also penetrate the buccal mucosa through the longer and 
tortuous pathway between the cells (intercellularly). In order to pass by this mechanism, the drug 
should have a certain affinity for and diffusivity in the intercellular fluid (240). Despite that this 
route offers a smaller surface area of diffusion compared to the intracellular one, this pathway 
appears as the most common route of penetration for most pharmacologically active compounds 
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(263). Several studies showed the uppermost 25-30% layer of the buccal epithelium is the limiting 
membrane for the absorption of many compounds like horseradish peroxidase (264), lanthanum 
(265), thyrotropin-releasing hormone (TRH) (266) and salicylic acid (267). 
1.6.3 Buccal formulation design  
Buccal drug delivery offers a number of valuable features such as the large surface area available 
for drug absorption (approximately 100 cm2) and providing a useful alternative to the intestinal 
route for drug absorption in situations where the GI route is unfeasible. In addition, delivering 
drugs to the systemic circulation is expected to bypass the hepatic metabolism that affects the 
plasma concentration of drugs susceptible to liver metabolism. Due to the relative permeability 
and rich in blood supply of the buccal mucosa, it serves as an absorption site that can promote 
rapid and efficient delivery of drugs to the systemic circulation. Also, drugs administered through 
the buccal mucosa are usually avoid the enzymatic degradation that they might subject to during 
their passage through the rest of the GI tract. This is an important issue for the delivery of proteins 
and peptides to the systemic circulation. It should be mentioned that the potential of irritation and 
irreversible damage to the mucosal lining and the buccal mucosa is not a problem because of the 
rapid recovery of the buccal mucosa after stress or damage. It was also reported that buccal route  
of adminstration is more acceptable to patients compared to other non-oral routes of 
administration such as intravenous and intramuscular injections because buccal formulations are 
non-invasive and cost effective. It should be noted that this route offers easy withdrawal or 
termination of medication by the patient which is an important issue in the case of emergencies 
like hypersensitivity to the drug or excipients contained within the formulation (235, 243, 259). 
Due to their smaller size and reduced thickness, buccal films are reported to have an improved 
patients’ compliance compared to tablets (268),  and lozenges (269) 
On the other hand, only potent drugs with poor absorption characteristics are suitable candidates 
for this route of drug delivery due to the limitations of dosage form size, residence time and the 
permeation through the buccal mucosa. Drugs with an effective plasma concentration within or 
less than ng/mL are considered as ideal candidates for buccal drug delivery. In addition, peptides 
and proteins may be subjected to the metabolic activity of the enzymes present in the oral cavity. 
This factor affecting these types of drugs to a lesser extent compared to the metabolic enzymatic 
activity in the GI tract. The mucus and salivary clearance can also decrease the retention time of 
drugs, and this may affect their absorption through the buccal mucosa. It should be mentioned 
that the mucus layer may act as a physical limiting membrane for the diffusion of APIs via the 
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buccal mucosa. Also, mucus may inhibit the penetration of drugs through the mucosa by binding 
with the drug (270). 
Buccal dosage forms should possess certain general requirements to be suitable for the delivery 
of drugs through the buccal mucosa. These formulations should have specific adhesive 
characteristics to maintain the system in contact with the buccal mucosa but not so adhesive as it 
may cause damage to the underlying tissue upon the removal of the system. Also, the components 
of these products should be biocompatible, non-toxic, non-irritating to the buccal mucosa, not 
cause excessive salivary secretion, palatable and not bitter tasting. In addition, they should be 
convenient when applied and inconspicuous after application on the buccal mucosa. Furthermore, 
their surface should be smooth and not rough. It should be mentioned that unidirectional release 
buccal systems are more preferable to achieve buccal absorption and prevent swallowing of the 
drug to the GI tract (234, 271). These dosage forms are either used for treating local conditions 
within the buccal cavity or to deliver the pharmacologically active ingredients to the systemic 
circulation.  Recently, many researchers have designed dosage forms that can deliver drugs 
through the buccal mucosa to overcome some problems related to their delivery by other routes 
or to get benefits from the advantages of this site. The most common dosage forms include matrix 
tablets, patches, lipophilic gels, and transfersomes (272). 
The size and the shape of the buccal drug delivery systems are different according to the type of 
the dosage form. The buccal tablet may have a size range 5-8 mm in diameter, whereas buccal 
patches with flexible characteristics may have a surface area in the range 10-15 cm2. It was 
reported that patients are more accepting buccal patches with an average size 1-3 cm2 compared 
to buccal tablets. Buccal drug delivery systems are also variable with respect to their shapes, and 
the ellipsoid shaped systems seem to be more preferable (243). Because of the size limitations of 
buccal patches, only drugs with daily dosage 25 mg or less are suitable candidates for this route 
of administration (239).  Buccal dosage forms should have a thickness not exceeds few 
millimetres and the maximum application time is expected to be within the time limit of 4-6 hours 
because food and/or liquid intake may restrict their application for longer periods (243, 273). 
Buccal dosage forms can be classified according to their design into (274): 
1) Reservoir systems: In which the drug is enveloped by a polymeric membrane that controls 
the rate of release. When the polymeric membrane is the rate limiting membrane, and there 
is an access of the drug, this system provides a constant release profile. 
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2) Matrix systems: In this system, there is a uniform distribution of the drug within the 
polymer. The release rate and profile are controlled by many factors including solubility of 
the polymer, polymer diffusivity, the thickness of the polymer diffusional path. In addition, 
the drug’s aqueous solubility, partition coefficient and aqueous diffusivity are also 
important factors in controlling the release profiles. Furthermore, the thickness of the 
hydrodynamic diffusion layer, the amount of the drug loaded in the system and the surface 
area of the dosage form play a major role in the release pattern and rate of the incorporated 
drug. 
1.6.3.1 Matrix tablets 
The matrix tablets have a monolithic and a two-layered matrix structure that can be used for local 
or systemic purposes. The design of the simplest model of these tablets is a mixture of the active 
drug and a swelling polymer with sustained release and mucoadhesive features to liberate the drug 
in a bidirectional mechanism. This system can be modified by certain methods to obtain the 
desired release characteristics like for example the outer or all sides may be coated with water 
impermeable material to get a unidirectional release. Furthermore, the drug may be loaded in a 
release rate controlling layer that controls the drug release towards the buccal mucosa while the 
water impermeable layer ensures that the release is preceding to the direction of mucosa only.  
Matrix tablets are used for the delivery of different drugs such as naloxone HCl, propranolol, 
timolol, metronidazole, metoclopramide, morphine sulphate, nitroglycerin and codeine. This type 
of dosage forms is also used for the delivery of peptides, such as insulin, calcitonin and glucagon-
like peptide (272, 275-277). 
1.6.3.2 Buccal patches  
Recently, several research approaches are focused on the formulation of buccal patches due to 
their patients’ higher acceptability and compliance compared to buccal tablets due to their higher 
flexibility and the reduced thickness which make them more comfortable compared to buccal 
adhesive tablets. Buccal patches can be designed as multi-layered systems that composed of an 
outer impermeable layer and an underlying layer containing the drug substance in addition to 
other excipients. The drug containing layer has adhesive properties, and through this layer, the 
release of the drug to the mucosa in a unidirectional way is happened (272). This type of dosage 
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forms used for the delivery of many drugs such as diclofenac, thyrotropin-releasing hormone, 
octreotide, oxytocin, buserelin, calcitonin and leuenkephalin (278, 279).    
1.6.4 Mucoadhesive drug delivery systems 
The term ‘bioadhesion’ refers to the adherence of synthetic or natural macromolecules to 
biological tissues. Mucoadhesion represents the attachment of various polymeric macromolecules 
to the mucous membrane lining the mucosal epithelium (280). It was noticed that the attachment 
of the gut bacteria to the GI mucosa represents a natural example of mucoadhesion through the 
linkage between the proteins on the surface of the bacterial cells and the mucus membrane lining 
the GI mucosa (280, 281). The earlier attempts to use the bioadhesive drug delivery systems dated 
back to 1947 when researchers tried to deliver penicillin through the oral mucosa using tragacanth 
gum and dental adhesive powders (282). This approach became more interesting for researchers 
in the field of controlled-release drug delivery in the early 1980s (283). After that, many 
researchers are focused on the investigation of various biopolymers with bioadhesive 
characteristics for the development of many products for different therapeutic purposes. 
Bioadhesive polymers can generally be classified into two types: specific (like fimbrin and 
lectins) and non-specific (such as polyacrylic acid and cyanoacrylates) bioadhesive polymers. The 
difference between these two groups is related to their ability to bind to the biological membranes 
where the former have the potential to form a sort of attachment to specific chemical structure 
while the latter have the ability to adhere to both the surface membrane and the mucus layer (284).  
Mucoadhesive systems are dosage forms that contain one or more mucoadhesive polymers that 
act as an essential part of their composition. They have the ability to adhere to the mucus layer by 
means of mucoadhesion, and they are useful for the targeted delivery of drugs where the drug 
retained at the site of absorption for extended periods (285). These systems were used to achieve 
sustained release purposes of medicines brought by the prolonged residence time on the ocular 
(286), nasal (287), vaginal (288) and buccal (289) mucosal membranes. More recently, 
bioadhesive drug delivery systems have gained a great interest for the delivery of peptides and 
proteins because the adhesive properties resulted from the use of bioadhesive polymers can 
provide an additional protection mechanism to the therapeutic drugs against enzymatic attack that 
may occur between the dosage form and mucosa (290, 291). Different kinds of forces are involved 
in binding the polymer with the biological tissue to promote bioadhesion which may include 
covalent (cyanoacrylate), hydrogen (carbopol, polycarbophil and acrylates) and weak 
electrostatic bonding (chitosan). Bioadhesion involves covalent bonding seems to be suitable if 
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the polymeric material is non-toxic. Several studies showed that most bioadhesive polymers are 
capable of forming weak polar or electrostatic interactions. To maintain the drug in contact with 
the biological tissue for the predetermined time period, there must be a relatively strong bonding 
between the polymer chemical group and the biological surface (292). Ideally, mucoadhesive 
polymers should promote mucoadhesion in different biological environments with different water 
contents. In addition, water and oil soluble drugs can be easily accommodated by the polymer for 
the controlled release purposes. Mucoadhesive polymers are also preferable if they possess 
additional properties such as the ability to inhibit local enzymes, help in enhancing the absorption 
of drugs, being safe, inert, biocompatible, provide excellent mechanical properties and being 
easily handled during the formulation and manufacturing processes (292, 293). 
Polymers with mucoadhesive features are either of natural or synthetic sources. Examples of the 
synthetic type including polyacrylic acid derivatives (such as polyacrylic acid) and cellulose 
derivatives (such as carboxymethyl cellulose). On the other hand, natural materials can also be 
used as bioadhesive excipients such as chitosan and various gums such as xanthan, pectin and 
alginates (294). 
1.6.5 Mechanisms of mucoadhesion 
Mucoadhesion as a process involves three steps, in the first step there is an intimate contact 
between the mucoadhesive polymer and the biological tissue followed by the interpenetration 
between the macromolecules then the formation of interfacial bonds (295). These bonds are 
relatively weak bonds of the secondary type like hydrogen bonds, van der Waals forces, 
electrostatic forces and hydrophobic interactions (296). Due to the large number of charged 
groups such as hydroxyl (-OH), carboxyl (-COOH), sulfuric acid (-SO3H), and amino (-NH2), 
electrostatic interactions and hydrogen bonds seem to play an important role in the process of 
mucoadhesion. On the other hand, hydrophobic interactions result from the association of non-
polar groups also participates in this process. The van der Waals binding energies between 
hydrophobic groups were estimated within the range 1-10 Kcal/mol, while the binding energy of 
hydrogen bonds between polar groups is about 6 Kcal/mol (297). 
The process of mucoadhesion can be explained by several theories including electronic, 
adsorption, diffusion, wetting and fracture theories. In a particular situation, the formation of 
bioadhesive bonds can be explained by one or more of these theories (239). 
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Electronic (electrostatic) theory 
This theory assumes the formation of an electrical double layer between the mucoadhesive 
material and the biological tissue. This electrical double layer is resulting from the electronic 
transfer between the two sides when they come in contact of each other as a result of their different 
electronic structures. The attractive forces across this electrical double layer are believed to be 
responsible about the mucoadhesion (298).  
Adsorption theory 
The adsorption theory states that the molecules of the biological tissue adsorbed at the surface of 
the mucoadhesive substrate resulting in a kind of interaction between these two systems (299, 
300).        
Diffusion theory 
The diffusion theory suggested that the interpenetration and entanglement of the mucoadhesive 
polymer are responsible about mucoadhesion. The concentration gradient across the interface 
between the two substrates is the driving force for the interpenetration of the polymer chains into 
the biological side and vice versa. It is believed that interpenetration between the two substrates 
of about 0.2-0.5 µm is essential to produce an effective adhesion (301). 
Wetting theory 
The wetting theory suggests that for mucoadhesion to take place, there must be a certain degree 
of spreadability or wettability between the mucoadhesive material and the biological substrate. 
According to this theory, the angle of contact Ɵ is the reflection of the wetting power of liquid on 
solid and mucoadhesion is predicted as a function of wettability between the two substrates (280, 
302, 303).  
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Fracture theory 
This theory describes the force needed for the separation of two surfaces after mucoadhesion. The 
fracture strength is equal to mucoadhesive strength as explained in Equation 1.21. This theory is 
useful for the study of mucoadhesion by tensile apparatus. 
                                     σ  =  (E × ε/L)1/2 …………….....Equation 1.21     
where σ is the fracture strength, E fracture energy, ɛ young modulus of elasticity, and L is the 
critical crack length (296). 
1.7 Objectives of this project 
Solid dispersions are most commonly prepared as binary drug-polymer models which are not 
necessarily reflecting the situation in real life complex pharmaceutical preparations. There is a 
lack of knowledge about the behaviour of complex solid dispersions with respect to the 
solubilisation of the drug, processing parameters, physical and chemical stability during and after 
preparation and the pharmaceutical properties of the fabricated products. This study aimed to 
prepare complex solid dispersions systems using a variety of blends of felodipine with different 
pharmaceutical excipients having various applications to produce final form products. These solid 
dispersions were designed using two different approaches with diversity in formulation 
objectives. The first approach was through the use of hot melt extrusion in conjunction with 
injection moulding (HME-IM) as a single step processing, environmentally friendly and efficient 
method to prepare felodipine buccal patches for enhancing the systemic bioavailability of 
felodipine via solubility/dissolution enhancement and avoidance of the extensive first pass effect 
of the drug. The second approach was the use of fused deposition modelling (FDM) 3D printing 
utilising various combinations of pharmaceutically approved excipients as a novel method of 
enhancing their printability. Successful preparation of dosage forms using FDM 3D printing is 
expected to play a major role towards more patient personalised medicines which in turn can 
improve patients’ adherence to medications and treatment efficiency. Also, this study used two 
novel characterisation techniques: thermal analysis by structural characterisation (TASC) and X-
ray micro computed tomography (XµCT) as a tool for investigating the heterogeneity and the 
spatial distribution of phases of the complex formulations prepared in this study.  
The specific aims of the study include: 
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1. Investigating the physicochemical properties of the raw materials and their compatibility 
with the model drug that are used throughout this study.  
2. Design, characterisation and evaluation of felodipine mucoadhesive buccal patches using 
HME-IM processing containing either Tween 80 or TPGS as surfactant-rich drug 
solubilisation and stabilisation phases.  
3. Using TASC and XµCT as novel techniques for the assessment of heterogeneity and the 
phase distribution of the complex solid dispersions prepared by HME-IM. 
4. Investigating the stability of the prepared HME-IM patches after storage at four different 
conditions of temperature and relative humidity and the impact of the role of surfactant 
type on the stability of the system and the recrystallisation of the incorporated drug.  
5. Exploring the approach of using polymeric mixtures to improve the FDM 3D printability 
of pharmaceutical solid dispersions. This also involves the development of oral felodipine 
solid dispersions discs using FDM 3D printing and investigating their microstructure, 
loading efficiency and their release characteristics as a personalised oral dosage form for 
felodipine. 
 
  
 
 
 
 
 
2. Chapter 2. Materials and methods 
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2.1 Introduction 
In this study, the model drug selected was felodipine which was mixed with blends of a variety 
of pharmaceutical excipients including polyethylene glycol (PEG) 4000, polyethylene oxide 
(PEO), polyoxyethylene sorbitan monooleate (Tween) 80, d-α-tocopheryl polyethylene glycol 
1000 succinate (vitamin E TPGS), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol 
graft copolymer (Soluplus), dimethylaminoethyl methacrylate-butyl methacrylate- methyl 
methacrylate copolymer (Eudragit E PO) and polyvinyl alcohol (PVA) in different combinations 
and loading percentages as solid dispersion based formulations. This chapter introduced the 
chemical and physical properties of these compounds and reviewed the current applications of 
these materials.   
Solid dispersions were prepared using either hot melt extrusion in conjunction with injection 
moulding (HME-IM) or fused deposition modelling (FDM) 3D printing. HME-IM was used to 
prepare buccal patches containing felodipine which would bypass its extensive hepatic 
metabolism when taken orally, improving its systemic bioavailability and allowing a minimum 
dose to be given through the buccal route. FDM 3D printing was used the potential of providing 
patients personalised formulations based on pharmaceutically approved excipients with improved 
dissolution profiles via a solid dispersions approach.  
In order to fully understand the characteristics of the HME-IM and FDM 3D printed products, it 
is essential to investigate the physicochemical properties of their individual components, 
intermediate blends, and finished products using a wide range of techniques. In this chapter, the 
characterisation tools used for the analytical purposes are introduced and discussed in details. 
These techniques include differential scanning calorimetry in standard (DSC) and modulated 
(MTDSC) modes, attenuated total reflectance Fourier transform infrared spectroscopy (ATR-
FTIR), powder X-ray diffraction (PXRD), scanning electron microscopy (SEM), element 
dispersive spectroscopy (EDS), X-ray micro computed tomography (XµCT), thermal analysis by 
structural characterisation (TASC), thermogravimetric analysis (TGA), dynamic vapour sorption 
(DVS), polarised-light hot stage microscopy (PL-HSM) and Fourier transform infrared (FTIR) 
imaging.  Furthermore, the techniques used to assess the in vitro performance of the formulations 
including stability testing, mucoadhesive study using texture analyser, and in vitro dissolution 
studies were also described in this chapter. 
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2.2 Materials  
2.2.1 Model drug 
In this study, felodipine as one of the potent calcium channel antagonists normally used to treat 
patients suffering from hypertension and for prevention of angina pectoris was used as the model 
drug. As a member of the dihydropyridine family, felodipine exerts its effect by selective 
relaxation of the vascular smooth muscles through inhibition of calcium influx via the slow 
channels (304, 305). Felodipine was used as the model drug to be formulated as buccal patches 
using HME-IM and personalised medicine prepared by FDM 3D printing. Felodipine was 
selected because: 
1. It is poorly water soluble drug (practically insoluble in water) and has high permeability 
through body membranes. It is classified as class II according to Biopharmaceutical 
Classification System (BCS) and therefore using solid dispersion technology is expected to 
improve its dissolution and bioavailability which potentially improve the therapeutic 
outcomes of the drug (306, 307). 
2. The drug is marketed as oral modified release tablets containing 2.5, 5, and 10 mg per tablet 
as single drug tablets and as combination film coated tablets with ramipril containing 2.5 and 
5 mg felodipine (308). The daily dose of felodipine is 5-10 mg (307) and its small molecular 
weight make this model drug as a typical candidate to be delivered through buccal mucosa 
where minimum drug absorption is expected to reach its therapeutic window (239, 309). In 
addition, the single daily dosing of the drug suits well with the frequency of dosing using 
buccal drug delivery.  
3. Felodipine shows an extensive first pass metabolism when absorbed through the 
gastrointestinal (GI) tract and approximately 84% of the administered dose deactivated 
through the liver (310). Therefore, buccal drug delivery is better alternative route of 
felodipine administration.  
2.2.1.1 Physicochemical and pharmacokinetic properties 
The chemical structure, physicochemical and pharmacokinetic properties of felodipine (ethyl 
methyl (4RS)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate) are 
shown in Figure 2.1 and Table 2.1 (311). 
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Figure 2.1: Chemical structure of felodipine, adapted from reference (312) 
The complete single crystal structure details of four polymorphic forms of felodipine reported in 
literature. Their melting peak onsets are 143.8 ± 0.2, 134.8 ± 0.2, 143.7 ± 0.2 and 145.7 ± 0.2 ̊C 
for forms I-IV, respectively (312-314). In addition, the FTIR data indicated that these 
polymorphic forms showed different strengths of intermolecular hydrogen bonds between the NH 
group and the C=O groups. The NH stretching in their IR spectra have been reported at 3372, 
3334, 3370, 3329 cm- 1 for the four crystalline polymorphic forms I-IV, respectively (313-315). 
Furthermore, the amorphous form showed NH stretching peak at ~ 3339 cm-1. The non-hydrogen 
bonded C=O group and the hydrogen-bonded C=O stretching peaks were detected at (1699 and 
1690 cm-1) for form I, (1698 and 1683 cm-1) and form II, (1703 and 1654 cm-1) for form IV and 
(1701 and 1682 cm-1) for the amorphous form (313, 314, 316-318). No data is found for the C=O 
stretching of form III in literature. It should be mentioned that the crystal habits of the different 
forms were found to be blocky shaped for polymorphs I and II and platy like crystals for form III 
(319). No available information about the crystal habit of polymorph IV of felodipine has been 
reported (319). 
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Table 2.1: Physicochemical and pharmacokinetic properties of felodipine 
 Property Details References 
CAS 72509-76-3 (311) 
Chemical formula C18H19Cl2NO4 (311) 
Molecular weight 384.254 g/mole 
Polymorphic forms 4  
 
(312, 314) 
Melting temperature onsets 
(Tm) 
Form I = 143.8 ± 0.2 ºC 
Form II = 134.8 ± 0.2 ºC 
Form III = 143.7 ± 0.2 ºC 
Form IV = 145.7 ± 0.2 ºC 
Glass transition temperature 
(Tg) 
43.5 ºC (320) 
Solubility in water Less than 0.5 mg/L (321, 322) 
PKa 5.71 (323) 
Log P 4  
(307) Oral dose 5-10 mg/day 
Cmax 12 ± 4 (nmol/L)  
 
(324)  
tmax 2.2 ± 1 (hrs) 
Vss 10.3 ± 3 (L) 
Cl  934 ± 210 (mL/min) 
Cloral  10.3 ± 3 (L/min) 
t1/2  13.6 ± 4 (hrs) 
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2.2.2 Excipients 
2.2.2.1 Polyethylene glycol (PEG) 4000 
Polyethylene glycols (PEG) are widely utilised as pharmaceutical excipients in the formulation 
of different dosage forms including parenteral, topical, ophthalmic, oral, and rectal products (325). 
They are used as vehicles in the preparation of solid dispersions because they have good 
solubilising properties, low melting temperatures, high solidification rates, economic cost, and 
low toxicity (62, 326, 327). As shown in Figure 2.2, PEG is a group of hydrophilic semicrystalline 
polymers that show both amorphous and crystalline regions at different proportions depending on 
their method of manufacturing and thermal history involved during preparation (328, 329). 
 
Figure 2.2: Schematic representation of the crystalline-amorphous structures of PEG, adapted from 
reference (329) 
The molecular formula of PEG is [H(-OCH2CH2-)nOH] where n represents the number of ethylene 
oxide (-OCH2CH2-) monomers within the polymer chain depending on its molecular weight (330). 
The chains of crystalline domains of PEG are composing of seven monomer units with two turns 
per fibre identity period (chain repetition distance) of 19.3 ̊A as illustrated in Figure 2.3a. It 
should be mentioned that the helical structures of PEG chain in their crystals was confirmed by 
using scanning tunneling microscopic (STM) imaging as shown in Figure 2.3b (331). 
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Figure 2.3: a) Molecular model representing single-stranded helix of PEG consisting of seven 
monomer units with two turns per repeat unit and b) STM image of single- and double-stranded 
helices of PEG; adapted from reference (331). Reproduced with permission from the publisher 
The crystallographic unit cell of the PEG composes of four molecular chains with a monoclinic 
crystal system in which a = 7.96 ̊A, b = 13.11 ̊A, c = 19.39 ̊A and β = 124.48 ̊ (332). The PEG 
single crystal has a flat or plate like structures named lamellae in which the helical chains extend 
perpendicular to the larger sides of the lamellae and the ends rejected to the surface of the crystal 
as illustrated in Figure 2.4a (332-334). The lamellae are organised in the spherulites in a way that 
the chains are oriented parallel to the tangential plane of the spherulite boundary which is 
responsible about the overall spherulitic morphology. The spherulites may be as big as 1 cm in 
diameter due to the slow nucleation rate of melt crystallisation (Figure 2.4b) (335).  
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Figure 2.4: a) Model illustrating single layer extended chain PEG crystal; adapted from reference 
(332) and b) polarised light hot stage microscope image of crystallised PEG 4000; adapted from 
reference (336) 
Inside each of the lamellae, the polymer chains are present in both the extended (stable) and the 
folded (metastable) forms in addition to the amorphous random coil fraction. The folded chains 
have lower melting points compared to the extended ones and are considered as the metastable 
form of the polymer. The melting point of the polymer is found to decrease as the number of folds 
in the chains increases. In addition, the kinetic stability of the metastable form increases as the 
molecular weight of the PEG increases (328, 330). The folded form may transform to the more 
stable extended form. The ordered helical structure of the polymer is converted completely into 
random coils on melting when the polymer melts (337).   
PEG 4000 used in this study with an average molecular weight (4060 g/mole) is solid at room 
temperature and has a melting point of (58.9) °C measured by DSC using a heating rate of 4 °C 
/min (335). It is well known that PEG 4000 crystalline forms were detected in its lamellae as a 
mixture of single folded form with the more stable extended form (328, 330). The thickness of 
the crystal is found to decrease as the number of folds increased and thus the volume to surface 
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ratio being the lowest for the single folded form making it the less stable form of the polymer 
(328, 330). The fraction of the unstable folded form of this polymer is greatly affected by the 
cooling rate of the polymer when cooled from its molten state. It was reported that as the rate of 
cooling of this polymer from its molten state increased, the fraction of the folded form generated 
increased too (338).  
PEG 4000 has been used widely as a carrier in the preparation of solid dispersions for enhancing 
the aqueous solubility and improving the bioavailability of many drugs (198, 339-342). It was 
found that the in vitro release profile of lonidamine was improved by formulating the drug with 
PEG 4000 and the extent of enhancement is dependent on the polymer content in the dispersion 
(340). In addition, the same polymer was reported to form solid dispersions with piroxicam with 
faster dissolution rate compared to simple physical mixtures resulting in a significant increase in 
the bioavailability of the drug in rabbits (341). Similarly, faster dissolution rate of extruded 
carbamazepine-PEG 4000 solid dispersions was achieved compared to simple physical mixtures 
with equivalent compositions (342). This polymer forms various kinds of solid dispersions in 
which the drugs might be either present as a molecular dispersion or as a nano amorphous 
aggregates dispersed in the amorphous phase of the polymer (343-345). In addition, monotectic 
solid dispersions of drugs with poor water solubility can also be produced using this polymer in 
which the eutectic temperature of the mixture is very close to one of the formulation components 
(PEG 4000) (38, 346). The stability of solid dispersions is dependent on many factors including 
the experimental conditions (temperature, humidity, duration of storage), nature of the dispersion 
components (drug and the carrier) and the physical characteristics of the dispersion formed. For 
example, it was found that PEG 4000 forms solid dispersion with oxazepam in which the 
dissolution behaviour was unchanged during the storage at room temperature for 6 months (47). 
On the other hand, the dissolution profile of the aged PEG 4000 dispersions of glyburide was 
found to be lower than that of the fresh samples due to the possible phase separation of the drug 
when aged at room temperature (339).  The mechanism of dissolution/solubility enhancement of 
water poorly soluble drugs from solid dispersions using PEG 4000 was shown to be due to the 
increase in surface area of the molecularly dispersed drug from solid solutions (126), formation 
of the metastable highly soluble amorphous form of the drugs (339), increased solubility of drugs 
in the fluids of the diffusion layer (44) and/or improvement the wettability of the drug by the 
carrier used (126). 
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2.2.2.2 Polyethylene oxide (PEO) 
Polyethylene oxide (PEO) is semi-crystalline, thermoplastic hydrophilic polymer has the same 
molecular formula as that of PEG [H(-OCH2CH2-)nOH]. The nomenclature of the two groups of 
polymers refers to the number of ethylene oxide monomers forming its chain. PEO polymer 
grades have a molecular weight range between 105 to 7 × 106 g/mole depending on the number of 
monomeric units included in its chain. These polymers are white to off-white, free-flowing 
powders with slight ammoniacal odour. They have a melting range of about 65–70 ˚C, true density 
1.3 g/cm3 and moisture content less than 1% w/w (347, 348).  In contrast to PEG which is existing 
as relatively viscous fluid to waxy like solids, PEO is a real thermoplastic polymer having the 
ability to form tough and moulded shapes. This difference in physical properties is related 
principally to the molecular mass between the two groups of polymers and most importantly the 
higher fraction of hydroxyl terminal group in PEG compared to PEO (349).  PEO has many 
applications in the formulation of various pharmaceutical products like sustained release tablets 
(350) matrix tablets (351), beads (352) and film dressing for wound healing (353). This polymer 
has many characteristic features including its excellent mucoadhesivness, good water solubility, 
high viscosity, good swelling capacity (higher molecular weight PEO), poorly absorbed by the 
GI tract, and low level of toxicity regardless the route of administration. This polymer is 
incompatible with strong oxidising agents (348).  
The molecular weights for PEO used in this study are 900,000 g/mole (PEO K900) for HME-IM 
and 100,000 g/mole (PEO K100) for FDM 3D printing. The number of polyethylene oxide units 
in the polymeric chains for both grades are approximately 20,000 and 2,275 monomers 
respectively (348). This class of polymers are used to control the release of drugs by forming a 
strong swellable matrix upon hydration that is less liable to erosion compared to the lower 
molecular weight PEO grades (354, 355). PEO polymers have been recognised as a successful 
carrier for the preparation of solid dispersions by HME method due to their thermoplastic nature 
(144, 356). When used to control the release of drugs using HME, this polymer offers a number 
of advantages including the possibility of incorporating drugs with liable to degradation when 
processed at high temperatures, zero-order release kinetics, and easy preparation. It was reported 
that this polymer offers great flexibility in adjusting the release profiles by altering various 
formulation and processing parameters like the molecular weight of the polymer used in the 
formulation as shown in Figure 2.5 (357). 
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Figure 2.5: Influence of PEO molecular weight on the release profile of theophylline from the hot 
melt extrudates in phosphate buffer pH 7.4; adapted from reference (357) 
As an example, this polymer was found to form a stable solid solution of chlorpheniramine 
maleate in which the drug is molecularly dispersed in the carrier polymer using low loading 
percentages. The release profile of the drug from the solid dispersion was sustained by polymeric 
erosion and the diffusion of the drug through the swollen layer formed at the surface of the tablet 
(356). 
The thermal stability of pure PEO was found to be dependent on the storage temperature and the 
molecular weight of the polymer. It was shown that as the molecular weight of the polymer 
increased, the thermal stability resulting from resistance to thermal oxidative degradation was 
increased (144). This has been explained this in terms of the thickness of polymer crystals rather 
than the degree of crystallinity of the polymers.  It was argued that the higher molecular weight 
polymers crystallise in thicker crystals which are less susceptible thermal oxidation compared to 
the thinner crystals formed by the polymer members of lower molecular weights (144). The 
stability of the practically insoluble drug clotrimazole in PEO N80 and PEO N750 (molecular 
weight 200,000 and 300,000 g/mole respectively) solid dispersions using HME method was 
investigated by Prodduturi and co-workers (358). It was found that the drug was more chemically 
stable in PEO N750 than in PEO N80 due to the lower water sorption capacity of the PEO N750 
polymer grade. Also, it was noticed that the physical stability of the extruded films was good as 
solid dispersions for 1 month at 25 ˚ C and 65% RH. However, the appearance of the characteristic 
PXRD peaks after 3 and 6 months indicated recrystallisation of the solubilised drug in the carrier 
polymer (358).  
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The bio/mucoadhesive properties of PEO polymers are very attractive for many researchers 
aiming to develop bioadhesive dosage forms with zero order release kinetics (358, 359). These 
polymers showed direct proportion between the molecular weight of the polymer and the 
adhesiveness and the work of adhesion of the prepared dosage forms. In this case, the 
mucoadhesion mechanism is explained according to the diffusion theory in which the magnitude 
of stickiness depends on the degree of penetration of the polymeric chains into the mucus 
glycoprotein chains (359). 
2.2.2.3 Polysorbate (Tween®) 80   
Polysorbate 80 (polyoxyethylene 20 sorbitan monooleate, molecular weight = 1310 g/mole) is a 
non-ionic surfactant commonly used in the production of cosmetics, food and pharmaceutical 
products. This surface active agent has an HLB value of 15 and used for its dispersing, 
emulsifying, solubilising, suspending, plasticising, penetration enhancing and wetting activities 
(360, 361). At 25 ˚C, it presents as yellow oily liquid miscible with water and ethanol and 
immiscible with vegetable and mineral oils. Tween 80 is regarded as hygroscopic material and 
should be stored in well-closed containers protected from light in a cool and dry place (360). In 
general, Tweens are stable compounds when mixed with electrolytes, weak acids and bases, 
however, they show gradual saponification with strong acids and bases and the oleic acid 
derivatives like Tween 80 were found to be sensitive to thermal autoxidation and hydrolysis. 
Tween 80 is moderately toxic when administered by intravenous (IV) route (LD50 = 4.5 g/kg) and 
mildly toxic after ingestion (LD50 = 25g/kg) in mouse (143, 360-362). Tween 80 has a CMC of 
0.012 mM in water at 25 ˚C (363). The chemical structure of Tween 80 is shown in Figure 2.6. 
 
Figure 2.6: Chemical structure of Tween 80 (x + y + z = 20); adapted from reference (364) 
Various surfactants were used in the preparation of solid dispersions for their plasticisation effect 
and their ability to improve the solubility of poorly soluble drugs in the carrier polymers. Many 
researchers demonstrated that these agents have the ability to enhance the solubility of drugs in 
their formulations by improving their wettability and the solubility. The capability of surfactants 
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to achieve this target is dependent on their HLB value, solubilisation power, and the possible 
interactions with both the drug and the carrier polymer (361, 365-368). Tween 80 has also been 
reported to act as a permeation enhancer to facilitate the penetration of various drugs into the 
systemic circulation across different biological membranes like the intestine (369), skin (370, 371) 
and buccal mucosa (372). Compared to anionic and cationic surfactants like sodium lauryl 
sulphate and cetyl trimethyl ammonium bromide, non-ionic surfactants were reported to be less 
damaging to the skin as permeation enhancers (373). It should be mentioned that the enhancement 
of drug penetration by using surfactants as chemical enhancers is variable because of its 
dependence on the type of the targeted membrane utilised in the experiment (373). Tween 80 is 
considered as an effective surfactant for stabilising and preventing the crystallisation of drugs 
from their supersaturated solid dispersions (374). 
2.2.2.4 D-α-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS, 
Kolliphor® TPGS)    
Vitamin E TPGS is a water soluble non-ionic surfactant obtained by esterification of vitamin E 
with polyethylene glycol (PEG) 1000. Due to its hydrophilic-lipophilic moieties represented by 
the fat soluble vitamin and the water soluble PEG, this surface active agent shows an amphiphilic 
character with an HLB value of 13.2 and critical micelle concentration of 0.02% w/w in water 
(375). This compound is waxy solid at room temperature and has a melting point peak 
approximately at 37-41 ̊C. The molecular weight of TPGS is 1513 g/mole (375). The chemical 
structure of vitamin E TPGS is illustrated in Figure 2.7. 
 
Figure 2.7: Chemical structure of vitamin E TPGS; adapted from reference (376) 
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TPGS has been widely used in pharmaceutical formulations for its valuable properties as 
solubilising (377, 378), plasticising (200), stabilising (379), antioxidant (144, 380), absorption 
enhancing (381), emulsifying agent (382), and as a nutritional supplement of vitamin E (383). For 
example, TPGS based formulations showed to significantly improve the solubility of poorly water 
soluble drug indomethacin over a wide range of pH values (377). Another case, the aqueous 
solubility of paclitaxel was found to be increased linearly as the concentration of TPGS increased 
(378).  It was also reported that mixing this compound with blends of polymers containing 
hydroxypropyl cellulose (HPC) and polyethylene oxide (PEO) revealed a decrease of more than 
11 ̊C in the Tg of the mixture indicating the plasticising action of TPGS (200). TPGS also showed 
to be able to solubilise and stabilise the amorphous form of itraconozole in solid dispersions 
prepared by microwave with the result of improving the dissolution properties of this poorly water 
soluble drug (384). The surfactant in a concentration of 1-2% solution was also reported to 
stabilise itraconozole in its supersaturated solutions compared to the drug alone (385). The TPGS 
needs to be hydrolysed to release the α-tocopherol succinate unit (vitamin E) which is well known 
to have free radical scavenger activity (386). Crowley and his co-workers showed that 
incorporating this surfactant successfully retarded the thermal oxidative degradation of PEO 
contained in chlorpheniramine maleate extrudates prepared by hot melt extrusion (144). In 
addition, this amphiphilic compound is shown to have a permeability enhancing effect by 
increasing the intraluminal amprenavir concentration in a concentration-dependent manner (387).   
2.2.2.5 Poly(butyl methacrylate-co-(2-dimethylaminoethyl)methacrylate-co-
methyl methacrylate) (Eudragit® E PO) 
Eudragit E PO is a cationic polymethacrylate copolymer used to provide gastric targeted release 
profiles due to its pH dependent solubility in acidic media (pH < 5). The E PO grade of this 
polymer is a white powder with a characteristic amine-like odour (388). The average molecular 
weight of this amorphous polymer is about 74,000 g/mole, and its Tg is 48.6 ̊C (389, 390). The 
chemical structure of Eudragit® E PO is illustrated in Figure 2.8. 
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Figure 2.8: Chemical structure of eudragit® E PO; adapted from reference (391) 
Eudragit® E PO has many applications in the pharmaceutical field including film coating (388), 
solid solution carrier to improve the dissolution properties of poorly water soluble drugs (392) 
and to mask the taste of bitter drugs (393). This copolymer has been used as a principle component 
of many formulations like solid dispersions (392), nanoparticles (394) and rapid disintegrating 
tablets (393). It has been used as a carrier in the preparation of solid dispersions using HME as a 
single polymer or as a polymeric blend to improve the dissolution properties of poorly water 
soluble drugs like felodipine and indomethacin (73, 389). This polymer has relatively low glass 
transition temperature which makes it as a good polymeric candidate for preparing solid 
dispersions for poorly water soluble drugs at an acceptable temperature. Eudragit E PO was found 
to significantly improve the dissolution properties of felodipine using 10% drug loadings as a 
binary and ternary mixture using PVPVA. Also, the concentration of Eudragit E PO in the 
dissolution medium of pH = 1.2 at 25 ̊C was found to solubilise felodipine in the aqueous solution 
to higher extent compared to corresponding concentrations of PVPVA and their polymeric blend 
(73).  The thermal dissolution of indomethacin in Eudragit E PO melt was reported to be 
convective and can be enhanced by increasing processing temperature and extruder screw speed 
(389). In addition, it was found that a stable supersaturated concentration of indomethacin over 
100 minutes of dissolution at pH 1.2 was achieved using a higher processing temperature 
indicating the formation of molecularly dispersed drug in the polymer matrix (389). It should be 
mentioned that due to the cationic character of this polymer, it can form strong interactions with 
anionic drugs resulting in stabilisation of their molecular level amorphous solid dispersions (395).  
In this study, Eudragit E PO was used as a principle polymer in the fabrication of felodipine solid 
dispersions using FDM 3D printing technology due to its reported use as a carrier for drug loaded 
solid dispersions processed using HME indicating its good thermoplastic, solubilising and 
stabilising properties. In addition, the pH dependent solubility of this polymer makes it as a 
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suitable pharmaceutically approved carrier for immediate release of felodipine from the designed 
formulations.  
2.2.2.6 Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft 
copolymer (Soluplus)  
Soluplus is a novel amphiphilic graft copolymer designed specifically for improving the 
dissolution properties of poorly water soluble drugs (BCS class II) using HME. The copolymer 
performs this role by its interesting dual functionality of dispersing the drugs as molecularly 
dispersed in the polymeric matrix and its ability to form micelles in aqueous media (396).  This 
recently developed polymer has a white to slightly yellowish freely flowing granules with a 
molecular weight within the range of 90,000-140,000 g/mole. The copolymer is soluble in water, 
acetone (up to 50%), methanol (up to 45%), ethanol (up to 25%) and dimethylformamide (DMF) 
(up to 50%) at room temperature. The chemical structure of soluplus is illustrated in Figure 2.9 
(56). The measured critical micelle concentration (CMC) for soluplus and its extrudates were 
found to be 1.93 µg/mL and 4.24 µg/mL at 37 °C, respectively. The determination of two critical 
micelles values for soluplus was attributed to the partial splitting of chains of the polymer (397). 
It was reported that the presence of dissolved ions in the solution of hydrophilic polymers like 
soluplus which exhibit sol-gel behaviour can affect the solubility of the polymer (398, 399). 
Dissolved ions in the media have the ability to dehydrate this polymer by competing with it on 
the water of hydration resulting in precipitation of the polymer in a phenomenon called salting 
out (400). For these polymers, as the temperature increases, they start to precipitate and form a 
gel at the gelation temperature and thus the transmission of light will decrease due to precipitation. 
The temperature at which 50% of the transmission light is reduced is termed the cloud point (401). 
The presence of the dissolved ions was reported to reduce the cloud point and this phenomenon 
was also previously reported to happen in solutions of hydrophilic polymers like hypromellose 
(402), poloxamer (403) and soluplus (149). 
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Figure 2.9: Chemical structure of soluplus; adapted from reference (404) 
Soluplus is an amorphous polymer with a Tg of approximately 70 ̊C with excellent thermoplastic 
properties making it a suitable for HME as processing technique at relatively safe temperatures. 
This polymer was used principally as a solubiliser for BCS class II drugs for the production of 
amorphous solid dispersions using different fabrication techniques including HME, 
electrospining, spray drying and freeze drying, etc. (87, 396, 404). In addition, this amphiphilic 
copolymer showed an interesting absorption enhancing activity which can be used as additional 
functionality to improve the bioavailability of drugs through the biological membranes (405).  
This polymer was used effectively to improve the dissolution properties of drug like atorvastatin 
calcium (406), efavirenz (407) ezetimibe and lovastatin (408). It should be mentioned that this 
polymer was used as a single carrier or as a component of polymeric blend for the production of 
molecular level amorphous solid dispersions (118, 407). In this study, soluplus was used as the 
main polymer in a blend of excipient used for fabricating felodipine solid dispersions by FDM 
3D printing.  
2.2.2.7 Polyvinyl alcohol (PVA) 
PVA is one of the widely used synthetic pharmaceutical polymers because it is water soluble, 
thermally stable, it has low gas permeability, good adhesiveness, biocompatibility and 
biodegradability (409). It functions as a coating, lubricant, stabilising and viscosity increasing 
agent in different pharmaceutical dosage forms and drug delivery systems. This partially 
crystalline polymer occurs as an odourless white to creamy granular powder with variable degrees 
of hydrolysis and molecular weights. This polymer exists as wholly or partly hydrolysed with 
different degrees of hydrolysis. The partially hydrolysed form is a copolymer of vinyl alcohol and 
vinyl acetate units originally synthesised by polymerisation of polyvinyl acetate followed by 
alkaline aqueous hydrolysis (in the presence of sodium hydroxide) to substitute the acetate by a 
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hydroxyl group. The extent of hydrolysis ranging from 30-99% and the hydrolysis is dependent 
on the concentration of the catalyst, reaction temperature and time and the molecular weight of 
the polymer (410). The degree PVA hydrolysis affects the aqueous solubility of the polymer 
which increases with the increase in the degree of hydrolysis. Also, the crystallinity is reported to 
increase with increasing the extent of hydrolysis (410). The reported melting points for the fully 
and partially hydrolysed grades are 228 ̊C and 180-190 ̊C respectively. The water solubility is 
reported to be higher for highly hydrolysed grades compared to the grades with the lower 
percentage of hydrolysis (185, 411). The molecular structure of this polymer is shown in Figure 
2.10. 
 
Figure 2.10: Chemical structure of hydrolysed PVA; adapted from reference (412) 
PVA is considered as a component for the formulation of variety of pharmaceutical preparations 
such as hydrogels (413), solid dispersions (414) and nanoparticles (415).  
PVA was used as a thermoplastic hydrophilic polymer for solubilising and stabilising drugs in 
solid dispersions prepared by HME. Indomethacin was found to be partially miscible in the 
amorphous domains of the semicrystalline structure of PVA as revealed by the consistent results 
of thermal analysis using hot stage microscopy and DSC. The same study indicated immiscibility 
between PVA and lacidipine as indicated by the detection of two glass transition temperature 
belonging to the amorphous drug and the amorphous fraction of the semicrystalline PVA (416). 
Recently, it was reported that partially hydrolysed PVA grades with a degree of hydrolysis higher 
than 70% were able to solubilise celecoxib and hydrochlorothiazide with improved release 
profiles. The release profiles of the two drugs from the grades of the lower degree of hydrolysis 
were found to be influenced by the ionic strength of the dissolution medium. To overcome the 
degradation problems that may affect the stability of thermosensitive drugs due to the high 
processing temperature of the binary systems (180 ̊C), sorbitol was used as a plasticiser to reduce 
the extrusion temperature of PVA. The plasticised extrudate was cryomilled, mixed with 
celecoxib and re-extruded at relatively acceptable processing temperature (140 ̊C) with reduced 
mechanical shearing stress (screw speed reduced from 100 to 60 rpm). The dissolution profile of 
the ternary system for celecoxib was found to be superior in maintaining the supersaturation in 
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0.1 N HCl compared to the marketed product (Celebrex®) with highly comparable 
pharmacokinetic data (410). 
PVA is one of most commonly used polymers in the recently introduced FDM 3D printing to the 
pharmaceutical research field to produce formulations loaded with a variety of APIs as a 
promising approach in the direction of personalised medicine. The standard PVA filaments 
produced for general printing purposes were used in the literature to print tablets loaded with 
drugs like 5- aminosalicylic acid (5-ASA, mesalazine), 4-aminosalicylic acid (4-ASA) and 
prednisolone using FDM 3D printing at processing temperature higher than 200 C̊ (226, 417).  In 
order to load the prednisolone in PVA filaments, the filaments were incubated in a prednisolone 
saturated methanolic solution at 30 ̊C for 24 hours followed by drying at 40 ̊C and weighing the 
loaded filaments every hour until stable weight was achieved indicating evaporation of the organic 
solvent. It was found that PVA filaments loaded with prednisolone were able to be printed into 
regular ellipse-shaped tablets using this technology. The fabricated tablets with 1.9% w/w loading 
were able to extend the release of prednisolone to 24 hours (226). PVA was used as the benchmark 
polymer in this study because of its excellent thermoplasticity and good FDM 3D printability.  
 
2.3 Characterisation methods 
2.3.1 Thermogravimetric analysis (TGA) 
In principle, this technique uses the mass change of the sample under investigation (as a function 
of temperature or time) to identify and quantify chemical or, to a lesser extent, physical events 
(like sublimation) caused by the application of certain temperature program under defined 
atmosphere. The temperature range of the commercially available TGA equipments are from 
ambient to more than 1000˚C enabling this technique to perform many flexible analytical tasks. 
The gaseous environment employed varies depending upon the experimental requirements and it 
could be an inert (like nitrogen, helium, and argon), oxidising (such as air or oxygen) or reducing 
(8-10% hydrogen in nitrogen) gases. The most important part of any TGA is the thermobalance 
which is responsible about the measurement of the mass change as a function of temperature or 
time (94).  
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In pharmaceutical practice, TGA has many applications like estimation the thermal degradability 
and desolvation studies of different pharmaceutical materials (94). In this project, TGA was used 
to evaluate the thermal stability of the raw materials involved in the preparation of felodipine 
formulations to prove their ability to withstand the temperature used during the HME-IM and 
FDM 3D printing techniques. In addition, the moisture content of these materials was also 
investigated as this considered as an important factor that affects the physical stability of the drug 
in the final solid dispersed patches.       
In this study, TGA Q5000 (TA Instruments, Newcastle, USA) was used to evaluate the thermal 
stability of raw materials, physical mixtures and processed samples. In addition, TGA was used 
to assess the percentage of moisture entrapped within the samples under investigation.   
2.3.2 Differential scanning calorimetry (DSC) and modulated temperature 
differential scanning calorimetry (MTDSC) 
Differential scanning calorimetry (DSC) is an essential tool for the thermal analysis of materials 
in many fields including pharmaceutical product development. The principal of this analytical 
technique involves the detection heat changes accompanied thermal events like melting, 
crystallisation, glass transitions, and decomposition reactions induced by applying controlled 
temperature program (heating, cooling or isothermal) to the sample under a defined atmosphere 
(94).  There are two kinds of DSC machines, these are heat flux and power compensation. Heat 
flux DSC uses two pans (crucibles) for the sample and the reference in a single furnace. Both 
crucibles are heated under the same temperature program and the difference in temperature 
between the pans is detected and converted into energy. On the other hand, power compensation 
DSC uses two furnaces for both of the sample and the reference and both of them are heated and 
maintained at the same temperature. The difference in energy supply to maintain the sample and 
the reference temperatures identical during the DSC experiment is then measured as sample 
thermal event (94). In this study, heat flux type of DSC was used. 
Heat flow from the furnace to each crucible can be explained in Equation 2.1: 
dQ/dt = ΔT /R  …………….....Equation 2.1     
where dQ/dt represents heat flow, ∆T is the temperature difference between the furnace and the 
pan and R is the thermal resistance in the heat flow between the furnace and the crucible (94). 
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The other fundamental parameter involved in DSC analysis is the heat capacity of the sample (Cp) 
which is defined as the energy supplied to increase the temperature of the certain material by one 
degree Kelvin (1 K). This parameter generally gives an estimation of the sample capability to 
hold energy at specified conditions. In DSC practice, this function can be expressed by the 
Equation 2.2: 
dQ/dt = Cp . dT/dt  …………….....Equation 2.2     
where dT/dt is the heating rate of the program (94). 
Modulated temperature differential scanning calorimetry (MTDSC) is an extension of standard 
DSC in which the addition of sine waves to the temperature programme and a mathematical 
procedure are introduced for the purpose of separation (deconvolution) of various events that the 
sample might exhibit during the course of experiment. The deconvolution of these behaviours can 
be explained in Equation 2.3: 
dQ/dt = Cp . dT/dt + f(t,T)  …………….....Equation 2.3    
where f(t,T) is the time and temperature function that represents a response accompanying 
physical or chemical transitions. This equation separates between the reversible processes 
(processes in which the heat flows are correlated with the heat capacities of the samples) and 
irreversible processes (processes involve the contribution of the enthalpies of reactions) which 
cannot be separated using standard DSC. The temperature programme for MTDSC can be 
explained by Equation 2.4: 
T = T0  + bt + B . sin (ωt )  …………….....Equation 2.4     
where T represents the temperature at time t, T0 is the temperature at time zero, b is the heating 
rate, t is the time, B is the amplitude of oscillation, ω is the frequency of oscillation. Accordingly, 
the heat flow Equation 2.3 can be rewritten in the following expression: 
dQ/dt = Cp (b + Bω . cos(ωt))+  f (t,T) + C sin(ωt)  …………….....Equation 2.5     
where Bω . cos (ωt) represents the modulated heating rate, f(t,T) is the kinetic effect excluding 
the effect of modulation, and C is the amplitude of the kinetic response. The heating and cooling 
rates in MTDSC should be programmed in very slow rates for pharmaceuticals (1-3 ˚C/min) to 
prevent the appearance of artifacts into the reversing and non-reversing signals generated from 
the deconvolution of modulated heat flow signal (94). 
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In this study, thermal analysis of raw materials, their physical mixes, and processed formulations 
was conducted using the Q-2000 MTDSC (TA Instruments, Newcastle, USA) attached to RC90 
cooling unit. Full calibration was performed before samples measurements. DSC in both standard 
and temperature modulated modes was used to investigate the thermal properties of raw materials, 
physical mixtures and fabricated formulations. 
2.3.3 Thermal analysis by structural characterisation (TASC) 
TASC is a recently developed technique by Reading et al as an optical analogue of micro/nano 
thermal analysis. This new microscopic tool has many applications like thermal dissolution 
analysis, glass transition kinetics, analysis of melting behaviour, analysis of heterogeneity as T-
map mode and thermomechanical analysis (418, 419). This technique has the advantage of 
running the analysis in fast, easy and cheap cost in addition to its multiple applications. Figure 
2.11 represents the shape of the TASC signal corresponding to thermal events such as the melting 
of felodipine. 
 
Figure 2.11: Thermal analysis by structural characterisation (TASC) of felodipine melting at 10 °C/ 
min; A) selection of ROI and TA for TASC analysis and B) TASC signal corresponding to felodipine 
melting  
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During the TASC experiment, heating, cooling and/or isothermal temperature programs with 
different ranges and rates can be applied to the sample under investigation. The method of analysis 
by TASC consists of quantifying changes in successive micrographs while at the same time 
allowing for any movement by the sample during the ramps. As illustrated in Figure 2.12a, a 
region of the sample is selected that is designated the region of interest or ROI (within which lies 
the structure of interest). Also, a larger area (the target area or TA) over which the ROI is scanned 
is selected (in this case, the TA is the entire 7 × 7 pixels). Figure 2.12b shows the extracted ROI 
that is the template that is raster scanned over the TA. At each point, in the scan, the corresponding 
pixels are subtracted and the sum of the modulus of all differences is calculated. In this simplified 
representation, subtracting the same pixel values gives zero and subtracting different pixels gives 
1. After the scan is completed, it is the minimum value for the sum of all differences obtained 
during the course of the scan that is returned by the TASC algorithm. Figure 2.12c shows the 
start of the raster scan in the top left-hand corner. Because no structure is present in this part of 
the TA, when the ROI template is subtracted, the total sum of all subtractions is 1 (there is only 
one pixel where the ROI template is different from the selected region of the TA). The next step 
in the raster scan is to move the ROI template one pixel to the right as shown in Figure 2.12d; 
the value obtained is again 1. The ROI template is moved another pixel to the right, and the 
process continues until the entire TA has been scanned. The value zero is only obtained when the 
ROI template is in the centre of the TA as indicated in Figure 2.12a. This zero value is the 
minimum obtained during the course of the scan; thus, zero is returned by the TASC algorithm 
indicating no change. If the black pixel that represents the structure of interest moves as shown 
in Figure 2.12e, the value at the first point of the raster scan (such as the step illustrated in Figure 
2.12c) is now zero. At all other positions, the value is greater than zero. It follows that the 
minimum value returned by the TASC algorithm at the end of the scan is still zero indicating no 
change even though the structure has moved. When the black pixel disappears, i.e., the structure 
has changed, the value returned at all points during the raster scan is 1 and TASC returns the value 
1. Under this working principle, when the structure moves but does not change, the TASC value 
does not change, but when the structure changes, the TASC value increases. However, it is worth 
mentioning that for this to work the TA must be big enough so that the structure of interest does 
not travel outside of its limits. This is not difficult to achieve in practice simply by inspecting the 
first and last images.  
For real-life samples of the type studied here, as the sample is heated, it often softens and all 
apparent structures vanish giving rise to a featureless image. In a typical experiment of this kind, 
there is no further change beyond this point; i.e., the intensity difference values are unchanging. 
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Thus, the TASC value reaches a plateau (of course decomposition will occur if the temperature 
is taken very high but this was always avoided in this study). All the values calculated relative to 
this plateau are then normalised because the absolute TASC values change with the size of the 
ROI and lighting conditions. Variations due to slight differences in lighting conditions are best 
removed by normalizing. Similarly, comparisons between different sized ROIs are best achieved 
by comparing normalised values.  
 
Figure 2.12: Working principle of TASC a) represents an image of 7×7 pixels that is the Target Area 
(TA). The Region of Interest (ROI) is designated by the dashed box and the black pixel represents 
the only structure in the ROI. b) is the extracted ROI which acts as a template that is raster scanned 
over the TA. Under b) the results of subtracting the different values for the pixels are given; in this 
simplified case subtracting the same values gives zero and subtracting different pixels gives 1. The 
raster scan starts in the top left corner as shown in c) with the dashed line, the sum of all differences 
in this case is 1 (only one pixel is different). When the ROI is moved one pixel to the right as shown  
in d) (the next step in the raster scan) the same value is obtained. If the black pixel moves as shown 
in e) the value at the start of the raster scan is zero 
In this study, TASC was used as a novel thermal characterisation technique to investigate the 
heterogeneity of complex pharmaceutical solid dispersions prepared by HME-IM technology. 
The TASC system is composed of a Linkam MDSG600 automated temperature controlling 
(heating-cooling) stage (Linkam Scientific Instruments Ltd, Surry, UK), which is fixed to a 
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Linkam imaging station (Linkam Scientific Instruments Ltd, Surry, UK), and an imaging capture 
and analysis interface powered by TASC software provided by Cyversa (Cyversa, Norwich, UK). 
The microscope used in this study has a reflective LED light source and a lens with X10 
magnification. 
2.3.4 Dynamic vapour sorption (DVS) 
Dynamic vapour sorption is a gravimetric method that measures the rate and the extent of solvent 
(like water) absorption and desorption by the sample under specified conditions of temperature 
and relative humidity as a function of time. This technique is widely utilised in the development 
of pharmaceutical products using a variety of modes in which the relative humidity inside the 
chamber is either stepped (sorption isotherm), ramped (adsorption-desorption isotherm) or 
maintained constant at constant temperature (isohume experiments) (420). DVS is normally used 
for many applications including modelling the process of moisture uptake, characterisation of 
recrystallisation, stability and structural changes of pharmaceuticals (420-423).  
In this project, TGA Q5000 (TA Instruments, New Castel, USA) was used to measure the extent 
of moisture uptake by the raw materials and the impacts of processing techniques and the loading 
percentage of felodipine in the matrices. Isohume mode was used at constant relative humidity 
(RH) 75% and temperature 25 ˚C.  
2.3.5 Polarised-light hot stage microscopy (HSM) 
It is one of the thermoptometric methods in which the sample under investigation is analysed for 
its optical properties as a function of time or temperature using specific atmosphere. The recent 
advances in the design and applications of this analytical technique make it a very useful tool to 
understand the thermal behaviour of different compounds and mixtures (424). In this study, the 
system used consists of an AV camera attached to a microscope equipped with polarised light 
facility and the hot stage containing the sample on glass slide is placed on the stage of the 
microscope for visual observation. The main purpose of using this apparatus is to visualise 
thermal transitions like melting, thermal dissolution and crystallisation for raw materials and 
different forms of formulations as a complimentary analytical technique to support the results 
obtained by DSC. HSM experiments were conducted using a Mettler Toledo FP90 Central 
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Processor and an FP82HT Hot Stage, a Leica DM LS2 Microscope and a JVC digital colour video 
camera connected to a PC. 
2.3.6 Scanning electron microscopy (SEM) 
Scanning Electron Microscopy (SEM) is one of the most widely used technique for the analysis 
of microstructural properties of solid systems. The basic components of this versatile microscopic 
instrument are the lens system, electron gun, electron collector, cathode ray tubes for visual a 
photo recording and other related electronics. The electrons are generated and accelerated by the 
electron gun (tungsten hairpin) into small beam having an energy range (0.1-40 keV) which is 
then demagnetised and focused into the sample under investigation. SEM has many applications, 
but the most important use is to capture topographic images within the magnification range 10-
1000,000X (425).  
SEM used in this study was JSM 5900LV Field Emission Scanning Electron Microscope (Jeol 
Ltd, Japan) equipped with a tungsten hairpin electron gun. The purpose of the analysis was to 
scan the surfaces and cross-sections of the formulations to provide an understanding of the 
microstructure of the formulations as fresh and aged samples.  
2.3.7 Energy dispersive spectroscopy (EDS) 
EDS is one of the frequently used chemical characterisation techniques as an attachment to SEM 
or TEM. This tool offers a number of valuable advantages including rapid analysis, easy 
interpretation of results and good spatial resolution (426). The principle of this technique is the 
stimulation of the sample to emit characteristic X-rays by focusing high energy beam of photons, 
electrons or X-rays. The charged particles like the electrons cause the excitation of electron in an 
inner energy level and eject it creating an electron hole. This cause an electron from higher energy 
level to fill the hole and the energy difference between the outer and the inner energy levels may 
be released in the form of X-rays that can be detected and measured by the energy dispersive 
spectrophotometer. Because the difference in the energy levels is characteristic for the atomic 
structure of each emitting element, EDS can provide information (qualitative and quantitative) 
about the atomic composition of the sample spot under analysis (425). In order to confirm the 
identity of the detected crystal growth and taking advantage of the presence of the two chlorine 
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atoms in the structure of felodipine which serve as a chemical marker for the identification, EDS 
(INCA Energy manufactured by Oxford Instruments) combined with SEM was used in this study.  
2.3.8 Powder X-ray diffraction (PXRD) 
X-rays are high energetic electromagnetic radiations having an energy ranging from 200 eV to 1 
MeV which specifies their location in the spectrum between γ-rays and ultraviolet (UV) radiations 
(427). The principle of X-ray diffraction is explained by Bragg who noticed that atoms or 
molecules of crystals are arranged in a regular way in space and this arrangement can be described 
as parallel plates separated by certain distance d. When X-rays applied on crystals, the scattering 
centres in the plane act as a mirror for the incident beam of X-rays. A constructive interference 
results from the reflection of X-rays by two planes separated by certain distance. This 
phenomenon is explained by Bragg’s law (Equation 2.6): 
2d sin Ɵ = nλ …………….....Equation 2.6 
where d is the interplanar spacing of the diffracting planes, Ɵ is the incidence angle of X-rays, n 
is an integral number of wavelengths, and λ is the wavelength of the X-ray beam. 
Generally, X-ray diffraction is composed of three basic components including X-ray source, 
sample under investigation and the X-ray detector. These parts lie in the circumference of single 
circle known as the focusing circle and the angle between the X-ray source and the plane of the 
specimen is Ɵ while the angle between the X-ray projection and the detector is 2Ɵ. PXRD is 
considered as one of the fundamental methods for the analysis of crystalline structures in the 
pharmaceutical field. Because the majority of drugs are crystalline solids, this analytical technique 
has been used mainly for the determination of structural fingerprints of solid matter qualitatively 
and quantitatively (427, 428). The purpose of using PXRD (Thermo ARL Xtra X-ray 
diffractometer; Thermo Scientific, Switzerland) in this project is to investigate the presence or 
absence of crystalline felodipine and detecting the possible polymorphic transformation in 
different formulations.  
2.3.9 X-ray micro computed tomography (XμCT) 
XµCT is a 3D X-ray imaging technique that has been widely used in a diverse range of 
applications to study the microstructure of objects without causing damage to the original sample. 
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In contrast to X-ray diffraction methods, where X-rays are not absorbed but are reflected by an 
ordered array of matter, with a XµCT experiment it is the absorption of X-rays that results in the 
image, in a manner analogous to transmission microscopy. The differentiation of different phases 
by XµCT relies on the electron density differences that are characteristic of different elements. In 
the pharmaceutical industry, XµCT is used routinely to identify physical imperfections in solid 
dosage forms showing a high density contrast such as voids and cracks in tablets and coatings 
(429, 430). Therefore, the ability of the technique to distinguish materials with similar attenuation 
coefficients such as amorphous and crystalline forms of the same drug can be extremely limited 
(431) unless synchrotron radiation is used to improve the phase contrast (432, 433). However, for 
the conventional XµCT used in this study, in theory, if sufficient electron density differences are 
present between different phases contained within a sample, XµCT should be effective for 
resolving the distribution of these phases in 3D. The distribution of solid excipients in compressed 
tablets has been studied using XµCT based on this principle (434). However, it has not been 
widely used to investigate phase separation in solid dispersions. In this study, XµCT instruments 
have been used to investigate the heterogeneity and spatial distribution of different phases in 
felodipine solid dispersions with various drug loading percentages (0–30% w/w). Two types of 
XµCT equipment were used to achieve this objective; Phoenix v[tome]x m system (General 
Electric, Wunstorf, Germany) and SkyScan1172 high-resolution X-ray micro computed 
tomography (XµCT) scanner (Bruker-microCT, Kontich, Antwerp, Belgium). 
2.3.10 Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) 
spectroscopy 
ATR-FTIR is considered as one of very common vibrational spectroscopic characterisation 
technique that has many applications in the pharmaceutical field basically for elucidating the 
chemical structure of different materials. Normally, this spectrophotometric tool uses the mid-
infrared electromagnetic radiation within the wavenumber range of (4000-400 cm-1) to stretch or 
bend the chemical bonds within the molecules absorbing these radiations resulting in a complex 
and unique fingerprint specific for the sample under investigation (435). 
The sampling in ATR-FTIR is based on contact mode in which a crystal of high reflective index 
and excellent IR transmittance features such as diamond is used. This method offers a number of 
advantages compared to the other methods because this technique is quick and there is no need 
for further processing (such as milling and mixing with other materials) which is required during 
Chapter 2   Materials and methods  
 
87  School of Pharmacy / University of East Anglia 
 
sample preparation prior to scanning using other methods. This has great impact on removal of 
the destructive effect of preparation which might change the characteristics of the sample. 
The basic principle of ATR accessory is depending on measuring the changes that occur in totally 
internally reflected infrared radiation when they come into contact with a sample. In order for the 
internal reflectance to occur, the angle of incidence of IR beam should be greater than a critical 
angle Ɵc (a function of the refractive indices between the sample and ATR crystal) as expressed 
in Equation 2.7.  
  Ɵc = sin -1(n2/n1)  …………….....Equation 2.7 
where n2 is the refractive index of the sample and n1 is the refractive index of the crystal. Moderate 
angles of incidence are obtained by using crystals like Ge, ZnSe, or diamond which have a much 
higher refractive index compared to that of organic compounds. As a result of the internal 
reflectance of the IR beam, the generation of an evanescent wave which extends behind the 
surface of the sample into the sample held into contact with the crystal. The effective penetration 
depth (dp) defined as the distance from the ATR crystal-sample interface to the depth at which 
the decay in the intensity of the evanescent wave reaches 37% of its original intensity and can be 
expressed by Equation 2.8: 
  dp = λ /2πnp (sin2Ɵ - nsp 2)1/2 …………….....Equation 2.8 
where λ is wave length of IR beam, np is the refractive index of the ATR crystal, Ɵ is the angle 
of incidence of IR radiation, and nsp= n2/n1 is the ratio of the refractive indices between the sample 
and the internal reflective element (crystal) (436). 
In this study ATR-FTIR was used to characterise felodipine solid dispersions prepared by HME-
IM and FDM 3D printing. The attention was focused on understanding the fingerprints of the raw 
materials, physical mixes and processed samples and investigating the possibility of polymorphic 
transformation of the model drug and its ability to interact with the components of the carrier 
mixtures. IFS 66/S FTIR spectrometer (Bruker Optics Ltd, Coventry, UK) fitted with a Golden 
Gate® ATR accessory with temperature controllable top plate (Specac, Orpington, UK) and 
diamond internal reflection element was used in this study. 
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2.3.11  Fourier transform Infrared (FTIR) imaging  
FT-IR imaging is a powerful characterisation techniques well suitable for investigating the 
distribution and the dynamics of different components in heterogeneous multicomponent 
formulations. In this method, the spatial resolution of individual components is achieved 
according to the spectral response of each detection element. The collected spectra are used to 
build up a chemical map of the sample under investigation (437, 438). This technique is operating 
in different methods including absorption, transmission or reflection modes (the last two modes 
through the use of ATR as complimentary accessary). ATR-FTIR imaging has many advantages 
over the original FTIR imaging including the minimal sample preparative procedures which may 
be useful to maintain the integrity of the sample and suitability for samples having high spectral 
absorption properties like water containing systems. Generally, ATR- FTIR imaging has many 
pharmaceutical applications including studying dynamic systems (tablets dissolution, water 
sorption, crystallisation and polymer dissolution in organic solvents) and the chemical distribution 
of heterogeneous samples (439).  In this study, the heterogeneity of the surface composition was 
assayed with a Nicolet iN10MX infrared microscope operating in reflection mode.  
2.3.12 Laser diffraction (LD) particle size analysis 
Particle size is a critical formulation parameter that affects many physicochemical and 
biopharmaceutical properties of drugs in their final dosage forms like release profile, absorption 
rate, flow properties, mixing and segregation of powders and irritability of ophthalmic 
preparations. There are different methods used for the analysis of particle size including: 
microscopy and image analysis, laser diffraction, dynamic light scattering, coulter counter, etc. 
with different principles of operation and applications. Among these techniques, laser diffraction 
is widely used in pharmaceutical industry due to its fast analysis, robustness, reproducibility and 
precision of results and suitability for broad spectrum of products like liquid, solid, and gaseous 
dispersions. The principle of operation for laser diffraction is based on the relationship between 
the particle size and the angle and the intensity of the diffracted laser light. The detected 
information about the intensity and the angle of diffracted light is then processed using an 
algorithm based on Mie scattering theory that transform these data into particle size results (440). 
In this study, laser diffraction (Helos/Rodos 1636, Sympatec GmbH, Germany) was used to 
measure the particle size of felodipine form different batches as received from the supplier to 
investigate the impact batch to batch particle size variability on the formulation process. 
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Felodipine particles were dispersed in a filtered saturated aqueous solution of felodipine under 
sonication and stirring inside 50 mL quartz cuvette. Five replicates for each sample were analysed. 
2.4 Evaluation methods 
2.4.1 In vitro release profiles 
In vitro drug release is a critical evaluation test to provide quantitative and kinetic information 
about the ability of the dosage form to liberate the drug and make it available at the site of 
absorption. For HME-IM patches designed for buccal administration, unidirectional dissolution 
studies to simulate the release profile for systemic buccal administration were conducted using 
the paddle over disc method (similar to USP apparatus 5) as illustrated in Figure 2.13 using a 
dissolution apparatus (Caleva 8ST, Germany). 
 
Figure 2.13: Schematic representation of the paddle over disc apparatus used for dissolution profile 
study; adapted from reference (441) 
Under sink and non sink conditions, patch samples having the equivalent of the maximum daily 
dose of felodipine (10 mg) attached to a glass disc using double adhesive tape were immersed in 
900 mL of phosphate buffer saline pH 6.8 (simulated salivary fluid) at 37 ± 0.5°C and 100 rpm 
paddle rotation. At different pre-determined time intervals, 5 mL samples were withdrawn and 
filtered using a 0.45 um filter unit (Minisart NML single use syringe, Sartorius, UK). The filtered 
samples were then diluted with an equal volume of absolute ethanol and the samples were 
analysed using a UV-VIS spectrophotometer (Perkin Elmer lambda 35, USA) at 363 nm. Samples 
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withdrawn were substituted with dissolution media at the same temperature after each sample was 
taken. All drug release studies were conducted in triplicate.   
The in vitro drug release profiles for felodipine FDM 3D printed discs were measured in 
dissolution testing apparatus (Caleva 8ST, Germany) using the paddle method (USP apparatus 1). 
A paddle rotation speed of 100 rpm and 900 mL of pH 1.2 HCl or phosphate buffer pH 6.8 at 37 
± 0.5 ̊C were used for all experiments. The pure crystalline drug (approximately 5 mg in powder 
form) and disc shaped dispersions containing the equivalent of the daily dose (5 mg) of the drug 
were used in this study. Under non-sink conditions, 5 mL dissolution samples were withdrawn at 
pre-determined time intervals. The samples were directly filtered through a membrane filter with 
0.45 µm pore size (Minisart NML single use syringe, Sartorius, UK). The filtered sample solutions 
were diluted with equal volume of ethanol. 5 mL of fresh pre-warmed (37 ± 5 C̊) dissolution 
media was added to the dissolution vessel after each sampling. The samples were analysed using 
a UV–VIS spectrophotometer (Perkin Elmer lambda 35, USA) at 363 nm. All dissolution tests 
were performed under non-sink conditions with no addition of surfactants in the media in order 
to minimise the effect of polymer-surfactant interactions on the drug release behaviour from the 
formulations. All drug release studies were conducted in triplicate. 
2.4.2 Determination of drug loading efficiency 
Accurately weighed drug loaded FDM 3D printed discs of different formulations were dissolved 
in a beaker containing 200 mL of 50:50 simulated gastric fluid pH 1.2 and absolute ethanol. The 
beaker was covered with a parafilm tape to minimise solvent evaporation during dissolution. The 
medium was stirred using magnetic stirrer at room temperature. After complete dissolution, 5 mL 
samples were withdrawn and filtered using 0.45 µm pore size (Minisart NML single use syringe, 
Sartorius, UK). The filtered samples then scanned for their content of felodipine using a UV–VIS 
spectrophotometer (Perkin Elmer lambda 35, USA) at 363 nm. The loading efficiency 
measurements for the loaded discs were carried out in triplicate. 
2.4.3 In vitro mucoadhesion study 
Mucoadhesion is considered as a critical parameter for the successful delivery of drugs from 
buccal patches to the systemic circulation. The description of mucoadhesion is generally related 
to the degree of interaction between the polymers with adhesive properties with the epithelium of 
Chapter 2   Materials and methods  
 
91  School of Pharmacy / University of East Anglia 
 
the site of application. Mucoadhesivness of buccal patches can be estimated by measuring the 
force required to detach the patch from substrate and work of adhesion or which give insights for 
the retention pattern of these patches at the application surface (441). There are many approaches 
for quantitative determination of mucoadhesion force based on measuring the shear strength to 
evaluate the force mucoadhesion (442-444). Measuring the tensile strength is the most widely and 
accurate method to assess the mucoadhesivness of buccal films especially after the development 
of benchtop texture analyser (441). 
In this study, the mucoadhesive measurements were carried out on felodipine buccal patches 
prepared by HME-IM technique using a TA-XT2 Texture Analyser (Stable Micro Systems, 
Surrey, U.K.) fitted with a 5 kg load cell in tension mode. Felodipine loaded buccal patches (n = 
5) having an area of 1.56 cm2 were attached to the cylindrical perspex probe (1.2 cm diameter and 
4.5 cm length) using double-sided adhesive tapes. Aqueous gelatin solution in a concentration of 
6.67% w/v was allowed to set as solid gel in a Petri dish (diameter 88 mm), which was used to 
simulate the adhesion of buccal mucosa. Prior to each measurement, the gelatinous substrates 
were equilibrated with 1 mL of 2% w/v porcine mucin solution (pH of 6.8) and fixed on the 
platform of the texture analyser. For all tests, the probe moved at a pretest speed of 0.5 mm/s, a 
test speed of 0.5 mm/s, and a post-test speed of 1 mm/s, with an applied force of 0.5 kg, a return 
distance of 10 mm, and a contact time of 60 s. During the post-test period, the probe was lifted 
automatically with 0.05 kg force. 
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3.1 Introduction 
The production of solid dispersions by thermal processing such as HME and FDM 3D printing is 
considered as an efficient approach to improve the dissolution properties of poorly water-soluble 
drugs (8, 445-447). Preformulation studies are essential part for the development of any 
pharmaceutical product as they provide the scientific basis needed during the formulation and 
evaluation processes. These studies involve physical and chemical characterisation of the drug(s) 
under investigation together with the pharmaceutical excipients needed for the fabrication of the 
intended product. These investigations use a wide variety of physicochemical characterisation 
techniques, prediction methods and evaluation studies to be used as a framework during the next 
stages of drug development process (151).  In this chapter, the physicochemical properties of 
felodipine and the other excipients presented in Chapter 2 were characterised using different 
thermal and spectroscopic characterisation techniques including ATR-FTIR, DSC, MTDSC, 
PXRD, DVS and SEM. These tools were used to provide information about the thermal properties 
of the drug and the excipients including melting, glass transition (Tg), recrystallisation, thermal 
history, crystallinity, thermal stability and moisture uptake of the formulation components. In 
addition, spectroscopic methods were used to provide details about crystalline and amorphous 
transformations, detecting functional groups that may be involved in intermolecular interactions 
and morphological properties. Furthermore, DSC was used to investigate the suitable blends of 
the excipients to be used for the development of the loaded formulations. Estimating drug-
excipient(s) miscibility using solubility parameter based on group contribution (Hoftyzer and Van 
Krevelen and Hoy) and melting point depression methods were used to predict the miscibility of 
the components as explained in Chapter 1 (83, 84).  
Research Objectives: 
1. To investigate the physicochemical properties of the raw and physical mixtures of drug-
excipients materials used in the formulation of solid dispersions. 
2. To study the thermal properties of PEG/PEO blends and how the addition of surfactants 
could affect their behaviour. 
3. To estimate the solubility parameters of felodipine and other formulation components in 
order to predict their miscibilities. 
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3.2 Materials and Methods 
3.2.1 Materials 
Felodipine (MWT =384.25 g/mole) (batch no. FP140602) was purchased from Afine Chemicals 
Ltd (Hangzhou, China). Polyethylene glycol (PEG) 4000 (average MWT = 4060 g/mole) and 
polysorbate (Tween®) 80 (MWT = 1310 g/mole) were purchased from Sigma-Aldrich (Dorset, 
UK). Vitamin E TPGS (MWT = 1513 g/mole) and two grades of polyethylene oxide (PEO K900) 
WSR 1105 (MWT= 900,000 g/mole) and (PEO K100) WSR N10 LEO (MWT= 100,000 g/mole) 
were kindly donated by BASF (Ludwigshafen, Germany) and Colorcon Ltd (Dartford, UK) 
respectively. Soluplus (average MWT 116000 g/mole), eudragit® E PO (average MWT 116000 
g/mole) and 33-38% partially hydrolysed polyvinyl alcohol (PVA LM 25) (MWT = 18,000-
25,000) were kindly donated by BASF (Ludwigshafen, Germany), Evonik Industries (Darmstadt, 
Germany) and Kuraray Co., Ltd.  (Tokyo, Japan), respectively.   
3.2.2 Methods 
3.2.2.1 Preparation of amorphous felodipine 
Amorphous felodipine was prepared by melting the drug in an aluminium weighing dish using a 
preheated hot plate at 160 C̊ using melt-cool method.  
3.2.2.2 Preparation of binary and ternary excipients’ extrudates 
PEG 4000/PEO K900 extrudates with or without surfactants (Tween 80 or TPGS) were prepared 
using co-rotating twin screw mini-extruder (HAAKE™ MiniLab II Micro Compounder, Thermo 
Electron, Karlsruhe, Germany). The physical mixtures of different binary and ternary 
combinations were mixed using mortar and pestle for at 2 minutes before feeding into the extruder. 
The extrusion process was performed at 65 °C, 100 rpm for 5 minutes. After the specified 
residence time, excipients extrudates were flushed and collected for characterisation.  
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3.2.2.3 Physicochemical characterisation of raw materials  
3.2.2.3.1 Thermogravimetric analysis (TGA) 
In order to investigate the thermal stability of felodipine and other excipients and estimate the 
suitability of these materials to processing conditions, TGA analyses were conducted. A Q5000 
(TA Instruments, Newcastle, USA) TGA equipment was used to analyse the samples (5-10 mg) 
by applying a temperature program of 10 ºC/min over the temperature range 25-500 ºC. 2-3 
replicates for each sample were tested and Universal Analysis software was used to analyse the 
obtained results. 
3.2.2.3.2 Differential scanning calorimetry (DSC) and modulated temperature DSC 
(MTDSC) 
In this study, Q-2000 MTDSC equipped with an RC90 cooling unit (TA Instruments, Newcastle, 
USA) was used to detect the thermal transitions of raw and processed samples. Before analysis, 
baseline temperature and heat capacity calibrations were performed. The samples were prepared 
using standard aluminium pans and lids (TA Instruments, Newcastle, USA). Dry nitrogen gas was 
used as the purge gas with a flow rate of 50 mL/min. For standard DSC mode, temperature 
programs at a heating rate of 10 ˚C/min in a range of temperatures between -80 to 180 ˚C 
(depending on the individual experimental settings) were used to scan the samples for heating, 
cooling and/or reheating cycles. For MTDSC experiments, a temperature program with an 
amplitude of ± 0.318˚C, a period of 60 second and a scanning rate of 2 ˚C/min from -80 ˚C to 180 
˚C was used. Three replicates of each sample were measured. Universal Analysis software was 
utilised for the analysis of the collected thermograms. 
3.2.2.3.3 Dynamic vapour sorption (DVS) 
DVS was used to measure the extent of moisture uptake by the raw materials used in the 
fabrication of felodipine solid dispersions using HME-IM. Isohume mode was used at constant 
relative humidity (RH) 75% and temperature 25 ˚C. Raw materials and freshly prepared samples 
were loaded in a previously tared pan of the DVS (TGA Q5000) (TA Instruments, Newcastle, 
USA). For each experiment, a drying step is initially conducted to remove the already existing 
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water in the samples by holding the sample at 0% relative humidity (RH) at 25 ˚C for 2880 
minutes or when the percentage of weight loss is ≤ 0.01% for 30 minutes indicating reaching 
equilibrium with complete removal of moisture. After that, an isohumic step is initiated at 75% 
relative humidity (RH) and 25 ˚C for 2880 minutes or when the percentage of weight gain is ≤ 
0.01% for 30 minutes indicating reaching a plateau with the maximum percentage of moisture 
absorption by the sample. The analysis was conducted for each sample as triplicate, and the 
collected data were analysed using the Universal Analysis software.  
3.2.2.3.4 Attenuated total reflectance-Fourier transform infrared spectroscopy 
(ATR-FTIR) 
Raw and processed samples were scanned using an IFS 66/S FTIR spectrometer (Bruker Optics 
Ltd, Coventry, UK) fitted with a Golden Gate® ATR accessory (Specac, Orpington, UK) equipped 
with diamond internal reflection element. All ATR-FTIR spectra were obtained using a scanning 
resolution of 2 cm-1 with 32 repeated scans in absorbance mode in the range of wavenumbers of 
4000-550 cm-1. Opus software was used for analysing the collected results. All measurements 
were performed in triplicates.  
3.2.2.3.5 Scanning electron microscopy (SEM) 
The SEM images for felodipine particles was conducted using JSM 5900LV Field Emission 
Scanning Electron Microscope (Jeol Ltd, Japan) equipped with a tungsten hairpin electron gun. 
Felodipine particles were spread over the double adhesive of the SEM stubs using double adhesive 
tape and then coated with gold using a Polaron SC7640 sputter gold coater (Quorum Technologies, 
Laughton, UK) before imaging.  
3.2.2.3.6 Powder X-ray diffraction (PXRD) 
The diffraction patterns of felodipine and all other excipients were collected using Thermo ARL 
Xtra X-ray diffractometer (Thermo Scientific, Switzerland) equipped with a copper X-ray Tube 
(λ =1.540562 Å). All samples were measured using an X-ray beam with a voltage of 45 kV and a 
current of 40 mA. The measurements were performed using an angular scan range (5 ˚ < 2Ɵ < 60 
˚), step scan mode with a step width of 0.01˚ and scan speed of 1 sec/step. 
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3.2.2.3.7 Solubility measurements 
The saturated solubility of felodipine in Tween 80 was measured by adding an excess amount of 
felodipine to 40 mL of Tween 80. The mixture was incubated at room temperature for 72 hours 
with continuous shaking at 200 rpm using a shaking incubator (MaxQ 4000, Thermo Scientific, 
USA) to facilitate the dissolution of the crystalline drug in Tween 80. After 72 hours, the 
supernatant was filtered using a 0.45 µm Millipore filter pore size membrane filters (Minisart 
NML single use syringe, Sartorius, U.K.) and 0.5 mL of the filtered solution was diluted to 100 
mL with phosphate buffer saline PBS pH 6.8. Due to the high concentration of felodipine which 
gives higher absorbance values, the solution was further diluted to 2000 mL using PBS pH 6.8 
containing 0.5% v/v Tween 80. The saturated solubility of felodipine in Tween 80 was determined 
by UV-VIS spectrophotometer (Perkin-Elmer Lambda 35, USA) at λmax 363 using the same 
standard curve constructed for measuring the solubility of felodipine in phosphate buffer saline 
(PBS) pH 6.8 containing 0.5% v/v Tween 80 (Appendix 2).  All measurements were repeated 
three times. 
3.3 Results  
3.3.1 Physicochemical characterisation of raw materials 
3.3.1.1 Felodipine 
Figure 3.1a illustrates the percentage and derivative of weight loss signals of felodipine heated 
at 10 ̊ C / min using TGA. The thermal degradation of felodipine occurred as a single step process 
with an onset at approximately 166 ̊ C and complete decomposition at 280 ̊ C. Standard DSC 
results show that felodipine form I has a melting peak at 144.6 ± 0.1 ̊C and ∆Hf about 81.66 ± 
1.64 J/g using 10 ̊ C / min (Figure 3.1b). Amorphous felodipine Tg and ∆Cp measured using 
MTDSC were 46.5 ± 0.2 ̊C and 0.34 ± 0.07 J/g.°C respectively at a heating rate of 2  ̊C / min, 
0.318 amplitude and 60 sec period as shown in Figure 3.1c. Due to the hydrophobic nature of 
felodipine, this drug has low tendency (0.21 ± 0.02% w/w) for moisture uptake as shown in 
Figure 3.2. 
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Figure 3.1: a) TGA analysis of felodipine using heating program of 10 ̊ C / min from ambient to 300 
°C (n=2); b) standard DSC thermogram of crystalline felodipine form I using 10 ̊ C / min heating 
ramp (n=3); c) reverse signal of MTDSC thermogram showing amorphous felodipine glass transition 
(Tg) using 2 ̊ C / min, 0.318 amplitude and 60 sec.s period (n=3) 
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Figure 3.2: Moisture uptake capacity of pure crystalline felodipine form I at 25 ̊C and 75% RH (n=3) 
The NH stretching vibrations in the IR spectra has been reported at 3372, 3334, 3370, 3329 cm- 1 
for the four crystalline polymorphic forms I-IV of felodipine, respectively (313-315, 318). 
Furthermore, the amorphous form shows an NH stretching peak at ~ 3339 cm-1 and peaks at 1701 
and 1682 cm-1 corresponding to the non-hydrogen bonded C=O group and the hydrogen-bonded 
C=O group respectively. The ATR-FTIR spectra for crystalline felodipine form I used in this study 
and amorphous form prepared from it by rapid cooling of the melt are shown in Figures 3.3a and 
b respectively which are consistent with data reported in the literature (315, 317). The most 
important difference between the spectra of form I and the amorphous form of felodipine are the 
peaks associated with the NH stretching, C=O stretching and CN stretching which reflects 
different strengths of intermolecular hydrogen bonding (448). Table 3.1 shows the characteristic 
absorption peaks of crystalline felodipine form I, amorphous felodipine and all other excipients 
used in this study.  
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Figure 3.3: ATR-FTIR spectrum of a) pure crystalline felodipine form I and b) amorphous felodipine 
(n=3) 
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Table 3.1: Characteristic ATR-FTIR absorption peaks of crystalline and amorphous felodipine  
Compound Chemical group Peak wavenumber (cm-1) 
Crystalline felodipine form I 
 
 
 
 
 
 
 
 
 
 
NH Stretching 3367 
aromatic CH stretching  3071 
CH stretching  2949 
C=O stretching 1688 
NH Bending 1643 
C = C ring stretching  1619, 1492 and 1445 
CN stretching 1202 
C-O-C stretching 1095 
Substituted benzene ring 725 and 800  
Cl stretching 561 
Amorphous felodipine NH stretching  3333 
aromatic CH stretching 3105 
CH stretching for CH3  2979  
CH stretching for CH2 2948 
C=O stretching 1697  
CN stretching  1206 
 
Since the determination of felodipine form I crystal structure in 1986, several studies have been 
published reporting new polymorphic forms (II-IV) obtained from various solvents (312-315, 318, 
319). The PXRD patterns of these forms are shown in Figure 3.4.  
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Figure 3.4: PXRD diffractograms of crystalline felodipine forms I-IV; adapted from reference (312) 
In this study, crystalline felodipine with the characteristics PXRD patterns of form I was used in 
the preparation of felodipine solid dispersions using HME-IM and FDM 3D printing as illustrated 
in Figure 3.5.  
 
Figure 3.5: PXRD pattern of pure crystalline felodipine form I used in this study  
It should be mentioned that the crystal habits of the polymorphs were reported to be block-shaped 
for polymorphs I (recrystallised from grown from methanol, ethanol or acetonitrile) and II 
(recrystallised in the presence of succinic acid, malonic acid or isonicotinamide in methanol). For 
form III (recrystallised in the presence of maleic acid or 4-hydroxybenzoic acid in acetonitrile), 
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plate-like crystals were reported (312, 319). However, there is no available information about the 
crystal habit of polymorph IV (recrystallised by slowly evaporation of methanol and NaOH 
mixture pH =10.0) of felodipine (319) is available. SEM image of felodipine particles is shown 
in Figure 3.6.  
 
Figure 3.6: SEM image of pure crystalline felodipine form I particles 
3.3.1.2 PEG 4000 
In this study, PEG 4000 was used as the main polymer for preparing the solid dispersions of 
felodipine using HME-IM. It was also used as one of the polymeric blend mixtures for preparing 
felodipine matrices using FDM 3D printing technique. In order to understand the basic 
physicochemical properties of PEG 4000, characterisation using TGA, DSC, ATR-FTIR and 
PXRD techniques was performed. The TGA analysis of PEG 4000 is shown in Figure 3.7a. A 
single-step degradation process was observed with extrapolated degradation onset of 376.3 ± 
5.0 ̊C. The moisture uptake capacity of this hydrophilic partially crystalline polymer was shown 
in Figure 3.7b. The results revealed that the equilibrium water absorption capacity is 1.18 ± 0.02 
using 25 ̊C and 75% RH. This low percentage of moisture uptake may be due to the small 
amorphous fraction of this polymer available for occupying moisture in addition to its high 
crystalline properties.  
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Figure 3.7: a) TGA analysis of PEG 4000 using heating program of 10 ̊C / min from ambient 
temperature to 450 ̊C (n=2) and b) the moisture uptake capacity of PEG 4000 at 25 C̊ and 75% RH 
(n=3)  
DSC analysis of PEG 4000 using standard mode is shown in Figures 3.8a-c. This polymer has a 
melting onset and peak at 55.4 ± 0.2 and 59.0 ± 0.2 ̊C respectively using heating rate of 10 ̊C/min 
as seen in Figure 3.8a. This makes this polymer as a good candidate for preparing solid 
dispersions of poorly water soluble drugs at relatively low processing temperature (38, 341, 343). 
The % crystallinity was calculated based on the results obtained from the DSC experiments (∆Hf 
=187.9 ± 4.9) and the ∆Hf of the 100% crystalline form of PEG 4000 reported in literature (449) 
which is 214.6 J/g. Using Equation 3.1, the % crystallinity of the raw material can be calculated 
as 87.6%. 
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% Crystallinity = ( Δ Hf raw / Δ Hf 100% crystalline) × 100% …………….....Equation 3.1 
 
Figure 3.8: Partial standard DSC thermograms showing semicrystalline PEG 4000 melting (a), 
crystallisation (b) and re-melting (c) transitions using 10 ̊ C / min heating and cooling ramps (n=3) 
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In addition, PEG 4000 also shows a recrystallisation peak at 40.9 ± 0.7 ̊C and ∆Hc =173.1 ± 1.2 
J/g on cooling at a rate of 10 ̊C / min from 80 ̊C as shown in Figure 3.8b. The immediate reheating 
cycle (Figure 3.8c) of the recrystallised PEG after cooling revealed the presence of two partially 
separate peaks representing the single folded and the extended crystalline forms of PEG in 
addition to a shoulder indicating twice folded form (38, 328, 450-452).  The metastable single 
folded and the stable extended forms show melting peaks at 58.2 ± 0.1 and 61.7 ± 0.1 ̊C, 
respectively. It should be mentioned that the reported Tg for PEG 4000 is -61 ̊C (449, 453).   
The ATR-FTIR spectrum of PEG 4000 is shown in Figure 3.9a and characteristic peaks 
summarised in Table 3.2 which are consistent to the reported assigned peaks (454). For PXRD, 
due to the highly semicrystalline nature of PEG 4000, it shows a characteristic diffraction patterns 
associated with the crystal lattice arrangements as seen in Figure 3.9b. 
 
Figure 3.9: a) ATR-FTIR spectrum (n=3) and b) PXRD PEG 4000 
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Table 3.2: Characteristic ATR-FTIR absorption peaks of PEG 4000, PEO K900 and PEO K100 
Compound Chemical group Peak wavenumber (cm-1) 
PEG 4000, PEO K900 and 
PEO K100 
OH stretching  3413 
CH stretching 2883 
C–O–C stretching 1145, 1096 and 1059  
crystal peak of PEO moiety 959 
C–C–O  841  
 
3.3.1.3 PEO WSR 1105 (PEO K900) 
PEO K900 was used in the fabrication of felodipine solid dispersions using HME-IM method. As 
mentioned in Chapter 2, this polymer has high molecular weight (900,000 g/mole) and good 
thermoplastic, drug release controlling and mucoadhesive properties (356-359). TGA, DSC, 
MTDSC, ATR-FTIR and PXRD techniques were used to investigate the basic physicochemical 
properties of this polymer.  Figure 3.10a illustrates the thermal stability profile of PEO using 
10 ̊C / min ramp from ambient temperature to 500 ̊C. The degradation of PEO occurred as a single 
step process with an extrapolated degradation onset at 356.3 ± 0.3 ̊C. The Tg of PEO K900 was 
found to be -53.9 ± 1.9 ̊C with ∆Cp of 0.01 ± 0.00 J/g. ̊C measured using MTDSC using heating 
rate of 2 ̊ C / min, 0.318 amplitude and 60 sec. period as shown in Figure 3.10b. The capacity of 
moisture uptake of PEO K900 was measured using DVS and found to be 1.80 ± 0.03% w/w after 
incubation at 25  ̊C and 75% RH as shown in Figure 3.10c.  
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Figure 3.10: a) TGA analysis of PEO K900 using heating program of 10 ̊ C / min from room 
temperature to 500 ̊ C (n=2); b) MTDSC thermogram showing PEO K900 glass transition (Tg) using 
2 ̊ C / min, 0.318 amplitude and 60 sec.s period (n=3) and c) moisture uptake capacity of PEO K900 
at 25 ̊C and 75% RH (n=3) 
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Due to the difference in their molecular weights, PEG/PEO polymers exist in different physical 
states with different physical properties. Members with molecular weights 300-600 g/mole are 
liquids, 1500 g/mole is semisolid, 3000-20000 are semicrystalline solids and polymers with 
molecular weight higher than 100000 have resinous nature. The difference in their molecular 
weight is also reflected on their melting, crystallisation, crystallinity and their existence in single 
or multiple crystal forms. It was reported that the melting temperatures of PEG.s increase with 
increasing the molecular weight up to 6000 g/mole above which the melting point remains 
practically constant as the melting is dependent on the thickness of the lamellae rather than the 
molecular weight of the polymer (452).  The melting, crystallisation and re-melting of PEO K900 
are shown in Figure 3.11a-c. PEO K900 showed a folded form melting peak at 70.2 ± 0.3 ̊C with 
a ∆Hf of 172.4 ± 3.9 J/g using a heating rate of 10 ̊C/min (Figure 3.11a). This indicates that the 
% crystallinity of the raw polymer is 84.1% using 205 J/g as melting enthalpy for the 100% 
crystalline form reported in literature (455, 456). The polymer shows a crystallisation temperature 
at 50.3 ± 0.1 ̊C with a ∆Hc of 97.4 ± 3.0 J/g using 10 ̊C/min cooling ramp as shown in Figure 
3.11b. Furthermore, the immediately reheating cycle (Figure 3.11c) indicated lower melting 
temperature (66.0 ± 0.1 ̊C) and heat of fusion (∆Hf = 117.6 ± 2.3 J/g) compared to the first heating 
cycle using the same heating rate. This indicates that the recrystallised polymer in the reheating 
cycle is more folded (thinner lamellae) and metastable relative to the first cycle (452).  
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Figure 3.11: Partial standard DSC thermograms show semicrystalline PEO K900 melting (a), 
crystallisation (b) and re-melting (c) transitions using 10 ̊ C / min heating and cooling ramps (n=3) 
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The ATR-FTIR spectrum of PEO K900 (Figure 3.12a) shows the same characteristic IR peaks 
like those of PEG 4000 (Table 3.2) because both polymers are composed of the same monomeric 
ethylene oxide units as mentioned in Chapter 2. In addition, Figure 3.12b shows the PXRD 
diffraction patterns of PEO K900 polymer with its characteristics peaks indicating its 
semicrystalline structure.  
 
Figure 3.12: a) ATR-FTIR spectrum (n=3) and PXRD pattern of PEO K900 
3.3.1.4 Tween 80 
Tween 80 was used as solubilisation non-ionic surfactant for preparing felodipine solid 
dispersions using HME-IM and 3D FDM printing. This compound was selected for its 
solubilisation, plasticisation and absorption enhancing effects as mentioned in Chapter 2.  The 
physicochemical properties of this surfactant were investigated using TGA, MTDSC, DVS and 
ATR-FTIR. The TGA profile for Tween 80 (Figure 3.13a) illustrated that Tween 80 has an 
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extrapolated degradation temperature onset of 372.4 ± 0.8 ̊C as a single step degradation process. 
Using MTDSC, the melting, crystallisation and glass transition (Tg) of Tween 80 were found to 
be -10.2 ± 2.3, -44.6 ± 1.2 and -64.2 ± 0.6 ̊C, respectively (Figure 3.13b). In addition, this 
hydrophilic liquid surfactant has high tendency for moisture uptake estimated as 14.44 ± 0.89% 
w/w using DVS as shown in Figure 3.13c. This is an important parameter that may play a 
significant role in the physical stability of formulated solid dispersions exposed to high relative 
humidity environment.   
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Figure 3.13: a) TGA analysis of Tween 80 using heating program of 10  ̊C / min from ambient to 
500 ̊C (n=2); b) MTDSC thermogram showing the thermal events (glass transition Tg, crystallisation 
and melting) of Tween 80 using temperature program of 2 ̊ C / min, 0.318 amplitude and 60 sec.s 
period (n=3) and c) moisture uptake capacity of Tween 80 at 25 ̊C and 75% RH (n=3) 
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The ATR-FTIR spectrum (Figure 3.14) shows the characteristic FTIR bands of Tween 80 which 
are listed in Table 3.3.   
 
Figure 3.14: ATR-FTIR spectrum of Tween 80 (n=3) 
 
Table 3.3: Characteristic ATR-FTIR absorption peaks of Tween 80 
Compound Chemical group Peak wavenumber (cm-1) 
Tween 80 OH stretching  3493  
CH stretching for CH3  2922 
CH stretching for CH2 2857 
C=O stretching 1735  
C–O–C stretching 1096 
3.3.1.5 TPGS 
Vitamin E TPGS was used in this study as a semisolid surfactant to illustrate the impacts of 
surfactant physical state on the solubility and stability of felodipine solid dispersions. TPGS 
showed an extrapolated degradation onset at 353.4 ± 1.1 ̊C (Figure 3.15a). TPGS has high ability 
to uptake moisture despite its semicrystalline structure and semisolid state. The equilibrium 
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moisture absorption capacity of this hydrophilic surfactant is 12.80 ± 0.72 % w/w measured using 
DVS which is only slightly less but much slower compared to Tween 80 (Figure 3.15b). 
 
 
Figure 3.15: a) TGA analysis of TPGS using heating program of 10 ̊ C / min from ambient to 500  ̊C 
(n=2) and b) moisture uptake capacity of TPGS at 25 ̊C and 75% RH (n=3) 
TPGS is a semicrystalline non-ionic surfactant that has an asymmetric melting peak at 37.2 ± 
0.2 ̊C and ∆Hf of 100.01 ± 1.09 J/g using 10 ̊C/min temperature program as shown in Figure 
3.16a. The surfactant recrystallised in two peaks at 0.3 ± 1.2 and -15.9 ± 0.2 ̊C as shown in Figure 
3.16b. The asymmetric melting and the two distinct recrystallisation peaks suggest the presence 
of small fractions of the di-ester form of vitamin E TPGS in addition to the main mono-esterified 
form with free residuals of PEG 1000 (56, 457, 458). The reheating cycle indicates that the 
surfactant re-melted at 38.3 ± 0.4 ̊C and ∆Hf of 104.00 ± 1.3 J/g. The Tg of TPGS was measured 
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using the immediate reheating cycle at 10 C̊ after cooling at the same rate of standard DSC and 
found to be -20.0 ± 0.9 ̊C with ∆Cp of 0.32 ± 0.06 J/g. ̊C as shown in Figure 3.16c. 
 
Figure 3.16: Partial standard DSC thermograms showing semicrystalline TPGS melting (a), 
crystallisation (b) and glass transition (Tg) with re-melting (c) events using 10 ̊ C / min heating and 
cooling ramps (n=3) 
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The ATR-FTIR spectrum of TPGS indicated the presence of bands characteristics of polyethylene 
oxide (PEO) and vitamin E moieties in addition to the C=O band at 1735 cm-1 of the succinate 
group as shown in Figure 3.17a and Table 3.4. The PXRD pattern of TPGS (Figure 3.17b) 
revealed the presence of the diffraction peaks of the crystalline polyethylene oxide moiety 
especially those at 19.4° and 23.5° 2Ɵ indicating the semicrystalline nature of this surfactant 
(385). 
 
Figure 3.17: a) ATR-FTIR spectrum (n=3) and b) PXRD pattern of TPGS 
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Table 3.4: Characteristic ATR-FTIR absorption peaks of TPGS 
Compound Chemical group Peak wavenumber (cm-1) 
TPGS OH stretching 3428 
CH stretching for CH3  2885 
C=O  1735 
C–O–C stretching 1147, 1105 and 1060 
crystal peak of PEO moiety 969 
 
3.3.1.6 PEO WSR N10 LEO (PEO K100) 
PEO K100 was used as a constituent of the polymeric blend utilised in the fabrication of 
felodipine solid dispersions by FDM 3D printing. PEO K100 shows a single step degradation with 
extrapolated onset of 369.3 ± 0.3 ̊C as illustrated in Figure 3.18.  
 
Figure 3.18: TGA analysis of PEO K100 using heating program of 10  ̊C / min from room temperature 
to 475 ̊ C (n=2) 
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Thermal analysis using standard DSC revealed an intermediate melting peak between those of 
PEG 4000 and PEO K900 at 65.6 ± 0.1 ̊C with ∆Hf of 180.3 ± 4.4 J/g using 10 ̊C/min temperature 
program as shown in Figure 3.19a. This grade of PEO shows a recrystallisation peak at 41.9 ± 
0.4 ̊C with ∆Hc of 133.6 ± 10.2 J/g using 10 ̊C/min cooling rate as shown in Figure 3.19b. In 
addition, using the same heating rate, the immediate reheating cycle showed an asymmetric 
melting peak of the polymer having peak at 62.4 ± 0.1 ̊C with ∆Hf of 143.0 ± 8.6 J/g revealing 
more folding and thinner crystals as shown in Figure 3.19c (328). 
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Figure 3.19: Partial standard DSC thermograms show semicrystalline PEO K100 melting (a), 
crystallisation (b) and re-melting (c) events using 10 ̊ C / min heating and cooling ramps (n=3) 
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The ATR-FTIR spectrum and PXRD pattern for PEO K100 are shown in Figures 3.20a and 
3.20b respectively.  Due to the similarity in the monomeric unit of this polymer and PEG 4000 
and PEO K900, this polymer showed similar IR absorption bands and diffraction peaks as 
summarised in Table 3.2. 
 
Figure 3.20: a) ATR-FTIR spectrum (n=3) and b) PXRD pattern of PEO K100 
3.3.1.7 Eudragit E PO 
Eudragit E PO is a copolymer used as a main constituent of felodipine solid dispersions prepared 
by FDM 3D printing. This polymer is degraded in a two steps process at 253.0 ± 2.8 and 362.4 ± 
4.9 ̊C as shown in Figure 3.21a. Eudragit E PO is an amorphous polymer has a Tg at 46.7 ± 1.0 ̊C 
and ∆Cp of 0.40 ± 0.02 J/g. ̊C as shown in Figure 3.21b using 2 ̊ C / min, 0.318 amplitude and 60 
sec.s period MTDSC program. 
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Figure 3.21: a) TGA analysis of eudragit E PO using heating program of 10 ̊ C / min from ambient 
temperature to 500 ̊ C  (n=2) and b) reverse signal of MTDSC thermogram showing eudragit E PO 
glass transition (Tg) using 2 ̊ C / min, 0.318 amplitude and 60 sec.s period (n=3) 
The ATR-FTIR spectrum of Eudragit E PO is shown in Figure 3.22a reveals the characteristic IR 
peaks which are listed in Table 3.5. The PXRD pattern of eudragit E PO indicates the amorphous 
nature of this copolymer as illustrated in Figure 3.22b. 
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Figure 3.22: a) ATR-FTIR spectrum (n=3) and b) PXRD pattern of eudragit E PO 
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Table 3.5: Characteristic ATR-FTIR absorption peaks of eudragit E PO 
Compound Chemical group Peak wavenumber (cm-1) 
Eudragit E PO CH stretching for CH3 2949 
CH stretching for CH2 2821  
CH stretching for CH 2770  
C=O stretching 1723  
CH bending 1453  
C-O stretching 1388 
C-O-C stretching 1268 and 1239  
C-C stretching 1144  
 
3.3.1.8 Soluplus 
Soluplus is also a copolymer used in this study as the main polymer for preparing felodipine solid 
dispersions using FDM 3D printing. The TGA of soluplus indicated the degradation in two step 
processes with extrapolated onsets at 282.7 ± 0.3 and 370.4 ± 1.1 ̊C as shown in Figure 3.23a. 
MTDSC thermogram using 2 ̊ C / min, 0.318 amplitude and 60 sec.s period indicated the 
amorphous character of soluplus with a Tg of 74.1 ± 0.3 ̊C and ∆Cp of 0.42 ± 0.04 J/g  ̊C as shown 
in Figure 3.23b.  
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Figure 3.23: a) TGA analysis of soluplus using heating program of 10  ̊C / min from room temperature 
to 500 ̊ C (n=3) and b) reverse signal of MTDSC thermogram showing soluplus glass transition (Tg) 
using 2 ̊ C / min, 0.318 amplitude and 60 sec.s period (n=3) 
The ATR-FTIR spectrum of soluplus is shown in Figure 3.24a revealing its absorbance peaks 
listed in Table 3.6. The PXRD pattern of this copolymer Figure 3.24b indicates its amorphous 
character due to the absence of any diffraction peaks. 
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Figure 3.24: a) ATR-FTIR spectrum (n=3) and b) PXRD pattern of soluplus 
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Table 3.6: Characteristic ATR-FTIR absorption peaks of soluplus 
Compound Chemical group Peak wavenumber (cm-1) 
Soluplus OH stretching  3447  
CH stretching for CH3 2926  
CH stretching for CH2 2857  
C=O stretching 1732  
O-C-N stretching 1630  
CH bending 1477  
C-O stretching 1370  
C-O-C stretching 1234 
C-C stretching 1195  
 
3.3.1.9 Polyvinyl alcohol (PVA) 
PVA was used as a benchmark FDM 3D printing polymer for fabricating felodipine solid 
dispersions due to the reported good printability properties. In order to understand the properties 
of this polymer, TGA, MTDSC, ATR-FTIR and PXRD techniques were used to investigate its 
physicochemical properties. The TGA of PVA is shown in Figure 3.25a revealing degradation 
in two-step degradation process due to the partial hydrolysis state of this polymer. Also, this grade 
of PVA is completely amorphous due to the absence of any melting peak and the presence of 
single Tg at 46.1 ± 0.2 ̊C with ∆Cp of 0.60 ± 0.02 J/g  ̊C as shown in Figure 3.25b. 
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Figure 3.25: a) TGA analysis of PVA using heating program of 10 ̊ C / min from room temperature 
to 500 ̊ C (n=3) and b) reverse signal of MTDSC thermogram showing PVA glass transition (Tg) using 
2 ̊ C / min, 0.318 amplitude and 60 sec.s period (n=3) 
The ATR-FTIR spectrum of PVA is shown in Figure 3.26a revealing the characteristic IR peaks 
listed in Table 3.7. The PXRD pattern of PVA (Figure 3.26b) indicates the absence of any 
crystalline diffraction peaks revealing the amorphous nature of this grade of PVA. 
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Figure 3.26: a) ATR-FTIR spectrum (n=3) and PXRD pattern of PVA 
Table 3.7: Characteristic ATR-FTIR absorption peaks of PVA 
Compound Chemical group Peak wavenumber (cm-1) 
PVA 
 
OH stretching 3424  
CH stretching for CH2 2823  
C=O stretching 1730  
CH bending 1432  
C-O stretching 1372 
C-O-C stretching 1230 
C-C stretching 1095  
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3.3.2 Theoretical calculations of the solubility parameters of the ingredients 
The calculations of solubility parameters of felodipine and other excipients (chemical structure 
are shown in Chapter 2) using Hoftyzer and Van Krevelen and Hoy methods can be found in 
Appendix 1. Table 3.2 summarises the results of the calculations by averaging of the solubility 
parameters determined by the two approaches as recommended in literature to ensure the accuracy 
of prediction (459).  
 
Table 3.8: Summary of solubility parameter predictions calculated using group contribution methods 
Compound  δ Van Krevelen δ Hoy δ  average  δ difference* 
Felodipine 20.60 21.08 20.84 - 
PEG 4000 
PEO K900 
PEO K100 
22.00 21.44 21.72 0.88 
Tween 80 20.90 22.71 21.81 0.97 
TPGS 20.38 21.18 20.78 0.06 
Eudragit E PO 18.80 18.55 18.68 2.17 
Soluplus 18.94 24.34 21.64 0.80 
PVA 30.53 28.79 29.66 8.82 
* (difference between the solubility parameters of the drug and each one of the excipients) 
Based on the results obtained from these prediction methods, the miscibility of felodipine in the 
individual excipients at room temperature can be ranked in the following order: TPGS > soluplus 
> (PEG 4000, PEO K900, PEO K100) > Tween 80 > eudragit E PO > PVA. The rule of thumb for 
estimating miscibility reported in literature is a difference in solubility parameter (∆δ) of less than 
7 (MJ/m3)½ indicates that the substances are miscible; a ∆δ value more than 10 (MJ/m3)½ predicts 
unfavourable interaction and immiscibility between the components of the blend leading to phase 
separation. A ∆δ value of 7-10 (MJ/m3)½  indicates partial miscibility of the ingredients (60, 361). 
Based on this, all excipients used in this study are expected to possess good miscibility at room 
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temperature with felodipine except PVA which is predicated to form a partially miscible binary 
mixture with the model drug. 
3.3.3 Experimental estimation of the miscibility of PEG 4000 and PEO K900 
using DSC 
PEG 4000 and PEO K900 are the main constituents used for preparing felodipine mucoadhesive 
buccal patches using HME-IM because they provide solubilisation, mucoadhesion, low 
temperature processing properties and most importantly their easy removal after moulding 
making them suitable candidate excipients for IM processing (151).  Due to the difference in the 
molecular weights of these two grades and the inability of the theoretical methods to predict their 
miscibility due to the similarity in their monomeric units and molecular configurations, it is 
important to investigate their behaviour in order to select the most suitable combination blend. 
Thermal properties of the two polymers at different proportions using 10% w/w increments of 
PEG 4000 relative to PEO K900 were analysed using DSC. The results of the first heating cycle 
of the physical mixtures show both melting peaks and the magnitude of each peak is 
corresponding to the proportions of their mixing ratios as seen in Figure 3.27a.  This indicates 
their immiscibility within the timescale and conditions of the DSC run. On cooling, the molten 
mixtures with the higher ratios of PEO K900 (PEG:PEO 1:9, PEG:PEO 2:8, and PEG:PEO 3:7) 
show two partially resolved crystallisation peaks corresponding to the crystallisation of the two 
polymers (Figure 3.27b). On the other hand, as the percentage of PEG 4000 increased the mixture 
started to form single crystallisation peak shifted to lower temperature as the amount of PEG 4000 
increased in the mixture. However, the reheating cycles indicate the presence of two partial 
overlapped melting peaks shifted to lower temperatures compared to the first heating cycle as 
shown in Figure 3.27c.   The appearance of two peaks during the heating, cooling and reheating 
cycles of the DSC runs with more peak separation for the mixtures containing high proportions 
of PEO K900 either indicates partial miscibility of the two polymers and/or the high viscosity of 
PEO K900 prevents the complete mixing between the two polymers inside the sealed DSC pans.  
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Figure 3.27: Standard DSC thermogram showing the a) heating cycle melting peaks; b) cooling cycle 
crystallisation peaks and c) reheating cycle melting peaks of PEG 4000 and PEO K900 physical 
mixtures with different proportions using 10 ̊ C / min heating and cooling ramps (n=3) 
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In order to further understand the effect of preparing processes on the miscibility and crystallinity 
of PEG 4000 /PEO K900, extruded blends of mixtures with different mixing proportions (3:7, 4:3 
and 7:3) were investigated using DSC after HME processing at 65 °C. The results revealed single 
asymmetric melting peaks for 7:3 and 4:3 and partially separated two melting peaks for 3:7 
PEG/PEO extruded blends as shown in Figure 3.28. Compared to physical mixtures with same 
mixing proportions, HME processing significantly enhances the miscibility of the two polymers 
especially for mixtures contain higher percentage of PEG 4000. The observation of two melting 
peaks for the 3:7 PEG 4000 /PEO K900 mixture indicates their partial miscibility after processing 
using HME experimental conditions. No significant difference in the melting temperatures of the 
blends showing single melting peaks was observed. The resultant single melting peaks’ 
temperatures are lower than that of PEO K900 and higher than that of PEG 4000. This may 
indicate that mixing different grades with different melting temperatures of this polymer can 
produce a miscible semicrystalline mixture with intermediate melting points depending on the 
proportion of mixing. 
 
Figure 3.28: Standard DSC thermogram showing melting peaks of PEG 4000 and PEO WSR 1105 
extrudates using 10 ̊ C / min heating ramp (n=3) 
The mixture of PEG/PEO K900 in a proportion of 4:3 was selected as the suitable blend that gives 
a maximum reduction in polymer crystallinity (maximum amorphous fraction available for drug 
solubilisation) and expected to provide balancing effect of poorly water soluble drug 
solubilisation and mucoadhesion by the two polymers.  
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Figures 3.29a and b show the MTDSC thermograms of adding Tween 80 to the polymer blend 
as a physical mixture and HME extrudates respectively. As it is evident from the data, the 
transitions of the three excipients are present before processing. However, the miscibility between 
the ingredients is significantly improved after HME processing as indicated by the presence of 
single melting peak for PEG/PEO K900 blend the reduced melting peak of Tween 80. The 
presence of Tween 80 melting peak reflects the partial miscibility between this surfactant and the 
polymers. In addition, the presence of endothermic shoulder before the melting of PEG/PEO 
K900 blend (Figure 3.29b) may be due to the formation of folded form of PEG/PEO K900 
polymers representing their metastable polymorphic forms (328, 330).   
 
Figure 3.29: MTDSC thermogram showing transitions of PEG 4000- PEO K900-Tween 80 (4:3:3) 
physical mixture (a) and extrudate (b) using 2 ̊ C / min, 0.318 amplitude and 60 sec.s period (n=3) 
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The addition of TPGS to the polymeric blend as a physical mixture or extrudates is shown in 
Figures 3.30a and b. The results indicate that processing also improves the miscibility of 
PEG/PEO K900 blend as revealed by the appearance of single melting peak of the two polymers. 
However, the observation of TPGS melting peak in the physical mixture and the extrudate of this 
blend indicates its partial miscibility with the polymeric blend.  
 
Figure 3.30: MTDSC thermogram showing transitions of PEG 4000- PEO K900-TPGS (4:3:3) 
physical mixture (a) and extrudate (b) using 2 ̊ C / min, 0.318 amplitude and 60 sec.s period (n=3) 
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3.3.4 Estimation of the miscibility of felodipine and excipients used in HME-
IM formulations 
Standard DSC was used to investigate the miscibility of felodipine with the different excipients 
used in the fabrication of felodipine solid dispersions using HME-IM. The depression in the 
melting onset of felodipine was used as indicators for the miscibility of the drug in the excipients 
(Figure 3.31) (57, 87, 416, 460). The results indicate that greater depression was in the onset of 
melting in the mixture with PEG compared to other excipients using 0.6-0.8 w/w felodipine 
fractions. The depression of felodipine melting was the lowest for the mixtures containing PEO 
K900 in all proportions. Also, TPGS causes greater depression in the onset of felodipine melting 
compared to Tween 80 using felodipine fractions higher than 0.7.  It should be mentioned that the 
experimentally measured solubility of felodipine in Tween 80 using UV-VIS spectrophotometry 
was 100.24 ± 0.001 mg/mL at room temperature. 
 
Figure 3.31: Depression in the extrapolated onset of melting of felodipine in different excipients as a 
function of felodipine weight fraction (n=3) 
3.4 Discussion 
This chapter aimed to investigate the thermal and spectroscopic properties of the raw materials 
used in this study as a preformulation step in order to facilitate formulations development. TGA 
results showed that all excipients utilised in the different formulations were more thermally stable 
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compared to felodipine which is more susceptible to thermal degradation at approximately 166 ̊C. 
This may suggest a maximum processing temperature of 150 ̊C for safe processing of this model 
drug using HME-IM and FDM 3D printing. Processing PEG 4000 with PEO K900 using HME 
at 65 ̊C for 5 minutes using different proportions shows mixing improvement of the two polymers 
compared to physical mixtures. The two polymers with 4:3 and 7:3 blends of PEG 4000 and PEO 
K900 respectively show single melting peaks indicating the formation of single semicrystalline 
structure. In order to provide good solubilisation and mucoadhesion properties for the intended 
felodipine buccal patches formulations, PEG 4000-PEO K900 4:3 blend was selected as it shows 
good mixing properties between the two polymers. 
 
Tween 80 and TPGS are non-ionic surfactants with semicrystalline properties. Due to the partial 
miscibility between these two surfactants with PEG-PEO K900 polymer blend, the phase 
separated surfactant domains will be used as a solubilisation compartments to solubilise and 
stabilise felodipine as an embedded molecular dispersion within the matrix. According to 
solubility parameter predictions and the depression of onset of melting, TPGS has higher 
solubilisation capacity for felodipine compared to Tween 80. This is expected to play a significant 
role in the solubilisation and stabilisation of felodipine in the formulations. In addition, TPGS has 
higher temperatures of melting, crystallisation and Tg compared to Tween 80. Due to its melting 
at approximately 37 ̊C, TPGS is not expected to be 100% available for felodipine solubilisation 
as Tween 80 (liquid at room temperature) assuming no depression in its melting occurs when 
mixed with the drug. This may affect the extent of felodipine solubilisation by TPGS. On the 
other hand, the semisolid nature of TPGS may act as stabilisation parameter that restrict the 
diffusion of molecularly dispersed felodipine to form aggregates leading to phase separation.  
 
DSC results indicate that the melting temperature and crystallinity of polyethylene oxide polymer 
grades are affected by thermal treatment. The reduction in the melting points and crystallinity 
indicates the conversion of part of the polymer to the less stable and more folded forms. Changes 
in crystallinity of the polymers can be considered as an important parameter that may affect the 
solubilisation capacity of the carrier mixture. Reduction in crystallinity (increasing amorphous 
fraction) of the carrier polymers is expected to increase the solubilisation capacity for the drug. 
On the other hand, the stability of the amorphous and crystalline domains of the carrier mixtures 
can play a critical role in the stability of the prepared solid dispersions. Instability of the 
amorphous domains and the tendency of the polymer to increase its crystallinity may act as a 
contributing factor for drug phase separation. Therefore, monitoring the physical stability of 
semicrystalline excipients used for preparing solid dispersions is necessary.    
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As mentioned in Chapter 1, FDM 3D printing technology is recently introduced to the 
pharmaceutical field as a promising technique to provide patients individualised medicine (224-
226). Due to the limited number of pharmaceutically approved excipients are only available to 
use for fabricating formulations using this method, the use of excipient blends is suggested as an 
approach to improve the printability of excipients and provide different functionalities for 
formulations using this technique. Soluplus and eudragit E PO are widely used polymers for 
preparing solid dispersions of poorly soluble drugs using HME due to their good thermoplastic 
and solubilisation properties (73, 87, 149, 461). Blending these two polymers with polymers like 
PEG, PEO K100 and/or Tween 80 is expected to form miscible mixtures based on solubility 
parameter calculations. As mentioned in Chapter 2, PEG, PEO K100 and Tween 80 possess good 
plasticising and drug solubilisation properties that can help to reduce the processing temperature 
of FDM 3D printing and solubilise the incorporated drug.   
3.5 Conclusion 
Preformulation studies conducted in this chapter aimed to provide an insight into the fundamental 
physicochemical properties of the raw materials (model drug and excipients) and their mixing 
behaviour prior to their incorporation in the formulation using HME-IM and FDM 3D printing. 
Thermal, spectroscopic and imaging characterisation techniques were used to achieve this 
purpose. Prediction studies using group contribution and the depression in the melting onset were 
used to provide an estimation about the miscibility of the excipients with felodipine. Theoretical 
calculations revealed that felodipine is expected to have good miscibility with all excipients 
except with PVA.  The various excipients have a solubility parameter differences (from lower to 
higher) relative to felodipine with an order of magnitude ranked as TPGS > soluplus > (PEG 4000, 
PEO K900, PEO K100) > Tween 80 > eudragit E PO > PVA.  The addition of Tween 80 and 
TPGS surfactants as plasticisers to PEG/PEO K900 polymeric blend leads to the formation of 
surfactant phase in addition to the two phases of the semicrystalline polymeric blend. The 
surfactant phase separate domains can provide a solubilisation compartments for the poorly water 
soluble model drug used in this study. This will be used as a formulation strategy as illustrated in 
Chapter 4. Finally, polymer blends are suggested as an approach to improve the printability of 
pharmaceutical excipients to produce personalised medicines using FDM 3D printing technology.  
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4.1 Introduction 
Poor aqueous solubility and/or dissolution of many active pharmaceutical ingredients (APIs) 
including BCS class II drugs like felodipine is a challenging problem that affects their systemic 
absorption due to slower dissolution compared to permeation leading to inter- and intra-patient 
pharmacokinetics and absorption variations (1, 2, 462). Felodipine is widely used calcium channel 
antagonist as a potent antihypertensive and for prevention of angina pectoris. However, this drug 
is extensively metabolised in the liver (84%) into inactive metabolites which further reduce its 
systemic bioavailability (310, 462).  
As discussed earlier in Chapter 1, solid dispersion technology is considered as an effective 
formulation-based method used to overcome the poor dissolution problem with high flexibility in 
processing techniques and excipients’ choices (25, 31, 177). Fabricating transmucosal solid 
dispersions to be delivered via the buccal route processed by HME-IM offers a number of 
potential advantages including avoiding hepatic first pass effect and improving the dissolution 
profile of this poorly water soluble drug which was suggested as an approach to improve its 
systemic bioavailability (372, 463-466). HME-IM is a single step, environmentally friendly and 
cost-effective processing technique capable of producing final dosage forms with uniform content 
and thickness and much defined shape and geometry compared to the conventional solvent casting 
and direct compression methods normally used to prepare buccal formulations (208, 372, 467).  
In order to prepare solid dispersions to be used as buccal patches for delivering felodipine, two 
matrices composed of PEG 4000 and PEO K900 polymeric blend with either liquid (Tween 80) 
or waxy solid (vitamin E TPGS) non-ionic surfactants were used as carrier mixtures (abbreviated 
as CM1 for Tween 80 and CM2 for TPGS containing formulations) in this study. The excipients 
used in the fabrication of felodipine buccal patches were selected to provide solubilisation, 
stabilisation, plasticisation and promote mucoadhesive functionality to the formulations with easy 
peel-off from the IM mould (62, 151, 326, 327, 355, 360, 361, 373, 468). The theoretical and 
experimental approaches to assess the miscibility between the different constituents of the 
formulations were discussed in details in Chapter 3. Based on the miscibility predictions, the 
hypothesis of the phase behaviour of the formulation can be generated. The hypothesis behind the 
solubilisation and stabilisation of the carrier matrices is based on creating surfactant-rich 
solubilisation compartments via phase separation between the components of the carrier mixtures. 
Within this chapter, the effects of the type of surfactants used in the dispersion patches on the 
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physicochemical properties and in vitro performance of the patches were compared and discussed 
in order to gain insights into how to choose the suitable surfactants for such formulations.   
Research Objectives: 
1. To design and manufacture felodipine mucoadhesive buccal patches containing 
surfactant-rich solubilisation compartments that function to solubilise and stabilise 
felodipine using HME-IM as a single step processing at low temperature (65 ̊C).  
2. To investigate the phase separation behaviour and microstructure of the designed buccal 
patches using a range of thermal, microscopic and spectroscopic characterisation 
techniques including DSC, MTDSC, SEM, EDS, ATR-FTIR, PXRD and IR imaging.  
3. To evaluate the enhancement in the in vitro release profiles compared to crystalline 
felodipine and investigate the mucoadhesion properties of the fabricated patches. 
4.2 Materials and Methods 
4.2.1 Materials 
The selected API for this project, felodipine (batch no. FP140602), was purchased from Afine 
Chemicals Ltd (Hangzhou, China). Polysorbate (Tween® 80) MWT is 1310 g/mole was ordered 
from Sigma-Aldrich (Dorset, UK). Polyethylene glycol (PEG) 4000 average MWT is 4060 
g/mole was supplied from Sigma-Aldrich (Poole, UK). Polyethylene Oxide (PEO) WSR 1105 
(average MWT= 900,000 g/mole) was kindly donated by Colorcon Ltd (Dartford, UK). Vitamin 
E TPGS MWT is 1513 g/mole was kindly donated by BASF (Ludwigshafen, Germany). 
4.2.2 Felodipine loaded buccal patches prepared by HME-IM 
Felodipine loaded in CM1 (Tween 80 containing carrier mixture) and CM2 (TPGS containing 
carrier mixture) buccal patches were prepared using HME-IM with mixing proportions as shown 
in Table 4.1.  
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Table 4.1: Composition of felodipine loaded CM1 and CM2 buccal patches produced by HME-IM 
technique  
Formulation Felodipine (w/w) 
PEG 4000 
(w/w) 
PEO K900 
(w/w) 
Tween 80 
(w/w) 
TPGS 
(w/w) 
Placebo CM1 ----- 40% 30% 30% ----- 
10% w/w CM1 10% 36% 27% 27% ----- 
20% w/w CM1 20% 32% 24% 24% ----- 
30% w/w CM1 30% 28% 21% 21% ----- 
Placebo CM2 ----- 40% 30% ----- 30% 
10% w/w CM2 10% 36% 27% ----- 27% 
20% w/w CM2 20% 32% 24% ----- 24% 
30% w/w CM2 30% 28% 21% ----- 21% 
 
The buccal patches were prepared using a co-rotating twin screw mini-extruder (HAAKE™ 
MiniLab II Micro Compounder, Thermo Electron, Karlsruhe, Germany) connected to injection 
moulding apparatus (HAAKE™ MiniJet System, Thermo Electron Corporation, Karlsruhe, 
Germany). Felodipine and Tween 80 or TPGS (melted at 65 ̊C) were pre-mixed before being 
blended with PEG and PEO using mortar and pestle for approximately 2 minutes. The physical 
mixtures were fed into the extruder and extruded at 65˚C with a screw speed of 100 rpm and 5 
minutes of residence time. The reason for selecting 65˚C for HME-IM in this study was to 
minimise any possible thermally induced degradation (oxidation) of PEG and PEO K900 and still 
provide complete melting and sufficient mixing of the excipients. After HME, the extruded 
materials were directly flushed into the reservoir of the IM machine for producing the final buccal 
patches. The reservoir and mould temperatures were set at 65˚C for the IM process with 300 bars 
of moulding pressure for 20 seconds. After the injection process, the mould with an inner film-
shaped cavity dimension of 25 mm × 25 mm × 0.5 mm, was removed from the apparatus and 
allowed to cool at room temperature for 1 hour followed by the disassembly of the mould and the 
collection of the final HME-IM patches. The relative w/w ratios of the components of the carrier 
mixtures remain constant for all formulations with different drug loading. Images for the prepared 
patches were presented in Figure 4.1. 
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Figure 4.1: Images of the felodipine loaded HME-IM extrudates and buccal patches: A and C are 
placebo CM1 and CM2 extrudates respectively, B and D are placebo CM1 and CM2 buccal patches 
respectively, E and G are 10% w/w felodipine CM1 and CM2 extrudates respectively, F and H are 
10% felodipine CM1 and CM2 buccal patches respectively, I and K are 20% w/w felodipine CM1 
and CM2 extrudates respectively, J and L are 20% felodipine CM1 and CM2 buccal patches 
respectively, M and O are 30% w/w felodipine CM1 and CM2 extrudates respectively and N and P 
are 30% felodipine CM1 and CM2 buccal patches respectively 
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4.2.3 Physicochemical characterisation and evaluation of CM1 and CM2 
formulations 
4.2.3.1 Differential scanning calorimetry (DSC) and modulated temperature 
DSC (MTDSC) 
All samples investigated in this study using standard DSC and MTDSC were analysed using the 
same parameters as described in Chapter 3, section 3.2.2.2.2. 
4.2.3.2 Scanning electron microscopy (SEM) and energy dispersive 
spectroscopy (EDS)  
A JSM 5900LV Field Emission Scanning Electron Microscope (Jeol Ltd, Japan) equipped with a 
tungsten hairpin electron gun was used to visualise the surfaces and the cross-sections of placebo 
and felodipine loaded buccal patches. For the surface investigation, samples were used directly 
with care to avoid damaging their surfaces, while for cross-section examinations the samples were 
cut immediately after dipping the samples into liquid nitrogen. The samples were attached to SEM 
specimen stubs by double-side tape and coated with gold using Polaron SC7640 sputter gold 
coater (Quorum Technologies, Laughton, UK) before imaging. Elemental analysis imaging using 
EDS was performed to understand the uniformity of drug distribution on the flat surface of the 
patches by tracking the chlorine (Cl) atoms present in the structure of felodipine. EDS (INCA 
Energy manufactured by Oxford Instruments, Abingdon, UK) connected to the SEM was used to 
map the distribution of drug clusters using Cl in felodipine as the marker. Samples were tested 
using mapping mode. 
4.2.3.3 Powder X-ray diffraction (PXRD) 
PXRD parameters as mentioned in Chapter 3, section 3.2.2.2.6 were utilised to analyse all samples 
investigated in this study using this characterisation technique. 
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4.2.3.4 Attenuated total reflectance-Fourier transform infrared spectroscopy 
(ATR-FTIR) 
ATR-FTIR scanning for all samples was carried out using the same experimental parameters as 
mentioned in Chapter 3, section 3.2.2.2.4. 
4.2.3.5 Fourier transform infrared microscopy imaging  
The heterogeneity of the surface composition was assayed with a Nicolet iN10MX infrared 
microscope. (Thermo Fisher Scientific, Madison, WI, USA) with 25 µm spatial resolution in 
reflection mode, using an aluminium mirror as a reference. Fast maps were acquired with 1 scan 
at 16 cm-1 resolution per pixel, and detailed maps with 64 scans at 4 cm-1 resolution. Principal 
component analysis (PCA) of the spectra data in the 1800-900 cm-1 region was used to 
deconvolute the spectra in order to map the distribution of the individual components. 
4.2.3.6 In vitro mucoadhesion study 
The in vitro mucoadhesive measurements were carried out on felodipine buccal patches using a 
TA-XT2 Texture Analyser (Stable Micro Systems, Surrey, UK) fitted with a 5 kg load cell in 
tension mode (442, 469, 470). Felodipine loaded buccal patches (n=5) having an area of 1.56 cm2 
were attached to the cylindrical perspex probe (1.2 cm diameter and 4.5 cm length) using double-
sided adhesive tapes. Aqueous gelatin solution in a concentration of 6.67% w/v was allowed to 
set as solid gel in a petri-dish (diameter 88 mm), which was used to simulate the adhesion of 
buccal mucosa. Before each measurement, the gelatinous substrates were equilibrated with 1 mL 
of 2% w/v porcine mucin solution (pH of 6.8) and fixed on the platform of the texture analyser. 
For all tests, the probe moved at a pre-test speed of 0.5 mm/s, a test speed of 0.5 mm/s and a post-
test speed of 1 mm/s, with an applied force of 0.5 Kg and a return distance of 10 mm and a contact 
time of 60 s. During the post-test period, the probe was lifted automatically with 0.05 Kg force. 
4.2.3.7 In vitro drug release studies 
The in vitro drug release profiles were measured in dissolution testing apparatus (Caleva 8ST, 
Germany) using paddle over disc method (similar to USP apparatus 5) in which a unidirectional 
release is achieved to simulate the situation inside the buccal cavity. A paddle rotation speed of 
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100 rpm and 900 mL of phosphate buffer saline pH 6.8 (simulated salivary fluid) at 37 ± 0.5 ˚C 
was used for all measurements.  Patches containing 10 mg of the drug were fixed to glass disks 
(5 cm in diameter) using double adhesive tape to allow complete immersion of these patches into 
the dissolution media. For sink condition dissolution tests, 0.5% (v/v) Tween 80 was added to the 
dissolution media. For the non-sink condition dissolution tests, no additional surfactant was added 
into the dissolution media. 5mL of the dissolution samples were withdrawn at pre-determined 
time intervals. The samples were directly filtered through a membrane filter with 0.45 µm pore 
size (Minisart NML single use syringe, Sartorius, UK). For the non-sink condition tests, the 
filtered sample solutions were diluted with equal volume of ethanol. 5 mL of fresh pre-warmed 
(37 ± 0.5 ˚C) dissolution media was added to the dissolution vessel after each sampling. The 
samples were measured using a UV–VIS spectrophotometer (Perkin-Elmer Lambda 35, USA) at 
363 nm. The measured absorbance values for the dissolution samples at different time intervals 
were converted to concentration values using the calibration curves described in Appendix 1. All 
drug release studies were conducted in triplicates.  
4.3 Results  
4.3.1 Physicochemical characterisation of placebo and felodipine loaded 
HME-IM buccal patches 
4.3.1.1 Thermal characterisation of CM1 and CM2  
In this Chapter, DSC and MTDSC were used to investigate the solubilisation limits of CM1 and 
CM2 matrices for felodipine different loadings, felodipine physical state in the different 
formulations and the impacts of felodipine loading on the behaviour of CM1 and CM2 phases 
before and after HME-IM processing. Preformulation studies indicated that CM1 and CM2 are 
partially miscible with detectable Tween 80 and TPGS surfactant phases even after processing 
using HME. As PEG and PEO K900 are semi-crystalline polymers, in literature APIs have been 
claimed to be solubilised in the amorphous regions of these two polymers for the drugs having 
favourable interactions with them (471-474). Therefore, this study takes the assumption that the 
formation of amorphous molecular dispersion with felodipine largely occurs in the amorphous 
regions of CM1 and CM2 blends as suggested in the literature (471-474).  
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CM1 patches 
For CM1 system, as mentioned in Chapter 2, felodipine has an experimentally measured solubility 
of 100.24 ± 0.001 mg/mL in Tween 80 at room temperature. Based on the prediction of the drug 
containing binary systems, Tween 80 has more solubilisation capacity for felodipine, followed by 
PEG and PEO K900 due to the low proportion of amorphous content in these polymers. Therefore, 
one could predict that an under-saturated drug dispersion containing all these materials should 
contain three types of domains of Tween 80-felodipine, amorphous PEG-PEO -felodipine and 
crystalline PEG-PEO K900, with Tween 80-felodipine domains having the higher drug content 
than PEG-PEO-felodipine domains. However, this prediction is based on the assumption of 
minimal interaction between Tween 80 and PEG-PEO K900 phases. Within the thermodynamic 
solubility between all ingredients, domains with complex compositions containing more than two 
ingredients may also present. Altering the concentration of any one of the ingredients in the 
quaternary system could lead to dynamic changes in the phase separation behaviour of the system. 
Figure 4.2 shows there is no melting of crystalline felodipine was detected in the physical 
mixtures and HME-IM CM1 patches loaded with 10-30% felodipine. The disappearance of drug 
melting peak in all loaded formulations is due to thermal dissolution of crystalline felodipine 
fraction in samples loaded with 20-30% drug loading during DSC ramps in the lower melting 
excipients forming CM1 blend as confirmed by other characterisation techniques like SEM, EDS, 
ATR-FTIR and PXRD shown later in this chapter.   
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Figure 4.2: Standard DSC (10ºC/min scanning rate) thermograms of CM1 physical mixtures and 
drug loaded patches with 10-30% loading (n=3) 
It is also noted that the onset and peak temperatures of the melting transitions PEG-PEO K900 of 
all felodipine loaded CM1 matrices are lower than the ones of the placebo patches (Figure 4.2 
and Table 4.2). It can be seen that with increasing the drug load from placebo to 20%, the melting 
peak temperatures depressed by approximately 3.6 ˚ C. The depression in the melting of crystalline 
PEG-PEO K900 is likely to be associated with the dissolution of felodipine in the amorphous 
fractions of the mixture, which leads to reduced degree of order and possibly smaller size of 
crystalline regions of the polymers (475). Increasing the loading percentage to 30% causes less 
depression in melting temperatures compared to lower loading percentages. This may be 
attributed to the saturation of felodipine in the PEG-PEO K900 phase (as evidenced by the 
presence of the crystalline drug in these patches). Thus no additional drug is dissolved in PEG-
PEO K900 phase to cause further melting depression. The melting enthalpy values can be used as 
a measure of the crystallinity level of the polymers. There is no significant reduction in the 
crystallinity of the polymers are observed after drug incorporation up to 20% loading considering 
the proportion of the two polymers in the different mixtures. However, samples loaded with 30% 
felodipine show 8.2% reduction in crystallinity compared to placebo sample. The decrease in 
crystallinity of 30% loaded samples may be attributed to the presence of the crystalline fraction 
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of felodipine leading to defective crystallisation of PEG-PEO K900 blend reflected as a reduction 
in crystallinity.  
Table 4.2: Melting Temperature (Tm) depression of PEG-PEO K900 and surfactant phases caused 
by drug loading in different CM1 HME-IM patches using DSC at 10°C/ min (n=3; average ± SD) 
Formulation PEG-PEO 
K900 Tm Peak 
(˚C) 
PEG-PEO 
K900 
∆Hf (J/g) 
Tween 80 Tm 
Peak (˚C) 
Tween 80 ∆Hf 
(J/g) 
Placebo CM1 63.6 ± 0.3 125.3 ± 0.4 -10.3 ± 0.2 6.2 ± 0.1 
10% CM1 61.8 ± 0.1 112.0 ± 3.9 --- --- 
20% CM1 60.0 ± 0.1 98.9 ± 1.8 --- --- 
30% CM1 59.7 ± 0.1 80.5 ± 0.9 --- --- 
 
Compared to placebo CM1 patch, the melting of Tween 80 almost disappeared in the non-
reversing signals of all felodipine-loaded CM1 patches as seen in Figure 4.3. The fact that during 
the pre-mixing and HME-IM process, crystalline felodipine was pre-dispersed and some 
proportion was dissolved in the Tween 80 is possibly responsible for the absence of the melting 
of Tween 80 in these systems. The dissolved felodipine in the Tween 80 could significantly disrupt 
and even prevent the crystallisation of Tween 80. In addition, the incorporation of the hydrophobic 
drug in the mixture could improve the miscibility of Tween 80 and PEG-PEO K900, as the drug 
could better mix with the hydrophobic tail group of Tween 80 and allow better interaction of the 
hydrophilic head group of Tween 80 with PEG-PEO K900. This again can prevent the 
crystallisation of Tween 80; thus no melting of Tween 80 was observed. This may suggest the 
creation of single Tween 80- rich amorphous phase which can act as a solubilisation domains for 
felodipine.  
 
Chapter 4   Formulation of felodipine HME-IM patches 
 
150  School of Pharmacy / University of East Anglia 
 
 
Figure 4.3: Non-reversing heat flow signal of the MTDSC results of CM1 physical mixes and buccal 
patches of placebo and patches loaded with 10% - 30% w/w felodipine (n=3) 
The Tg values of PEO K900, Tween 80 and TPGS were measured as -53.9 ± 1.9, -64.2 ± 0.6 and 
-20.0 ± 0.9 ºC, respectively. The Tg values for PEG was reported in the literature as -61 (449, 453). 
Drug incorporation also led to the changes in the Tg of CM1 patches. As seen in Figure 4.4 and 
Table 4.3, although PEG and PEO K900 are semi-crystalline polymers, a single Tg of the 
amorphous portions of their mixture with Tween 80 can be clearly detected indicating single 
amorphous phase for three compounds within the detection limits of the DSC. For CM1 patches 
with 10 and 20% drug loading, the amorphous content of the matrices increased by approximately 
20% and 52% (w/w), respectively compared to physical mixtures using the ∆Cp values as shown 
in Table 4.3. This may indicate the increase in miscibility between the PEG-PEO K900 and Tween 
80 caused by drug solubilisation in the amorphous fraction. There is no significant increase in 
amorphous fraction after HME-IM in the patches with 30% felodipine loading compared to the 
physical mixture. 
By comparing the ∆Cp values of the physical mixtures (without pre-heating) at the glass transition, 
it is noted that adding a crystalline drug to the physical mixture of PEG-PEO-Tween 80 leads to 
Chapter 4   Formulation of felodipine HME-IM patches 
 
151  School of Pharmacy / University of East Anglia 
 
increase in ∆Cp values. This increase in ∆Cp could be explained by the dissolution of felodipine 
in PEG-PEO-Tween 80 amorphous phase during mixing.  
 
Figure 4.4: MTDSC Reversing heat flow signals of CM1 physical mixes and buccal patches of placebo 
and patches loaded with 10% - 30% w/w felodipine (n=3) 
It should be borne in mind that the formation of molecular dispersions of felodipine in the matrix 
should shift the Tg to a higher temperature, as the Tg of amorphous felodipine is 46.5 ± 0.2 ºC 
(measured by MTDSC as shown in Chapter 3). The increases in the Tg temperatures (by up to 
approximately 6.7 ± 0.3 ºC) of the physical mixtures with felodipine in comparison to the placebo 
physical mixture further confirm the hypothesis of felodipine being dissolved into the Tween 80 
rich phase. Further increases of Tg values are clearly observed for all CM1 HME-IM drug-loaded 
patches indicating higher level of molecular mixing of felodipine into the Tween 80-PEG-PEO 
K900 amorphous phase. However, with 30% drug loading the Tg of the patches shifted to similar 
temperature as 10% loaded systems, indicating similar amount drug to the 10% systems was 
molecularly dispersed in the matrices. This effect of drug loading on the ternary blend of Tween 
80-PEG-PEO K 900 can be clearly seen in Table 4.3 and Figure 4.5 in the changes in both the Tg 
temperature and ∆Cp values at Tg with drug loading. Table 4.3 shows the detailed measurements 
of the values of ∆Cp and Tg of the glass transition regions of all physical mixtures and patches. It 
can be clearly seen that placebo mixtures and patches have the lowest Tg and the incorporation of 
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felodipine increases the Tg of the mixtures and patches. With increasing the drug loading from 0-
20%, the Tg and ∆CP values increase indicating the increased amount of amorphous material in 
CM1 patches. However, further increasing the drug loading to 30% led to the presence of the 
crystalline drug in the formulation and this is also reflected by the reduced Tg and ∆CP values in 
comparison to the values of the samples with 20% drug loading. These results indicate that 20% 
drug loaded patches are likely to be supersaturated with dissolved drug.  
Table 4.3: Tg and ∆Cp values of placebo and felodipine loaded CM1 physical mixtures and HME-IM 
patches (10% - 30% w/w) measured using MTDSC (n=3; average ± SD)   
Drug loading Tg (˚C) mid-point ∆CP (J/g.°C) 
Placebo CM1 PM -62.1 ± 0.5 0.18 ± 0.03 
Placebo CM1 patch -60.8 ± 0.6 0.13 ± 0.01 
10% CM1 PM -56.4 ± 0.1 0.25 ± 0.03 
10% CM1 patch -51.0 ± 0.2 0.30 ± 0.02 
20% CM1 PM -55.4 ± 0.3 0.23 ± 0.01 
20% CM1 patch -38.7 ± 0.2 0.35 ± 0.03 
30% CM1 PM -55.9 ± 0.0 0.25 ± 0.00 
30% CM1 patch -51.3 ± 0.5 0.24 ± 0.02 
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Figure 4.5: Tg and ∆Cp values of the CM1 samples plotted against felodipine loading percentage (10% 
- 30% w/w) using MTDSC (n=3; average ± SD) 
CM2 patches 
The predicted miscibility of felodipine with different excipients used in CM2 revealed that TPGS 
has better solubilisation properties for felodipine compared PEG-PEO K900 polymeric blend. In 
addition, the miscibility of felodipine in TPGS is also predicted to be higher than that of Tween 
80. On the other hand, TPGS has shown to have lower miscibility with PEG and PEO K900. All 
these preformulation predictions may provide an indication that the phase behaviour of CM2 will 
be different compared to CM1 formulations. After felodipine had been incorporated in the CM2 
patches, no crystalline felodipine melting was detected by DSC in any patches as seen in Figure 
4.6. As earlier, the ATR-FTIR and PXRD results indicated that crystalline felodipine was present 
in at least in the 30% drug loaded patches, this result suggests that thermal dissolution of 
crystalline felodipine in the molten excipients occurred during DSC runs. These results are also 
confirmed by the absence of felodipine melting peak in felodipine 10-30% w/w loaded CM2 
physical mixtures. 
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Figure 4.6: Standard DSC (10ºC/min scanning rate) thermogram of CM2 physical mixtures and drug 
loaded patches with 10-30% loading (n=3) 
For CM2 felodipine loaded HME-IM samples, Figure 4.6 and Table 4.4 indicate that the TPGS 
crystalline phase is detectable in all samples with different drug loadings. The melting transitions 
of TPGS and PEG-PEO K900 in the drug loaded patches shifted to lower temperatures than those 
observed for the placebo CM2 patches. These melting point depressions of the excipients are 
likely caused by the dissolved felodipine in the TPGS and PEG-PEO K900 phases during the 
HME-IM process which may lead to higher level of crystal defects compared to the placebo CM2 
formulation (476). In addition, no significant reduction in the crystallinity of the PEG-PEO K900 
polymers is observed after drug incorporation up to 20% loading. However, samples loaded with 
30% felodipine show 4.5% reduction in crystallinity compared to placebo CM2 sample. This 
slight reduction in crystallinity may be attributed to the presence of the crystalline fraction of 
felodipine leading to defective crystallisation of PEG-PEO K900 blend. The melting transition 
temperatures show drug-loading dependence, as seen in Figure 4.6 and Table 4.4. It was noted 
that the lowest melting points of TPGS and PEG-PEO K900 were obtained in the patches with 
20% drug loading. This may indicate that the 20% patches contain most solubilised drug in the 
matrices which approaches the saturation or even potentially supersaturation of the drug in the 
polymer matrices. Further increasing the drug loading to 30% leads to the presence of 
undissolved/recrystallised crystalline drug accompanied by a shift in the melting peaks of TPGS 
to higher temperatures than were observed in the 10 and 20% loaded patches. However, the 
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melting temperatures of TPGS are still lower than those of the placebo suggesting the presence 
of solubilised drug in the matrices. 
Table 4.4: Melting temperature (Tm) depression of PEG-PEO K900 and surfactant phases caused by 
drug loading in different CM2 HME-IM patches DSC 10°C/ min (n=3, average ± SD) 
Formulation PEG-PEO 
K900 Tm Peak 
(˚C) 
PEG-PEO 
K900 
∆Hf (J/g) 
TPGS Tm 
Peak (˚C) 
TPGS 
∆Hf (J/g) 
Placebo CM2 64.1 ± 0.3 124.7 ± 2.1 37.5 ± 0.1 22.2 ± 1.0 
10% CM2 62.1 ± 0.3 105.5 ± 5.6 28.9 ± 0.3 15.2 ± 0.9 
20% CM2 59.6 ± 0.1 96.8 ± 3.0 20.4 ± 0.4 6.2 ± 0.4 
30% CM2 58.4 ± 0.3 83.9 ± 0.3 24.9 ± 1.5 5.6 ± 1.0 
 
For CM2 formulations, due to the high semi-crystalline nature of PEG, PEO K900 and TPGS, no 
Tg was detected for the placebo samples using standard and MTDSC modes of the DSC for both 
the physical mixture and the HME-IM samples. In addition, no Tg also was detected for the 
physical mixtures of all felodipine loaded mixtures as seen in Figure 4.7 indicating limited 
miscibility between TPGS and PEG-PEO K900 phases and limited miscibility of felodipine in 
the phase separated domains. However, loading felodipine in the HME-IM CM2 matrices causes 
the appearance of Tg events close to the detected Tg of TPGS at -20.0 ± 0.9 ºC. As seen in Figure 
4.7, the Tg for the 10, 20 and 30% w/w were detected at -23.7 ± 0.4, -22.2 ± 0.4 and -21.4 ± 0.8 
ºC respectively. The detection of the Tg values close to that of pure TPGS together with depression 
in the melting of this surfactant strongly suggests felodipine solubilisation in TPGS phase. Slight 
shifting the Tg values to higher temperature reveals the antiplasticising effect of the drug. The 
measured ∆Cp values for the 10,20 and 30% w/w were 0.24 ± 0.04, 0.33 ± 0.02 and 0.29 ± 0.02 
J/ g.°C respectively indicating more amorphous fraction present following this order: 20% > 30% 
> 10% drug loading. The increase in the felodipine -TPGS amorphous fraction is attributed to the 
reduction in the crystallinity of TPGS and the solubilisation of felodipine in the created 
solubilisation amorphous compartment of TPGS. 
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Figure 4.7: Standard DSC results of CM2 physical mixes and buccal patches of placebo and patches 
loaded with 10% - 30% w/w felodipine (n=3) 
A brief comparison between CM1 and CM2 mixtures can be concluded based on the observed 
thermal events of the two series of mixtures. Felodipine was solubilised in the PEG-PEO K900-
Tween 80 amorphous phase of CM1 HME-IM patches while in case of CM2 formulations, the 
drug was mostly dispersed in the TPGS phase. The melting peak of TPGS was detected in all 
placebo and felodipine loaded CM2 patches, while in CM1 formulations, the Tween 80 phase was 
only detected in placebo CM1 sample. This indicates that loading felodipine enhances the 
miscibility of Tween 80 with PEG-PEO K900 blend in CM1 loaded formulations. For CM2, drug 
loading did not show any observable improvement in the miscibility of CM2 carrier components. 
In addition, drug loading was found to antiplasticise the amorphous phase of CM1 patches to 
greater extent compared to the antiplasticisation effect of the drug on the TPGS phase. This is 
indicated by the larger increase in the Tg of the solubilising phase in CM1 compared to CM2 
mixtures. It should be mentioned that the ∆Hf values of the PEG-PEO K900 in CM1 and CM2 
formulations with the same loading percentages were comparable. 
 
Chapter 4   Formulation of felodipine HME-IM patches 
 
157  School of Pharmacy / University of East Anglia 
 
4.3.1.2 Comparisons of morphological properties of CM1 and CM2 patches  
As seen in Figure 4.8, SEM images of placebo and felodipine loaded CM1 patches show similar 
elongated micron-pore structures at the surfaces and cross-sections with the exception of the clear 
presence of particles with defined edges and 10-20 µm in diameter in the patches with 30% drug 
loading. In addition, SEM images captured for CM2 placebo and loaded patches (Figure 4.9) 
revealed that the surfaces of the solid dispersion patches, except for those with 20% drug loading, 
show the presence of small cracks and air voids and increased roughness with increasing the drug 
loading. The cross-sectional images of the patches show increased roughness in the interior in 
comparison to the surfaces and a clear porous character for all samples. Large air pockets between 
100-300 µm in diameter and particles (often with defined edges) with diameters of 10-20 µm, can 
be observed only in the patches with 30% drug loading.  
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Figure 4.8: SEM images surfaces (a, c, e, g) of CM1 placebo and patches with 10%, 20% and 30% 
felodipine loading and their corresponding cross-sections (b, d, f, h) 
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Figure 4.9: SEM images surfaces (a, c, e, g) of CM2 placebo and patches with 10%, 20% and 30% 
felodipine loading and their corresponding cross-sections (b, d, f, h) 
Using the chlorine (Cl) in felodipine molecules as a chemical marker, the elemental analysis 
performed by EDS for the SEM images of both CM1 and CM2 loaded samples confirmed these 
particles being highly concentrated felodipine clusters (Figure 4.10). This leads to the conclusion 
that these clusters being crystal felodipine due to the absence of chlorine in the structures of the 
other excipients used in fabricating CM1 and CM2 HME-IM patches. This is also confirmed by 
the PXRD and ATR-FTIR data shown later.  
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Figure 4.10: Scanning electron microscopic (left) and elemental analysis images (right) of the surfaces 
of CM1 and CM2 patches with different drug loadings 
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4.3.1.3 PXRD and IR characterisation of CM1 and CM2 patches 
As seen in Figure 4.11 A and B, clear crystalline felodipine form I diffraction peaks at 9.3 ̊, 10.2 ̊, 
16.3 ̊ and 16.6 ̊  can be identified in the diffraction pattern of the patches with 30% drug loading 
for both formulations (312). For all drug-loaded CM1 and CM2 patches, no significant changes 
of matrix excipient related peaks were observed. Knowing the presence of crystalline felodipine 
in 30% loaded patches, the absence of crystalline felodipine melting in the DSC results shown in 
Figures 4.2 and 4.6 indicates the felodipine dissolved in the molten matrices at temperatures 
above the polymers melting points during the DSC runs. Therefore, only the melting transitions 
of PEG-PEO K900 matrices were observed.  
 
Figure 4.11: PXRD patterns of A) raw materials, CM1 placebo and 10-30% (w/w) felodipine loaded 
felodipine patches and B) raw materials, CM2 placebo and 10-30% (w/w) felodipine loaded felodipine 
patches 
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ATR-FTIR spectra of CM1 and CM2 HME-IM patches are shown in Figures 4.12 a and b. 
Patches with 30% drug loading revealed an NH peak at 3367 cm-1 which is assigned to crystalline 
felodipine form I. This is also confirmed by the results obtained from the PXRD. The detection 
of the NH stretching of felodipine in the spectrum of 30% loaded samples confirming the presence 
of crystalline felodipine in these patches.  
 
Figure 4.12: Partial ATR-FTIR spectra of felodipine NH stretching region of CM1 (a) and CM2 (b) 
HME-IM patches with different drug loadings in comparison to crystalline and amorphous 
felodipine. The dotted lines highlight the signature crystallisation and amorphous felodipine peaks 
(n=3) 
It should also be mentioned that the shape of the NH peak of 30% loaded CM2 patches is 
asymmetric, with absorbance in a region corresponding to amorphous felodipine, indicating the 
coexistence of amorphous and crystalline materials (108, 316, 317). However, CM1 loaded with 
30% w/w felodipine samples show a more symmetric NH stretching peak indicating less 
amorphous and more crystalline felodipine existing in the patch compared to 30% CM2 
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formulation. This is also confirming the higher solubilisation capacity of CM2 compared to CM1 
mixtures. For the patches with 10% and 20% drug loading, no crystalline felodipine NH peak was 
observed (Figure 4.12).  
The analysis of the spectra of carbonyl region of felodipine between 1800 and 1400 cm-1 for CM1 
and CM2 patches is shown in Figures 4.13a and b respectively. The C=O peaks of crystalline 
felodipine detected at 1688 cm-1 (dotted line) are upshifted to 1697cm-1 for the patches with 10 
and 20% drug loading of both CM1 and CM2 formulations. This perfectly aligns with the C=O 
peak of the amorphous felodipine indicating the amorphous nature of the drug in patches with 
20% drug loaded patches due to the stronger amorphous felodipine-felodipine intermolecular 
hydrogen bonding (448). In addition, this also may indicate the formation of hydrogen bonds 
between the NH group of felodipine and the -C-O-C backbone of ethylene oxide moieties of the 
other formulation components especially for samples with a drug loading of 10% w/w (68). A 
shift to lower wavenumber towards the C=O of crystalline felodipine for CM1 and CM2 patches 
with 30% drug loading at 1693 cm-1 and 1695 cm-1 respectively may be a result of the presence of 
both crystalline and amorphous felodipine (108, 316, 317).  
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Figure 4.13: Partial ATR-FTIR spectra of felodipine C=O carbonyl region of CM1 (a) and CM2 (b) 
HME-IM patches with different drug loadings in comparison to crystalline and amorphous 
felodipine (n=3) 
The interpretation of the CN region is shown in Figures 4.14a and b for CM1 and CM2 patches 
respectively. The CN peak of pure amorphous felodipine shifted to 1206 cm-1 (dotted line) in 
comparison to the 1202 cm-1 CN peak of crystalline felodipine indicating stronger intermolecular 
H-bonding in the amorphous state (448). The CN peak further shifted further to 1210 cm-1 for the 
patches with 10% and 20% drug loading of both formulations, indicating the presence of 
additional hydrogen bonding between the drug and the ethylene oxide chains which may 
contribute to the formation of a molecular dispersion of felodipine in amorphous fractions of CM1 
and CM2 carriers. However, the CN peak of the CM1 and CM2 patches with 30% loading was 
observed at 1206 cm-1. This is consistent with the presence of crystalline together with amorphous 
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and/or  molecularly dispersed felodipine interacting with the other excipients (448). It should be 
mentioned that there is no change in the position of the C=O stretching groups of both Tween 80 
and TPGS indicating the absence of felodipine hydrogen bonding with these groups of the 
surfactants. 
 
Figure 4.14: Partial ATR-FTIR spectra of felodipine CN stretching region of CM1 and CM2 HME-
IM patches with different drug loadings in comparison to crystalline and amorphous felodipine (n=3)   
4.3.1.4 Investigation of heterogeneity HME-IM patches using IR imaging 
IR imaging was utilised in the first instance to rapidly screen compositional heterogeneity of CM1 
and CM2 HME-IM patches and confirm the phase separation being drug loading dependent. 
Increased compositional heterogeneity was observed with increasing the drug loading. As it was 
preliminary fast screening, the IR imaging was constructed based on both compositional and light 
Chapter 4   Formulation of felodipine HME-IM patches 
 
166  School of Pharmacy / University of East Anglia 
 
reflectivity difference at the surface of the samples. The combinations of these differences were 
analysed using principle component analysis (PCA) to construct the IR map seen in Figure 4.15.  
It can be seen that the IR spectra of the areas with red, green and blue are distinctively different, 
indicating areas with different colours are also with different chemical composition (Figure 
4.15a). The IR images of the surfaces of the placebo and 10% CM1 loaded patches are dominated 
by red colour with a spectrum containing a little contribution of drug spectrum loading indicating 
a lower level of heterogeneity (Figure 4.15b and c). At 10% drug loading, most of the surface 
was dominated by PEG-PEO K900. Increased heterogeneity of the colour differences is observed 
in the patches with higher drug loadings. With 20% CM1 HME-IM (Figure 4.15d) the surface 
showed a few isolated domains which appeared to be drug-rich and the rest of the surface had 
similar IR features as the patches with 10% loading. However, the spectra of the surfaces of the 
patches with 30% drug loading (Figure 4.15e), were interpreted as a patchwork of small PEG-
PEO K900-rich and Tween 80-rich areas, the latter showing small bands which may indicate the 
presence of dissolved felodipine. It was noticed that the sizes of the separated domains are larger 
for 20% than for 30% patches. In addition, many domains with spectra in the 30% loaded patches 
indicating high crystalline drug loading can be seen.  
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Figure 4.15: (a) IR reflectance spectra are coding for the composition of different colours in the IR 
images. Red spectrum indicates areas containing drug as molecularly dispersed or amorphous form; 
green spectrum indicating areas indicating areas rich with the drug (supersaturated matrix which 
may contain very tiny crystals); purple spectrum indicating areas with crystalline drug); correlation 
IR map (left), optical image (right) and the IR spectrum of the point of interest (bottom) of the 
surfaces of CM1 HME-IM patches with (b) placebo, (c) 10%, (d) 20% and (e) 30% felodipine loading 
IR imaging (Figure 4.16) shows that CM2 patches with up to 20% w/w loadings have a very 
homogenous composition (no heterogeneity within the limits of the scrutiny of the instrument). 
For example, comparing the red with the green spots in the 10 and 20% w/w loadings shows 
identical spectra. Differences in correlation coefficients are probably only due to physical effects 
such as reflection and/or surface roughness indicating no microscale phase separation on the 
surface of these samples. However, the 30% loading patches show the presence of the blue spots 
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with different spectrum indicating the phase separation of the crystalline drug on the surface of 
the sample. 
 
Figure 4.16: Correlation IR maps for placebo (a), 10% (b), 20% (c) and 30% (d) CM2 HME-IM 
patches; (e) is the IR reflectance spectra for the different areas of the maps  
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4.3.2 Influence of drug loading and phase separation on mucoadhesion  
The mucoadhesion properties of CM1 and CM2 HME-IM patches were estimated using standard 
adhesion testing (477). As the focus of this study is to investigate the effect of phase separation 
on the in vitro performance of the patches, mucoadhesion results presented here are purely for 
comparison purpose between different formulations. Figure 4.17 shows representative 
mucoadhesion analysis using TA-XT2 Texture Analyser for placebo CM1 patch.  As seen in Table 
4.5, no significant difference is seen in the mucoadhesivness of the placebo and 10% drug loaded 
CM1 patches. This indicates that 10% drug loading as molecular dispersion did not significantly 
affect the surface hydrophobicity and overall mucoadhesive properties of the patches. However, 
with increasing the drug loading the mucoadhesivness of the patches reduces. It should be borne 
in mind that the content of the main mucoadhesive material, PEO K900, reduced by 22% (w/w) 
from 10% loaded patches to 30% loaded patches. However, the mucoadhesion force reduced by 
40% and 39% for CM1 and CM2 respectively indicating the effect is not only related to the 
lowered mucoadhesive material content. The increased amount of hydrophobic drug could also 
increase the overall hydrophobicity of the surface of the patches and reduce the wetting and 
mucoadhesion of the patches. The presence of phase-separated Tween 80 and PEG-PEO K900 
areas may also lead to the patch surface with discontinuous adhesive areas which also contributed 
to the reduced adhesion of the patches. 
Compared to CM1, CM2 placebo and 10% w/w loaded patches showed an insignificant reduction 
in their mucoadhesive properties revealing that changing surfactant type has no effect on these 
properties below the saturation limits of the two systems. However, the mucoadhesion of 20% 
w/w loaded patches were found to be significantly lower than that of the corresponding CM1 
matrices. This may be due to the lower miscibility of TPGS phase compared to Tween 80 phase 
with the PEG-PEO K900 polymeric blend and the depressed melting of TPGS by the dissolved 
drug. The molten TPGS phase at room temperature on the surface of the patches may decrease 
the adhesion properties of the system. Additionally, phase separation of 30% w/w felodipine 
loaded CM2 patches together with the presence of the crystalline fraction of felodipine may be 
the causes for the reduction in the mucoadhesive properties of the formulation.     
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Figure 4.17: Mucoadhesion analysis for placebo CM1 sample using TA-XT2 Texture Analyser 
 
Table 4.5: In vitro mucoadhesion measurements of CM1 and CM2 placebo and felodipine loaded 
HME-IM buccal patches (n = 5, average ± SD) 
Formulation Peak adhesive force (N) Total work of adhesion 
(N.mm) 
Placebo CM1 0.825 ± 0.115 0.159 ±0.030 
10% w/w CM1 0.927± 0.149 0.194± 0.046 
20% w/w CM1 0.775± 0.090 0.158± 0.027 
30% w/w CM1 0.536± 0.040 0.100± 0.005 
Placebo CM2 0.992 ± 0.340 0.211 ±0.087 
10% w/w CM2 0.882 ± 0.304 0.205 ± 0.079 
20% w/w CM2 0.393 ± 0.090 0.086 ± 0.016 
30% w/w CM2 0.345 ± 0.171 0.076 ± 0.028 
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4.3.3 Influence of drug loading and phase separation on the in vitro 
felodipine release profiles from the HME-IM patches  
Figure 4.18 shows the in vitro unidirectional drug release behaviour of CM1 and CM2 patches 
under sink (PBS pH = 6.8 containing 0.5% v/v Tween 80) and non-sink (PBS pH = 6.8 only) 
conditions. The release profile of CM1 patches under sink condition (Figure 4.18a), with the 
presence of surfactants in the dissolution media, no significant difference in the release profiles 
of felodipine from the HME-IM patches with different loading percentages can be identified. The 
release is dominated by zero-order kinetics. This indicates that the dissolution is not controlled or 
affected by the phase separation and presence of the crystalline drug. In this case, it is likely that 
the dissolution of the matrix is the rate-limiting factor of the drug release.  
The in vitro release of CM1 under non-sink condition was conducted to eliminate the impact of 
the sink condition promoting surfactant on the release profile of different mucoadhesive patches. 
The supersaturation of felodipine in the dissolution media had a clear impact on the release 
profiles of the patches.  As seen in Figure 4.18b, the patches with 30% drug loading show similar 
dissolution behaviour as pure crystalline felodipine, indicating the dissolution of the crystalline 
drug is the rate-limiting factor in this case. The patches with 10 and 20% drug loadings showed 
higher dissolution rates and better maintained supersaturation state of felodipine in dissolution 
media than the patches with 30% drug loading.  
The unidirectional felodipine release profile from CM2 patches with different drug loading tested 
under non-sink conditions are shown in Figure 4.18c. For the 10% and 20% patches, 10-15 fold 
increases in maximum drug release were achieved within 2-2.25 hours in comparison to the 
crystalline drug alone. This may be attributed to the fact that the majority of the drug in these two 
formulations is in the molecularly dispersed and the amorphous states, which led to faster 
dissolution. However, with increasing the drug loading to 30%, the increase in drug release 
reduced to only 2-fold increase in comparison to the pure crystalline drug. The presence of phase 
separated crystalline drug in the patches is likely to be responsible for this result. The dissolution 
results indicate that the phase-separated carrier systems that contain no crystalline drug can 
significantly improve drug release. Even with only one side of the intact patches in contact with 
the dissolution media, this dissolution enhancement is comparable with other binary solid 
dispersion systems reported in the literature where milled extrusion powders with a much higher 
total surface area for dissolution were used (73). 
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The two mixtures show approximately similar release percentages at the corresponding loading 
fraction of felodipine. The only difference noticed between the two formulations is the higher 
ability of CM2 patches loaded with 20% felodipine to stabilise the dissolved felodipine in the 
dissolution media compared to CM1 constituents. These self-emulsified drug delivery systems 
are assumed to prevent the after dissolution crystallisation of felodipine. Knowing that the 
proportions and the constituents of the two mixtures at this loading percentage are the same except 
the type of the surfactants, this difference in felodipine stabilisation in the dissolution media is 
more likely due to the more stabilisation effect of TPGS compared to Tween 80. It should be 
mentioned that the concentrations of both surfactants in the dissolution medium after their 
dissolution is less than their CMC reported in the literature (363, 375).  
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Figure 4.18: In vitro release profiles of felodipine from HME-IM buccal mucoadhesive patches; a) 
CM1 patches under sink conditions, a) CM1 patches under non-sink conditions and c) CM2 patches 
under non-sink conditions (n=3; average ± SD) 
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4.4 Discussion 
Formulating solid dispersions of poorly water soluble drugs like felodipine using HME-IM as 
single step processing is an attractive approach for improving their dissolution properties with 
fast and environmentally friendly processing. However, in order to achieve the desired 
formulation features of the product such as systemic delivery via the buccal cavity in this study 
to avoid the extensive liver inactivation of 84% of the drug in addition to dissolution enhancement, 
it requires the inclusion of a number of excipients resulting in an increase in the complexity of 
the system. The primary objective of this chapter was to design and investigate the 
physicochemical properties of felodipine quaternary solid dispersions using carefully selected 
excipients to solubilise and stabilise the dispersed drug in the matrices. Liquid (Tween 80) and 
waxy solid (vitamin E TPGS) surfactants were used as intentionally created solubilisation 
compartments. In addition, the excipients also chosen to permit processing at low temperature (65 
ºC) with easy to peel off from the mould after cooling which cannot be achieved for the vast 
majority of excipients used in HME due to the requirement of high processing temperature and 
stickiness to the mould after moulding which interferes with the purpose of using this processing 
technique.  
The binary miscibility between excipients was first estimated in order to establish the preliminary 
understanding of the complex phase separation of the quaternary dispersions. Crystalline 
felodipine showed good solubility in Tween 80 and TPGS surfactants. The partial miscibility of 
Tween 80 and TPGS with PEG-PEO K900 was indicated by the thermal method leads to the 
formation of phase-separated systems. Felodipine was predicted be to miscible with PEG-PEO 
K900 by solubility parameter method but was experimentally proven to be very low due to the 
low amorphous content of PEG-PEO K900 at the stated processing parameters. The ability of 
semi-crystalline PEG-PEO K900 mixture to solubilise poorly water-soluble drugs is generally 
governed by the kinetics of crystallisation of the drug and the presence of favourable interactions 
between the drug and the polymers below their saturation capacity. Dissolved drugs are normally 
occupying the amorphous fraction of the polymeric blend. Drugs with weak interactions with 
these polymers or strong devitrification tendencies are most likely translocate to the interfibrillar 
or interspherulitic regions. The magnitude of drug solubilisation has significant impact on the size 
of the amorphous fraction and consequently their overall crystallinity (88).  
Thermal and spectroscopic characterisation techniques like DSC, MTDSC, SEM, EDS, ATR-
FTIR and PXRD were used to characterise the prepared HME-IM matrices. SEM, EDS and 
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PXRD revealed that dispersions with up to 10% CM1 and 20% CM2 are free of crystalline 
fraction of felodipine. Samples with 20% CM1 and 30% CM2 loading clearly showed the 
presence of crystalline felodipine form I as indicated by the identified felodipine crystals on the 
surface and interface of the samples using SEM and EDS and the appearance of the characteristics 
diffraction peaks of form I using PXRD. Using ATR-FTIR, the physical state of the drug in the 
different dispersions was revealed. Broadening of the NH stretching peak of felodipine in the 10% 
loading most likely indicating that the drug is molecularly dispersed in the phase separated. The 
appearance of felodipine NH stretching in 3333 cm-1 suggesting the presence of the drug as 
amorphous domains in the matrix. The asymmetric NH stretching peak detected at 3367 cm-1 in 
the spectrum of the 30% loading indicate that felodipine exists as crystalline and amorphous 
fractions in the mixture. These results also supported by changes in the CN stretching of the drug. 
IR imaging revealed the same conclusion obtained from the other techniques indicating 
microscale heterogeneity of 30% loaded patches.  
DSC analysis provided more information about the miscibility of the PEG-PEO K900 and Tween 
80 or TPGS phases and the impact of drug loading on the phase separation in the different HME-
IM buccal patches. As revealed from melting point depression approach in Chapter 3, TPGS has 
higher solubilisation capacity for felodipine than PEG-PEO K900 blend and Tween 80. The phase 
separated Tween 80 phase detected in placebo CM1 patches is completely absent by felodipine 
loading revealing improved miscibility of the phases by drug solubilisation. The high 
semicrystalline nature of TPGS and the presence of vitamin E moiety in its structure limits its 
miscibility with the hydrophilic PEG-PEO K900 polymer blend. Dispersing felodipine in CM2 
phase separated system is strongly depressing the melting of TPGS compared to PEG-PEO K 900 
up to 20% loading supporting that TPGS acts as semisolid phase separated solubilisation 
compartments embedded in the patches. This is also clearly reflected in the Tg region analysis. 
Due to the high semi-crystalline character of TPGS and PEG-PEO K 900 phases and their limited 
miscibility, the Tg of either of them was undetectable in the placebo CM2 sample. Interestingly, 
as the loading percent of the drug increase, a clear Tg in a temperature very close to the Tg of 
TPGS was detected indicating an increase in the amorphous fraction of TPGS by felodipine 
solubilisation. It should be mentioned that felodipine has less antiplasticising effect on TPGS 
phase of CM2 formulations compared to CM1 loaded patches. In addition, the dissolved drug in 
TPGS seems has no effect on increasing the miscibility of the separate phases compared to CM1 
formulations.   
It was found that the saturation limit and the concentration of the drug affecting the mucoadhesion 
parameters of the fabricated HME-IM patches of CM1 and CM2 blends. Samples below the 
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saturation (10% loading) revealed similar mucoadhesion properties, however, increasing drug 
loading to 20-30% loading significantly reduced the force and work of adhesion may be due to 
the presence of a crystalline fraction of felodipine and/or lowering the melting of the surfactant 
phase. The designed felodipine loaded CM1 and CM2 mucoadhesive buccal patches also showed 
an enhancement in the dissolution properties of felodipine with 10% loading being the maximum 
with approximately 60% drug release after 2.5 hours under non-sink conditions compared to the 
crystalline drug. This significant enhancement in the solubility/dissolution properties of 
felodipine using the HME-IM fabricated patches together with using the buccal route for systemic 
delivery of felodipine is expected to improve the bioavailability of the drug under investigation.   
4.5 Conclusion 
Formation of phase separated compartments in-situ with different functionalities that can improve 
the bioavailability of poorly soluble drugs was the main formulation strategy presented in this 
chapter. The characterisation results presented in this chapter confirmed the formation of the 
phase-separated systems with the drug being solubilised predominately in the Tween 80 and 
TPGS rich phases. The results of this chapter have also demonstrated the feasibility of using 
HME-IM as a simple pharmaceutical process to produce patches that are suitable for the buccal 
route of administration which can provide the advantage of avoiding the first-pass metabolism. 
Using the solubility difference between the excipients and drug, Tween 80-rich or TPGS-rich 
compartments with the primary function of solubilising drug and PEG-PEO-rich phase with the 
main function of providing mucoadhesion and acting as a hydrophilic carrier for easing 
dissolution were successfully created in-situ. To be able to formulate such phase separated 
systems requires a clear understanding of the miscibility between ingredients. Successfully 
designed mucoadhesive patches show good mucoadhesive properties and maximum in vitro 
release profile with matrices loaded with 10% felodipine. With this information, formulations 
with the desired level and type of phase separation can be designed and produced by varying the 
composition of the different ingredients in the mixtures. However, despite the clear indications of 
the phase separation in the patches, it is not possible to obtain detailed information on the spatial 
distribution of the separate phases. This characterisation challenge is addressed in Chapter 5. 
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5.1 Introduction 
The heterogeneity of material in a complex formulation is often a key parameter that requires 
monitoring during quality control of pharmaceutical products. In multi-component formulations, 
which is the case for most pharmaceutical products, the uniformity of the distribution of excipients 
and active therapeutic drugs across the dosage form is extremely important for ensuring the 
quality such as physical stability over shelf-life and in vivo performance such as drug release rate, 
which are critically responsible for the overall therapeutic efficiency of the product (175). 
However, to characterise and assess heterogeneity within a single formulation often requires the 
use of multiple off-line localised analytical techniques, which is time-consuming and costly 
process. In the case of the solid dispersion based patches produced in this project, the multi-
components also phase separate in the patches. The understanding of how these separate phases 
distribute across the patches is important for further investigation and modification of the in vitro 
stability and drug release behaviour of the patches.   
Traditionally, solid dispersions have been often loosely classified into single-phase molecular 
dispersions and phase separated systems with varying degrees of structural complexity (474, 478, 
479). Phase separation in solid dispersions is the result of the diversity in the physicochemical 
properties of the drugs and excipients used in the formulations which affects their miscibility. 
Normally, phase separation of drug from the excipients has often been considered as an indication 
of instability or incompatibility between the drug and excipients and therefore been avoided in 
industrial formulation development (480, 481). The most commonly detected phase separation 
behaviour in solid dispersions is the separation of the dispersed drug from the carrier matrix (8, 
24) as either amorphous or crystalline domain (129, 482, 483). However, in this project phase 
separation was intentionally used as a strategy to improve stability and modulate the drug release 
profile. As described in Chapter 4, for both CM1 and CM2, the conventional characterisation 
results indicated that the excipients used showed partial miscibility which led to phase separation 
of the excipients. Each separate excipient phase contained different amount of solubilised drug.   
Although conventional characterisation techniques such as DSC, MTDSC, PXRD and 
spectroscopic methods including IR, Raman and terahertz spectroscopy often allow the 
confirmation of the presence of phase separation, understanding the phase separation behaviour 
in solid dispersions can still be challenging. The overlapping diffraction patterns or spectra from 
different phases or the thermal dissolution of one phase into another during heating in the DSC 
often lead to the difficulty in accurate data interpretation (385, 484, 485). Many excipients and 
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active ingredients are organic materials which make SEM analysis in combination with EDS 
powerless for identifying detailed phase separation due to the lack of elemental variability 
between samples. In addition, the conventional characterisation methods mentioned above have 
not been able to effectively provide information on two important aspects of phase separation in 
formulations, heterogeneity and the 3D spatial distribution of different phases. Addressing these 
two aspects of phase separated solid dispersions will advance our understanding of how to control 
the formation and kinetics of phase separation behaviour in complex solid formulations and in 
turn enable the rapid development of phase separated dispersions which may be used for the 
delivery of multiple active pharmaceutical ingredients in one formulation. It should be mentioned 
that micro/nano thermal analysis using a heated probe in a scanning probe microscope can provide 
information on sample heterogeneity using either local thermal analysis or photothermal IR 
spectroscopy (486-488). However, it is slow and can take over an hour for a single high spatial 
resolution image using TTM (489).  
This chapter introduces the use of two non-conventional methods, thermal analysis by structural 
characterisation (TASC) and X-ray micro computed tomography (XµCT), as novel techniques for 
studying phase separation in complex pharmaceutical products designed by HME-IM. The 
potential of these techniques has been evaluated for characterising heterogeneity and spatial 
distribution of phases in the prepared samples. TASC uses conventional and user-friendly hot 
stage microscopy with a novel algorithm for quantifying changes in successive micrographs of 
the samples during heating or cooling. The detailed working principle of TASC has been 
explained previously in Chapter 2. The subtle changes in the appearance of the sample during 
heating or cooling detected by TASC can then be converted into thermal transition graphs. XµCT 
used as a non-invasive method to investigate the 3D internal microstructure of the patches and to 
estimate the size, shape and spatial distribution of the phases in situ. In this technique, the 
absorption of X-rays results in the generation of series of images in a manner similar to 
transmission microscopy. Different phases having different electron densities depending on the 
characteristics of their elements can be differentiated by XµCT and represented as 3D models. In 
this chapter, the same series of complex solid dispersions studied in Chapter 4 (placebo and 10-
30% w/w felodipine loaded CM1 and CM2 HME-IM mucoadhesive buccal patches) were 
analysed using TASC and XµCT.   
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Research objectives   
1. To use TASC as a new, fast and cheap thermal characterisation technique for detecting 
heterogeneity in complex solid dispersions prepared by HME-IM technique. 
2. To compare the data generated by TASC with results obtained by standard DSC in order 
to observe the possible additional advantages of TASC analysis like detecting thermal 
dissolution, providing localised analysis and impacts of the rate of heating and cooling 
ramps during thermal analysis.      
3. To investigate the ability of XµCT to detect heterogeneity and spatial distribution of phase 
separation in the prepared solid dispersions at micron-scale. 
4. To assess the use of XµCT for providing quantitative/semi-quantitative information about 
the phase separation of drug above the saturation limits of the carrier mixture.  
5.2 Materials and Methods 
5.2.1 Materials 
Same batches of the HME-IM patches studied in Chapter 4 were prepared and characterised using 
TASC and XµCT. 
5.2.2 Methods 
5.2.2.1 Thermal analysis by structural characterisation (TASC) 
The TASC system was composed of a temperature controlled heating/cooling Linkam MDSG600 
automated stage fixed to a Linkam imaging station that was attached to a microscope working in 
reflective mode (LED light source and X10 magnification lens) and was equipped with a digital 
camera to capture images that correspond to thermal events as a function of temperature. For 
cooling ramps, the temperature of the stage is controlled using a cooling unit that operates by 
purging liquid nitrogen into the stage.  
For all samples analysed, thin slices of the prepared patches (0.6 - 1.2 mm × 0.6 mm × 0.2 mm) 
were cut using a sharp blade and placed in standard DSC pans (TA Instruments, Newcastle, USA). 
A pre-designed temperature program (10 °C/min) for heating, cooling and reheating cycles with 
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an isothermal period of 1 minute separating the ramps was applied to the prepared samples within 
the range of -10 to 150 °C. Before starting the experiments, the image-capturing mode was 
activated at an image acquisition rate of 1 frame/ ˚C. The captured images were then collected 
and analysed using the TASC software provided by Cyversa (Norwich, UK). The results obtained 
were statistically analysed by using one way analysis of variance (ANOVA). Statistical 
significance was accepted at the p ≤ 0.05 level.   
5.2.2.2 Differential scanning calorimetry (DSC) and modulated temperature 
DSC (MTDSC) 
All samples investigated in this study using standard DSC were analysed using the same 
parameters as described in Chapter 3, section 3.2.2.2.2.  Heating only MTDSC experiments were 
also performed (at 2 ºC/min scanning rate, 40 sec period and 0.212 ºC amplitude) to investigate 
the hidden melt-recrystallisation behaviour of the patches. All samples analysed have a weight of 
about 2-3 mg and standard TA crimped pans (TA Instruments, Newcastle, USA) were used. All 
analyses were performed in triplicates. 
5.2.2.3 Variable temperature attenuated total reflectance Fourier transform 
infrared spectroscopy (VT-ATR-FTIR)  
All experiments were conducted using an IFS 66/S FTIR spectrometer (Bruker Optics Ltd, 
Coventry, UK) fitted with a Golden Gate® ATR accessory with a temperature-controllable top 
plate (Orpington, UK) equipped with diamond internal reflection element. ATR-FTIR spectra, in 
absorbance mode, were obtained using a scanning resolution of 2 cm-1 and 32 scans for each 
sample. The system was connected to a high stability temperature controller (Specac, USA) and 
the VT-ATR-FTIR spectra were collected using heat-cool-heat program with a heating rate of 
2ºC/min. All spectra were analysed using OPUS software.  
5.2.2.4 X-ray micro computed tomography (XμCT) 
Two XµCT types of equipment were used to investigate CM1 and CM2 buccal patches designed 
using HME-IM. XµCT images for the placebo and felodipine loaded CM1 patches were 
characterised using a Phoenix v[tome]x m system (General Electric, Wunstorf, Germany). 3D 
images of the formulations were reconstructed from a large series of two-dimensional 
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radiographic images taken around a single axis of rotation. The following settings were applied: 
voxel size: 4µm, number of images: 1500, Voltage 60 kV, Current 100 µA and timing 500: ms.  
For CM2 samples, CM2 felodipine solid dispersions with different drug loading percentages were 
analysed using SkyScan1172 high-resolution X-ray micro computed tomography (XµCT) 
scanner (Bruker-microCT, Kontich, Antwerp, Belgium). The analysed samples were imaged 
using an aluminium filter to cut-off high energy X-rays at an isotropic voxel resolution of 3 µm 
over a total of 20 min acquisition time and a subsequent image reconstruction time took 
approximately 20 min per sample, using the NRecon program (version 1.6.8.0, Bruker-microCT). 
The reconstructed images were analysed using CTan and CTvol software in which the images for 
a small section (designated as a region of interest ROI) for each sample are converted to binary 
images followed by thresholding each component according to differences in density and 
represented in 3D models. CM2 Powder compacts made of the physical mixtures of crystalline 
felodipine and the rest of the excipients with consistent compositions to those used in the HME-
IM formulations were prepared for the quantitative studies. The compacts (13 mm in diameter) 
were prepared by compressing (500 mg) of the premixed physical blends into flat-faced disks 
using an IR press (Specac, Kent, UK) with 10 kN pressure held for 5 minutes.  
5.3 Results  
5.3.1 TASC analysis of the phase separation of the HME-IM patches 
5.3.1.1 Fast detection of heterogeneity in solid dosage forms 
The TASC software is designed to track changes in the sample during heating or cooling ramps 
and any change in the structure as seen by the microscope can be detected. Samples frequently 
move when heated or cooled, but TASC tracks these movements and compensates for them, so 
only structural changes are measured.  As seen in Figure 5.1, the blue frame is the region of 
interest (ROI) while the red square defines the target area (TA) scanned by the centre of the ROI 
thus movement over this range is compensated for. TASC tracks these movements by fixing on 
an optical feature.  
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Figure 5.1: Light microscopic image of an example slice of 10% w/w CM1 felodipine mucoadhesive 
buccal patch analysed by TASC software 
Sequences of images were collected during the heating or cooling of patches using TASC. Initially, 
the ROI was selected as shown in Figure 5.1. TASC follows the subtle changes of structure of 
the selected ROI and converts this information into phase transition signals plotted against 
temperature. The detailed algorithm of TASC is described in chapters 2. Figure 5.2 shows an 
example for the thermal events detected by TASC algorithm. 
 
Figure 5.2: Thermal events of placebo CM2 sample detected by TASC at different points (-10°C, 
40°C, and 80°C) during the heating ramp at 10 °C/ min 
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Compared to DSC, TASC detected the of thermal transitions of placebo CM1 and CM2 for the 
heating -cooling and reheating cycles in temperatures comparable to DSC as shown in Figure 5.3. 
TASC detected the offset of melting transitions of PEG-PEO K900 and TPGS at similar 
temperatures for all cycles. Similar results are also obtained for the onset and offset of 
crystallisation events during the cooling cycles. However, the detection of the onset of melting 
transitions is delayed in the heating cycles because the method of detection by TASC is different 
from that of DSC. TASC detects the change on the top surface of the sample, which means that 
when the lower part of the sample in contact with the pan starts to melt (onset of melting in DSC) 
no TASC signal can be detected until the change appears on the top surface where the algorithm 
is scanning for the ROI change. This is the case when the sample under investigation is opaque 
as the matrices used in this study due to the semicrystalline nature of some of the excipients used 
in this study. This leads to a temperature gradient sometimes appears as a delay in the TASC signal 
compared to DSC.   
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Figure 5.3: TASC compared to standard DSC averaged thermograms of placebo CM1 during the 
heating (A and B), cooling (C and D) and reheating (E and F) cycles and placebo CM2 during the 
heating (G and H), cooling (I and J) and reheating (K and L) cycles at 10 °C/ min for all cycles (n=3; 
average ± SD) 
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For CM1 and CM2 placebo and patches with up to 20% w/w drug loading, the results obtained 
from TASC were more reproducible (low standard deviation for 3-5 repeated tests) for the heating, 
cooling and reheating cycles than the data obtained from the system with 30% drug loading 
(Figures 5.3-5.5). This low inter-sample variation indicates a low level of heterogeneity, at least 
at this scale of scrutiny, of the formulations with drug loadings at and below 20% loading. This is 
confirmed by the SEM results of the internal microstructure of the patches as seen in Chapter 4. 
The reproducibility of the TASC results of the patches with 30% felodipine was much lower as 
reflected by the high variation of the TASC data for the initial heating cycle of the patches (Figure 
5.6), note that regions of similar area were used for all of the samples. As TASC is a form of local 
thermal analysis, each testing area is different from another (such as containing different amount 
of crystalline/amorphous material or structural features). Therefore, the high inter-sample 
variation (with statistically significance P < 0.5) in the 30% patches should be an indication of 
high heterogeneity of the sample with average testing areas of (2500-10000 µm2). 
 
Figure 5.4: TASC thermograms of 10% felodipine in CM1 during the heating (A), cooling (C) and 
reheating (E) cycles; and 10% felodipine in CM2 during the heating (B), cooling (D) and reheating 
(F) cycles using 10 °C/ min for all cycles (n=3; average ± SD) 
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Figure 5.5: TASC thermograms of 20% felodipine in CM1 during the heating (A), cooling (C) and 
reheating (E) cycles; and 20% felodipine in CM2 during the heating (B), cooling (D) and reheating 
(F) cycles using 10 °C/ min for all cycles (n=3; average ± SD) 
The TASC results of CM2 patches with 30% w/w felodipine content (Figure 5.6B) show a 
complex triple transition. The melting peak of TPGS can be clearly seen at approximately 33ºC 
which is in agreement with the DSC data. Two further melting transitions were detected at 60 and 
76ºC followed by the absence of the plateau region seen in the placebo and 10% loaded samples. 
DSC data of the 30% loaded patches only show the melting of the PEG-PEO K900 phase at 60ºC 
(Figure 5.7B). However, it is known from the other characterisation methods in Chapter 4 that 
there were crystalline drug particles present in the 30% patches. Therefore, the 76ºC transition 
detected by TASC is likely to be associated with the thermal dissolution of the remaining 
crystalline drug into the molten matrix. The absence of a plateau region indicates the continuous 
changes captured by TASC were not completed at 90 ºC.  The poorer reproducibility of data in 
the high temperature region was also noted in comparison to the results of the samples with lower 
drug loadings. It should be mentioned that the 30% CM2 loaded patches show better 
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reproducibility compared to the corresponding CM1 patches confirming the results of better 
solubilisation capacity of CM2 for felodipine compared to CM1.  
 
Figure 5.6: TASC thermograms of 30% felodipine in CM1 during the heating (A), cooling (C) and 
reheating (E) cycles; and 30% felodipine in CM2 during the heating (B), cooling (D) and reheating 
(F) cycles using 10 °C/ min for all cycles (n=3; average ± SD) 
The high heterogeneity of the patches with 30% load is confirmed by the rich variety of interior 
features of the patches seen by SEM (Chapter 4; Figures 4.4g and h and Figure 4.5g and h) 
including the presences of air pockets and non uniform distribution of particles with 5-20µm in 
average diameter and defined edges which are likely to be felodipine crystals.  
As seen in Figure 5.7, this sensitivity to the heterogeneity of the sample is absent in the DSC 
results which provide only global information. The significant difference in weight of sample 
analysed by the two methods may contribute to the difference in their detective sensitivities. The 
calculated weight range of the analysed areas by TASC (the area framed by the blue square 
indicated in Figure 5.2) was estimated to be 0.6-3.7 µg in comparison to 2-3 mg sample size used 
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in the DSC experiments. As a consequence of this, as seen in Figure 5.7B and D, the 30% loaded 
samples analysed by DSC showed high reproducibility.  
 
Figure 5.7: TASC and DSC results of the heating cycle of CM1 (A and B) and CM2 (C and D) placebo 
and felodipine loaded mucoadhesive buccal patches with 10, 20 and 30% w/w loading (n=3; average 
± SD) 
The low reproducibility and failure to reach a plateau with the individual replicates of the 30% 
w/w loaded CM1 and CM2 formulations were further investigated by altering the size of ROI and 
increasing the terminal temperature of the analysis to above the melting point of crystalline 
felodipine. As seen in Figure 5.8, the reproducibility of the data collected by analysing small 
areas (ROIs, approximately between 2.5 × 10-3 and 10 × 10-3 mm2) is lower than that obtained 
from larger areas (between 40 × 10-3 and 90 × 10-3 mm2). The results obtained using larger tested 
areas often overlooks the differences present locally on a micro scale (heterogeneity). This is 
demonstrated by the highly reproducible DSC data in which the samples were tested as a bulk 
material with no localised information being obtainable (Figure 5.7B and D). The poor 
reproducibility of the TASC results obtained from small ROIs indicates a high variability in the 
thermal transitions detected locally. The size of drug crystals detected by SEM is approximately 
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10-20 µm in diameter which is smaller than the smallest ROI used in this analyses. The thermal 
properties detected for each ROI is the average of all materials within the area which should, 
therefore, be a mixture of drug crystals, excipients and amorphous dispersions of drug dissolved 
in the excipients. The variation of the thermal properties is likely to represent differing amounts 
of drug crystals, excipients and amorphous drug dispersions being present in each ROI. This was 
not observed in placebo and samples with 10% drug loading (Figure 5.9). This is a clear 
indication of the high heterogeneity of the distribution of the separate phases in the patches with 
30% drug loading at the micron scale. The attempt of validating such finding by XµCT is 
described later in this chapter.  
 
Figure 5.8: Comparison of the TASC results of the heating cycle of CM1 (left) and CM2 (right) 30% 
w/w felodipine patches using (A, B) small sampling spots (to provide localise thermal analysis), (C 
and D) larger sampling spots; (E and F) extended heating to 150ºC to demonstrate that the drug 
dissolution/melting occurred in the 30% drug loaded samples as the TASC signal reaches the plateau 
at higher temperature above 100 °C (n=3; average ± SD)  
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Figure 5.9: The TASC results of the heating cycle of 10% (A and B) and 30% (C and D) CM2 
felodipine loaded patches using a small sampling area (A and C) and a larger sampling area (B and 
D). It can be seen that there is no obvious difference in the error bars of the data collected from the 
two areas with different sizes for 10% indicating the high homogeneity of the samples with low drug 
loading compared to 30% loading (n=3; average ± SD) 
It was also noticed that TASC was able to detect the double crystallisation in CM2 placebo sample 
at a temperature comparable to that of the DSC as seen in Figure 5.10. There is also a reduction 
of the crystallisation temperatures with increasing drug loading of all CM1 and CM2 which can 
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be explained by the incorporation of drug in the different phases (although not necessarily in equal 
proportions) which disrupted the crystallisation of the excipients. However, only a single phase 
can be seen in the TASC and DSC results of the cooling cycles of the patches with 30% CM2 
drug loaded patches. This may indicate that TPGS did not crystallise due to the presence of the 
dissolved drug in these patches.  
 
Figure 5.10: TASC and DSC results of the cooling cycle of CM1 (A and B) and CM2 (C and D) 
placebo and felodipine loaded mucoadhesive buccal patches with 10, 20 and 30% w/w loading (n=3; 
average ± SD) 
5.3.1.2 Detection of thermal dissolution of crystalline drug in excipients  
The presence of crystalline felodipine in the patches cannot be detected using DSC because the 
drug crystals are thermally dissolved in the molten carrier matrices.  TASC results of the samples 
with 30% CM1 and CM2 drug loadings have shown clear indication of a process occurs above 
the melting temperatures of PEG-PEO K900 blend. As seen in Figure 5.7A and C, in the initial 
heating cycle the TASC signals reach a plateau at higher temperatures as the drug load increases. 
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This effect is particularly significant for the patches with 30% felodipine. As seen in Figure 5.8E 
and F, a reproducible TASC signals of the 30% patches only reaches the plateau when the 
temperature is close to the melting temperature of crystalline felodipine (100-140 ºC). This result 
suggests the dissolution process of felodipine in the molten excipients’ blends can be detected by 
TASC. 
The dissolution of the crystalline drug into the molten carrier mixture during heating was 
confirmed by the variable-temperature ATR-FTIR. As seen in Figure 5.11, the disappearance of 
the NH stretching peak characteristic of crystalline felodipine at 3367cm-1 during heating between 
60-70 ºC indicating the loss of drug crystallinity and the dissolution of the drug into the molten 
carrier matrix.  
 
 
Figure 5.11: VT- ATR-FTIR (a) 2D and (b) 3D spectra of demonstrating the dissolution of the 
crystalline drug in CM1 matrix in the patches with 30% drug loading during heating 
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5.3.1.3 Sensitivity to the presence of metastable form of PEG 
For all samples, the transition temperatures detected by TASC during the first heating and cooling 
cycles are highly comparable with the DSC data. However, double transitions are clearly detected 
by TASC during the reheating cycle as seen in Figure 5.12A and C. The detection of the double 
transitions seen as a shouldered peak is highly reproducible indicating the occurrence of a true 
thermal event. The double transitions may be associated with the melting of the folded and 
extended forms of the PEG 4000 as the transition temperature is just below the melting of 
PEG/PEO K900 (328, 330, 337). However, this bimodality is not detected by conventional DSC 
(as seen in Figure 5.12B and D) using the same scanning rate which is 10ºC/min in this case. The 
changes seen by TASC are subtle while simple inspection of the images does not suggest complex 
behaviour as illustrated in Figure 5.13 for CM1 as representative results. In addition, these two 
evident thermal events tend to overlap as the percentage of drug loading increased as indicated 
by the reduction in the temperature range between them due to drug solubilisation inside the 
matrix. It should be mentioned that CM1 placebo sample does not show this shoulder which may 
be attributed to the low fraction of the folded form present in this sample. 
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Figure 5.12: TASC and DSC results of the reheating cycle of CM1 (A and B) and CM2 (C and D) 
placebo and felodipine loaded mucoadhesive buccal patches with 10, 20 and 30% w/w loading 
showing the detection of metastable folded form of PEG by TASC (n=3; average ± SD) 
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Figure 5.13: Enhanced sensitivity for the detection of hidden thermal transitions. Optical images at 
different temperatures of the TASC measurement during heating of the PEG/PEO K900 based CM1 
patch with 10% drug loading. The areas with no specular effect were chosen for the measurements 
In order to further investigate the details of the samples’ structure, MTDSC and VT-ATR-FTIR 
were used. The MTDSC data of the reheating cycle of the patch with 10% drug loading, shown 
in Figure 5.14, unambiguously confirms bimodal behaviour in both reversing and non-reversing 
signals at a temperature between 45 to 58 ºC, which are below the main melting of PEG-PEO 
K900 (62ºC). In the non-reversing signal, an endothermic (melting) followed by an exothermic 
(recrystallisation) peak can be clearly seen.  
Frame no. 50 
Frame no. 10 
Frame no. 35 
Frame no. 65 
Frame no. 30 
Frame no. 42 
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Figure 5.14: MTDSC results of the melting region of CM1 patches with 10% drug loading indicating 
the present of solid form transformation of PEG at the transition temperature identified by TASC 
during the reheating cycle (n=3) 
The first heating cycle of the VT-ATR-FTIR data (Figure 5.15a) shows the melting of crystalline 
PEG-PEO K900 blend that agrees well with the spectra reported in the literature for these semi-
crystalline polymers (328, 332). However, the spectra of the reheating cycle following the cooling 
of the first heating cycle, shown in Figure 5.15b (highlighted by the dash-line box and a red 
arrow), demonstrate the appearance of an additional peak at 1106 cm-1. The intensity of this new 
peak decreases with increasing temperature during heating and disappears when the temperature 
reaches above 70°C when PEO K900 melts (Figure 5.15c). It suggests that the material created 
by the cooling cycle is different from the as-received material, something that is clearly indicated 
by TASC but is not immediately obvious from the DSC results. Although in literature there is no 
report of this particular IR band being associated with a metastable form of PEG, the thermal 
behaviour of the PEG detected by MTDSC matches the documented thermal events related to the 
metastable PEG (328, 332, 490). All these data confirm the presence of a metastable form of PEG 
after heating followed by immediately cooling which support the TASC data. It follows that in 
this case at least, TASC is sensitive to an event that conventional DSC does not clearly detect 
using the same heating rate at 10ºC/min. DSC shows only one process because the two melting 
events are broad and overlap. The reversing signal from the MTDSC experiment detected a two-
stage process because it is sensitive to re-arrangement, in effect it is more directly influenced by 
the kinetics of the melting process than the total signal. It is reasonable to infer that these kinetics 
will influence the softening process; as melting starts there is an increase in fluidity but this is 
arrested because at least some recrystallisation occurs as the more stable form is created before it, 
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in turn, melts. In this way, TASC can follow the consequences of changing the structure on a 
length scale it cannot directly interrogate. 
 
Figure 5.15: VT- ATR-FTIR spectra of the heating a and c reheating cycle of the CM1 10% loaded 
patches indicating the crystallisation and melting of the metastable form of PEG; and (d) the ATR-
FTIR spectra intensity changes of the additional peak at 1106 cm-1 with temperature indicating the 
presence of metastable form PEG 
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5.3.1.4 Scanning rate effects on the detection sensitivity  
Resolving events that have similar transition temperatures is typically more easily achieved at 
slow heating rates. This is particularly true when the events take place over a wide temperature 
interval and overlap. When using conventional DSC, low heating rates can improve resolution 
but decrease sensitivity; they also increase the time taken for the analysis. In Figure 5.16 DSC 
results are shown in a variety of heating rates, they reflect the range typically used for routine 
DSC work, 10 to 40 ºC/min. In no case is a bimodal event detected. The TASC results detect the 
bimodal character of the sample’s behaviour during the reheating segment even at the fastest 
heating rate. This suggests TASC is suitable for routine rapid analysis such as that often required 
for quality control without any reduction in sensitivity and resolution. 
 
Figure 5.16: Influence of heating rate on TASC response in comparison to conventional DSC. CM1 
patches loaded with 10% felodipine were tested using TASC and DSC at 10, 20 and 40ºC/min. First 
heating and reheating cycle were recorded and compared (n=3; average ± SD) 
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5.3.2 XμCT analysis of phase separations in the HME-IM patches 
5.3.2.1 XμCT analysis of internal microstructure and spatial distribution of 
phase separations 
It is well known in the literature that the surface and interior of many extruded samples exhibit 
significantly different features (483, 491). Therefore, XµCT was further used as a non-invasive 
method to study the 3D microstructure of the patches and to estimate the size, shape and spatial 
distribution of the phases in the prepared formulations. It is important to bear in mind that the 
spatial resolution of XµCT is limited to micron scale (which is 4 µm in this case). Thus nanoscale 
phase separation cannot be detected by this technique. Two XµCT types of equipment were used 
in the investigation of CM1 and CM2 formulations as mentioned in the experimental part of this 
chapter. The XµCT images of CM1 placebo and the patches with 10% drug loading (Figure 
5.17a-d) revealed some dark and light blue colour distributed in the matrices of these samples. 
This effect is within the noise level of the measurement thus not a true feature of the samples. 
Therefore, no micron-scale phase separation is detected using micro-CT under the limit of 
detection of XµCT. 
 
Figure 5.17: XµCT images of CM1 placebo surface and cross-section images (a, b) and CM1 10% 
surface and cross-section images (c, d) 
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With increasing the drug loading to 20% (w/w), large clusters (approximately 100 µm in diameter) 
and small (approximately 5-20 µm in diameter) particles with higher density (red dots and clusters) 
can be observed being predominately distributed at the surface and interior of the patches, 
respectively, as seen in Figure 5.18. The small particles are likely to be crystalline felodipine as 
crystalline material has higher density than the molecularly dispersed state and chlorine in the 
chemical structure of felodipine also provides improved electron density thus gives higher 
contrast in comparison to PEG, PEO K900 and Tween 80 (492). The presence of drug particles in 
the matrices agrees well with the SEM results shown in Chapter 4. The fact that significant amount 
of dense drug areas at the surface of the patches may be associated with the faster cooling rate at 
the surface after HME-IM, which promote the phase separation of drug from the matrix. This 
surface crystallisation phenomenon is also reported to present in other drug-polymer extrudates 
in the literature (483, 491). This important 3D spatial distribution of the phase separated drug 
particles cannot be observed using other conventional characterisation methods.  
 
Figure 5.18: XµCT images of CM1 HME-IM patches containing 20% (w/w) felodipine 
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The XµCT images of the HME-IM patches with 30% drug loading (Figure 5.19) revealed rich 
interior features including evenly distributed air pockets and dense drug particles with a larger 
particle size (approximately at or below 150 µm) than the ones observed in the patches with 20% 
loading. It is also possible to distinguish phases with different densities (discontinuous light blue 
having a lower density and dark blue having a higher density). It is interesting to note that the 
dense drug particles are mostly distributed in the dark blue phases and many located at the edges 
of air pockets. According to literature data, the true density of PEG and PEO K900 are 1.15-
1.21g/mL and 1.3g/mL at 25°C, respectively, whereas Tween 80 has a true density of 1.064g/mL 
(348, 493, 494). Taking into account the previous results indicating the low miscibility of Tween 
80 and PEG-PEO K900, it is reasonable to argue that the light blue phases, with an average 
diameter of 250-750 µm are Tween 80 rich phases and the dark blue areas are PEG-PEO K900 
rich phases. As the solubility of felodipine in PEG-PEO K900 is limited by the low quantity of 
amorphous polymer, it is possible that the drug dissolved in the PEG-PEO-rich phase during melt 
extrusion at an elevated temperature above the melting of PEG-PEO K900 and crystallised out 
when the patches cooled and equilibrated at room temperature.  
 
Figure 5.19: XµCT images HME-IM CM1 patches containing 30% (w/w) felodipine. 
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XµCT analysis of CM2 placebo patches revealed that they are pore-free with little interior 
microstructure at the resolution used in XµCT (Figure 5.20) 
 
Figure 5.20: XµCT analysis of CM2 placebo sample; A) an example of a reconstructed binary image; 
B) selected Region of Interest (ROI) for analysis C) 3D object representing the different components 
according to their densities present in the selected ROI   
 At 10 and 20% drug loading, some internal air pockets are evident as seen in Figure 5.21. These 
occasional air pockets have no defined structure. With increasing the drug loading, the volume 
fraction of the patches occupied by the air voids was also increased. The few particles with high 
density shown as bright spots in the matrix were identified as silicone dioxide (SiO2) (with a 
density of 2.65 g/mL), which is an inorganic material present in the powder of PEO K900 at a 
concentration of 0.8-3 % w/w as a powder flowability enhancer (495).  
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Figure 5.21: (a) XµCT reconstruction of binary image of 10% CM2 loaded sample with selected 
Region of Interest (ROI) for analysis; b) 3D object representing the different components according 
to their densities present in the selected ROI; (c) XµCT reconstruction of binary image of 20% CM2 
loaded patches with selected Region of Interest (ROI) for analysis; d) 3D object representing the 
different components according to their densities present in the selected ROI 
No other phase separation can be observed in these patches with 10 and 20% drug loading. 
Although DSC and TASC confirmed the presence of separate TPGS and PEG-PEO K900 phases, 
both are organic materials with similar elemental composition in their structure which provide no 
electron density contrast that can be used in XµCT to resolve the different phases. Felodipine has 
chlorine atoms in its structure which have higher electron density compared to the elements in the 
excipients. When felodipine dissolved in the excipients as a molecular dispersion, the overall 
electron density of the local area will be elevated by the presence of felodipine. The fact that no 
isolated drug clusters can be identified using XµCT for these two patches indicates that felodipine 
is relatively evenly distributed across the patches. It should also be mentioned that the spatial 
resolution of XµCT used in this study is within the micron range. Therefore, if any drug clusters 
occur with sizes smaller than few microns, they would not be detectable by XµCT.  
As seen in Figure 5.22, the XµCT images of the CM2 patches with 30% drug loading show the 
presence of clear drug clusters and air voids with well-defined spherical shape. As PXRD and 
ATR-FTIR spectroscopy results (as mentioned in Chapter 4) indicated the presence of the 
crystalline drug, it can be stated with some confidence that these drug clusters, represent the 
crystalline felodipine particles and be described as crystalline drug particles in the following 
discussions. The crystalline drug particles are 10-20 µm in diameter, which is similar to the 
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crystals observed using SEM in Chapter 4.  
 
Figure 5.22: XµCT analysis of CM2 30% loaded sample; a) an example of reconstructed binary image 
with selected Region of Interest (ROI) for analysis b) 3D object representing the air pockets 
entrapped in the sample; c) 3D object representing the phase separated crystalline felodipine 
particles; d) 3D object representing the matrix  
As seen in Figure 5.22a, the crystals (light spots) are more frequently distributed at the interfaces 
between the air voids and the matrix. This is an interesting feature which was not detected by any 
other characterisation method used in this study. The DSC results indicate that felodipine has a 
higher miscibility with TPGS than PEG-PEO K900 and hence drug crystallisation after reaching 
supersaturation is more likely to occur in PEG-PEO K900-rich domains than in TPGS-rich 
domains. Therefore, it is reasonable to speculate that these crystalline felodipine-rich areas around 
the air pockets are also PEG-PEO K900 rich regions. 
5.3.2.2 XμCT analysis as a potential semi-quantitative method to study 
crystalline drug content   
In order to further explore the possibility of using XµCT as a quantitative method for 
characterising phase separation in solid dispersions, compressed compacts of CM2 physical mixes 
of crystalline felodipine with known drug content (the same drug content as was used in CM2 
patches) were prepared and analysed. As seen in Figure 5.23, crystalline felodipine particles are 
evenly distributed across the matrices. The volume fraction of the space occupied by the 
Chapter 5                      Characterisation of felodipine HME-IM patches using TASC and XµCT  
 
206  School of Pharmacy / University of East Anglia 
 
crystalline drug particles can be measured and the values for the compacts with 10-60% 
crystalline drug loading were plotted against their known drug contents (Figure 5.23d). It was 
noted that the linearity of the correlation was not ideal (with a regression R2 of 0.92). Therefore, 
these results should be regarded as semi-quantitative. It was noted that the compacts were much 
softer after compression than normal solid tablets and the surfaces of the compacts were slightly 
tacky. This softening indicates the lowered melting point of the mixture which could be caused 
by solubilisation of crystalline drug in the low melting excipients such as TPGS during the high-
pressure compression process. This may explain why the 60% drug loaded physical mixture 
shows more deviation from the linear correlation in comparison to results obtained from the 10-
40% drug loaded physical mixtures. Using systems that do not have dissolution or physical form 
changes of the drug during compaction with excipients may improve the accuracy and linear 
correlation between drug loading and XµCT measured volume. Nevertheless, the attempt of using 
the correlation as a calibration curve was made to estimate the amount crystalline drug in the 
HME-IM CM2 patches with 30% drug loading.  
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Figure 5.23: Representative 3D XµCT images of the distribution of crystalline felodipine in the 
compacts made of the physical mixes of crystalline felodipine-TPGS-PEG-PEO K900 with (a) 10%; 
(b) 30%; and (c) 60% crystalline felodipine loadings. (d) the correlation between crystalline drug 
content in these compacts and measured volume fraction of felodipine in their 3D XµCT images, 
which was used as a calibration curve for the quantitative estimation of crystalline felodipine in 
HME-IM patches with 30% drug loading  
The volume fraction of the crystalline drug particles in the 30% CM2 patches observed in Figure 
5.22 is 0.078. Using the linear correlation shown in Figure 5.23d the weight fraction of the 
crystalline drug can be calculated as 10.3% (w/w). This indicates that 19.7% felodipine was 
molecularly dispersed in the matrices in the HME-IM CM2 patches with 30% drug loading. As 
no crystalline drug was detected in the HME-IM patches with 20% drug loading, it indicates that 
the 20% is close to the saturation of the solubility of felodipine in the matrices. Therefore, for the 
patches with 30% loading, approximately 10% w/w drug should be phase separated as a 
crystalline drug. The XµCT quantitative estimation agrees well with this. 
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5.3.3 Comparison of heterogeneity assessment by XμCT and TASC 
The heterogeneity of CM2 patches with 30% drug loading was studied using XµCT in order to 
make a comparison with the measurements on heterogeneity performed by TASC. The same 
methodology used with TASC for measuring heterogeneity was adapted, and areas of interests 
(ROI) with various sizes were taken from 2D XµCT images. Using the quantitative calibration 
described above, the amount of crystalline felodipine in each ROI were calculated. As shown in 
Figure 5.24a, a single XµCT slice (grey scale image) was used and 6 small (100 × 100 µm 
equivalent to 10 × 10-3 mm2) ROIs and 6 large ROIs (300 × 300 µm equivalent to 90 × 10-3 mm2) 
were randomly selected and analysed. These areas are similar in size to the ones used in TASC 
measurements. Same thresholding procedure was adapted for the estimation of the volume 
fraction of phase separated crystalline felodipine in all of these ROIs. It can be seen in Figure 
5.24b that the amounts of crystalline felodipine measured in larger ROIs have a lower standard 
deviation in comparison to those measured in the smaller ROIs indicating the high heterogeneity 
at the scale of 100 × 100 µm.  These findings agree well with the results obtained by TASC and 
confirm that integrating large areas reduces the sensitivity to heterogeneity and explained why 
heterogeneity is not detected by DSC analysis.  
 
Figure 5.24: Estimation of heterogeneity by XµCT: (a) Illustration of the selection of a range of ROIs 
with different sizes on a representative 2D XµCT image of CM2 patches with 30% drug loading; (b) 
the comparison of the calculated volume fraction of crystalline felodipine in the ROIs with large 
(300×300 µm) and small (100×100 µm) areas 
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5.4 Discussion 
Formulating solid dispersions of poorly water soluble drugs using HME-IM as single step 
processing is an attractive approach for improving their dissolution properties with fast and 
environmentally friendly processing. However, in order to achieve the desired formulation 
features of the product such as systemic delivery via the buccal cavity in this study, it requires the 
inclusion of a number of excipients resulting in an increase in the complexity of the system. In 
Chapter 4, two sets of HME-IM mucoadhesive buccal patches were designed and characterised 
using conventional characterisation techniques like DSC, MTDSC, ATR-FTIR, SEM, EDS, 
PXRD and IR imaging. Due to the nature of the fabricated systems being intentionally phase 
separated to provide surfactant-rich solubilisation and stabilisation domains for felodipine, it is 
important to further investigate the heterogeneity of the different phases and their microstructure 
spatial distribution. This chapter investigated the effect of drug-excipient miscibility on the 
heterogeneity and spatial distribution of phase separation in pharmaceutical solid dispersions at a 
micron-scale using two novel and complementary characterisation techniques, TASC and XµCT, 
to provide complimentary information in conjunction with conventional characterisation methods 
used in Chapter 4. 
As a recently developed characterisation technique, TASC was used to assess the heterogeneity 
of placebo and felodipine loaded HME-IM patches. As a rapid and cheap technique, TASC 
revealed the melting transitions of the PEG-PEO K900 and/or TPGS separate phases in the 
different CM1 and CM2 formulations. CM1 samples up to 20% w/w loading have homogeneous 
microstructure compared to 30% w/w loading. In addition, increasing the loading percentage of 
the drug in CM2 blend up to 20%, the TPGS phase is reduced in intensity and shifted to lower 
temperature compared to the PEG-PEO K900 phase. This may indicate the solubilisation of the 
drug in TPGS phase is more than that in PEG-PEO K900 phase. However, increasing the loading 
percentage to 30% in CM2 mixture resulting in an increase in the intensity of the TPGS peak 
revealing the phase separation of the crystalline fraction of felodipine from this phase.  
Due to the low melting transitions of the components of both CM1 and CM2 HME-IM mixtures, 
melting transition of the crystalline fraction cannot be detected using standard DSC experiments 
due to the thermal dissolution during the heating ramp. However, using TASC, it was possible to 
detected thermal dissolution due to the ability to detect changes before reaching equilibrium. 
Reaching the plateau with TASC signal indicates that the system in a state of equilibrium. Placebo 
and 10% loaded CM1 and CM2 samples reach the sharp plateau revealing that equilibrium was 
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achieved after the melting of PEG-PEO K900 polymer blend. The less sharp plateau was detected 
with 20% loading of both mixtures indicates the small fraction of crystalline drug present in the 
formulations. However, failure to achieve the equilibrium compared to lower loadings 
significantly indicate the presence of considerable amount of crystalline drug in the matrices of 
both CM1 and CM2 blends. Using this analysis, it would be possible to detect the thermal 
dissolution of the drug in the molten carrier and consequently assess the saturation limits of the 
carrier for a particular drug. This hidden thermal dissolution can be easily detected using this 
technique compared to DSC as the complete dissolution of felodipine is only achieved when the 
TASC signal reaches the plateau which is also confirmed by VT-ATR-FTIR using 30% CM1 
sample. In addition, because TASC can perform microscale thermal analysis for the sample using 
single experiment with multiple data-based analysis which can be considered as time and cost 
saving approach, it could be possible to detect microscale heterogeneity of the samples. 
Reproducibility of TASC signal indicates microscale homogeneity as seen in the case of placebo 
and loaded patches up to 20% loading. However, the signals of the 30% loading were 
irreproducible resulting in large error bars representing intra- and inter- sample variations. The 
heterogeneous distribution of crystalline fraction is more likely the cause of the lack of 
reproducibility of the samples. The detected heterogeneity of 30% CM1 patches was higher 
compared to CM2 reflected by the lower reproducibility of former than the later indicating more 
drug phase separation and lower solubilisation capacity in CM1 compared to CM2 blend.  
Furthermore, the reheating cycles of TASC analysis were sensitive for the detection of metastable 
folded forms of PEG 4000 which is not observable using DSC using the same heating rate. It 
should be mentioned that the results collected by TASC analysis are not affected by the heating 
rate indicating the potential of this thermal analysis technique for achieving the same results as 
DSC at shorter time without a decrease in the sensitivity.  
Using previous characterisation techniques revealed valuable information about the 
microstructure of the samples. However, the spatial distribution of phases cannot be revealed by 
any of the aforementioned techniques. XµCT was used as a novel technique to detect and simulate 
the distribution of phase separate solid dispersions using the difference in their electron densities. 
The distribution of crystalline felodipine predominately in the PEG-PEO K900-rich phase is not 
detected by any other characterisation methods but XµCT. This observation can be explained by 
the difference in the solubility values of felodipine in Tween 80 and semi-crystalline PEG-PEO 
K900. XµCT results not only confirmed the findings from the thermal and spectroscopic methods 
but also allowed the estimations of the size, shape and spatial distribution of different phases and 
revealed the distinct interior microstructure difference between dispersions with different drug 
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loadings. Due to the similarity in density between the PEG-PEO K900 and TPGS phases and the 
possible nanoscale phase separation, XµCT was unable to detect the phase separation of the 
different phases of the carrier. However, the high electron density of felodipine compared to the 
other components of the carrier mixture, crystalline drug fraction in 30% loaded samples can be 
thresholded and represented in 3D views together with some processing malfunctions such as the 
presence of air voids and heavy metal impurities. In addition, this study also explored the use of 
felodipine physical mixtures compacted discs loaded with 0-60% w/w that can be used as a 
calibration curve of the crystalline fraction of felodipine. Using this method, the fraction of 
crystalline felodipine in 30% loaded patches was estimated semiquantitatively and found to be 
10.3% w/w.  
5.5 Conclusion 
This chapter introduces the use of two novel characterisation methods for studying phase 
separation behaviour in pharmaceutical solid dispersions, TASC and XµCT. The characterisation 
techniques were challenged by the set of complex multi-component solid dispersions studied in 
Chapter 4. The results confirmed that both techniques not only could provide complementary 
information to conventional characterisation tools, including DSC, MTDSC, PXRD, ATR-FTIR, 
SEM and EDS to reveal the correlation between drug-excipient miscibility and phase separation 
but also are able to provide a new and important understanding of the heterogeneity and 
distribution of separate phases in the systems. TASC allowed rapid identification of heterogeneity 
in the dispersions containing phase separation but does not have the capability of analysing the 
spatial distribution of the phases. As a non-destructive technique, XµCT analysis provided the 3D 
microstructure of the interior of the patches and the spatial distribution of the separated phases. 
This detailed understanding of the dispersions will provide confidence in product quality of 
dispersions formulations. However, it should be highlighted that XµCT cannot be used as 
identification method on its own for distinguishing crystalline and amorphous drug domains. The 
first attempt of using XµCT as a quantitative method to estimate phase separated drug clusters 
(identified as crystalline drug with confirmation by PXRD and ATR-FTIR) in processed 
formulations indicated its potential application for such purposes. However, the results reported 
here can only be regarded as semi-quantitative. Further studies are needed to validate XµCT as a 
quantitative method.  
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6.1 Introduction 
Surfactants, such as Tween 80 and TPGS, have been suggested in the literature for use as 
plasticisers for HME based solid dispersions (200, 329, 361, 496, 497). In Chapter 4, the addition 
of a significant amount of surfactant was adapted as a strategy aiming to improve the solubility 
of the poorly soluble drugs in the matrix via creating phase separated surfactant concentrated drug 
solubilisation compartments (498, 499). However, it was reported that surfactants can destabilise 
the drug and cause crystallisation of drug from the dispersions during storage (93, 201, 385, 500). 
The mechanism of this destabilising effect has been mainly attributed to the low Tg of such 
materials. It should be mentioned that the benefit of facilitating processing was described as often 
outweighing the minimal amount of destabilisation, thus the addition of surfactants is often 
recommended (201, 385, 501). However, there is no fully developed guidance for surfactant 
selection and how to minimise their destabilising effects in the literature.  
This chapter aimed to contribute to a fuller understanding of the destabilisation effect of the use 
of surfactants in hot melt extruded formulations by investigating the stability of two types 
surfactant-containing hot melt injection moulded patches. CM1 and CM2 placebo and 10-30% 
w/w felodipine loaded HME-IM patches were used as surfactant containing solid dispersions in 
this chapter. Due to their complex phase behaviour resulting from the differences in the 
miscibilities between the individual constituents, their stabilities can be affected by storage 
temperature and relative humidity. Both of these storing conditions can affect molecular mobility 
in the formulations (97, 100). For the well-studied molecular dispersions of a binary polymer-
drug system, a single global mobility is generally reflected by a single Tg. Water has a strong 
plasticising activity and moisture uptake from humid environment during storage is known to 
increase the global mobility of the system enhancing phase separation of the drug from its 
dispersion (106-110). In terms of storage temperature, as a general rule amorphous dispersions 
are stored at temperatures 50 ̊C below their Tg to minimise the crystallisation tendency of the drug 
(24). However, the effects of storage temperature are often more complex. For example, storing 
amorphous polymeric based solid dispersions at low temperatures can decrease the 
recrystallisation rate of the molecularly dispersed drug because of reduced molecular mobility. 
However, at lower temperatures, the miscibility of the polymer and drug is usually decreased 
leading to increased risks of increasing the degree of saturation of the drug in the dispersions (24, 
105). When the supersaturation is reached, if the molecular mobility allows, the drug could still 
crystallise even at low temperatures. Therefore, the storage temperature may have a positive or 
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negative impact on the physical stability of the system under investigation depending on the 
balance between the speed of diffusion of the drug molecules and the thermodynamics of the 
mixing between the drug and the polymers.  
In this study, the effects of humidity and/or temperature on the individual phases and overall 
stability of placebo and felodipine loaded CM1 and CM2 HME-IM patches was examined in 
order to provide an insight into the how the complex interplay of the effect of surfactants, the 
stability of the semi-crystalline carrier material and the degree of drug saturation in the 
formulation can impact on the stability of the entire dispersions.  
Research objectives   
1. To investigate the impacts of storing temperature and relative humidity on the stability of 
CM1 and CM2 placebo and 10-30% w/w felodipine patches.   
2. To understand the effect of surfactants on the stability of different formulations. 
3. To compare the two formulations to provide good understanding of the selection criteria 
that governs the suitability of surfactants for solid dispersions prepared by HME-IM 
technique. 
4.  To assess the crystallisation tendency of felodipine from formulations at different 
conditions and evaluating the most important parameters that control the crystallisation 
process.  
6.2 Materials and Methods 
6.2.1 Materials 
The raw materials used for the fabrication of placebo and felodipine loaded CM1 and CM2 HME-
IM buccal patches were the same as those mentioned in Chapter 4, section 4.2.1 except for using 
different batch no. of felodipine (20100601) from the same supplier. Phosphorus pentoxide (P2O5) 
99.0 % was ordered from Sigma-Aldrich (Dorset, UK) and NaCl extra pure (≥ 99.0 %) was 
purchased from Thermo Fisher Scientific (Geel, Belgium).  
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6.2.2 Methods 
6.2.2.1  Storage conditions for HME-IM patches and amorphous felodipine 
After the preparation of the placebo and drug loaded HME-IM patches (as described in Chapter 
4, section 4.2.2), they were immediately stored at four different conditions of temperature and 
relative humidity (%RH): room temperature and 0% RH (condition A), room temperature and 
75 % RH (condition B), 40 C̊ and 0% RH (condition C) and 40 ̊C and 75% RH (condition D). The 
conditions selected are the most likely used conditions for investigating the stability of 
pharmaceutical products. Storing jars containing phosphorus pentoxide (P2O5) were used to 
represent the 0% RH while supersaturated NaCl solution was used to provide the 75% RH. In 
order to investigate the dual effect of relative humidity and the temperature, two sets of the 
humidity conditioned jars (0 and 75%) were stored either at room temperature or incubated in an 
incubator (Genlab incubator, Genlab Ltd, Cheshire, UK) operating at 40 ̊C. The stored samples 
were characterised to investigate the stability of the system especially the crystallisation tendency 
of felodipine. After incubation for 3 months, the samples were analysed to monitor the changes 
in each sample resulting from aging at each storing condition. Amorphous felodipine samples 
were immediately stored at 40 ̊C and 75% RH for 7 days after preparation (as described in Chapter 
3, section 3.2.2.1) before characterisation using different techniques. 
6.2.3 Characterisation of HME-IM aged solid dispersions 
The HME-IM patches and amorphous felodipine were characterised using the SEM, DSC, ATR-
FTIR, PXRD and TGA using the same methods previously described in Chapters’ sections 3.2 
and 4.2. EDS characterisation was performed using the same method described in Chapter 4.2 
except for using single point X-ray acquisition mode (at least 3 points were analysed for each 
morphological feature such as crystals, matrix surface, matrix cross-section) instead of the 
mapping mode. The results obtained using DSC were statistically analysed using (ANOVA). 
Differences of p < 0.05 were considered to be significant. 
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6.3 Results  
6.3.1 Effect of surfactant on the stability of semi-crystalline carrier in placebo 
patches 
The addition of surfactant to a semicrystalline mixture of PEG and PEO K900 contains two phases: 
an amorphous phase and a crystalline phase may result in the formation of an extra phase(s) 
depending on the physical state of the surfactant and its miscibility in the amorphous fraction of 
the blend. As seen in Figure 6.1 and 6.2, in the fresh placebos both Tween and TPGS were phase 
separated as indicated by their detectable melting endothermic peaks at -10.3 ± 0.2 and 37.5 ± 0.1 
°C, respectively. This implies that CM1 contains a liquid Tween surfactant phase at ambient 
temperature whereas CM2 contains a solid TPGS phase. The melting enthalpy values of pure 
Tween 80 and TPGS are known to be 45.53 ± 0.59 and 100.01 ± 1.09 J/g, respectively, it is 
possible to estimate the degree of crystallinity of the two surfactants in the freshly prepared 
placebo patches. These are for Tween in CM1 45.5% which is significantly less than the one of 
TPGS in CM2 (74.1%) with considering the fraction of each surfactant incorporated in the 
formulations. This result indicates that higher weight percentage of Tween is mixed with PEG-
PEO K900 in the CM1 than TPGS in CM2. This difference in the physical state of the phase 
separated surfactant domains may affect the stability as the diffusion rate of drug molecules in the 
liquid state in general is faster than in solid and semi-solid environments which may promote 
faster nucleation and crystallisation of drug. The melting peaks of raw PEG and PEO K900 are 
59.3 ± 0.3 and 70.2 ± 0.3 while their crystallinity are 87.6% and 84.1% calculated by dividing the 
melting enthalpy of studied samples by the melting enthalpy of fully crystalline polymers values 
obtained from the literature (449, 455, 456), which are 214.6 J/g and 205 J/g respectively. The 
PEG-PEO K900 melting points of the fresh placebo CM1 and CM2 samples are 63.6 ± 0.2 and 
64.1 ± 0.3 respectively. The proportion of PEG to PEO K900 in both mixtures is 4:3 which means 
that the theoretical % of crystallinity is 86.1% assuming no interaction between the two polymers. 
The calculated % of crystallinity based on experimental results of PEG-PEO K900 polymers in 
placebo CM1 and CM2 were found to be 59.5% and 59.2% indicate a significant reduction in 
their crystallinity. 
The DSC results of placebo CM1 samples are shown in Figure 6.1. It was noticed that all aged 
samples maintain their solid structures except the patches stored at 40°C/75%RH. Placebo CM1 
patches stored at 40°C/75%RH lost their solid structure ‘liquefied’ after storage at condition D. 
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The liquefied samples show complex behaviour: a recrystallisation peak at about the 
crystallisation temperature of Tween 80. However, the enthalpy of the peak is 39.3 J/g which is 
much higher than 7.9 J/g the expected crystallisation enthalpy for Tween 80. A single endothermic 
phase transition at 33.5°C is also observed. There are no melting peaks of Tween and PEG-PEO 
K900. This indicates the presence of low molecular weight degradation products of PEG-PEO 
K900 which crystallise and form complexes with Tween at a lower temperature and subsequently 
melt at 33.5°C (144, 145, 502-505). 
DSC investigation indicates that good physical stability of CM2 placebo under conditions A, B 
and C, but some changes after 3-month ageing under 40°C/75%RH (Figure 6.2). There are no 
significant changes in the TPGS phase. Two additional shoulder peaks at 55 and 59.5 °C are 
observed at the melting of PEG-PEO K900 phase which may be attributed to a small extent of 
degradation of PEG-PEO K900. The significantly less degradation of CM2 is highly likely to be 
associated with antioxidant nature of TPGS which protected PEG-PEO K900 from extensive 
oxidation (144, 207, 386, 387). 
 
Figure 6.1: DSC thermograms of placebo CM1 fresh and aged samples using 10 ̊C/ min (n=3) 
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Figure 6.2: DSC thermograms of placebo CM2 fresh and aged samples using 10 ̊C/ min (n=3) 
After ageing, SEM images revealed no significant morphological changes for both placebo CM1 
and CM2 at different ageing conditions (Figures 6.3-4) except for CM1 patches which lost their 
original shape and liquefied under 40ºC/75% RH (condition D).  
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Figure 6.3: SEM images for CM1 placebo fresh and 3 months aged samples; (a and b) are surface 
and cross-section of fresh sample, (c and d) are surface and cross-section of sample stored at condition 
A, (e and f) are surface and cross-section of sample stored at condition B and (g and h) are surface 
and cross-section of sample stored at condition C 
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Figure 6.4: SEM images for CM2 placebo fresh and 3 months aged samples; (a and b) are surface 
and cross-section of fresh sample, (c and d) are surface and cross-section of sample stored at condition 
A, (e and f) are surface and cross-section of sample stored at condition B, (g and h) are surface and 
cross-section of sample stored at condition C, and (i and j) are surface and cross-section of sample 
stored at condition D 
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As mentined in Chapter 3, isohume (at 75%RH) DVS studies of Tween 80 and TPGS revealed 
that they could take up to 14.44 ± 0.89 % and 12.80 ± 0.72% w/w moistures, respectively, whereas 
PEG and PEO K900 only could take up less than 2% w/w moisture when reached equilibrium. 
Using these data, it is possible to estimate the theoretical moisture uptake of the two placebos 
(assuming of the ingredients have complete phase separation) being 5.35 ± 0.28 and 4.85 ± 0.23 
% (w/w) for CM1 and CM2, respectively. As seen in Figure 6.5 and Table 6.1, a significant 
amount of weight loss up to 100 °C (14.48 ± 1.28 % w/w) during TGA measurement was observed 
in the liquefied CM1 placebo after 3-month storage under 40ºC/75%RH. This is more than the 
theoretical amount of moisture uptake capacity estimated using the individual ingredient data. It 
is also noted that the weight loss of the 40ºC/75%RH aged CM1 placebo sharply increased by 
5.44 % up to 150 °C. It is well-known in literature that Tween and PEG-PEO K900 exhibits 
thermally initiated autoxidation (143, 145, 206, 506, 507). Thus, this continued weight loss at 
temperature below the thermal decomposition temperatures of the constituents of the mixture 
(which are 376.3 ± 5.0, 369.3 ± 0.3 and 372.4 ± 0.8 °C for PEG, PEO and Tween 80, respectively) 
is likely to be attributed to the loss of low molecular weight degradation products during heating. 
It should be mentioned that the apparent weight gain at 0% RH samples is more likely due to 
moisture uptake in handling after removal of from the storage. The moisture uptake of CM2 
placebo after 3-month at 40ºC/75%RH shows close to the theoretical estimation indicates TPGS 
exhibited its full capacity. 
 
Figure 6.5: TGA results of 3-month aged CM1 placebo patches (n=3) 
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Table 6.1: Percentage of weight loss of the formulations measured by TGA after three months ageing 
(n=3, average ± SD) 
Formulation Condition A Condition B Condition C Condition D 
 
Placebo CM1 0.12 ± 0.00 2.6 ± 0.52 0.18 ± 0.10 14.48 ± 1.28 
10% CM1 0.08 ± 0.04 5.00 ± 0.33 0.10 ± 0.05 3.40 ± 0.12 
20% CM1 0.10 ± 0.01 2.99 ± 0.38 0.05 ± 0.03 3.32 ± 0.22 
30% CM1 0.04 ± 0.00 2.48 ± 0.11 0.03 ± 0.00 2.43 ± 0.07 
Placebo CM2 0.11 ± 0.03 3.02 ± 0.00 0.12 ± 0.03 3.40 ± 0.12 
10% CM2 0.05 ± 0.01 2.67 ± 0.08 0.15 ± 0.06 3.37 ± 0.13 
20% CM2 0.04 ± 0.01 2.14 ± 0.05 0.05 ± 0.01 2.73 ± 0.17 
30% CM2 0.02 ± 0.02 1.74 ± 0.04 0.03 ± 0.00 1.90 ± 0.07 
 
This is also supported by the ATR-FTIR spectrum of the sample seen in Figure 6.6a and b. The 
placebo CM1 sample after three months shows a broad band centred around 3409 cm-1 and new 
peaks at 1645 and 1750 cm-1. The peaks at 1750 and 1645 cm-1 were assigned to water and 
carbonyl respectively. The broad peak is from water and hydroxyl groups. There is also a loss of 
resolution across the whole spectrum consistent with degradation and loss of crystallinity (145, 
506). 
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Figure 6.6: A) The high wavenumber and B) is the low wavenumber ATR-FTIR spectra of placebo 
CM1 fresh and aged samples (n=3) 
6.3.2 Effect of drug loading on semi-crystalline carrier 
The morphologies of the surfaces and cross-sections of the patches after drug incorporation (10-
30% w/w) in both CM1 and CM2 blends can be seen in Figure 6.7-12. With increasing the drug 
loading for both formulations, the roughness of the samples increased. These figures will be used 
explain the crystallisation tendency of felodipine from aged samples later in this chapter.   
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Figure 6.7: SEM images for 10% CM1 fresh and 3 months aged samples; (a and b) are surface and 
cross-section of fresh sample, (c and d) are surface and cross-section of sample stored at condition A, 
(e and f) are surface and cross-section of sample stored at condition B, (g and h) are surface and 
cross-section of sample stored at condition C, and (i and j) are surface and cross-section of sample 
stored at condition D 
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Figure 6.8: SEM images for 10% CM2 fresh and 3 months aged samples; (a and b) are surface and 
cross-section of fresh sample, (c and d) are surface and cross-section of sample stored at condition A, 
(e and f) are surface and cross-section of sample stored at condition B, (g and h) are surface and 
cross-section of sample stored at condition C, and (i and j) are surface and cross-section of sample 
stored at condition D 
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Figure 6.9: SEM images for 20% CM1 fresh and 3 months aged samples; (a and b) are surface and 
cross-section of fresh sample, (c and d) are surface and cross-section of sample stored at condition A, 
(e and f) are surface and cross-section of sample stored at condition B, (g and h) are surface and 
cross-section of sample stored at condition C, and (i and j) are surface and cross-section of sample 
stored at condition D 
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Figure 6.10: SEM images for 20% CM2 fresh and 3 months aged samples; (a and b) are surface and 
cross-section of fresh sample, (c and d) are surface and cross-section of sample stored at condition A, 
(e and f) are surface and cross-section of sample stored at condition B, (g and h) are surface and 
cross-section of sample stored at condition C, and (i and j) are surface and cross-section of sample 
stored at condition D 
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Figure 6.11: SEM images for 30% CM1 fresh and 3 months aged samples; (a and b) are surface and 
cross-section of fresh sample, (c and d) are surface and cross-section of sample stored at condition A, 
(e and f) are surface and cross-section of sample stored at condition B, (g and h) are surface and 
cross-section of sample stored at condition C, and (i and j) are surface and cross-section of sample 
stored at condition D 
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Figure 6.12: SEM images for 30% CM2 fresh and 3 months aged samples; (a and b) are surface and 
cross-section of fresh sample, (c and d) are surface and cross-section of sample stored at condition A, 
(e and f) are surface and cross-section of sample stored at condition B, (g and h) are surface and 
cross-section of sample stored at condition C, and (i and j) are surface and cross-section of sample 
stored at condition D 
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The phase behaviour of the patches can be analysed using the DSC. For CM1 loaded samples 
(Figures 6.13-15), in contrast to the placebo samples, no melting of Tween was observed. A 
shoulder at the onset of the melting of PEG-PEO K900 is developed with increasing the drug load 
above 10%. At 30% drug loading, a separate melting at 87 °C can be seen. This is assigned to the 
depressed melting of crystalline felodipine, indicating the presence of significant amount of 
crystalline felodipine in CM1 patches with 30% drug loading. The detection of felodipine melting 
peak in the 30% CM1 loading fresh sample (Figure 6.15) was attributed to the difference in 
particle size between the two batches of pure felodipine used in this study. The characterisation 
of the two batches of the pure drug is shown in Appendix 3.  
 
Figure 6.13: DSC thermograms of 10% CM1 fresh and three months aged samples using 10 ̊C/ min 
heating ramp (n=3) 
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Figure 6.14: DSC thermograms of 20% CM1 fresh and three months aged samples using 10 ̊C/ min 
heating ramp (n=3) 
 
Figure 6.15: DSC thermograms of 30% CM1 fresh and three months aged samples using 10 ̊C/ min 
heating ramp (n=3) 
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Investigating the Tg regions (Figures 6.16-18) revealing the detection of single Tg temperatures 
for all drug loaded fresh CM1 patches at -49.0 ± 0.6, -38.0 ± 0.3 and -46.6 ± 0.5 °C for 10, 20 and 
30% w/w drug loadings, respectively. As shown in Chapter 4, the presence of felodipine in the 
Tween 80/PEG/PEO K900 system results in a single amorphous phase consisting of four 
components. The increase of Tg for 20% CM1 patches indicates the increased amount of 
molecularly dispersed drug in the Tween rich phase. The decrease of Tg of 30% CM1 is consistent 
with the increased amount of crystalline drug in the samples indicating drug phase separation.  
 
Figure 6.16: Part of DSC thermograms samples showing the Tg regions of 10% CM1 fresh and three 
months aged samples using 10 ̊C/ min heating rate (n=3) 
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Figure 6.17: Part of DSC thermograms samples showing the Tg regions of 20% CM1 fresh and three 
months aged samples using 10 ̊C/ min heating rate (n=3) 
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Figure 6.18: Part of DSC thermograms samples showing the Tg regions of 30% CM1 fresh and three 
months aged samples using 10 ̊C/ min heating rate (n=3) 
As seen in Figures 6.19-21, drug loaded fresh CM2 patches show the separate melting peaks of 
the TPGS phase at 28.9 ± 0.3, 20.4 ± 0.4 and 24.9 ± 1.5 °C for 10, 20, and 30% w/w drug loaded 
systems, respectively. The drug solubilised in TPGS phase would cause the significant depression 
of the TPGS melting compared to the pure TPGS. Assuming the lowering of melting point is an 
indicator of drug solubility it is clear that 20% drug loaded systems had more drug dissolved in 
the TPGS than 10 and 30% loaded systems. For the 30% drug loaded system, in comparison CM1, 
no depressed drug melting is detected indicating the higher drug solubilisation capacity of the 
CM2 carrier than CM1. In contrast to CM1, no melting of felodipine is seen in the 30% loaded 
sample of CM2 although there is evidence from FTIR and PXRD that crystals exist. It was 
assumed therefore that on heating crystalline felodipine dissolves in the molten TPGS phase. 
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Figure 6.19: DSC thermograms of 10% CM2 fresh and three months aged samples using 10 ̊C/ min 
heating ramp (n=3) 
 
Figure 6.20: DSC thermograms of 20% CM2 fresh and three months aged samples using 10 ̊C/ min 
heating ramp (n=3) 
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Figure 6.21: DSC thermograms of 30% CM2 fresh and three months aged samples using 10 ̊C/ min 
heating ramp (n=3) 
As mentioned in Chapter 4, DSC analysis of Tg regions of fresh1 0, 20 and 30% drug loaded CM2 
formulations indicated the detection of single Tg at -23.7 ± 0.4, -22.2 ± 0.4  and -21.4 ± 0.8 ºC 
respectively. The impacts of different storing conditions on CM2 formulations are shown in 
Figures 6.22-24 and will be discussed in the next sections.  
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Figure 6.22: Part of DSC thermograms samples showing the Tg regions of 10% CM2 fresh and three 
months aged samples using 10 ̊C/ min heating rate (n=3) 
 
Figure 6.23: Part of DSC thermograms samples showing the Tg regions of 20% CM2 fresh and three 
months aged samples using 10 ̊C/ min heating rate (n=3) 
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Figure 6.24: Part of DSC thermograms samples showing the Tg regions of 30% CM2 fresh and three 
months aged samples using 10 ̊C/ min heating rate (n=3) 
6.3.3 Carrier stability of drug loaded patches aged under 0%RH 
The changes of the drug loaded patches on ageing were monitored by examination of four 
transition regions in the DSC experiments: the Tg region and the melting regions associated with 
Tween, TPGS and PEG-PEO K900. Results are summarised in Table 6.2.  
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Table 6.2: Summary of the changes of thermal properties of the aged patches in comparison to the 
properties of the fresh patches 
Thermal 
Tra
nsiti
on 
Storing 
condition 
Formulations 
CM1(Tween 80) CM2 (TPGS) 
  0% 10% 20% 30% 0% 10% 20% 30% 
 
 
Tg 
 
A ↔ ↔ ↓ ↓ ↔ ↓ ↓ ↓ 
B ↔ ↔ ↓ ↓ ↔ ↓ ↓ ↓ 
C ↔ ↔ ↓ ↓ ↔ ↔ ↓ ↓ 
D ↔ ↔ ↓ ↓ ↔ ↓ ↓ ↓ 
 
 
∆Cp 
A ↔ ↔ ↔ ↔ ↔ ↓ ↓ ↓ 
B ↔ ↔ ↓ ↔ ↔ ↔ ↓ ↓ 
C ↔ ↔ ↓ ↑ ↔ ↔ ↓ ↓ 
D ↔ ↔ ↓ ↔ ↔ ↔ ↓ ↓ 
 
 
PEG/PEO 
T
m
 
A ↑ ↑ ↑ ↑ ↔ ↔ ↑ ↑ 
B ↑ ↑ ↑ ↑ ↔ ↔ ↑ ↑ 
C ↑ ↑ ↑ ↑ ↑ ↔ ↑ ↑ 
D * ↔ ↑ ↑ ↑ ↔ ↑ ↑ 
 
 
PEG/PEO 
∆Hf 
A ↑ ↔ ↔ ↑ ↑ ↑ ↔ ↑ 
B ↑ ↔ ↔ ↑ ↑ ↔ ↔ ↔ 
C ↑ ↑ ↑ ↑ ↑ ↔ ↑ ↑ 
D * ↔ ↑ ↔ ↑ ↔ ↔ ↔ 
 
 
Surfactant  
T
m
 
A ↑ X ↔ X ↑ ↑ ↑ ↑  
B ↑ X X X ↔ ↓ ↑ ↑ 
C ↑ X X X ↑ ↑ ↑ ↑ 
D * ↔ X X ↔ ↓ ↑ ↑ 
 
 
Surfactant 
∆Hf 
A ↑ ↑ ↔ ↑ ↔ ↔ ↑ ↑ 
B ↓ ↑ ↑ ↑ ↑ ↔ ↑ ↑ 
C ↑ ↑ ↑ ↑ ↑ ↔ ↑ ↑ 
D * ↔ ↑ ↑ ↔ ↔ ↑ ↑ 
(*) Stands for the sample liquefied after three months storage and not testable 
(↑) Value increased in comparison to fresh samples 
(↓) Value decreased in comparison to fresh samples 
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(↔) Value showed no significant change in comparison to fresh samples 
(X) Detection of Tween 80 melting peak 
For placebo CM1 and CM2 samples, no changes in the Tg regions were observed, and there was 
a significant increase in the melting temperature and corresponding heat of fusion of PEG-PEO 
K900. This is attributed to the removal of moisture from the patches leading the formation of 
more crystals. For 10% drug loaded, CM1 samples stored at both room temperature and 40 °C 
ageing resulted in the appearance of Tween melting transitions in these samples. There was also 
increase in the crystallinity of the PEG-PEO K900 reflected by the increase in the melting point 
and/or ∆Hf. On the other hand, only 10% CM2 samples stored at room temperature showed a 
decrease in Tg and ∆Cp with an increase in PEG-PEO K900 crystallinity. However, both samples 
stored at room temperature and 40 °C revealed a significant increase in TPGS melting with no 
change in ∆Hf as illustrated in Table 6.2. 
For the aged CM1 and CM2 patches with 20 and 30% drug loadings, both Tg and associated ∆Cp 
tended to be reduced. As discussed above, the observation of a single Tg in the system implies 
that the glassy material is a mixture of the surfactant and the amorphous PEG/PEO K900 with 
drug dissolved in it.  As the drug behaves as an antiplasticiser, the decreases in Tg values after 
ageing are an indication of a reduction in the amount of drug in the surfactant-rich phases. For 
both CM1 and CM2, the changes much more greater for patches with 20% drug loading than the 
30% samples. This may be attributed to the supersaturation of 20% loaded samples and the lower 
content of solubilised felodipine in 30% compared to 20% patches.  
In the PEG-PEO K900 melting region, peak shape changes are observed. As seen in Figures 6.14, 
6.15, 6.20 and 6.21 the shoulder before the onset of PEG-PEO K900 melting for 20 and 30% 
CM1 and CM2 samples stored at 0% RH and 40 °C is absent indicating unfolding of the folded 
form of PEG-PEO K900 polymers. For 30% drug loaded CM1 samples, stored at room 
temperature and 40 °C, clearly partially separated depressed melting of crystalline felodipine with 
melting peak ranging at temperatures 81-89 °C can be identified suggesting a significant amount 
of crystalline felodipine present.   
For the 20 and 30% CM1 samples, the melting of Tween is detectable for all aged samples except 
the 20% aged at room temperature and 0%RH. There was a slight difference in Tween melting 
peak temperatures and heat of fusion between the aged samples. In CM2 patches, the melting 
peak of TPGS moved to a higher temperature closer to the melting point of pure TPGS with 
increased melting enthalpy values. This indicates drug phase separation and increased the degree 
of crystallinity of TPGS after ageing. The enthalpy of melting of the TPGS in the 30% sample is 
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greater than that of the 20% sample. This implies more drug dissolved in the TPGS in the 20% 
sample than the 30% sample. It should be mentioned that storing 20 and 30% CM2 patches at 
40 °C leads to greater increases in the melting enthalpy values of the surfactant than room 
temperature. In addition, this melting enthalpy increases of the surfactant phases are more 
profound for CM2 compared to CM1. Once the surfactants are phase separated in their crystalline 
form, it is likely that drug is no longer solubilised in the surfactant phases. This suggests that more 
crystalline drug is likely to be present in 30% drug loaded samples under 40 °C and 0% RH. 
6.3.4 Carrier stability of drug loaded patches under 75%RH 
Under 40 °C/75%RH, the development of multiple peaks on the shoulder of the peak of the 
melting of PEG-PEO K900 were observed in all samples. These peaks were assigned to the 
melting of degradation products of PEG-PEO K900 due to the random chain scission of the two 
polymers caused by oxidative thermal degradation (144, 145, 502-505). Except this feature, little 
significant changes as indicated in Table 6.2 were seen for 10% loaded CM1 and CM2. The 
depression of Tg of the surfactant phase is greater for 20 and 30% drug loaded samples compared 
to 10% loading. However, there is a significantly higher degree of Tg shift for 20-30% samples 
stored at 75% RH in comparison to the samples aged under 0% RH. The increases in the melting 
peak points of PEG-PEO K900 (compared to fresh samples) showed no significant difference to 
the aged samples under 0%RH. For 30% drug loaded CM2 samples, depressed melting of 
felodipine can be detected under both room temperature and 40 °C which were absent in the 
samples aged under 0%RH. This indicates that high humidity led to more drug crystallisation in 
TPGS containing samples. 
6.3.5 Effect of surfactant on crystallisation tendency and crystal growth of 
felodipine on ageing 
As mentioned in Chapters 2 and 3, the flexibility of felodipine molecular structure is responsible 
about the appearance of its polymorphic forms (312, 508). Four polymorphic forms (I-IV) were 
obtained by precipitation from various solvents (312-315, 318, 319). This part of the study focuses 
on the felodipine crystallisation within the aged samples and the identification of the polymorphs 
formed. SEM was used to study the crystal growth of felodipine in the patches. Using chlorine as 
a marker for felodipine, it is possible to identify the grown crystals in the formulations using EDS. 
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Table 6.3 summarises the drug crystallisation tendency and crystal habits after three months 
ageing under the four different conditions. The SEM data of the fresh samples indicates that CM2 
is better at solubilising felodipine than CM1 as no drug crystals were observed in any patches 
with 10-30% loading. This highlights the better drug solubilisation capacity of TPGS than Tween 
as discussed earlier. As seen in Figures 6.7-12, drug recrystallisation at the surfaces during ageing 
occurred to all formulations, except 20% CM1 under condition C (40 ̊ C and 0% RH) and 10% 
CM2 under condition D (40 ̊ C and 75 % RH). Generally, more drug crystallisation was observed 
on the surface of the patches and the interior of the air pockets than the bulk matrix of the samples. 
This is likely to be due to the surface being the hydrophobic (air exposed) interface experiencing 
highest temperature and humidity at least at the initial few hours of the ageing process. These 
results are consistent with data reported in literature revealing faster surface to bulk drug 
crystallisation (509, 510). There are three main types of felodipine crystal habits observed, blocks, 
plate and needles arranged in spherulitic pattern as illustrated in Figures 6.7-12. In the literature 
the crystal habits of the polymorphs were reported to be blocks shaped for polymorphs I and II 
and plate-like crystals for form III, but no available information about the crystal habit of 
polymorph IV of felodipine is available (319). In this study the spherulitic crystals only tend to 
growth either in the interior or after ageing under 40 °C. The blocks and plate crystals are more 
common than the needle crystals and their growths are promoted by ageing on the surfaces and 
interior of most formulations as summerised in Table 6.3.  
Table 6.3: Summary of surface morphology and crystal growth of the 3-month aged HME-IM 
patches  
Drug 
loading 
Formulation CM1 (with Tween 80) CM2 (with TPGS) 
Location Surface Cross-section Surface Cross-section 
Ageing 
condition A B C D A B C D A B C D A B C D 
10% 
w/w 
Fresh - - - - 
Aged B B B+S S - - - - P B P - - - - - 
20% 
w/w 
Fresh P - - - 
Aged P P - S - - - - B B P S - - - S 
30% 
w/w 
Fresh B P+S - - 
Aged B B S S S B+S S S B B B S B B B S 
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(S) Spherulitic crystals; (B) Blocky crystals; (P) Plate crystals and (-) No crystals were detected 
 
In order to further identify the polymorphic form of the recrystallised felodipine, PXRD and ATR-
FTIR were used to characterise the aged samples. No clear drug PXRD crystallisation peaks were 
observed in any of CM1 and CM2 10% drug loaded patches (Figures 6.25-26).  
 
Figure 6.25: PXRD patterns of 10% w/w fresh and three months aged CM1 drug loaded patches 
 
Figure 6.26: PXRD patterns of 10% w/w fresh and three months aged CM2 drug loaded patches 
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As seen in Figure 6.27 for 20% w/w CM1 patch, the appearance of diffraction peaks in the pattern 
of the aged sample stored in condition A indicates the presence of form I which are consistent 
with those of raw felodipine pattern and with the reported data in the literature (312). This is 
consistent with the SEM results as form I is the usually present in the block-shaped habit (319). 
The PXRD results of the CM1 sample stored in condition B indicate the presence of a mixture of 
form I and II. New peaks at 9.3 ̊ and 12.4 ̊ are observed in the diffraction patterns of the sample 
stored in condition C and D. These diffraction peaks do not match with any known polymorphs 
of felodipine in the literature, suggesting the presence of unknown new polymorph growth.  
 
Figure 6.27: PXRD patterns of 20% w/w fresh and three months aged CM1 drug loaded patches 
For 20% w/w CM2 samples (Figure 6.28), fewer recrystallisation diffraction peaks were 
identified compared to the corresponding CM1 loaded samples owing to the higher solubilisation 
capacity and stabilisation ability of TPGS containing matrix compared to Tween 80. The 
diffraction peaks at 9.3 ̊, 10.2 ̊ (form I) and 12.4 ̊ are all visible in all CM2 samples stored at all 
conditions indicating the mixture of form I and the new form and the crystallisation of the new 
polymorph favoring the TPGS containing matrices.   
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Figure 6.28: PXRD patterns of 20% w/w fresh and three months aged CM2 drug loaded patches 
For the 30% w/w drug loaded samples (Figure 6.29-30), it is noted that there are form I drug 
crystals present in both the fresh CM1 and CM2 samples. The diffraction patterns of the 30% w/w 
CM1 samples indicate the coexistence of the new form and form I. However, it is noted that 
regardless of the humidity, room temperature storage resulted in the formation of more form I 
than the new form. However, at 40 °C more of new form than form I was formed. For 30% w/w 
CM2 formulations stored in the conditions A, B, C, diffraction patterns of the crystallised drug 
indicated the presence of form I; whereas the sample stored in condition D (40°C 75% RH) 
formed needle felodipine crystals showing diffraction peaks of both form I and the new form. The 
30% loaded samples contain crystallised drug immediately after extrusion. The presence of these 
crystals favour the formation of form I. However high temperature and humidity can initiate the 
formation of the new form. It should be mentioned that felodipine undergoes form I to metastable 
form II polymorphic transformation in the presence or absence of polymeric additives at different 
temperatures (511, 512).  
Chapter 6                                               Physicochemical stability of felodipine HME-IM patches  
 
246  School of Pharmacy / University of East Anglia 
 
 
Figure 6.29: PXRD patterns of 30% w/w fresh and three months aged CM1 drug loaded patches 
 
Figure 6.30: PXRD patterns of 30% w/w fresh and three months aged CM2 drug loaded patches 
As mentioned in Chapter 3, the NH stretching vibration in the infrared has been reported at 3372, 
3334, 3370, 3329 cm- 1 for the four crystalline polymorphic forms I-IV, respectively (313-315, 
318). Furthermore, the amorphous form showed an NH stretching peak at ~ 3339 cm-1 and peaks 
at 1701 and 1682 cm-1 corresponding to the non-hydrogen bonded C=O group and the hydrogen-
bonded C=O group respectively (316, 317). Using these signature peaks, it is possible to facilitate 
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the identification of the polymorphic forms detected by PXRD. Figures 6.31-34 illustrate the 
ATR-FTIR spectra for CM1 and CM2 10% loaded samples before and after ageing at different 
conditions. 
 
Figure 6.31: The NH stretching region of the ATR-FTIR spectra of CM1 10% fresh and aged samples  
(n=3) 
 
Figure 6.32: Partial ATR-FTIR spectra of CM1 10% fresh and aged samples for the low wavenumber 
range (n=3) 
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As seen in Figure 6.31-32, only sample stored at room temperature and 75% RH clearly shows 
the characteristic NH stretching at 3367 cm-1, the C=O stretching is more similar to that of the 
raw crystalline felodipine (form I), the appearance of other peaks at 865 and 725 cm-1 indicating 
recrystallisation of felodipine into form I. For 10% CM2 samples (Figures 6.33-34), no 
significant changes in the spectra of the aged samples compared to freshly prepared samples. 
 
Figure 6.33: The NH stretching region of the ATR-FTIR spectra of CM2 10% fresh and aged samples 
(n=3) 
 
Figure 6.34: Partial ATR-FTIR spectra of CM2 10% fresh and aged samples for the low wavenumber 
range (n=3) 
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20 and 30% w/w CM1 samples stored at 40 ̊C and CM2 samples stored at all conditions revealed 
the NH stretching at 3321 cm-1 which is not related any known polymorphs or the amorphous 
form (Figures 6.35-42).  
 
Figure 6.35: The NH stretching region of the ATR-FTIR spectra of CM1 20% fresh and aged samples 
(n=3) 
 
Figure 6.36: Partial ATR-FTIR spectra of CM1 20% fresh and aged samples for the low wavenumber 
range (n=3) 
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Figure 6.37: The NH stretching region of the ATR-FTIR spectra of CM2 20% fresh and aged samples 
(n=3) 
 
Figure 6.38: Partial ATR-FTIR spectra of CM2 20% fresh and aged samples for the low wavenumber 
range (n=3) 
Chapter 6                                               Physicochemical stability of felodipine HME-IM patches  
 
251  School of Pharmacy / University of East Anglia 
 
 
Figure 6.39: The NH stretching region of the ATR-FTIR spectra of CM1 30% fresh and aged samples 
(n=3) 
 
Figure 6.40: Partial ATR-FTIR spectra of CM1 30% fresh and aged samples for the low wavenumber 
range (n=3) 
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Figure 6.41: The NH stretching region of the ATR-FTIR spectra of CM2 30% fresh and aged samples 
(n=3)  
 
Figure 6.42: Partial ATR-FTIR spectra of CM2 30% fresh and aged samples for the low wavenumber 
range (n=3) 
As the PXRD results indicated that the growth of the new form is favoured at 40 ̊C, it is reasonable 
to suggest that the NH stretching peak at 3321 cm-1 is a possible signature peak for a new 
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polymorphic crystal form of felodipine. The ATR-FTIR results show good agreement with PXRD 
data. 
In summary, it is clear that the growth of the new polymorphic form favours TPGS containing 
dispersions when the drug loading at the border of being saturated. When form I already present 
in the fresh samples, the growth of the new form is more in favoured by higher storage temperature 
but not sensitive to humidity. 
6.3.6 Characterisation of felodipine recrystallised from its glassy state under 
stressful conditions of temperature and humidity 
 In order to provide better understanding of the crystallisation of felodipine from its solid 
dispersion matrices especially those with the higher loading percentage and investigate the impact 
of other excipients on the process, amorphous felodipine was prepared  from crystalline felodipine 
form I melt by quench cooling and subsequent storage at 40 ̊C and 75% RH as this condition is 
the most likely driving the drug in its formulation to recrytallise in its spherulitic (needle) pattern 
having different characterisation properties as seen above. Images of the prepared glassy 
felodipine samples before (A) and after recrystallisation at 40 ̊C and 75% RH (B) are shown in 
Figure 6.43.   
 
Figure 6.43: Images of felodipine in its glassy state (A) and after recrystallisation at 40 ̊C and 75% 
RH (B) 
SEM images (Figure 6.44) illustrated that the upper surface of the recrystallised drug shows a 
spherulitic pattern while this pattern is absent in the lower surface (in contact with the Aluminium 
dish). This indicates that the spherulitic growth is more likely to occur in free surfaces exposed 
to high humidity air at a temperature close to the Tg of felodipine.   
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Figure 6.44: SEM images of felodipine after recrystallisation at 40 ̊C and 75% RH; A is the upper 
surface and (B) is the lower surface of the sample 
In addition, DSC analysis (Figure 6.45) shows an interesting finding related to the melting of 
felodipine compared to the formulations where its melting is absent due to thermal dissolution in 
the molten excipients during the DSC heating ramp. The melting peak onset of raw pure 
crystalline felodipine form I used in this study is 140.9 ± 0.1 ̊C. However, pieces of the 
recrystallised drug without milling shows the appearance of two partially separated melting peaks 
having onsets at 118.3 ± 0.1 ̊C for the smaller peak and 136.0 ± 0.9 ̊C for the larger peak. These 
results clearly indicate that at least the lower melting peak is belonging to a new polymorphic 
crystal growth of felodipine. Milling the recrystallised sample using mortar and pestle shows 
significant reduction in the intensity of the lower melting peak indicating polymorphic 
transformation into the more stable form aided by milling and/or exposure to air. It should be 
mentioned that the melting onset of the higher melting peak of the milled recrystallised sample is 
139.5 ± 0.1 ̊C which may suggest the melting point depression of this peak by the lower melting 
fraction of felodipine. 
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Figure 6.45: DSC thermograms illustrating melting transition of pure felodipine form I and 
recrystallised felodipine at 40 ̊C and 75% RH before and after milling (n=3) 
In addition, PXRD results (Figure 6.46) show changes in the patterns of the recrystallised sample 
at 40 ̊C and 75% RH as small peaks at 9.3̊ and 12.6̊ as peaks of low intensity may be due to the 
small fraction of the new polymorphic growth. 
 
Figure 6.46: PXRD patterns of pure felodipine form I and recrystallised felodipine at 40 ̊C and 75% 
RH before and after milling   
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The ATR-FTIR data shown in Figure 6.47 do not reveal any differences in the spectra for the 
lower surface, upper surface and the milled recrystallised sample compared to the raw pure 
crystalline felodipine form I. These results may suggest that the new growth is more likely in the 
bulk of the sample and the detection is out of the penetration depth limits of the instrument used 
in the analysis. 
 
Figure 6.47: Partial ATR-FTIR spectra of pure felodipine form I and recrystallised felodipine at 40 ̊C 
and 75% RH before and after powdering; A and B are high and low wavenumber ranges respectively 
(n=3) 
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6.4 Discussion 
From the data three general observations can be summarised: 
1) For both 0% and 75% RH, it is clear that 40 °C led to a higher degree of phase changes than 
room temperature. 
2) For both CM1 and CM2, drug loading has a significant impact on the ageing behaviour of the 
carrier materials. The CM1 and CM2 patches with 20% drug loading, which is at the boundary of 
reaching saturation of drug in the carrier materials, showed the highest drug phase separation 
activity and microstructural changes of the patches. The patches with drug loadings below and 
above the saturation showed less phase separation activities highlighting the important 
relationship between the degree of saturation and stability.  
3) TPGS demonstrates better formulation and drug stabilising effects on ageing than Tween 80.  
The more significant effect of temperature on the physical stability than humidity can possibly be 
explained by molecular mobility. Although in the fresh drug loaded samples the drug was 
solubilised in the surfactant-rich phases, the Tg values of the drug containing phases are ranging 
from -49.0 ± 0.6 °C (10% CM1) to -24.9 ± 1.5 °C (30% CM2) for CM1 and CM2 patches. The 
difference between these Tg values and the storing temperatures for each formulation is higher for 
samples stored at 40 °C compared to room temperature. The bigger the temperature gap between 
the storing condition temperature and the Tg of the system is expected to exhibit lower drug 
physical stability for systems having Tg values lower than the storing temperatures. Thus, samples 
stored at 40 °C is expected to have higher degree of felodipine crystallisation (lower physical 
stability) compared to samples aged at room temperature. It should be mentioned that the viscosity 
of the solubilising phase is also expected to play a role in felodipine crystallisation process. 
Storing the samples at 40 °C also may result in a decrease in the viscosity of the dispersing phase 
leading to higher rate of drug diffusion and more crystallisation compared to room temperature 
(24, 105). In addition, the difference between Tg of the formulations and the stability testing 
temperatures (either at room temperature or 40 °C) is greater for CM1 than CM2. Therefore, the 
mobility of drug in the Tween phase is higher than the ones in the TPGS phase. The higher 
molecular mobility of the drug led to higher amount of drug recrystallised in CM1 patches than 
CM2 patches within the same time scale of ageing. The presence of the depressed melting of the 
crystalline drug between 80-90 °C seen in all 30% aged CM1 patches confirms this; whereas only 
the CM2 with 30% aged under 75%RH show this peak. This is also evidenced by the depression 
Chapter 6                                               Physicochemical stability of felodipine HME-IM patches  
 
258  School of Pharmacy / University of East Anglia 
 
of the Tg of the surfactant phase and the PXRD results. Using the diffraction peaks within the 9-
13° as the markers, it can be seen that less intensities of these peaks for aged CM2 than CM1 
samples with 20 % drug loading. Therefore, during formulation development of solid dispersions 
containing surfactants, the thermal properties of the surfactants should be carefully considered.  
The more profound changes of the 20% loaded samples on ageing demonstrated the importance 
of the relationship between drug-carrier solubility and stability. Boundary solubility should be 
avoided to minimise the instability associated with drug recrystallisation. The higher solubility of 
the drug in TPGS led to better drug stabilisation capacity of TPGS than Tween again indicates 
that impact of surfactant selection on the formulation stability.  
In addition, the chemical stability of the PEG/PEO based carrier material should also be carefully 
considered during formulation. In comparison to Tween containing CM1 samples, TPGS 
containing CM2 samples is much less vulnerable to degradation owing to the antioxidant activity 
of TPGS (144, 207, 386, 387). For drug loaded CM1 patches, fewer signs of degradation of PEG-
PEO K900 were observed under high temperature and high humidity environments in comparison 
to placebos suggesting the drug incorporation also had a protective effect on the carrier material 
from degradation, most likely to be antioxidation (513).  
6.5 Conclusions 
This chapter has investigated the effect of surfactants on the stability of multi-component 
dispersions which were intentionally formulated being phase separate. Semi-solid surfactant 
TPGS showed better stabilising effect on the drug than the liquid surfactant Tween 80. The higher 
Tg and semi-solid nature of TPGS which provides higher viscosity in the dispersion are believed 
to contribute to its higher stabilising effect of the model drug. However, such stabilising effect is 
only valid for the systems with drug loading below the saturation of drug in the carrier. With drug 
loading at the border and above the saturation, the stabilisation advantage is significantly reduced.  
In addition, a new polymorphic form of felodipine was observed in the aged samples. The 
crystallisation of the new form is more sensitive to temperature than humidity. 
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7.1 Introduction 
3D printing as a recently emerging technology in the pharmaceutical field has been identified as 
holding future promise for developing individualised medicines which in turn are expected to 
improve the efficacy of treatment and patients’ compliance (224-226, 514, 515). FDM 3D printing 
can play an important role in reducing the complexity of drug regimens through the incorporation 
of multiple drugs into a ‘polypill’ type of formulations. It can also be used to achieve the required 
drug release profile by changing the geometry and the structure of the dosage form or through 
using various carriers having different release characteristics (224, 514). Although industrial scale 
3D printing is used in other sectors, until now its applications in pharmaceutical research have 
been limited to the laboratory scale. One of the significant constraints for the development of 
pharmaceutical 3D printing is the extremely limited number of FDM printable materials currently 
available. In most reported cases, the printing of proposed solid dosage forms was performed 
using mostly PVA, PLA and PCL (224, 514, 516, 517). This chapter presents an approach of using 
polymer blends to overcome this problem and open the possibility of using pharmaceutically 
approved polymers in FDM printing of oral solid dosage forms. In addition, this study also 
demonstrates that the blends can be used to control the disintegration and drug release of the FDM 
printed solid dispersions.   
The nature of the current state-of-art FDM printing technique leads to three significant barriers to 
exploiting its application in pharmaceutical solids production: (1) pre-made filaments are required 
as an additional process step and currently available filament extruders are largely single screw 
extruders which may not be able to provide sufficient compounding and mixing between the 
active ingredients and the excipients. Therefore, some researchers have used either a 
commercially available single screw filament maker or twin screw hot melt extrusion to produce 
the filaments for printing (224, 514, 516-519). (2) Currently, there is no effective extrusion 
element in commercially available FDM 3D printers instead they rely on rollers at the top of the 
printer to push the molten materials to the printer nozzle. Rheologically this requires the material 
used to have a low melt viscosity at the printing temperature. (3) The molten materials need to 
solidify rapidly to allow the rapid deposition and accurate buildup of the 3D object according to 
the pre-set digital design (229). This requires the printing materials to be highly thermoplastic 
whereas most pharmaceutical grade polymers are not thermoplastic.  
The last two limitations of the technology can be overcome by selecting appropriate polymers. 
Polymers such as PVA, PLA and PCL have sufficient thermoplasticity to make them suitable for 
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FDM 3D printing. However, many printable grades of these polymers are not pharmaceutical 
grade excipients. In addition, use of these few polymers often provides little flexibility in tailoring 
the drug release profiles and limits the application of any delivery system produced from them. 
Recently the addition of plasticisers to improve the processability of controlled release polymers 
such as HPC and eudragit RL and RS during FDM printing has been reported (517, 518). However, 
to the best of our knowledge so far there is no report on the use of polymer blends to FDM print 
solid dispersions for the dissolution enhancement for poorly soluble drugs.  
Formulations fabricated using FDM 3D printing are mostly solid dispersion based formulations 
(224, 514, 516, 519). This explores the feasibility of using FDM 3D orienting to produce 
felodipine solid dispersions. PVA was used as the benchmark polymer in this study because of its 
excellent thermoplasticity and FDM printability (224, 226). Eudragit E PO and soluplus both have 
been widely used in pharmaceutical HME indicating their good thermostability and extrudability. 
However, they are not FDM printable on their own. They were selected as the two model polymers 
which were compounded with an adjustable mixture of PEG-PEO K100 and/or Tween 80. PEG 
has low melt viscosity and was used to adjust the printability of the blends. As a result of its high 
molecular weight, PEO K100 provides mechanical flexibility to the filaments to allow easy 
feeding into the FDM printer. Tween 80 was used primarily as a plasticiser in order to lower the 
processing temperature to safe temperatures and to overcome degradation issues for the drug 
under investigation. The secondary functions of PEG, PEO K100 and Tween 80 are associated 
with their good solubilising properties for poorly water soluble drugs and plasticising 
characteristics for solid dispersion mixtures (361, 498, 520).  
Research objectives   
1. To design felodipine solid dispersions using FDM 3D printing. 
2. To characterise the FDM 3D printed discs. 
3. To evaluate the in vitro release profiles of the FDM 3D printed discs. 
7.2 Materials and Methods 
7.2.1 Materials 
Felodipine, the model drug was purchased from Afine Chemicals Ltd (Hangzhou, China) (batch 
no. 20100601). Polyethylene glycol (PEG) (average MWT = 4000) was purchased from Sigma-
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Aldrich (Poole, UK). Polysorbate (Tween® 80) was purchased from Acros Organics (Geel, 
Belgium), Polyethylene oxide (POLYOX WSR N10 LEO) MWT= 100,000, soluplus, eudragit® 
E PO and 33-38% partially hydrolysed polyvinyl alcohol (PVA) MWT= 18,000-25,000 were 
kindly donated by Colorcon Ltd. (Dartford, UK), BASF (Ludwigshafen, Germany), Evonik 
Industries (Darmstadt, Germany) and Kuraray Co., Ltd.  (Tokyo, Japan), respectively.  The 
chemical structures of the materials are illustrated in Chapter 2. 
7.2.2 Preparation of placebo and felodipine loaded FDM filaments using HME 
Placebo and 10% w/w felodipine FDM filaments consisting of three sets of excipient mixtures 
(compositions are shown in Table 7.1) were prepared using a co-rotating twin-screw extruder 
(Haake MiniLab II Micro Compounder, Thermo Electron, Karlsruhe, Germany). The 
formulations containing eudragit E PO, soluplus and PVA as the main matrix materials are 
labelled with the abbreviations of CME, CMS and CMV, respectively. All ingredients were 
accurately weighed and premixed using a mortar and pestle for 2 minutes. For each extrusion 
experiment, 7 g of the pre-mixed blend was fed into the extruder and 3 g was kept for the 
characterisation of the physical mixtures.  
Table 7.1: Composition of placebo and 10% w/w felodipine loaded FDM dispersions. Proportions are 
expressed as % w/w 
Mixture  Felodipine Eudragit  Soluplus PVA Tween 80 PEG  PEO K100  
Placebo CME ----- 55.56 ----- ----- 11.10 16.67 16.67 
10% w/w CME 10 50 ----- ----- 10 15 15 
Placebo CMS ----- ----- 55.56 ----- 16.67 11.10 16.67 
10% w/w CMS 10 ----- 50 ----- 15 10 15 
Placebo CMV ----- ----- ----- 75 25 ----- ----- 
10% w/w CMV 10 ----- ----- 67.5 22.5 ----- ----- 
 
The extrusion was performed at the specified extrusion temperature (Table7.2) with 5 minutes 
retention time and 100 rpm screw speed. After decreasing the rotation speed of the screws to 25 
rpm, the extruded soft mass of the blends was flushed directly through a metal attachment with a 
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circular die of a diameter 1.75 mm onto a conveyor belt to produce placebo and 10% w/w 
felodipine loaded filaments.  
Table 7.2: HME-3D printing processing parameters of placebo and 10% w/w loaded felodipine 
filaments and 3D printed discs   
Mixture Code HME temp. (˚C) FDM printing temp. 
(˚C) 
Extrusion torque 
(N.cm) 
Placebo CME 100 150 24 
10% w/w CME 100 150 18 
Placebo CMS 120 150 7 
10% w/w CMS 120 150 8 
Placebo CMV 130 150 1 
10% w/w CMV 130 150 1 
 
7.2.3  Using FDM 3D printing to fabricate solid dispersions 
A MakerBot Replicator II desktop 3D printer (New York, USA) equipped with two thermal 
extruding nozzles (diameter 400 µm) was used for printing the prepared placebo and medicated 
filaments. The digital file for the selected 3D shape in STL (stereolithography) format was 
designed using Blender software (521) and printed using MakerBot MakerWare™. In this study, 
a model disc shape with dimensions of 12 mm diameter and 0.6 mm thickness and was used as a 
standard shape to compare the characteristics of different mixtures. Printing was performed using 
an extrusion temperature of 150 ˚C without heating the platform. The 3D object was printed using 
standard mode with 0.2 mm layer thickness and 100% infill. The time required to complete 
printing each disc was 24.7 ± 0.1 seconds. The images of the produced 3D printed discs with their 
corresponding filaments are shown in Figure 7.1.  
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Figure 7.1: Images of the prepared HME filaments and FDM 3D printed discs 
7.2.4 Characterisation and evaluation of FDM 3D printed solid dispersions 
7.2.4.1 Thermal gravimetric analysis (TGA) 
The same experimental setting parameters of TGA as mentioned in Chapter 3, section 3.2.2.2.1 
were used to scan the samples in this study. 
7.2.4.2 Differential scanning calorimetry (DSC) and temperature modulated 
DSC (MTDSC) 
All samples investigated in this study using standard DSC were analysed using the same 
parameters as described in Chapter 3, section 3.2.2.2.2. MTDSC experiments were also performed 
using a 2 ºC/min heating rate, 60 sec period and 1 ºC or 0.318 ºC amplitude (depending on the 
samples) with proper MTDSC calibration to detect the Tg temperatures of the different 
formulations. Sample weights were 2-3 mg contained in an aluminium standard TA crimped pans 
and lids (TA Instruments, Newcastle, USA). Universal Analysis software was used to analyse the 
obtained results. All analyses were performed with 2-3 replicates for each sample. 
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7.2.4.3 Attenuated total reflectance Fourier transform infrared spectroscopy 
(ATR-FTIR) 
ATR-FTIR scanning for all samples was carried out using the same experimental parameters as 
mentioned in Chapter 3, section 3.2.2.2.4. 
7.2.4.4 Scanning electron microscopy (SEM)  
The same experimental parameters of SEM as mentioned in Chapter 4, section 4.2.3.2 were used 
to scan the samples used in this study. 
7.2.4.5 Powder X-ray diffraction (PXRD) 
PXRD parameters as mentioned in Chapter 3, section 3.2.2.2.6 were utilised to analyse all samples 
investigated in this study using this characterisation technique. 
7.2.4.6 X-ray micro-computed tomography (XμCT) 
A SkyScan1172 high-resolution X-ray micro computed tomography (XµCT) scanner (Bruker-
microCT, Kontich, Antwerp, Belgium) was used to 3D visualise the microstructure of the most 
promising blend (eudragit E PO based filaments and FDM 3D printed discs). Placebo and 10% 
w/w loaded samples were scanned using an aluminium filter to cut-off high energy X-rays at an 
isotropic voxel resolution of 3 µm over a total of 20 min acquisition time and a subsequent image 
reconstruction time of approximately 20 min per sample, using the NRecon program (version 
1.6.8.0, Bruker-microCT). The collected data were then analysed using CTan and CTvol software 
in which the images for a small section (designated as a region of interest ROI) of each sample 
are converted to binary images followed by thresholding areas of different electron densities and 
represented in 3D models (499). 
7.2.4.7 Determination of drug loading efficiency 
Accurately weighed drug loaded FDM printed discs of different formulations were dissolved in a 
beaker containing 200 mL of 50:50 simulated gastric fluid pH 1.2 and absolute ethanol. The 
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beaker was covered with a parafilm tape to minimise solvent evaporation during dissolution. The 
medium was stirred using magnetic stirrer at room temperature. After complete dissolution, 5 mL 
samples were withdrawn and filtered using 0.45 µm pore size (Minisart NML single use syringe, 
Sartorius, UK). The filtered samples then scanned for their content of felodipine using a UV–VIS 
spectrophotometer (Perkin-Elmer Lambda 35, USA) at 363 nm. The loading efficiency 
measurements for the loaded discs were carried out in triplicate. 
7.2.4.8 In vitro drug release studies 
The in vitro drug release profiles were measured in dissolution testing apparatus (Caleva 8ST, 
Germany) using the paddle method (USP apparatus 1). A paddle rotation speed of 100 rpm and 
900 mL of pH 1.2 HCl (simulated gastric fluid without enzymes) or phosphate buffer pH 6.8 
(simulated intestinal fluid without enzymes) at 37 ± 0.5 ˚C were used for all measurements.  The 
pure crystalline drug and disc-shaped dispersions containing the equivalent of the daily dose (5 
mg) of the drug were used in this study. Under non-sink conditions, 5 mL dissolution samples 
were withdrawn at pre-determined time intervals. The samples were directly filtered through a 
membrane filter with 0.45 µm pore size (Minisart NML single use syringe, Sartorius, UK). The 
filtered sample solutions were diluted with equal volume of ethanol. 5 mL of fresh pre-warmed 
(37 ± 0.5 ˚C) dissolution media was added to the dissolution vessel after each sampling. The 
samples were analysed using a UV–VIS spectrophotometer (Perkin-Elmer Lambda 35, USA) at 
363 nm. All drug release studies were conducted in triplicate.  
7.3 Results  
7.3.1 FDM 3D printing processability of placebo and drug loaded solid 
dispersions  
The calculations of solubility parameters using group contribution methods for the individual 
compounds used in this chapter and their differences relative to that of felodipine were presented 
in Chapter 3 and Appendix 1. The solubility parameters for soluplus and the processing aid 
materials, PEG, PEO K100 and Tween 80, are nearly identical, indicating excellent miscibility of 
all excipients in CMS placebo. The ∆δ value is less than 4 for eudragit E PO with PEO K100, 
PEG and Tween 80 which also indicates good miscibility between excipients used in CME 
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dispersions. However, the ∆δ value of PVA with Tween 80 is greater than 7 suggesting partial 
miscibility of these two excipients for CMV formulations. Based on the ranking of the ∆δ values, 
the highest miscibility of felodipine with the individual excipients is expected to be in the order 
of soluplus > PEG 4000 = PEO K100 > Tween 80> eudragit E PO > PVA. This leads to the 
predicted the rank of the miscibility of felodipine in FDM printed formulations being CMS > 
CME > CMV. 
Eudragit E PO and soluplus have been widely reported for the preparation of HME solid 
dispersions for enhancing the dissolution of poorly soluble drugs (83, 119, 139, 522). Although 
both polymers on their own are HME extrudable, neither of them were FDM printable even with 
the addition of drug. After blending with PEG, PEO K100 and Tween 80, both polymers were 
FDM printable. However, due to the higher melting viscosity and lower Tg of eudragit E PO than 
soluplus, a greater quantity of PEG and reduced amount of Tween 80 were added to the CME 
blends in comparison to CMS blends (Table 7.1). The PVA used in this study was 33-38% 
hydrolysed, and the HME filament was brittle and not suitable for FDM printing. Therefore, 
Tween 80 was added to plasticise this material and improve the flexibility of the filaments which 
made feeding of the FDM printer easier.  
The PVA-based filaments are highly thermoplastic. As seen in Table 7.2, the low extrusion 
torques during HME indicating low melt viscosity of the materials, but readily formed the 
required shape upon cooling (Figure 7.1). For eudragit E PO based blends, the addition of 
felodipine plasticised the mixtures and reduced the extrusion torque during HME which allowed 
FDM printing. For soluplus based blends, the plasticisation effect of the drug is not significant 
and may be masked by the higher Tween 80 content in these blends in comparison to eudragit E 
PO based blends. Although both eudragit E PO and soluplus based blends gave higher extrusion 
torque during HME, the mixtures were FDM printable. Moreover, no clear deformation of the 
shape at a micron scale can be observed using SEM (Figure 7.2).  
Chapter 7                                  Formulation of felodipine FDM 3D printed solid dispersion discs 
 
268  School of Pharmacy / University of East Anglia 
 
 
Figure 7.2: SEM images for 10% w/w felodipine loaded FDM 3D printed discs. CME (a) surface and 
(b) cross-section; CMS (c) surface and (d) cross-section; CMV (e) surface and (f) cross-section. The 
dotted lines indicate the widths of filaments strips after FDM printing 
The surface roughness at the edges of each deposited strips of CMS is slightly higher than CME 
and CMV. This may be attributed to the combination of suitable viscosity for FDM deposition but 
poor thermoplasticity. The edge of each printed strip of the materials can be easily identified. It is 
noted that for all three formulations the road width of each strip is approximately 370 ± 10 µm 
instead of 400 µm which is the diameter of the printing nozzle. The uniformity of the small 
shrinkage of the road width of the printed materials indicates the similar thermal flow behaviour 
of the three blends.  
XµCT was used to study the morphology and internal microstructure of the FDM samples at the 
hundreds of microns to the mm scale. Representative XµCT results for the placebo and 10% 
loaded filaments and FDM printed discs of CME blend show some level of micron scale surfaces 
roughness, which matches the SEM observations (Figure 7.3).  
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Figure 7.3: Representative XµCT reconstructed 3D images of CME placebo and 10% w/w felodipine 
loaded CME discs. HME filaments (left) and FDM 3D printed discs (right). The phase separate 
particles are likely to be metal contaminations introduced during HME and FDM printing and/or 
some inorganic additives included in the raw polymers (499) 
The road width of the individual FDM strip also matches those observed in the SEM images. 
Small air pockets distributed inside the FDM printed discs can be seen which is absent in the 
HME filaments. The small air pockets are likely to be introduced during the deposition of each 
layer of strips. It was noted that for both HME filaments and FDM printed discs; some phase 
separated particles with high electron density are observed. It can be confirmed that they are not 
drug particles as they are also present in the placebo filaments and discs. They may be metal 
contamination introduced during the extrusion/3D printing processes and/or some inorganic 
additives included in the raw polymers (499). 
7.3.2 Loading efficiency of FDM 3D printed felodipine solid dispersions 
The weights of the designed placebo and felodipine 10% w/w loaded discs are summarised in 
Table 7.3.  
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Table 7.3: Weights of placebo and 10% w/w felodipine loaded FDM printed discs (n=3; average ± 
SD) 
Mixture Code Weights of 3D printed discs (mg) 
Placebo CME 61.48 ± 8.16 
10% W/W CME 61.33 ± 3.88 
Placebo CMS 64.82 ± 1.46 
10% W/W CMS 60.34 ± 3.27 
Placebo CMV 56.93 ± 7.41 
10% W/W CMV 55.34 ± 4.00 
 
It was reported in the literature that the drug loading efficiency of the FDM 3D printed samples 
prepared by passive diffusion of the drug from its organic solution into the ready-made placebo 
PVA filaments was often lower than the theoretical value by more than 15% (224, 417, 523). 
Using a high printing temperature also can lead to unsatisfactory loading efficiency due to the 
thermal degradation of the drug (224, 417, 523). A temperature of 150 ˚C was used in this study 
during the FDM printing. The loading efficiencies of felodipine in the 3D printed CMS, CME and 
CMV discs were 95.75± 0.66%, 94.62 ± 0.56% and 86.23 ± 0.83%, respectively. This suggests 
that processing the mixtures using HME with subsequent FDM 3D printing at a suitable 
temperature can produce solid dispersions with high loading efficiency (175). In addition, this 
result also indicates that the 3D printing process at 150 ˚C led to no thermal degradation of the 
active drug which was confirmed by the results obtained by TGA (Figures 7.4). The lower loading 
efficiency for 10% CMV than CME and CMS may be attributed to the large particle size of PVA 
granules used during preparation which led to poor mixing with the Tween 80 and the drug. 
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Figure 7.4: Thermal degradation of placebo and 10% w/w felodipine loaded physical mixture, 
filament and 3D printed discs. A) CME, B) CMS and C) CMV mixtures (n=3) 
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7.3.3 Physical characterisation of the FDM 3D printed solid dispersions 
Thermal transitions for the raw materials used in the various formulations were measured using 
DSC and are illustrated in Chapter 3. The Tg of eudragit E PO, soluplus, PVA, and Tween 80 were 
identified at 46.7 ± 1.0, 74.1 ± 0.3, 46.1 ± 1.7, and -64.2 ± 0.6, respectively. The melting peaks of 
other blend excipients including Tween 80 (after crystallisation at -44.6 ± 1.2 ˚C), PEG and PEO 
K100 and the model drug can also be identified at -10.2 ± 2.3, 59.3 ± 0.3, 65.6 ± 0.1 and 144.6 ± 
0.1 ˚C, respectively. The physical mixtures of the CME and CMS show melting of PEG and PEO 
K100, but no melting of the model drug (Figure 7.5). This is likely to be due to the thermal 
dissolution effect of the crystalline drug in the polymer mixtures (498). The melting of felodipine 
is evident in the DSC results of the physical mixtures of CMV. This confirms the partial 
miscibility between felodipine and PVA predicted previously. 
 
Figure 7.5: DSC thermograms illustrating different thermal events for physical mixtures and FDM 
3D printed discs of placebo and 10% w/w felodipine loaded CME, CMS and CMV (n=3) 
MTDSC was used to further investigate the Tg region of the samples. As seen in Figure 7.6a, the 
MTDSC results of the physical mixtures of CME show no detectable Tg. A Tg at approximately   
-55 ˚C can be detected for the physical mixtures of CMS which probably arises from the mixture 
of PEG/PEO K100/Tween 80 (Figure 7.6b). Two Tg temperatures can be clearly seen at -55.4 ± 
0.2 and 39.4 ± 4.3 ˚ C in the MTDSC results of the physical mixtures of CMV blends (Figure 7.7). 
As the first Tg is higher than the Tg of pure Tween and the second is lower than the Tg of pure 
PVA, they are likely to be the Tg events of Tween-drug and PVA-moisture phases, respectively. 
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These Tg events are shifted to higher temperatures (-51.8 ± 0.3 ˚C and 42.9 ± 4.4.5 ˚C) in the 
reheating cycle which may be caused by the further mixing of Tween 80 and PVA and moisture 
loss of the main PVA phase, respectively (Figure 7.7). 
 
Figure 7.6: MTDSC thermograms showing the Tg events of (a) CME formulations using temperature 
program of 1.0 ˚C amplitude, 60 sec period and 2 ˚C/ min heating rate and (b) CMS mixtures using 
a heat only temperature program of 0.318 ˚C amplitude, 60 sec period and 2 ˚C/ min heating rate 
(n=3) 
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Figure 7.7: MTDSC thermograms showing the Tg events of CMV mixtures using a heat only 
temperature program of 0.318 ˚C amplitude, 60 sec period and 2 ˚C/ min heating rate (n=3) 
In FDM printed CME and CMS discs containing 10% felodipine, DSC shows the joint melting 
of crystalline PEG and PEO K100. The melting enthalpy values of the crystalline PEG-PEO K100 
were similar in CME and CMS. However, it should be mentioned that there was 30% w/w PEG-
PEO K100 in CME and 25% in CMS. This indicates that a greater amount of the crystalline PEG-
PEO K100 phase was present in CMS in comparison to CME (Table 7.4).  
It was also noted that the melting point of the PEG-PEO K100 shifted to lower temperatures in 
comparison to those observed in the results of their physical mixtures.  The solubilisation of other 
excipients and felodipine may be responsible for this melting depression of the crystalline PEG-
PEO K100 phase in the printed dispersions.  
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Table 7.4: Experimental % crystallinity of PEG-PEO polymers in CME and CMS blends compared 
to the 100% theoretical values (n=3; average ± SD) 
Material  1
st
 Melting 
(˚C) 
2
nd
 Melting 
(˚C) 
∆Hf (J/(g) total Experimental 
% crystallinity 
Placebo CME PM 58.45± 0.15 65.41± 0.33 53.48± 5.70 87.14± 9.29 
Placebo CME filament 59.56± 0.50 
 
49.56± 0.44 80.75± 0.72 
Placebo CME 3D disc 57.50± 0.66 
 
49.56± 2.55 80.75± 4.15 
10% CME PM 59.90± 1.03 66.18± 0.61 50.38± 6.26 91.23± 11.34 
10% CME filament 58.15± 0.09 
 
45.53± 1.90 82.44± 3.44 
10% CME 3D disc 54.61± 0.14 
 
46.57± 0.49 84.33± 0.89 
Placebo CMS PM 56.99 ±0.65 62.75 ±0.83 55.32 ±18.49 108.67± 36.32 
Placebo CMS filament 56.76 ±0.56 
 
44.94 ±1.25 88.28± 2.46 
Placebo CMS 3D disc 56.37 ±0.14 
 
45.08 ±1.39 88.55± 2.73 
10% CMS PM 58.25 ±0.25 63.43 ±0.29 43.04 ±2.00 93.91± 13.66 
10% CMS filament 56.23 ±0.23 
 
41.09 ±3.03 89.66± 6.61 
10% CMS 3D disc 57.62 ±0.19 
 
43.18 ±1.16 94.22± 2.53 
 
For the drug loaded CME, the theoretical Tg of the blend calculated using Fox equation as 
described in Chapter 1, Table 7.5 and Appendix 4 is 18.9 ˚C. This is higher than the Tg of the 
FDM printed CME discs measured by MTDSC which is a broad transition at approximately -6 
˚C (Figure 7.6a). This negative deviation from the predicted Tg value reflects non-ideality of 
mixing which may result from the reduced crystallinity of the semicrystalline polymers by 
processing, increase in the free volume caused by the diffusion of the drug inside the polymer 
and/or the weaker drug-polymer interactions compared to the original drug-drug interactions (24, 
99). The detection of a single Tg is a good indicator of the formation of a molecular dispersion of 
the drug and the excipients in CME. For drug loaded CMS samples, the Tg of Tween 80 
disappeared and no clear joint Tg can be detected by MTDSC (Figure 7.6b). No drug melting was 
detected in the DSC and MTDSC results of CMV processed dispersions. Two Tg events are 
present in the MTDSC results of the CMV dispersions (Figure 7) indicating the phase separation 
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in printed CMV dispersions. The Tg of the PVA phase shifts to a lower temperature (25.7 ± 1.3 
˚C) in the FDM printed dispersions in comparison to the physical mixture. As the Tg of PVA is 
lower than amorphous felodipine and higher than Tween 80, this may indicate enhanced mixing 
of Tween with PVA after processing. The separate Tg at -51.6 ± 2.7 ˚C can be assigned to the 
Tween rich phase. It is likely that felodipine is molecularly dispersed in both PVA-rich and Tween 
80-rich phases.  
Table 7.5: Fox equation predicted Tg temperatures for different formulations   
Sample Fox equation Tg (˚C) 
Placebo CME 14.87 
10% w/w CME 18.91 
Placebo CMS 23.20 
10% w/w CMS 25.99 
Placebo CMV 3.83 
10% w/w CMV 7.57 
 
ATR-FTIR and PXRD were used to further confirm the physical states of felodipine in the solid 
dispersions. As seen in Figure 7.8 the NH stretching peak of crystalline felodipine form I at 3367 
cm-1 is visible in the physical mixtures. This peak transforms into a broad peak with low intensity 
in the spectra of the FDM printed CME, CMS and CMV discs. This broadening may be caused 
by a combination of the formulation of molecular dispersion of felodipine and the small quantity 
(less than 3% w/w) of moisture present in the printed discs as shown in the TGA results (Figure 
7.9).  
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Figure 7.8: Partial ATR-FTIR spectra of the physical mixtures (PM) and felodipine loaded FDM 
printed discs. The NH stretching peak of crystalline felodipine is highlighted with the dashed line 
(n=3)  
 
Figure 7.9: Moisture content of different FDM 3D printed discs using TGA at 10 ºC/min (n=3) 
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A few signature diffraction peaks of the crystalline felodipine are present in the PXRD diffraction 
patterns of the physical mixes for the three blends (Figure 7.10). Because both CME and CMS 
contain semi-crystalline PEG and PEO K100, the main diffraction peaks of these two polymers 
can be seen in the PXRD patterns of the FDM printed discs. The crystalline drug related peaks 
completely disappear in all patterns of the 10% w/w loaded printed discs. Taking into account of 
the miscibility prediction of felodipine and the excipients, the phase separation of amorphous 
felodipine is unlikely and the results indicate the formation of felodipine molecular dispersions at 
the detection limit of PXRD. These results agree well with the DSC results and confirm felodipine 
was molecularly dispersed in all three matrices. 
 
Figure 7.10: PXRD Diffraction patterns of physical mixtures and 10% w/w felodipine loaded FDM 
printed CME, CMS and CMV discs  
7.3.4 In vitro disintegration and drug release study of FDM printed felodipine 
dispersions 
A significant enhancement of the dissolution profile of felodipine from CME discs in comparison 
to crystalline model drug alone was obtained when pH 1.2 HCl was used as the dissolution media 
(Figure 7.11a). The rapid release of approximately 84.3% of the drug load was achieved within 
30 minutes. This dissolution improvement may be attributed to the formation of the molecular 
drug dispersion and the high solubility of eudragit E PO in pH 1.2 HCl. The rapid disintegration 
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of the CME discs can be observed within the first 5 minutes of the dissolution experiments 
(Figure 7.12). 
 
Figure 7.11: Felodipine release profile of FDM 3D printed discs using a) pH 1.2 HCl (simulated 
gastric fluid without enzyme) and b) pH 6.8 phosphate buffer saline (PBS) (n=3; average ± SD)   
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Figure 7.12: Visual appearances of felodipine loaded FDM printed CME discs during dissolution in 
pH 1.2 HCl and pH 6.8 PBS. The dash circles represent the diameters of freshly prepared dry CME 
discs  
Eudragit E PO is insoluble at pH 6.8, thus little drug release from the CME was expected. 
However, a delayed but 100% drug release of felodipine from the CME discs in pH 6.8 PBS was 
obtained (Figure 7.11b). Less than 8% drug release occurred in the first 90 minutes. However, 
from 90 minutes onwards, a linear zero-order release profile with 100% drug release by 6 hours 
was observed. The images of the discs during the dissolution in pH 6.8 PBS show the slow bulk 
erosion and disintegration of the discs which was completed by 6 hours (Figure 7.12). A minor 
level of swelling of the discs prior to the complete disintegration and dissolution was observed.  
CMS discs showed significantly slower drug release profile in pH 1.2 HCl than CME discs 
(Figure 7.11a). However, it is interesting to note that some improvement in drug dissolution in 
comparison to the crystalline drug alone was still observed from 1 hour onwards and the release 
follows a linear release pattern. The maximum release of 28% was achieved after 6 hours in vitro 
dissolution. Although soluplus has been reported to be a water-soluble polymer, the addition of 
the inorganic salts in the dissolution medium can depress the cloud point of the polymer and 
reduce the solubility of the polymer in the media (149). Figure 7.13 captures the start of the 
disintegration process of CMS discs between 60 to 90 minutes into the dissolution test. A closer 
examination of the images reveals the sequence of the disintegration of CMS discs into segments 
of printed strips which is significantly different from the disintegration of CME in pH 6.8 PBS. 
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Between 60-90 minutes, the individual printed polymer strips at the outer edge of the FDM discs 
started to unravel into single long strands. There were three printed layers stacked together to 
form the discs; the outer printed layer unravelled first to reveal the middle layers. This was 
followed by a further breakdown of the longer polymer strips into smaller segments. This unique 
disintegration process contributed to the increased release of drug and led to the observed increase 
in the amount of drug released from 1 hour onwards (Figure 7.11a).  
 
 
Figure 7.13: Visual appearances of the felodipine loaded FDM printed CMS discs during the 
dissolution tests in (a) pH 1.2 HCl and (b) pH 6.8 PBS. The dash circles in (a) and (b) represent the 
diameters of the dry and freshly prepared CMS discs 
This indicates that the disintegration process may be the limiting step for initiating the drug release 
from CMS in HCl. The linear release profile also suggests that the release kinetics of felodipine 
from disintegrated CMS strips is close to zero-order. In pH 6.8 PBS, CMS discs show no 
dissolution enhancement of felodipine despite the formation of the molecular dispersions of the 
drug by HME and FDM 3D printing (Figure 7.11b). It was noted that no disintegration occurred 
in any FDM printed discs during the period of the dissolution tests in pH 6.8 PBS. The increased 
amount of inorganic salt in the PBS may contribute to further limit the solubility of soluplus in 
the media. No significant swelling was observed through the 6 hours of dissolution and a minimal 
disintegration started by 6 hours (Figure 7.13b).  
In order to further understand the release behaviour, segments of the CMS samples after 6 hours 
dissolution were studied using ATR-FTIR and DSC. The ATR-FTIR results (Figure 7.14) show 
no changes of the drug and excipient peaks in comparison to the dry freshly prepared discs after 
6 hours dissolution in both media.  
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Figure 7.14: Partial ATR-FTIR spectra of CMS discs taken out of the media and dried after 6 hours 
dissolution. The dash lines in (c) highlight the felodipine related IR peaks and arrows highlight the 
changes of PEG/PEO K100 related peaks labelled with * before dissolution (n=3)  
This confirms that the drug was still in amorphous dispersion with the polymer matrix. These 
results are consistent with the transparency of the dried matrices and the absence of drug crystals 
in the SEM data of these samples (Figure 7.15). However, the peaks associated with PEG, PEO 
K100 and Tween 80, such as the peaks between 1500 - 850 cm-1, have shown significant changes 
in peak intensity and shape as observed in Figure 7.14 indicating dissolution of these excipients 
during the dissolution experiments.  
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Figure 7.15: Images (A and C) and SEM images (B and D) of 10% CMS samples after dissolution for 
6 hours and drying.  A and B in SGF pH 1.2, while C and D in PBS pH 6.8 
DSC detected much smaller PEG-PEO K100 melting peaks in the post-dissolution discs in 
comparison to the fresh dry sample (Figure 7.16), indicating the leaching of PEG-PEO K100 
during dissolution. The first heating cycle showed an overlapped peak of the Tg of soluplus and 
dehydration of the matrix. However, the second heating cycle revealed the Tg of soluplus. These 
results imply that the remaining segments after dissolution are largely soluplus which retains the 
unreleased drug.  
 
Figure 7.16: DSC thermographs of CMS discs taken out of the media and dried after 6 hours 
dissolution (n=3) 
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No significant release improvement of felodipine from CMV discs was observed in either pH 1.2 
HCl or pH 6.8 PBS in comparison to the crystalline drug (Figures 7.11a and b). The PVA used 
in this study was a low hydrolysis grade which led to the poor aqueous solubility of the polymer. 
In addition, the effect of ionic strength of the dissolution medium may also play a role in this case, 
reducing the dissolution of PVA in the media (410). For both cases, a degree of gelling of the discs 
during dissolution can be seen in Figures 7.17a and b. The gelation of CMV discs can be 
attributed to the hydrogel formation ability of PVA reported in the literature (524, 525). The discs 
in pH 1.2 HCl show significant softening that led to the folding of the wetted discs (which appears 
as a reduction in size), whereas there was no change in the size of the discs tested in pH 6.8 PBS.  
 
Figure 7.17: Visual appearances of the felodipine loaded FDM printed CMV discs during the 
dissolution tests in (a) pH 1.2 HCl and (b) pH 6.8 PBS 
The ATR-FTIR results of the dried CMV samples are shown in Figure 7.18. No changes can be 
observed in comparison to the dry freshly prepared discs indicating that there was no change in 
the state of the drug in the CMV solid dispersions after 6 hours exposure in both media. The DSC 
results of the dried discs after 6 hours dissolution reveal the absence of a Tg of Tween 80 which 
was present in the freshly prepared discs (Figure 7.19). This indicates the leaching of Tween 80 
during dissolution. 
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Figure 7.18: Partial ATR-FTIR spectra of CMV discs taken out of the media and dried after 6 hours 
dissolution. The arrows highlight felodipine related IR peaks (n=3) 
 
Figure 7.19: DSC thermographs of CMV discs taken out of the media and dried after 6 hours 
dissolution (n=3) 
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7.4 Discussion  
7.4.1 Linking phase behaviour with FDM printability of the dispersions 
Polymer blending is a widely used formulation strategy in the polymer and plastic industries to 
improve the processability of materials. This study tackled the FDM printability issues of two 
FDA approved and widely used pharmaceutical polymers, soluplus and eudragit E PO, by 
blending the polymers with a mixture of PEG, PEO K100 and Tween 80. Although both polymers 
have wide applications in preparation of pharmaceutical HME dispersions, they are not printable 
by conventional FDM 3D printers due to their high melt viscosity and poor fluidity. The addition 
of the mixture of PEG, PEO K100, Tween 80 as well as the model drug significantly improved 
the viscosity of the polymers during printing. As a result, these mixtures matched the printing 
performance of the PVA-based system that is one of the main matrix materials used currently in 
FDM 3D printing. This improved the thermal and mechanical properties allowing the felodipine-
loaded dispersions to be printed into disc shaped, triple layered matrices. A clear understanding 
of the phase behaviour of the printed system is crucial for further interpretation of the mechanism 
of formulation stabilisation and drug release. As a result of the large number of ingredients used 
in the printed discs, characterisation of the phase behaviour of the systems is complex. This study 
took the simplified approach of ranking the miscibilities between excipients in order to gain some 
insight into the phase behaviour of the blend matrices and the miscibility of felodipine with 
different polymer blends to allow the prediction of the likelihood of the formation of molecular 
dispersions of the drug with polymers. The prediction revealed soluplus and eudragit E PO were 
miscible with PEG-PEO K100 and Tween 80; whereas PVA is only partially miscible with Tween 
80. Therefore, the mechanism by which the printability of soluplus and eudragit E PO is improved 
by the addition of these excipients is probably the combination of improved melt viscosity and 
plasticisation of the polymers. Results indicated the formation of a molecular dispersion of 
felodipine at 10% loading in FDM printed CME and CMS dispersions. Therefore, drug 
incorporation further contributed to the plasticisation of the polymer matrices. The addition of 
Tween 80 reduced the stiffness of the PVA filaments and eased the printing process. The 
weakening of the stiffness may be attributed to the formation of discontinuous Tween 80 phases 
in PVA dispersions, as the two are partially miscible. The addition of felodipine further plasticised 
the polymer. 
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7.4.2 Linking phase behaviour with in vitro disintegration and dissolution 
performance 
The phase behaviour of the printed discs is important for understanding the differences in the drug 
release rates of the formulations. The slower drug release from the CMS system compared to 
CME blend is a result of the combination of lower solubility of soluplus than eudragit E PO in 
the media and the physical state of the excipients in the dispersions. Although both formulations 
were confirmed to be molecular dispersions of felodipine, their crystalline PEG-PEO K100 
contents are different. The higher crystalline PEG-PEO K100 content in the CMS compared to 
CME may contribute to the slower drug release from CMS discs. This is because that the 
crystalline PEG-PEO K100 required a wetting and hydration prior to dissolution; whereas these 
may not occur for the molecularly mixed PEG-PEO K100 in the polymer matrices. The reason 
for the higher crystalline content may be associated with the higher melt viscosity of eudragit E 
PO than soluplus as suggested by the HME processing torque values. As HME and FDM printing 
both were performed at temperatures above the melting point of the crystalline PEO K100 and 
PEG, higher melt viscosity of the matrix polymer would be more effective in limiting the diffusion 
of PEG and PEO K100 molecules to form large crystalline domains during recrystallisation on 
cooling (post-FDM printing). However, despite the fact that PEO K100 is a well-known 
controlled release matrix excipient which hydrates and swells once it is in contact with aqueous 
media (526-529), the limited amount of swelling observed in CME and CMS discs during 
dissolution, indicated that the dissolution of PEG-PEO K100 in the dispersions is the more 
dominant process in these blends. The intimate mixing between PEG-PEO K100 and soluplus 
and eudragit E PO may contribute to this observed behaviour.   
Another interesting feature of the dissolution behaviour of these FDM 3D printed discs is the 
difference in their disintegration behaviour, which in the case of CMS in pH 1.2 HCl and CME 
in pH 6.8 PBS led to the ‘switching on’ effect of the drug release (Figure 7.11). It indicates that 
the disassembly of the bulky 3D object that was fabricated by micron-size polymeric strips may 
be used as a novel mechanism of the drug release performance. Therefore, a clear understanding 
of the disintegration behaviour of the formulation is of vital importance. In the literature, the 
disintegration process of FDM printed 3D matrices is still poorly understood. The results of this 
study revealed the unravelling of the printed strips of CMS formulation and bulk erosion 
behaviour of CME discs. The exact mechanism for this difference is not clear, but (1) the degree 
of fusion between the printed strips and layers and (2) the speed of dissolution of the matrix 
polymer may be relevant. As seen in Figure 7.2, the edges of the printed strips of CMS are much 
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rougher than CME discs. This may be an indication of the low melt viscosity of the materials and 
rapid solidification of the materials after deposition. This should lead to the better-defined 
interfaces between strips and layers which may contribute to the observed ‘peeling’ effect of strip 
by strip during the disintegration of CMS. The higher solubility of eudragit E PO at pH 1.2 than 
soluplus is believed to responsible for the rapid disintegration and dissolution of CME in pH 1.2. 
For CMS, the drug release results strongly indicated that disintegration is the limiting step for 
drug release. Following disintegration, controlled release of drug following zero-order kinetics 
was observed. The zero-order release of CMS in pH 1.2 media may be explained by the small 
diameter of each strip segment, which contributes to the short diffusion path length of the drug 
molecules. This short path length led to the negligible effect of changes in diffusion length during 
dissolution. In addition, the continuous slow breakdown into shorter segments can provide a 
constantly increasing release surface for the drug molecules and led to the observed zero-order 
like release profile. This brings insight into the potential of controlling the drug release rate via 
manipulation of the disintegration behaviour of the bulky solid formulation. This study has 
demonstrated that this is achievable using FDM printing technology, with careful selection of 
excipients.  
Finally, the phase behaviour can also be used to explain why the prevention of drug 
recrystallisation in the formulations that have no drug dissolution enhancement (CMS and CMV). 
For CMV, as the solubility study suggested the separation of a Tween 80 rich phase and a PVA 
rich phase, one may expect the leaching of Tween during dissolution, which would liberate some 
drug. However, as extremely limited drug release was observed, it indicates that although the 
leaching of Tween may lead to some drug release, the majority of the drug is still held as a 
molecular dispersion in PVA matrices. This was confirmed by the DSC and ATR-FTIR results of 
the post-dissolution dried samples. The fact that no significant drug crystallisation occurred 
during the period of dissolution indicates that the polymer to drug ratio is efficient in stabilising 
and preventing crystallisation of the remaining drug in the matrices. This also applies to the CMS 
systems in which no drug recrystallisation was observed during 6 hours of dissolution.   
7.5 Conclusion 
This chapter demonstrated the use of polymer blends to overcome the poor printability of 
pharmaceutical polymers during FDM 3D printing. The solid dispersions of felodipine with 
eudragit E PO and soluplus were successfully prepared using FDM printing after blending with 
the process and drug release aids, PEG, PEO K100 and Tween 80. Distinctively different 
Chapter 7                                  Formulation of felodipine FDM 3D printed solid dispersion discs 
 
289  School of Pharmacy / University of East Anglia 
 
disintegration behaviour of the 3D discs with different polymer blends allowed the manipulation 
of the rate of drug release. The results demonstrated the effect of the complex interplay between 
the miscibility of the excipients in the blends, the solubility of the polymer in the media and the 
formation of interfaces between printed strips during the FDM printing on drug release behaviour 
of the dispersions. This brings new insights into the design principles for controlled release 
formulations manufactured using FDM 3D printing by using different geometries and internal 
structures during the formulation development process. 
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8.1 Conclusions 
8.1.1 Preformulation studies 
This study introduced the use of HME-IM as a single step, solvent-free processing technique for 
designing mucoadhesive buccal patches for systemic delivery of felodipine with defined shape 
and geometry. In addition, part of the study focused on the use of FDM 3D printing for fabricating 
felodipine oral solid dispersions using polymeric blends as a strategy for improving the 
printability of pharmaceutical excipients. As a preformulation step, Chapter 3 investigated the 
physicochemical properties of the raw materials (felodipine and all other excipients) used 
throughout the different stages of the study before starting formulation development stage. This 
also involved the careful selection of the suitable excipients used for fabricating the formulations 
using these two methods. In addition, the chapter provided some theoretical and experimental 
predictions for the miscibility between the different excipients and the drug under investigation. 
Several characterisation techniques used to investigate the properties of the raw materials 
including DSC, MTDSC, TGA, DVS, ATR-FTIR, PXRD, SEM and EDS.  
8.1.2 Formulation development strategies of felodipine HME-IM buccal 
patches 
Several key formulation strategies were adapted to ensure the success of the formulation process 
using HME-IM. As the precision of product geometry is one of the major advantages of HME-
IM over other methods like solvent casting for fabricating buccal and transdermal patches, the 
prepared patches should be easily removed from the mould after melt injection to ensure the 
integrity of the designed delivery systems. In order to achieve this, the excipients were selected 
for preparing felodipine dispersions in this study were non-sticky to the metal mould of the IM 
machine which facilitated the easy removal of the prepared patches after moulding. This function 
was provided by including PEG 4000 and PEO K900 polymeric blend as the main component of 
the patches. This polymeric blend provided easy peel off patches after cooling down the mould 
after HME-IM. Therefore, excipients should be selected carefully as sticky materials to IM 
moulds may be not suitable for preparing dosage forms using HME-IM.  
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Thermal degradation is the primary drawback for solid dispersions preparation by fusion methods 
in general including HME-IM. The formulation strategy to avoid thermal decomposition of 
formulative ingredients was through the selection of a range of excipients having low melting 
points which permitted processing at low and safe processing temperature (65 °C). The excipients 
used in the HME-IM study have melting temperatures ranging from -65 to 70°C. Thus, thermal 
degradation can be avoided by selecting carrier(s) having low melting points/Tg values to enable 
processing at safe temperatures.   
The main purpose of the study using HME-IM was to design formulations (solid dispersions) for 
delivering felodipine to the systemic circulation via the buccal route to improve its bioavailability 
by solubility/dissolution enhancement and avoiding extensive liver metabolism (84%). In order 
to fulfil all these formulation objectives, tertiary carrier mixtures composed of PEG/ PEO K900 
and either Tween 80 or TPGS blends were used as multi-functionality mixtures to provide drug 
solubilisation, mucoadhesion, stabilisation and absorption enhancing properties. The resultants 
mixtures were complex systems and they reflected the actual state of final pharmaceutical 
products which is rarely investigated as a strategy for preparing solid dispersion dosage forms 
using HME-IM.      
Physical stability of molecularly solubilised drugs in solid dispersions is one of the most 
challenging problems in the development of successful formulations. This study adapted a 
strategy of creating surfactant-rich drug solubilisation and stabilisation compartments for 
felodipine. The created solubilisation domains were formed due to the different miscibilities of 
components of the CM1 and CM2 mixtures as represented in Figure 8.1.      
 
Figure 8.1: Proposed schematic illustration of felodipine loaded phase separated solubilisation 
compartments created by HME-IM  
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The investigations for the HME-IM patches presented in Chapter 4 proved that felodipine 
solubilisation improved the miscibility between PEG/PEO K900 polymer blend and Tween 80 as 
indicated by the disappearance of Tween 80 melting peak. This led to the formation of PEG-PEO 
K900-Tween 80 solubilisation phase for felodipine. However, for CM2 matrices, felodipine 
loading did not seem to improve the miscibility between TPGS and PEG-PEO K900 blend and 
the drug was most likely solubilised in the TPGS phase. In addition, felodipine was completely 
solubilised in both CM1 and CM2 at 10% w/w loading as molecularly dispersed form. The drug 
was dispersed in PEG-PEO K900- Tween 80 amorphous fraction for CM1 and most likely 
distributed in TPGS phase for CM2. The absence of felodipine crystals in the surfaces and cross-
sections of the patches, broadening of felodipine NH stretching and absence of felodipine PXRD 
characteristic peaks indicated this. It was also found that increasing the loading percentage to 20% 
w/w led to more drug solubilisation in the surfactant-rich domains as revealed by the increase in 
the Tg of the mixtures and the ∆Cp values. Further increase in felodipine concentration to 30% 
w/w resulted in the detection of felodipine crystalline fraction by ATR-FTIR, SEM, EDS, PXRD, 
but not revealed by DSC and MTDSC due to the thermal dissolution of the crystalline drug in the 
molten carrier during the DSC runs. The 10% w/w loaded HME-IM patches revealed the 
maximum improvement in the dissolution profile of felodipine with approximately 10-12 times 
increase in the in vitro release after 2.5 hours compared to crystalline felodipine form I powder.  
It should be mentioned that loading felodipine at 10% w/w did not significantly affect the in vitro 
mucoadhesion properties of the HME-IM patches compared to placebo for both CM1 and CM2 
mixtures. However, increasing the loading to 20-30% w/w drug loading reduced the 
mucoadhesion force not only because of the reduced proportion of PEO K900 but also due to 
saturation of the mixtures with felodipine and impacts of crystalline drug fraction in the 
formulations.      
8.1.3 Characterisation challenges for investigating the microstructures of 
HME-IM patches 
Conventional characterisation techniques such as DSC, MTDSC, SEM, EDS, ATR-FTIR and 
PXRD provided qualitative and quantitative information about the microstructure of the prepared 
HME-IM patches as shown in Chapter 4. However, due to the complexity of these systems and 
the presence of phase separation domains, it was important to understand the degree of 
heterogeneity in the different formulations and the impacts of drug loading on the spatial 
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distribution of phases. Therefore, TASC and XµCT were used to achieve this target as explained 
in Chapter 5.  
TASC detected TPGS and PEG-PEO K900 for both CM1 and CM2 samples in comparable 
temperatures to standard DSC with slight variations related to the principle of detection of both 
techniques. DSC measures the heat flow accompanying thermal events while TASC detects 
changes in the appearance of the top surface of the sample under investigation. For CM1 and 
CM2 placebo HME-IM patches, TASC revealed that the different phases in the placebo and 10-
20% w/w loaded samples were uniformly distributed within the microscale detection limits of the 
technique using the localised thermal analysis function for TASC. However, the 30% w/w 
loadings were heterogeneous reflecting microscale heterogeneity of the samples. The 
heterogeneity represented by the different in composition of the analysed areas using TASC 
algorithm. It was also found that analysing large areas of 30% w/w loaded patches reduced the 
heterogeneous character of these samples due to the averaging effect which in turn explained the 
high reproducibility of the DSC results. Unlike DSC, TASC was able to detect the thermal 
dissolution of the crystalline fraction of felodipine in the 30% w/w loaded samples. Placebo and 
10% w/w loaded samples readily reached the plateau after the melting of PEG-PEO K900 blend. 
20% w/w loaded HME-IM reached the plateau in a less sharp way compared to lower loadings. 
However, 30% w/w drug loading failed to reach the plateau indicating the presence of real thermal 
event ‘thermal dissolution of crystalline felodipine’ occurred after the melting of PEG-PEO K900 
blend. These results complement the findings obtained by VT-ATR-FTIR. TASC also detected 
the unfolding of the folded form of PEG 4000 in the reheating cycle of the TASC experiments. 
This hidden event was unobservable using standard DSC at the same heating rate. The 
transformation of the folded to the more stable extended form is detected using MTDSC and VT-
ATR-FTIR. In addition to be fast and cheap thermal analysis technique, TASC proved that its 
sensitivity is not affecting by changing the rate of heating and cooling ramps which was 
considered as an advantage for TASC over DSC.  Thus, increasing the heating rate does not seem 
to reduce the resolution of analysis using TASC compared to DSC. 
Since XµCT has a micron scale, phase separations between the components of CM1 and CM2 in 
the placebo and 10% w/w felodipine loaded samples were undetectable. The presence of a 
crystalline fraction of felodipine in the 20-30% w/w loadings and because the drug has higher 
electron density compared to other formulation ingredients, the ability of XµCT to detect and 
threshold crystalline felodipine clusters permitted the simulation of the spatial distribution of this 
phase in the higher loaded formulations. In addition, XµCT was used to provide semi-quantitative 
data about the concentration of felodipine in the 30% w/w felodipine loaded CM2 HME-IM 
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patches using a series of CM2 physical mixture discs loaded with 0-60% w/w felodipine. The 
results revealed the presence of 10.3% w/w crystalline felodipine in the 30% w/w CM2 patches. 
It was also found that thresholding small areas in the CM2 sample loaded with 30% w/w loading 
revealed a high degree of heterogeneity for crystalline felodipine compared to thresholding large 
areas. These results confirmed the localised analysis performed using TASC. XµCT was also 
found to be unique not only to simulate the distribution of crystalline drug fraction if it has enough 
electron density to perform thresholding but also to detect processing defects like the presence of 
air pockets and heavy metal additives because these two have very high contrast difference to be 
thresholded and simulated as 3D models. 
8.1.4 Evaluations of physical stabilities of the HME-IM patches and their 
implications in formulation optimisation 
After completing the formulation stage of felodipine HME-IM buccal patches using different 
mixtures and drug loadings, the stability of the designed preparations was investigated under four 
different storing conditions with respect to temperature and relative humidity for 3 months. The 
stability follow-up for placebo and felodipine loaded CM1 and CM2 patches was explained in 
details in Chapter 6. The studies conducted indicated no significant changes in the morphology 
and the microstructure of CM1 and CM2 placebo patches stored under all conditions except 
placebo CM1 sample stored at condition D (40°C and 75%RH) which lost its solid structure 
‘liquefied’ during ageing. Using different characterisation techniques such as TGA and ATR-FTIR, 
this loss of solid structure was attributed to random scission oxidative degradation of PEG-PEO 
K900 blend and Tween 80. However, placebo CM2 samples were more resistant to oxidative 
degradation due to the antioxidant properties of TPGS which provided partial protection against 
the random polyethylene oxide chain degradation. Therefore, the prepared drug delivery system 
should be protected against high temperature and relative humidity conditions. 
Felodipine crystallisation was detected in all loaded formulations, however, the extent of 
crystallisation was found to be drug concentration dependent. 10% w/w CM2 loaded HME-IM 
stored at condition C (40 °C and 0% RH) and condition A (room temperature and 0% RH) revealed 
the lowest extent of felodipine recrystallisation with only few surface crystals detected on the 
surface with very slight changes in the different phase separated domains. Stability investigations 
for 10% w/w CM1patches also showed good felodipine stabilising properties, however, they were 
less stable compared to corresponding CM2 formulations. These results indicated that 10% w/w 
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CM2 HME-IM patches are the most likely suitable formulation for the next stage of product 
development. Interestingly, it was found that felodipine recrystallised from formulations as a 
plate, block or spherulitic needle habits as observed under SEM. This phenomenon was more 
prominent in the higher loading formulations (20-30% w/w loadings) compared to 10% w/w 
loading. All habits were identified as felodipine crystals using EDS. The spherulitic needle-
shaped crystals were grown on the surfaces (including the interior air pockets’ surfaces) of the 
patches of all loaded samples stored at condition D (40°C and 75% RH) except 10% w/w CM2 
patch and also seen in some of the patches aged under condition C (40°C and 0%RH). 
Characterisation of formulations contained the spherulitic crystals using ATR-FTIR and PXRD 
revealed different signatures compared to the already four identified polymorphic forms of 
felodipine. Most importantly, the detection of felodipine NH stretching peak at 3321 cm-1 in 
formulation loaded with 20-30% w/w loading is not related any known polymorphs or the 
amorphous form of the drug. In addition, the results of PXRD indicated new diffraction peaks at 
9.3 ̊ and 12.4 ̊ do not match with any known polymorphs of felodipine. These observations 
suggested that felodipine recrystallised as spherulitic needle shaped crystals from formulations 
stored at 40°C with or without 75% RH is more likely new form of felodipine. The general 
illustration for the stability study of the HME-IM patches is shown in Figure 8.2. 
 
 
 
Figure 8.2: An illustration showing the impacts of storing temperature and relative humidity on the 
stability of felodipine loaded HME-IM patches   
Crystallisation of felodipine from the glassy state under 40°C and 75% RH was also investigated 
and the results indicated the presence of new melting peak having an onset at 118.3 ± 0.1 ̊C in 
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addition to the main peak with onset detected at 136.0 ± 0.9 ̊C. In addition, PXRD of the 
recrystallised drug revealed peaks with low intensity at 9.3 ̊ and 12.6 ̊as peaks may be due to the 
small fraction of the new polymorphic growth. However, the ATR-FTIR did not show any change 
in the spectra of different regions of the crystallised drug compared to the raw pure crystalline 
felodipine form I which may be due to presence of the small fraction in the bulk of the sample 
which is out of the detection limits of the instrument.  
8.1.5 Using polymer blends as a strategy to improve FDM 3D printability of 
pharmaceutical solid dosage forms 
FDM 3D printing has recently attracted the attention of researchers working in pharmaceutical 
formulation field as a potential method for providing more personalised medicines, drug 
combination dosage forms and flexibility to design products with different structures, shapes and 
geometries. All these advantages are expected to improve patients’ adherence to medications 
which in turn lead to better therapeutic outcomes. However, the major challenge currently is the 
poor printability of the vast majority of pharmaceutically approved excipients. Chapter 7 explored 
the possibility of using of polymer blends as a formulation strategy to overcome this limitation. 
Felodipine as a model drug with a range of excipients normally processed by HME (eudragit E 
PO, soluplus, PVA, PEG 4000, PEO K100 and Tween 80) were used to develop felodipine 10% 
w/w FDM 3D printed oral discs.  
HME filaments and 3D printed formulation were successfully prepared using CME, CMS and 
CMV blends using acceptable HME and FDM 3D printing temperatures without affecting the 
chemical stability of all formulation ingredients. The physicochemical characterisation studies 
revealed that felodipine was solubilised in the three mixtures as no drug crystals were detected 
using SEM, the characteristics PXRD peaks were absent, and the NH stretching was very 
broadened using ATR-FTIR revealing molecularly dispersed drug in the systems. Felodipine was 
more likely dissolved in CME (eudragit E PO- PEG-PEO K100 -Tween 80) and CMS (soluplus- 
PEG-PEO K100 -Tween 80) amorphous phases. However, due to phase separation between PVA 
and Tween 80, the drug was molecularly dispersed in both PVA-rich and Tween 80-rich phases. 
The loading efficiency of felodipine in the different systems were 95.75 ± 0.66%, 94.62 ± 0.56% 
and 86.23 ± 0.83% for CME, CMS and CMV 10% w/w loaded discs, respectively. These results 
revealed good mixing achieved during HME processing for CME and CMS formulations, 
however, the large granules of PVA resulted in poor mixing with felodipine and Tween 80 and 
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reduced the loading efficiency of this mixture. The in vitro dissolution studies of felodipine 
showed significant enhancement in the solubility/dissolution properties of the drug from CME 
using 1.2 HCl as the dissolution medium. A maximum release of approximately 84.3% of loaded 
felodipine was achieved within the first 30 minutes which was attributed to the formation of the 
molecular drug dispersion and the high solubility of eudragit E PO in pH 1.2 HCl medium. In 
addition, the same formulation slowly but completely released in pH 6.8 PBS medium. The 
release of felodipine from CMS in pH 1.2 HCl medium was slightly improved and revealed an 
interesting fragmentation of the 3D object into the individual printing strips. However, no 
enhancement in the dissolution profile of felodipine was observed from CMS in pH 6.8 PBS and 
CMV in both media due to the entrapment of felodipine in the main insoluble polymers.    
8.2 Future outlook  
The conducted studies presented in this project provided information about the design, 
characterisation and in vitro evaluation of different formulations using HME-IM and FDM 3D 
printing. However, the most promising preparations need more investigation to ensure their 
suitability as candidates which may be developed to pharmaceutical products. One of most 
important areas to that require further investigation is the diffusion of felodipine from the most 
promising HME-IM buccal patches (10% w/w felodipine in CM1 and CM2 patches) through 
buccal mucosa from animal models or cultured buccal mucosa such as EpiOral™. These studies 
will provide critical information about the permeation of the drug through biological membranes 
to ensure the systemic delivery of felodipine. In addition, conducting an in vivo mucoadhesion 
study of the most successful formulation using buccal mucosa from animal models is also 
important to correlate the in vitro with the in vivo results. 
According to the results obtained using different characterisation techniques, 10% w/w loaded 
CM1 and CM2 formulations were well below the saturation limits of the carriers. However, the 
stability studies revealed the presence of very few crystals on the surfaces of the patches. Thus, it 
is important to investigate the causes behind felodipine crystallisation in these patches and the 
impacts of the slight drug phase separation on its release profiles. It is also important to consider 
formulating felodipine at lower loading percentage such as 5% w/w to avoid crystallisation 
problem if this loading can provide the therapeutic dosage. Also, conducting long-term stability 
monitoring (9-12 months) for the most successful formulations to make sure that their 
physicochemical properties and structures are comparable to fresh samples. Furthermore, deep 
investigation is required for identifying the new polymorphic form of felodipine recrystallised 
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from formulations stored at 40 °C and 75% RH and understanding its properties using different 
characterisation techniques especially single crystal XRD.    
In this project, the main concern behind the FDM 3D printing studies was to use excipients 
mixtures to enhance processing using this technique. This area needs to be expanded more to 
provide standard rules for selecting the suitable excipients candidates for FDM 3D printing. In 
addition, the prepared formulations using this technique also need to be studied further by using 
more sophisticated geometries, incorporating drug combinations and most importantly providing 
a clear vision about the future use of 3D printed medications as personalised products for patients 
at the care unit.  
Because TASC is a very flexible and recently developed characterisation technique with many 
interesting applications, developing more applications for this tool in the pharmaceutical field is 
very crucial and provide useful information in different areas such as drug-polymer compatibility, 
polymorphism and thermal rheology. XµCT was found as a useful technique for understanding 
the spatial distribution of phases. This study provided semi-quantitative results for the crystalline 
fraction of felodipine as a novel method for estimating the saturation limits of the carrier. Thus, 
more research is required to validate the method as quantitatively used for this purpose. In 
addition, the spatial resolution for the experiments conducted in this project was 3-4 µm; it could 
be very useful if the investigation will expand to the use of higher instrument sensitivity to detect 
phase separation within the nanoscale. 
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Appendix 1:  Solubility parameter calculations using group 
contribution methods  
The calculated solubility parameters of felodipine (chemical structure shown in Chapter 2) using 
Hoftyzer and Van Krevelen and Hoy methods the are presented in Tables 1 and 2. 
Table (1): Hoftyzer and Van Krevelen group contribution calculations used for the estimation of 
felodipine solubility parameter 
Structural Group   No. of 
groups 
Fdi (MJ/m3)½ . 
mol-1 
Fpi2 (MJ/m3) . 
mol-2 
Ehi J . mol-1 
CH3 4 1680 0 0 
CH2 1 270 0 0 
COO 2 780 480200 14000 
tri-substituted benzene 
ring 
1 1270 12100 0 
=C< 4 280 0 0 
CH 1 200 0 0 
NH 1 160 44100 3100 
Cl 2 900 605000 800 
Ring 1 190 0 0 
Ʃ 
 
5730 1141400 17900 
 
V = 304.77 cm3. mol -1   
δd = Ʃ Fdi  = 18.80 (MJ/m3)½  
δp = √Ʃ F2 pi  = 3.51 (MJ/m3)½ 
δh =  Ʃ Ehi
V
 = 7.66 (MJ/m3)½ 
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δ = δd2 + δp2+δh2 = 20.60 (MJ/m3)½ 
 
Table (2): Hoy group contribution calculations used for the estimation of felodipine solubility 
parameter  
Structural Group   No. of groups Ft (MJ/m3)½ . mol-1 V cm3. mol -1 
CH3 4 1214 86.2 
CH2 1 269 15.55 
COO 2 1280 47.4 
C ar 1 1407 51.94 
CH ar 4 964 53.68 
NH 1 368 11 
Cl 1 660 39 
6 ring 2 -48 0 
Ortho 1 20.2 0 
Meta 1 13.5 0 
Ʃ 
 
6147.7 304.77 
 
V = 304.77 cm3. mol -1   
δt = (Fi+ B)  = 21.08 (MJ/m3)½  
For PEG and PEO polymer grades (molecular formulas are shown in Chapter 2), the calculated 
solubility parameters calculated by both methods are presented in Tables 3 and 4. 
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Table (3): Hoftyzer and Van Krevelen group contribution calculations used for the estimation of 
PEG & PEO solubility parameters 
Structural Group 
  
No. of 
groups 
Fdi (MJ/m3)½ . 
mol-1 
Fpi2 (MJ/m3) . 
mol-2 
Ehi J . mol-1 
CH2 2 540 0 0 
O 1 100 160000 3000 
Ʃ 
 
640 160000 3000 
 
V = 37.55 cm3 . mol -1. 
δd = Ʃ Fdi  = 17.04 (MJ/m3)½ 
δp = Ʃ F2 pi  = 400 (MJ/m3)½ 
δh = Ʃ   = 106.52 (MJ/m3)½ 
δ = δd2 + δp2+δh2 = 22.00 (MJ/m3)½ 
Table (4): Hoy group contribution calculations used for the estimation of PEG and PEO solubility 
parameters 
V = 37.55 cm3. mol -1   
n = 0.5/∆T = 8.62 
δt = (Fi+ B/Q)  = 21.44 (MJ/m3)½  
Structural 
Group  
No. of groups Ft (MJ/m3)½. mol-
1
 
∆T V cm3. mol -1 
CH2 2 538 0.02 15.55 
O 1 235 0.018 6.45 
Ʃ  773 0.058 37.55 
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For Tween 80 (chemical structure is shown in Chapter 2), the calculated solubility parameters 
calculated by both methods are presented in Tables 5 and 6. 
Table (5): Hoftyzer and Van Krevelen group contribution calculations used for the estimation of 
Tween 80 solubility parameter 
Structural Group No. of 
groups 
Fdi (MJ/m3)½ . 
mol-1 
Fpi2 (MJ/m3) . 
mol-2 
Ehi J . mol-1 
CH 4 320 0 0 
CH2 58 15660 0 0 
O 41 4100 6560000 123000 
5 Ring 1 190 0 0 
OH 3 630 750000 60000 
COO 1 390 240100 7000 
CH3 1 420 0 0 
Ʃ 
 
21710 7550100 190000 
 
V = 1287.19 cm3. mol -1   
δd = Ʃ Fdi  = 16.87 (MJ/m3)½ 
δp = √Ʃ F2 pi  = 2.13 (MJ/m3)½ 
δh =  Ʃ Ehi
V
 = 12.15 (MJ/m3)½ 
δ = δd2 + δp2+δh2 = 20.90 (MJ/m3)½ 
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Table (6): Hoy group contribution calculations used for the estimation of Tween 80 solubility 
parameter  
 
V = 1287.19 cm3. mol -1   
δt = (Fi+ B)  = 22.71 (MJ/m3)½  
For TPGS (chemical structure is shown in Chapter 2), the calculated solubility parameters 
calculated by both methods are presented in Tables 7 and 8. 
 
 
 
 
 
 
 
Structural Group   No. of groups Ft (MJ/m3)½ . mol-1 V cm3. mol -1 
CH 4 704 38.24 
CH2 58 15602 901.9 
O 41 9635 264.45 
5 Ring 1 43 0 
OH 3 2025 37.35 
COO 1 640 23.7 
CH3 1 303.5 21.55 
Ʃ 
 
28952.5 1287.19 
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Table (7): Hoftyzer and Van Krevelen group contribution calculations used for the estimation of 
TPGS solubility parameter 
Structural Group No. of 
groups 
Fdi (MJ/m3)½ . 
mol-1 
Fpi2 (MJ/m3) . 
mol-2 
Ehi J . mol-1 
C 1 -70 0 0 
CH 3 240 0 0 
CH2 56 15120 0 0 
O 23 2300 3680000 69000 
6 Ring 1 190 0 0 
OH 1 210 250000 20000 
COO 2 780 480200 14000 
CH3 8 3360 0 0 
Ʃ 
 
23400 4422300 103000 
 
V = 1283.64 cm3. mol -1   
δd = Ʃ Fdi  = 18.23 (MJ/m3)½ 
δp = √Ʃ F2 pi  = 1.64 (MJ/m3)½ 
δh =  Ʃ Ehi
V
 = 8.96 (MJ/m3)½ 
δ = δd2 + δp2+δh2 = 20.38 (MJ/m3)½ 
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Table (8): Hoy group contribution calculations used for the estimation of TPGS solubility parameter 
V = 1280.08 cm3. mol -1   
δt = (Fi+ B)  = 21.18 (MJ/m3)½  
For eudragit E PO (chemical structure is shown in Chapter 2), the calculated solubility parameters 
calculated by both methods are presented in Tables 9 and 10. 
 
 
 
 
 
Structural Group   No. of groups Ft (MJ/m3)½ . mol-1 V cm3. mol -1 
C 1 65.5 3.56 
C aromatic  6 1206 44.52 
CH 3 582 28.68 
CH2 56 15064 870.8 
O 23 5405 148.35 
6 Ring 1 -48 0 
OH 1 675 12.45 
COO 2 1280 47.4 
CH3 8 2428 172.4 
Benzene ring substitutions 
(ortho, meta, para) 
1 231.4 0 
Ʃ 
 
26834.9 1280.08 
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Table (9): Hoftyzer and Van Krevelen group contribution calculations used for the estimation of 
eudragit E PO solubility parameter. 
Structural Group No. of 
groups 
Fdi (MJ/m3)½ . 
mol-1 
Fpi2 (MJ/m3) . 
mol-2 
Ehi J . mol-1 
>C< 3 -210 0 0 
CH2 7 1890 0 0 
N 1 20 640000 5000 
COO 3 1170 720300 21000 
CH3 7 2940 0 0 
Ʃ  5810 1360300 26000 
V = 150.85 cm3 . mol -1. 
δd = Ʃ Fdi  = 16.41 (MJ/m3)½ 
δp = Ʃ F2 pi  = 3.29 (MJ/m3)½ 
δh = Ʃ   = 8.57 (MJ/m3)½ 
δ = δd2 + δp2+δh2 = 18.80 (MJ/m3)½ 
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Table (10): Hoy group contribution calculations used for the estimation of eudragit E PO solubility 
parameter 
V = 354.08 cm3. mol -1   
n = 0.5/∆T = 0.87 
δt = (Fi+ B/Q)  = 18.55 (MJ/m3)½  
 
 
 
 
 
 
 
 
 
 
Structural Group No. of groups Ft (MJ/m3)½. mol-1 ∆T V cm3. mol -1 
>C< 3 196.5 0.12 10.68 
CH2 7 1883 0.14 108.85 
N 1 125 0.009 12.6 
COO 3 1920 0.15 71.1 
CH3 7 2124.5 0.154 150.85 
Ʃ  6249 0.573 354.08 
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For soluplus (chemical structure is shown in Chapter 2), the calculated solubility parameters 
calculated by both methods are presented in Tables 11 and 12: 
Table 11: Hoftyzer and Van Krevelen group contribution calculations used for the estimation of 
soluplus solubility parameter 
 Structural Group 
  
No. of 
groups 
Fdi (MJ/m3)½ . 
mol-1 
Fpi2 (MJ/m3) . 
mol-2 
Ehi J . 
mol-1 
CH 3 240 0 0 
CH2 9 2430 0 0 
O 1 100 160000 3000 
N 1 20 640000 5000 
7 membered ring 1 190 0 0 
COO 1 390 240100 7000 
CH3 2 840 0 0 
CO 1 290 592900 2000 
Ʃ  4500 1633000 17000 
V = 271.78 cm3 . mol -1. 
δd = Ʃ Fdi  = 16.56 (MJ/m3)½ 
δp = Ʃ F2 pi  = 4.70 (MJ/m3)½ 
δh = Ʃ   = 7.91 (MJ/m3)½ 
δ = δd2 + δp2+δh2 = 18.94 (MJ/m3)½ 
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Table 8.12: Hoy group contribution calculations used for the estimation of soluplus solubility 
parameter 
V = 271.78 cm3. mol -1   
n = 0.5/∆T = 1.29 
δt = (Fi+ B/Q)  = 24.34 (MJ/m3)½  
For PVA (chemical structure shown in Chapter 2), the calculated solubility parameters calculated 
using both methods are presented in Tables 13 and 14. 
Table (13): Hoftyzer and Van Krevelen group contribution calculations used for the estimation of 
PVA solubility parameter 
Structural Group No. of 
groups 
Fdi (MJ/m3)½ . 
mol-1 
Fpi2 (MJ/m3) . 
mol-2 
Ehi J . mol-
1
 
CH2 1 270 0 0 
OH 1 210 250000 20000 
CH 1 80 0 0 
Ʃ  560 250000 20000 
Structural Group No. of groups Ft (MJ/m3)½. mol-1 ∆T V cm3. mol 
-1
 
CH 3 528 0.039 28.68 
CH2 9 2421 0.18 139.95 
O 1 235 0.018 6.45 
N 1 125 0.009 12.6 
7 membered ring 1 92 0.007 0 
COO 1 640 0.05 23.7 
CO 1 538 0.04 17.3 
Ʃ  6400 0.387 271.78 
                                                                                                                              
Appendices 
 
352  School of Pharmacy / University of East Anglia 
 
V = 37.56 cm3 . mol -1 
δd = Ʃ Fdi  = 14.91 (MJ/m3)½ 
δp = Ʃ F2 pi  = 13.31 (MJ/m3)½ 
δh = Ʃ   = 23.08 (MJ/m3)½ 
δ = δd2 + δp2+δh2 = 30.53 (MJ/m3)½ 
 
Table (14): Hoy group contribution calculations used for the estimation of PVA solubility parameter 
 
 
 
 
 
V = 37.56 cm3. mol -1   
n = 0.5/∆T = 6.10 
δt = (Fi+ B/Q)  = 28.79 (MJ/m3)½  
 
 
 
 
 
Structural 
Group  
No. of groups Ft (MJ/m3)½. 
mol-1 
∆T V cm3. mol -1 
CH2 1 269 0.02 15.55 
OH 1 591 0.049 12.45 
CH 1 176 0.013 9.56 
Ʃ  1036 0.082 37.56 
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Appendix 2:  UV-Visible scans and standard calibration curves of 
felodipine in different dissolution media 
The UV-VIS scan for felodipine in PBS pH =6.8 indicated that the drug has λmax at 363 nm as 
shown in Figure 1. 
 
Figure (1): UV-Visible scan showing the λmax of felodipine (n=3) 
The calibration curves of felodipine in the different dissolution media are shown in Figures 2-4.  
 
Figure (2): Calibration curve of felodipine in phosphate buffer saline (pH = 6.8) containing 0.05% (V/V) 
Tween 80 at 363 nm (n=3) 
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Figure (3): Calibration curve of felodipine in phosphate buffer saline (PBS) (pH = 6.8) with absolute 
ethanol 50:50 measured at 363 nm (n=3) 
 
Figure (4): Calibration curve of felodipine in HCl simulated gastric fluid (SGF) without enzymes (pH 
= 1.2) with absolute ethanol 50:50 measured at 363 nm (n=3)  
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Appendix 3:  Characterisation of different batches of pure 
felodipine samples 
Two batches of felodipine were used in this study: sample 1 (batch no.  FP140602) and sample 2 
(batch no. 20100601). DSC, ATR-FTIR, PXRD, SEM and LD were used for characterising these 
samples. 
 
Figure (5): Standard DSC thermograms showing the melting of the two samples of felodipine using 
10 °C/min heating rate (n=3)    
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Figure (6): ATR-FTIR spectra of the two samples of felodipine scanned at 2 cm-1 and 32 repeated 
scans in absorbance mode (n=3)   
  
 
Figure (7): PXRD patterns of the two samples of felodipine scanned using the same method 
mentioned in Chapter 3, section 3.2.2.3.6 
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Figure (8): SEM images of the two samples of felodipine scanned using the same method mentioned 
in Chapter 3, section 3.2.2.3.4 
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Figure (9): LD particle size analysis of the two samples of felodipine scanned using the same method 
mentioned in Chapter 2, section 2.3.12 (n=6) 
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Appendix 4:  Calculation of Tg using Fox equation 
Fox equation was used to calculate the Tg for the different blends utilised in the fabrication of 
solid dispersions by FDM 3D printing (Chapter 7). The following method was adapted in the 
determination of these values: 
Fox equation for 10% w/w CME blend: 
1/Tg mix = (wfelodipine/Tg felodipine) + (wPEG/Tg PEG) + (wPEO/Tg PEO) + (weudragit E PO/Tg eudragit E PO) + (wTween 
80/Tg Tween 80) 
The Tg values and weight fractions of the different compounds (after normalisation based on the 
amorphous fraction of PEG and PEO) are: 
wfelodipine = 0.1358; Tg = 319.6 K 
wPEG = 0.0246; Tg = 212.2 K 
wPEO = 0.0250; Tg = 223.4 K 
weudragit E PO = 0.6788; Tg = 319.9 K 
wTween 80 = 0.1358; Tg = 209.2 K 
 
Tg mix = 292.1 K = 18.9 °C 
